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Head and neck cancer (HNC) is a heterogeneous disease with variable clinical outcomes. 
Several biomarkers for HNC prognosis have been identified and incorporated into clinical 
prediction models, but the ability of these models to predict outcome could be improved. 
 
Using self-report and peripheral blood-based DNA methylation (DNAm) predictors, I 
examined whether lifestyle and life-course exposures (smoking, alcohol-drinking, body mass 
index (BMI), education and biological aging) predict all-cause mortality and should be 
considered for inclusion in prognostic models. Additionally, I examined the association of 
circulating metabolites with all-cause mortality.  
 
I found that current smokers with HNC were twice as likely to die during follow-up than 
never-smokers (HR=2.0; 95% CI: 1.4, 3.0), after controlling for established prognostic 
predictors. In people with oropharyngeal cancer (OPC), DNAm-based predictors of smoking 
were associated with all-cause mortality. Based on a DNAm predictor that included 2,623 
CpG sites (Joehanes-Bonferroni) and on methylation levels at a single site (cg05575921) 
within the aryl-hydrocarbon receptor repressor (AHRR) gene, the change in risk of death (all-
cause) per unit increase in standardised DNAm score was approximately two-fold, where 1 
unit increase corresponds to the average increase in the measured methylation score 
experienced by current smokers compared with never smokers (HR=1.89 [95% CI:1.06, 
3.47] and 1.92 [95% CI:1.03, 2.33]). 
 
Two DNAm-age measures, comprising a set of 1,030 CpGs (AgeAccelGrim) and 71 CpGs 
(IEAAHannum), were associated with all-cause mortality in OPC. AgeAccelGrim had the 
largest magnitude of effect in fully adjusted models: each SD increase in AgeAccelGrim 
resulted in a 39% increased all-cause mortality risk (HR=1.39; 95% CI:1.06, 1.83). The 
addition of AgeAccelGrim to a standard clinical model slightly improved mortality risk 
prediction at 3-years (AUC: 0.80 vs. 0.77; p-value for difference=0.069).  
 
In adjusted models, acetate and creatinine were associated with mortality in OPC (HRs per 





This thesis demonstrates the potential of lifestyle, epigenetic and metabolomic measures to 
enhance survival prediction in people with HNC, though these findings need to be replicated 





I declare that the work in this dissertation was carried out in accordance with the requirements 
of the University's Regulations and Code of Practice for Research Degree Programmes and 
that it has not been submitted for any other academic award. Except where indicated by 
specific reference in the text, the work is the candidate's own work. Work done in collaboration 
with, or with the assistance of, others, is indicated as such. Any views expressed in the 
dissertation are those of the author.  
 





I am hugely grateful to my supervisors Professor Andy Ness and Professor Richard Martin. 
To Andy, thank you for giving me the opportunity to work as an intern at the former NIHR 
Biomedical Research Unit (BRU) in Nutrition, Diet and Lifestyle. Working at the BRU instilled 
in me the drive and confidence I needed to undertake a research project of my own. Without 
this experience, I would almost certainly not have been able to apply for an Epidemiology 
PhD, having no previous experience in the field; though I’m sure my knowledge of 
“Developmental Biology”, “host-parasite interactions” and “life in extreme environments” 
helped somewhere along the way. To Richard, I thank you for your continued enthusiasm 
and encouragement, which helped foster a stimulating and enjoyable working environment. 
You have never doubted my ability, even in the early days when I was having a meltdown 
over my first mini-project and my aversion to statistics.  
 
On that note, I am grateful to Professor Margaret May, who supervised me for a large part of 
this PhD and Dr Suzanne Ingle for stepping in when Margaret “went off Piste” to enjoy her 
retirement.  It was not an easy task coming on board so late in my PhD, when I had multiple 
analyses going on and a million different questions to ask. Margaret, whilst my relationship 
with statistics is still very much a work in progress, thanks to your influence, I now realise 
that it is an ally and not an enemy. In fact, I almost enjoy statistics, which I never thought I 
would say, and that is credit to your wonderful teaching and humility. Four years ago, if 
someone had told me I would be doing this thing called flexible parametric survival 
modelling, I would have said you’d got the wrong student but thanks to yours and Sue’s 
patience and approachability, I’m doing things I never imagined I’d be capable of and for that 
I am forever grateful.  
 
I would like to thank Dr Diana Dos Santos Ferreira, both for sharing her vast knowledge of 
metabolomics and for being a friend. I thoroughly enjoyed working with you and Dr Rebecca 
Richmond on my lycopene and green tea mini-project. I learnt so much from you both. I am 
sure I had the honour of working with future Professors! 
 
A special thanks goes to the participants of the Head and Neck 5000 study and the Head 
and Neck 5000 study team, especially Katrina Hurley, Stu Toms and Kate Ingarfield, who 




Outside of academia, I have so many people to be grateful for: my parents who I have put 
through so much but who never stopped cheering me on and being proud of me; my 
wonderful, feisty grandma Flora who sent me 21 kisses on my 21st birthday (some time ago 
now) and whom I miss very much; my great aunt Lexie, who enabled me to do my MSc in 
Biomedical Research Sciences; my brother Euan, who set the standards high and gave me 
someone to look up to, and my wonderful, bright, inspiring friends and office buddies. A 
special thank you to my wonderful husband Jody, who was my boyfriend at the start of this 
PhD. I know I am a nightmare at times but I know how lucky I am to have you there 
supporting me, believing in me and telling me to “just man the f***K up and get it done”.  
 









Beynon, R. A., Lang, S., Schimansky, S., Penfold, C. M., Waylen, A., Thomas, S. J., 
Pawlita, M., Tim, W., Martin, R. M., May, M. &, 2018. Tobacco smoking and alcohol drinking 
at diagnosis of head and neck cancer and all-cause mortality: Results from head and neck 
5000, a prospective observational cohort of people with head and neck cancer. International 
Journal of Cancer. 143, 5, p.1114-1127. 
 
Schimansky, S., Lang, S., Beynon, R., Penfold, C., Davies, A., Waylen, A., Thomas, 
S., Pring, M., Pawlita, M., Waterboer, T. & Ness, A., 2019. Association between comorbidity 
and survival in head and neck cancer: Results from Head and Neck 5000. Head and 
Neck. 41, 4, p.1053-1062. 
 
Lang, S., Schimansky, S., Beynon, R., Penfold, C., Davies, A., Waylen, A., Thomas, 
S., Pring, M., Pawlita, M., Waterboer, T. & Ness, A. R., 2019. Dietary behaviors and survival 
in people with head and neck cancer: Results from Head and Neck 5000. Head and 
Neck. 41, 7, p.2074-2084. 
 
Davies, A., Waylen, A., Leary, S., Thomas, S., Pring, M., Janssen, B., Beynon, R., Lang, S., 
Schimansky, S., Hurley, K. & Ness, A., 2020. Assessing the validity of EQ-5D-5L in people 
with head & neck cancer: Does a generic quality of life measure perform as well as a 
disease-specific measure in a patient population? Oral Oncology. 101, 104504. 
 
Langdon, RJ*., Beynon, RA*., Ingarfield, K., Marioni, RE., McCartney, DM., Richard, MM., 
Ness, AR., Pawlita, M., Waterboer, T., Relton, C., Thomas, SJ., Richmond, RC., 2020. 
Epigenetic prediction of complex traits and mortality in a cohort of individuals with 
oropharyngeal cancer. Clinical Epigenetics. 12:58. 
 *These authors contributed to the manuscript equally. 
 
Pre-prints:  
Beynon, RA., Ingle, S., Langdon, R., May, M., Ness, A., Martin, RM., Suderman, M., 
Ingarfield, K., Marioni, R., McCartney, D., Waterboer, T., Pawlita, M., Relton, C., Davey 
Smith, G., Richmond, RC., 2020. Epigenetic biomarkers of ageing are predictive of mortality 
risk in a longitudinal clinical cohort of individuals diagnosed with oropharyngeal cancer. 




Table of contents 
 
List of Appendices ................................................................................................................. 21 
List of abbreviations .............................................................................................................. 24 
Chapter 1: Thesis overview .................................................................................................. 28 
1.1. Thesis motivation and aim ........................................................................................ 28 
1.2. Organisation .............................................................................................................. 28 
Chapter 2: Introduction to head and neck cancer ............................................................. 30 
2.1. What is head and neck cancer?................................................................................ 30 
2.2. Head and neck cancer sub-sites .............................................................................. 30 
2.2.1. Oral cavity .......................................................................................................... 30 
2.2.2. Nasopharynx ...................................................................................................... 30 
2.2.3. Oropharynx ........................................................................................................ 31 
2.2.4. Larynx................................................................................................................. 31 
2.2.5. Hypopharynx ...................................................................................................... 31 
2.2.6. Nose and paranasal sinuses ............................................................................. 31 
2.3. ICD codes .................................................................................................................. 34 
2.4. How are head and neck cancers diagnosed? .......................................................... 38 
2.4.1. Signs and symptoms.......................................................................................... 38 
2.4.2. History and physical exam ................................................................................. 38 
2.4.3. Diagnostic tests .................................................................................................. 38 
2.5. Staging of head and neck cancer ............................................................................. 39 
2.5.1. TNM staging ....................................................................................................... 40 
2.5.2. Prognostic staging ............................................................................................. 45 
2.5.3. Pros and cons of the TNM system .................................................................... 46 
2.6. Head and neck cancer treatment .............................................................................. 47 
2.6.1. Treating early stage cancers ............................................................................. 47 
2.6.2. Treating locally advanced cancer ...................................................................... 48 
2.7. Summary ................................................................................................................... 49 
Chapter 3: Head and neck cancer epidemiology, biomarkers and prognosis ............... 50 
3.1. Introduction ................................................................................................................ 50 
8 
 
3.2. Prevalence of head and neck cancer ....................................................................... 50 
3.3. HNC Incidence rates ................................................................................................. 51 
3.3.1. UK incidence rates ............................................................................................. 51 
3.3.2. Global variations in incidence rates ................................................................... 54 
3.3.2.1. Lip and oral cavity cancer ........................................................................... 55 
3.3.2.2. Oropharyngeal cancer ................................................................................ 59 
3.3.2.3. Laryngeal cancer ........................................................................................ 59 
3.3.2.4. Other HNC sites.......................................................................................... 60 
3.4. Trends in head and neck cancer incidence rates ..................................................... 60 
3.4.1. UK trends in incidence rates .............................................................................. 61 
3.4.2. Global trends in incidence rates ........................................................................ 62 
3.5. Mortality rates ............................................................................................................ 64 
3.5.1. UK mortality rates .............................................................................................. 64 
3.6. Major risk factors for HNC ......................................................................................... 66 
3.6.1. Tobacco use....................................................................................................... 67 
3.6.2. Alcohol use ......................................................................................................... 69 
3.6.3. Human papilloma virus infection........................................................................ 70 
3.6.4. Epstein-Barr virus .............................................................................................. 73 
3.6.5. Diet and nutrition ................................................................................................ 73 
3.6.6. Body mass index ................................................................................................ 73 
3.6.7. Physical activity .................................................................................................. 74 
3.6.8. Oral hygiene ....................................................................................................... 74 
3.6.9. Socioeconomic position ..................................................................................... 75 
3.6.10. Family history of head and neck cancer ........................................................ 75 
3.6.11. Genetic risk factors ........................................................................................ 76 
3.7. Multi-omics profiling in HNC ...................................................................................... 81 
3.7.1. Genetic landscape ............................................................................................. 81 
3.7.2. Epigenetic signatures ........................................................................................ 82 
3.7.3. Metabolomic profiles .......................................................................................... 87 
3.8. Survival rates after HNC diagnosis ........................................................................... 93 
3.9. Head and neck cancer prognostic factors ................................................................ 94 
3.9.1. Individual-related HNC prognostic factors ......................................................... 94 
3.9.1.1. Age .............................................................................................................. 94 
3.9.1.2. Gender ........................................................................................................ 95 
9 
 
3.9.1.3. Race/ethnicity ............................................................................................. 95 
3.9.1.4. Socioeconomic position .............................................................................. 95 
3.9.1.5. Comorbidity ................................................................................................. 96 
3.9.2. Tumour-related HNC prognostic factors............................................................ 97 
3.9.2.1. Tumour stage .............................................................................................. 97 
3.9.2.2. HPV status .................................................................................................. 98 
3.9.2.3. Genetic predictors ...................................................................................... 98 
3.9.2.4. Epigenetic predictors .................................................................................. 98 
3.9.2.5. Metabolic predictors ................................................................................... 99 
3.9.2.6. Infection biomarkers ................................................................................... 99 
3.9.2.7. Other molecular biomarkers ..................................................................... 100 
3.9.3. Environment-related HNC prognostic factors .................................................. 100 
3.9.3.1. Smoking .................................................................................................... 100 
3.9.3.2. Alcohol drinking ........................................................................................ 101 
3.9.3.3. Diet ............................................................................................................ 101 
3.9.4. HNC prognostic models ................................................................................... 107 
3.10. Summary.............................................................................................................. 115 
Chapter 4: Capturing exposures to biological, environmental and lifestyle risk factors
................................................................................................................................................ 116 
4.1. Introduction .............................................................................................................. 116 
4.2. Self-reported phenotypes ........................................................................................ 116 
4.3. Biochemical measures of tobacco and alcohol exposure ...................................... 118 
4.4. Epigenetic predictors of health and lifestyle ........................................................... 118 
4.4.1. What is DNA methylation? ............................................................................... 118 
4.4.2. DNAm-based predictors of smoking, alcohol consumption, educational 
attainment and BMI ........................................................................................................ 122 
4.4.3. Epigenetic biomarkers of aging ....................................................................... 123 
4.4.3.1. Single-tissue DNA methylation-based age estimators ............................ 124 
4.4.3.2. Multi-tissue DNA-methylation based age estimators ............................... 125 
4.4.3.3. Phenotypic age estimator ......................................................................... 125 
4.4.3.4. GrimAge .................................................................................................... 126 
4.4.3.5. Epigenetic age acceleration ..................................................................... 127 
4.5. HPV detection methods in HNC.............................................................................. 128 
4.5.1. p16 immunohistochemistry .............................................................................. 129 
4.5.2. HPV in situ hybridization .................................................................................. 130 
10 
 
4.5.3. HVP polymerase chain reaction testing .......................................................... 130 
4.5.4. HPV serological testing .................................................................................... 131 
4.6. Metabolomic assessment of exposure ................................................................... 137 
4.7. Summary of the challenges and opportunities ....................................................... 140 
Chapter 5: The Head and Neck 5000 study ....................................................................... 142 
5.1. Study design and follow-up ..................................................................................... 142 
5.1.1. Inclusion criteria: .............................................................................................. 142 
5.1.2. Exclusion criteria: ............................................................................................. 142 
5.1.3. Consent ............................................................................................................ 143 
5.1.4. Recruitment rates ............................................................................................. 143 
5.1.5. Baseline data collection ................................................................................... 143 
5.1.6. Response rates ................................................................................................ 145 
5.1.7. Follow-up .......................................................................................................... 145 
5.2. Methods for collecting and processing materials ................................................... 147 
5.2.1. Blood sample collection, processing, and storage .......................................... 147 
5.2.2. Genotyping and imputation .............................................................................. 147 
5.2.3. DNA methylation profile generation ................................................................. 148 
5.2.4. Metabolite quantification .................................................................................. 149 
5.2.5. Determination of HPV status ........................................................................... 151 
5.3. Variable description ................................................................................................. 152 
5.3.1. Demographic variables .................................................................................... 152 
5.3.1.1. Gender ...................................................................................................... 152 
5.3.1.2. Age at consent .......................................................................................... 153 
5.3.1.3. Ethnicity .................................................................................................... 153 
5.3.2. Clinical variables .............................................................................................. 154 
5.3.2.1. Primary Diagnosis .................................................................................... 154 
5.3.2.2. TNM staging ............................................................................................. 156 
5.3.2.3. HPV status ................................................................................................ 157 
5.3.2.4. Body mass index ...................................................................................... 158 
5.3.2.5. Comorbidity ............................................................................................... 159 
5.3.2.6. Cancer care plan intent ............................................................................ 160 
5.3.3. Socioeconomic variables ................................................................................. 160 
5.3.3.1. Annual household income ........................................................................ 160 
5.3.3.2. Highest education level obtained ............................................................. 161 
5.3.3.3. Marital status ............................................................................................ 162 
11 
 
5.3.4. Lifestyle behaviour variables ........................................................................... 163 
5.3.4.1. Alcohol consumption ................................................................................ 163 
5.3.4.2. Baseline smoking status ........................................................................... 164 
5.4. Representativeness of the cohort ........................................................................... 165 
Chapter 6: A description of the datasets used in the thesis .......................................... 167 
6.1. Introduction .............................................................................................................. 167 
6.2. Participants included in the observational analysis ................................................ 168 
6.3. Participants included in the epigenetic analyses .................................................... 171 
6.4. Participants included in the metabolomics analysis ............................................... 174 
6.5. Discussion ............................................................................................................... 177 
Chapter 7: Associations of self-reported smoking status and alcohol use at diagnosis 
with survival in H&N5000 .................................................................................................... 178 
7.1. Introduction .............................................................................................................. 178 
7.2. Aims and objectives ................................................................................................ 179 
7.3. Methods ................................................................................................................... 179 
7.3.1. Study population .............................................................................................. 179 
7.3.2. Outcome assessment ...................................................................................... 180 
7.3.3. Defining exposures .......................................................................................... 180 
7.3.4. Assessment of HPV status .............................................................................. 180 
7.3.5. Statistical analysis ............................................................................................ 181 
7.3.5.1. Descriptive analysis .................................................................................. 181 
7.3.5.2. Accounting for missing data ..................................................................... 181 
7.3.5.3. Survival analysis ....................................................................................... 182 
7.4. Results ..................................................................................................................... 184 
7.4.1. Missing data ..................................................................................................... 184 
7.4.2. Baseline characteristics of study population ................................................... 187 
7.4.3. Kaplan-Meier survival plots.............................................................................. 189 
7.4.4. Variation in survival explained by smoking status and alcohol intake ............ 192 
7.4.5. Smoking status and survival ............................................................................ 193 
7.4.6. Alcohol intake and survival .............................................................................. 193 
7.4.7. Heterogeneity between centres ....................................................................... 194 
7.4.8. Influence of tumour stage on the associations of smoking and alcohol intake 
with survival .................................................................................................................... 194 
12 
 
7.4.9. Influence of HPV status on the associations of smoking and alcohol intake with 
survival 195 
7.4.10. Interaction of tobacco and alcohol ............................................................... 196 
7.5. Discussion ............................................................................................................... 200 
7.5.1. Principal findings .............................................................................................. 200 
7.5.2. Strengths and limitations of the study ............................................................. 201 
7.5.3. Conclusions...................................................................................................... 203 
Chapter 8: Epigenetic prediction of complex traits and mortality in oropharyngeal 
cancer in H&N5000 .............................................................................................................. 204 
8.1. Introduction .............................................................................................................. 204 
8.2. Aims and objectives ................................................................................................ 205 
8.3. Methods ................................................................................................................... 205 
8.3.1. Study population .............................................................................................. 205 
8.3.2. Assessment of tobacco, alcohol, BMI, and education .................................... 205 
8.3.3. Epigenetic profiling and pre-processing .......................................................... 206 
8.3.4. Epigenetic risk score generation ..................................................................... 206 
8.3.5. Multiple imputation ........................................................................................... 207 
Statistical analysis .......................................................................................................... 210 
8.3.5.1. Associations of epigenetic scores with self-reported phenotypes ........... 210 
8.3.5.2. Proportion of variance in survival explained by DNAm scores ................ 210 
8.3.5.3. Survival analysis ....................................................................................... 210 
8.4. Results ..................................................................................................................... 212 
8.4.1. Baseline characteristics of the study population ............................................. 212 
8.4.2. Correlation between covariates ....................................................................... 216 
8.4.3. Correlation between DNAm predictors ............................................................ 216 
8.4.4. Proportion of variance in phenotype explained by the DNAm scores ............ 216 
8.4.6. Proportion of variance in survival explained by the DNAm scores ................. 219 
8.4.7. Association of DNAm predictors with all-cause mortality ................................ 220 
8.5. Discussion ............................................................................................................... 225 
8.5.1. Principle findings .............................................................................................. 225 
8.5.2. Strengths and limitations of the study ............................................................. 226 
8.5.3. Conclusions...................................................................................................... 227 
Chapter 9: Associations of epigenetic biomarkers of ageing with mortality risk in 
oropharyngeal cancer ......................................................................................................... 228 
13 
 
9.1. Introduction .............................................................................................................. 228 
9.2. Aims and objectives ................................................................................................ 229 
9.3. Methods ................................................................................................................... 230 
9.3.1. Study population .............................................................................................. 230 
9.3.2. Estimation of epigenetic age ........................................................................... 230 
9.3.3. Statistical analysis ............................................................................................ 233 
9.3.3.1. Step 1: Examining the association of EAA measures with survival ........ 233 
9.3.3.2. Step 2: Assessing the prognostic value of EAA measures ..................... 234 
9.4. Results ..................................................................................................................... 237 
9.4.1. Baseline descriptives ....................................................................................... 237 
9.4.2. Pairwise correlations between measures of epigenetic age acceleration ...... 238 
9.4.3. Explained variation in survival ......................................................................... 240 
9.4.4. Association of DNA Methylation-Based Biological Age with survival ............. 240 
9.5. Discussion ............................................................................................................... 247 
9.5.1. Principle findings .............................................................................................. 247 
9.5.2. Strengths and limitations of the study ............................................................. 249 
9.5.3. Conclusions...................................................................................................... 249 
Chapter 10: Metabolic signatures of oropharyngeal cancer survival ........................... 251 
10.1. Introduction .......................................................................................................... 251 
10.2. Aims and objectives ............................................................................................. 252 
10.3. Methods ............................................................................................................... 252 
10.3.1. Study population........................................................................................... 253 
10.3.2. Measurement of metabolites ........................................................................ 253 
10.3.3. Issues of multiple testing .............................................................................. 258 
10.3.3. Missing data decisions ................................................................................. 261 
10.3.4. Statistical analyses ....................................................................................... 263 
10.3.5. Sensitivity analysis ....................................................................................... 264 
10.4. Results ................................................................................................................. 265 
10.4.1. Baseline characteristics ............................................................................... 265 
10.4.2. Differences in metabolic trait concentrations between HPV-positive and 
HPV-negative individuals ............................................................................................... 265 
10.4.3. Associations of pre-treatment metabolic traits with all-cause mortality ...... 266 
10.4.4. Sensitivity analyses ...................................................................................... 271 
14 
 
10.5. Discussion ........................................................................................................... 273 
10.5.1. Principle findings .......................................................................................... 273 
10.5.2. Challenges.................................................................................................... 275 
10.5.3. Strengths and limitations of the study .......................................................... 276 
10.5.4. Conclusion .................................................................................................... 278 
Chapter 11: Discussion ....................................................................................................... 279 
11.1. Introduction .......................................................................................................... 279 
11.2. Summary of findings and implications ................................................................ 279 
11.3. Strengths and limitations of this thesis ................................................................ 284 
11.3.1. Strengths ...................................................................................................... 284 
11.3.1.1. Prospective study design ......................................................................... 284 
11.3.1.2. Availability of baseline clinical, biological and lifestyle data. ................... 284 
11.3.1.3. Data linkage .............................................................................................. 285 
11.3.1.4. Sample size relative to other HNC studies .............................................. 285 
11.3.2. Weaknesses ................................................................................................. 286 
11.3.2.1. Selection into the H&N5000 study ........................................................... 286 
11.3.2.2. Selection into the analytic sample ............................................................ 286 
11.3.2.3. Missing covariate data .............................................................................. 287 
11.3.2.4. Power and sample size ............................................................................ 288 
11.3.2.5. Lack of cancer-specific mortality data ...................................................... 289 
11.3.2.6. Sample collection and handling ............................................................... 289 
11.3.2.7. Limited epigenetic and metabolomic data................................................ 290 
11.3.2.8. External validity......................................................................................... 290 
11.4. Future work .......................................................................................................... 291 
11.4.1. Mendelian randomization study of metabolite profiles ................................ 291 
11.4.2. Saliva and tissue metabolites and survival in HNC ..................................... 292 
11.4.3. HNC prognostic model development ........................................................... 293 
11.4.4 Application and impact of a new HNC prognostic model in clinical practice .. 293 





List of Tables 
 
Table 1: ICD-10 diagnosis codes for cancers of the head and neck. ..................................... 35 
Table 2a: Tumour (T) staging according to anatomical site. ................................................... 41 
Table 2b: Classification of lymph nodes by anatomical site ................................................... 44 
Table 3: AJCC (8th edition) prognostic stage groups for HPV-associated (p16+) OPC. ....... 47 
Table 4: Estimated number of prevalent cases of HNC in the UK (2018) as a proportion, 
ages 20-85+ years. .................................................................................................................. 51 
Table 5: UK estimated age-standardised incidence rates of head and neck cancer by site 
and gender, all ages (2018). .................................................................................................... 52 
Table 6: Global estimated age-standardized incidence rates of head and neck cancer by site 
and gender, all ages (2018). .................................................................................................... 55 
Table 7: Some of the most intensely studies genetic polymorphisms linked to HNC risk...... 78 
Table 8: HNC risk loci identified in GWAS. ............................................................................. 80 
Table 9: Frequency of selected genes recurrently mutated in HNC. ...................................... 85 
Table 10: Genes frequently hypermethylated in HNC. ........................................................... 86 
Table 11: Summary of metabolomic-based studies on HNC. ................................................. 90 
Table 12: Head and neck survival by sub-site for males and females. .................................. 94 
Table 13: The association of pre-treatment smoking with head and neck cancer outcomes.
................................................................................................................................................ 102 
Table 14: Association of pre-treatment alcohol consumption with head and neck cancer 
outcomes. ............................................................................................................................... 105 
Table 15: Summary description of HNC prognostic models described in the literature. ...... 112 
Table 16: A summary of some of the characteristics of available alcohol biomarkers, 
Adapted from 490 and 499......................................................................................................... 120 
Table 17: HPV detection methods in HNC. ........................................................................... 134 
Table 18: A comparison of the advantages and disadvantages of the two most common 
techniques used in metabolomics data acquisition. .............................................................. 139 
16 
 
Table 19: Baseline characteristics of the study sample, stratified by tumour site (n=1,403).
................................................................................................................................................ 169 
Table 20: Baseline characteristics of the individuals with oropharyngeal tumours, stratified by 
HPV status (n=656). .............................................................................................................. 170 
Table 21: Baseline characteristics of all participants included in the epigenetic analyses 
(n=408). .................................................................................................................................. 172 
Table 22: baseline characteristics of participants included in the epigenetic analysis, 
stratified by HPV status (n=408). ........................................................................................... 173 
Table 23: baseline characteristics of the study sample included in the metabolomic analysis 
(n=703). .................................................................................................................................. 175 
Table 24: baseline characteristics of the study sample, stratified by HPV status (n=703). . 176 
Table 25: Proportion of missing data, overall and stratified by tumour site. ......................... 186 
Table 26: Mortality hazard ratios (HR) according to baseline smoking and drinking status 
stratified by tumour site. ......................................................................................................... 197 
Table 27: Association of smoking status and alcohol intake with mortality risk, stratified by 
tumour stage. ......................................................................................................................... 198 
Table 28: Association of smoking status and alcohol intake with mortality risk, stratified by 
HPV status. ............................................................................................................................ 199 
Table 29: An overview of the DNAm scores employed in the current analysis. ................... 208 
Table 30: Proportion of missing data in the epigenetic dataset (n=408). ............................. 210 
Table 31: Average DNAm values for people who are alive at 3-years compared to people 
who are dead at 3-years. ....................................................................................................... 214 
Table 32: Pearson’s correlation coefficient matrix for included covariates........................... 217 
Table 33: Pearson’s correlation coefficient matrix for DNAm scores. .................................. 218 
Table 34: The proportion of phenotypic variance explained in each trait by the respective 
DNAm-based predictor. ......................................................................................................... 219 
Table 35: Overview of various measures of epigenetic age acceleration. ........................... 232 
Table 36: Baseline characteristics of the study sample stratified by 3-year mortality status 
(n=408). .................................................................................................................................. 239 
Table 37: Measures of model performance. ......................................................................... 245 




Table 39: An overview of the metabolic biomarkers included in the current analysis (n=145).
................................................................................................................................................ 255 
Table 40: The impact on effect estimates of removing potential outliers from the dataset, 
using different outlier-detection methods. ............................................................................. 272 
Table 41.  An overview of the research questions and findings of this thesis. ..................... 280 





List of Figures 
 
Figure 1: Research questions addressed in this thesis. ......................................................... 29 
Figure 2: Anatomy of the Head and Neck. .............................................................................. 32 
Figure 3: Anatomic regions of the oral cavity. ......................................................................... 32 
Figure 4: Anatomy of the oropharynx. ..................................................................................... 33 
Figure 5: Areas where laryngeal cancer may form or spread. ................................................ 33 
Figure 6: ICD code structure. .................................................................................................. 35 
Figure 7: Geographical distribution of oral cavity, oropharyngeal and laryngeal cancer 
incidences, UK (2007-2009). ................................................................................................... 53 
Figure 8: Average number of incident cases of HNC per year and age-standardised 
incidence rates per 100,000 persons in the UK (2013-2015). ................................................ 54 
Figure 9: Global incidence of HNC, by sub-site. ..................................................................... 56 
Figure 10: Total alcohol per capita consumption (15+ years; in litres of pure alcohol), 2016.
.................................................................................................................................................. 58 
Figure 11: Global prevalence of tobacco smoking among persons aged 15 years and older 
(2015). ...................................................................................................................................... 58 
Figure 12: Rise in HNC incidence in the UK, 1993-2017. ....................................................... 62 
Figure 13: Trend in UK smoking rates among males and females, 1950-2010. .................... 62 
Figure 14: Head and neck Cancer mortality trends over time in the UK (1971-2016). .......... 65 
Figure 15: Head and neck cancer European age-standardised mortality rates, by age, in UK 
males (1971-2016). .................................................................................................................. 65 
Figure 16: Head and neck cancer European age-standardised mortality rates, by age, in UK 
females (1971-2016). ............................................................................................................... 66 
Figure 17: HPV-16 genome ..................................................................................................... 72 
Figure 18: Image of web-based calculator developed by Emerick et al. .............................. 111 
Figure 19: Regulation of transcription by DNAm ................................................................... 119 
Figure 20: Microscope images of HPV-positive and HPV-negative oropharyngeal tumours by 
ISH and p16 IH. ..................................................................................................................... 131 
19 
 
Figure 21: A comparison of antibody-capture enzyme-linked immunosorbent assay (left) and 
bead-based multiplex serology (right). .................................................................................. 133 
Figure 22: The 76 H&N5000 Study centres 574. .................................................................... 146 
Figure 23: H&N5000 data collection points. .......................................................................... 146 
Figure 24: Proportion of male and female participants in H&N5000. ................................... 152 
Figure 25: Histogram showing age distribution in H&N5000. ............................................... 153 
Figure 26: Bar chart of ethnicity in HN5000. ......................................................................... 154 
Figure 27: Proportion of HNCs by sub-site in H&N5000. ...................................................... 156 
Figure 28: Bar chart showing the proportion of HNCs in each TNM stage group in H&N5000.
................................................................................................................................................ 157 
Figure 29: Bar chart showing the proportion of HN5000 participants who were HPV-positive 
or HPV negative, as determined by HPV-16 seropositivity. .................................................. 158 
Figure 30: Histogram of BMI distribution in H&N5000. ......................................................... 159 
Figure 31: Bar chart of showing the comorbidity burden of participants in H&N5000. ......... 159 
Figure 32: Bar chart showing the intended treatment plan for participants at baseline in 
H&N5000. ............................................................................................................................... 160 
Figure 33: Bar chart of participant income in H&N5000. ...................................................... 161 
Figure 34: Bar chart showing the education structure of respondents in H&N5000. ........... 162 
Figure 35: Bar chart showing H&N5000 participants’ marital status. ................................... 163 
Figure 36: bar chart showing the alcohol consumption levels of participants in H&N5000. 164 
Figure 37: Bar chart showing the proportion of never-, former- and current smokers in 
H&N5000. ............................................................................................................................... 165 
Figure 38: number of participants included in each of the primary analysis conducted in this 
thesis. ..................................................................................................................................... 167 
Figure 39: Flow of Head and Neck 5000 participants through the study. ............................. 185 
Figure 40: Kaplan-Meier plot of overall survival by HNC site. .............................................. 186 
Figure 41: Kaplan-Meier plot of overall survival by smoking status and alcohol consumption, 
stratified by tumour site. ......................................................................................................... 191 
Figure 42: Kaplan-Meier plot of overall survival by smoking status and alcohol consumption, 
stratified by HPV status. ........................................................................................................ 192 
20 
 
Figure 43:  Flow of participants included in the analysis. ..................................................... 207 
Figure 44: Forest plots showing the estimated hazard ratios and corresponding 95% 
confidence intervals for the associations of DNAm predictors with all-cause mortality 
(n=408). .................................................................................................................................. 223 
Figure 45: Flow of participants included in the Epigenetic Age analysis. ............................. 236 
Figure 46: Heat map showing the pairwise correlation coefficients between epigenetic 
measures of age acceleration. .............................................................................................. 238 
Figure 47: Association of epigenetic age acceleration measures with mortality risk. .......... 242 
Figure 48: Independent contribution of AgeAccelGrim to prognosis beyond clinical factors 
(n=408). .................................................................................................................................. 246 
Figure 49: A comparison of the area under the ROC curves (AUC) obtained for the models 
included in the sensitivity analyses (n=384). ......................................................................... 246 
Figure 50: Scree plot and Stata output showing the decreasing rate at which variance is 
explained by additional principal components....................................................................... 260 
Figure 51: Loading to PC1 and PC2. .................................................................................... 261 
Figure 52: OPC samples available for analysis .................................................................... 262 
Figure 53: Cox regression results for models 1 and 2 .......................................................... 267 
Figure 54: Cox regression results for models 3 and 4. ......................................................... 269 
Figure 55: Linear fit between complete case and full dataset models. ................................. 270 
21 
 
List of Appendices  
List of Tables .......................................................................................................................... 15 
Appendix A ........................................................................................................................... 296 
A1: A comparison of the baseline characteristics of people with and without BMI data 
available (n=3,890). 286 
A2: Baseline descriptives of people included in the imputed analysis (n=3,890). 296 
A3: Mortality hazard ratios (HR) according to baseline smoking and drinking status 
stratified by tumour site (n=3,890). 297 
A4: Mortality hazard ratios (HR) according to baseline smoking and drinking status 
stratified by tumour stage. 298 
A5: Mortality hazard ratios (HR) according to baseline smoking and drinking status 
stratified by HPV status. 299 
Appendix B ........................................................................................................................... 300 
B1: Kaplan-Meier plots of overall survival in univariate models (n=408). 300 
B2: Histograms showing the distribution of AHRR DNAm scores, overall and by self-
reported smoking status (n=408). 303 
B3: Histograms showing the distribution of Joehanes (Bonferroni) DNAm scores, overall 
and by self-reported smoking status. 303 
B4: Histograms showing the distribution of Joehanes (FDR) DNAm scores, overall and by 
self-reported smoking status. 304 
B5: Histograms showing the distribution of Zhang DNAm scores, overall and by self-
reported smoking status. 304 
B6: Histograms showing the distribution of McCartney DNAm scores, overall and by self-
reported smoking status. 305 
B7: Histograms showing the distribution of Lui DNAm scores (based on 5 CpGs), overall 
and by self-reported alcohol consumption. 305 
B8: Histograms showing the distribution of Lui (23 CpG) DNAm scores, overall and by 
self-reported alcohol consumption. 306 
B9: Histograms showing the distribution of Lui (78 CpG) DNAm scores, overall and by 
self-reported alcohol consumption. 306 
22 
 
B10: Histograms showing the distribution of Lui (144 CpG) DNAm scores, overall and by 
self-reported alcohol consumption. 307 
B11: Histograms showing the distribution of McCartney DNAm scores, overall and by self-
reported alcohol consumption. 307 
B12: Histograms showing the distribution of McCartney DNAm scores, overall and by self-
reported educational attainment level. 308 
B13: Histograms showing the distribution of McCartney DNAm scores, overall and by self-
reported BMI. 308 
B14: Stata code used to standardise DNAm scores, to allow direct comparison across 
scores with different scales. 309 
B15: Kaplan-Meier observed survival curves and cox predicted survival for the variable 
HPV status. 310 
B16: Log-log plot testing the PH assumption for the variable HPV status. 310 
B17: Kaplan-Meier observed survival curves and cox predicted survival for the variable 
comorbidity. 311 
B18: Log-log plot testing the PH assumption for the variable Comorbidity. 311 
B19: A comparison of the effect estimates obtained for the associations of DNAm scores 
with survival in the primary and complete case analyses. 312 
B20: Results of the sensitivity analysis, censoring data at 3-years, adjusted for age, 
gender, cell counts and batch effects. 314 
B21: Results of the sensitivity analysis, additionally adjusted for TNM stage, HPV status 
and comorbidity. 314 
B22: Results of the sensitivity analysis, additionally adjusted for the corresponding directly 
measured phenotype. 315 
B23: Results of the sensitivity analysis, additionally adjusted for the other directly 
measured phenotypes. 315 
Appendix C ........................................................................................................................... 316 
C1: Baseline characteristics of participants included in the complete case analysis. 316 
C2: Results of the complete case cox regression analysis (n=225). 317 
Appendix D ........................................................................................................................... 319 
23 
 
D1: Abbreviations, names and units of metabolic measures quantified on the Nightingale 
NMR platform. 319 
D2: PC loadings for the metabolic trait measures. 326 
D3: Proportion of missing data in the metabolomics dataset (n=1,483). 330 
D4: Density histograms showing the observed data distributions of metabolic trait 
measures (n=703). 331 
D5: Standardised mean difference in circulating metabolic trait concentrations for HPV (+) 
vs. HPV (-) OPCs. 380 
D6: Summary of Cox PH regression results, showing only those metabolites that reached 




List of abbreviations 
ACE-27 Adult comorbidity evaluation 
ADH Alcohol dehydrogenase 
AF Attributable fractions  
AIC Akaike Information Criterion 
AJCC American Joint Committee on Cancer 
ALAT Alanine aminotransferase  
ALDH Aldehyde dehydrogenase 
ANOVA Analysis of variance  
ASAT Aspartate aminotransferase  
ASR Age-standardised rate 
ASIR Age-standardised instance rate 
AUC Area under the receiver operating curve 
AUDIT Alcohol Use Disorders Identification Test 
BIC  Bayesian Information Criterion  
BMI Body mass index 
CCI Charlson Comorbidity Index  
CDK Cyclin-dependent kinase 
CDT Carbohydrate-deficient transferrin  
TCGA The Cancer Genome Atlas  
CHARGE Heart and aging Research in Genetic Epidemiology Consortium 
CI Confidence interval 
CpG Cytosine-guanine dinucleotide 
CRUK Cancer Research UK 
CT Computerised tomography 
cTNM Clinical TNM staging (see TNM staging) 
DCF Data capture form 
DFS Disease-free survival 
DNA Deoxyribonucleic acid 
DNAm DNA methylation 
DNMT DNA methyltransferase  
dNTP Deoxyribonucleotide triphosphate 
ddNTPs Dideoxynucleotides triphosphates 
DSS Disease-specific survival  
EAA Epigenetic age acceleration 
EEAA Extrinsic epigenetic age acceleration  
EBRT External beam radiotherapy  
EBNA1 Epstein-Barr nuclear antigen 1  
EBV Epstein-Barr virus  
ECS Extra capsular spread 
EDTA Ethylenediaminetetraacetic acid 
EGFR Epidermal growth factor receptor  
ELISA Enzyme Linked Immunosorbent Assay  
EOR Excess odds ratio  
25 
 
EPIC European Prospective Investigation into Cancer and Nutrition 
ER Estrogen receptor 
ER Endoplasmic reticulum  
ESP  European standard population 
EtG Ethyl glucuronide  
EU European Union 
EUCAN European Cancer Observatory  
E6AP E6-associated protein 
FAEE Fatty acid ethyl esters  
FDG Fluorodeoxyglucose  
FDR False Discovery Rate  
FFPE Formalin fixed paraffin embedded 
FNAC Fine needle aspiration cytology 
GGT Gamma–glutamyltransferase  
GST Glutathione S-transferase  
Gy Grays 
GWAS Genome wide association study 
HDL High density lipoprotein 
HDI Human development index  
HER2 Human epidermal growth factor receptor 2 
Hex Hexosaminidase 
His Histidine  
HNC Head and neck cancer 
H&N5000 Head and Neck 5000 
HNSCC Head ans Neck squamous cell carcinoma 
H&P History and physical exam 
HPV Human papilloma-virus 
HR  Hazard ratio 
HRF Haplotype reference panel  
HSCIC Health and Social care information Centre 
IARC International Agency for Research into Cancer 
ICD 
The International Classification of Diseases and Related Health 
Problems 
IDL Intermediate density lipoprotein 
IEAA Intrinsic epigenetic age acceleration  
IEU Integrative Epidemiology Unit 
IHC Immunohistochemistry  
IMD Index of Multiple Deprivation 
IMRT Intensity-modulated radiation therapy  
INHANCE International Head and Neck Cancer Epidemiology consortium  
IQR Interquartile range 
ISH In-situ hybridisation 
LASSO Least absolute shrinkage  
LCR Long control region  
LDL Low density lipoprotein 
IL6/7 Interleukin 6/7 
26 
 
LMP-1 Latent membrane protein 1 
LMR Lymphocyte-to-monocyte ratio 
LMWM Low molecular weight molecules 
LNM Lymph node metastasis 
LSOA Lower Layer Super Output Area 
mAB Monoclonal antibody 
MAR Missing at random 
MCAR Missing completely at random 
MDT Multi-disciplinary team  
MFI Median fluorescence intensity 
MI Multiple imputation  
MNAR Missing not at random  
MPG Multiplex HPV genotyping  
MRI Magnetic resonance imaging 
MS Mass spectrometry 
NADH Nicotinamide adenine dinucleotide  
NCIN National Cancer Intelligence Network  
NF-kB Nuclear factor kappa B 
NHANES National Health and Nutrition Examination Survey  
NHS National Health Service 
NHSCR NHS Central Register  
NHSIC  National Health Service Information Centre 
ncRNA Noncoding ribonucleic acids  
NICE  National institute for clinical excellence 
NK Natural killer cells 
NLR Neutrophil-to-monocyte ratio 
NMR Nuclear magnetic resonance 
NPC Nasopharyngeal cancer/carcinoma 
NPI Nottingham prognostic index 
OCC Oral cavity cancer 
OCIN Oxford Cancer Intelligence Network 
OLK Oral leukoplakia 
ONS Office for national statistics 
OPC Oropharyngeal cancer 
ORF  Open reading frame 
ORF  Odds ratio 
OS  Overall survival 
OSSC Oral squamous cell carcinoma 
Ossig Overall survival signature 
PA Physical activity 
PAH Polynuclear aromatic hydrocarbon 
PAR Population attributable risk 
PCR Polymerase chain reaction  
PET Positron emission tomography 
PH proportional hazards 
PLR platelet-to-lymphocyte ratio 
27 
 
pTNM  pathological TNM staging [see TNM staging] 
QC Quality control 
QoL Quality of life 
ROS Reactive oxygen species 
RR Rate ratio 
RT–PCR  Reverse transcriptase PCR 
SA Sialic acid  
SCC Squamous cell carcinoma 
SEER Surveillance, Epidemiology, and End Results 
SES Socioeconomic status 
SIR Standardised incidence ratio 
SMC Squared multiple correlations 
SNP single nucleotide polymorphism  
SPT Second primary tumour 
TF Transcription factor 
TNF-α Transforming growth factor alpha 
TNM Tumour node metastasis staging 
TS Tumour suppressor 
T-stage Describes the size of the primary tumour  
UADT Upper aerodigestive tract 
UICC Union for International Cancer Control 
UK United Kingdom 
US United states 
VEGF Vascular endothelial growth factor 
WGA Whole genome amplification 





Chapter 1: Thesis overview  
1.1. Thesis motivation and aim 
Assessing prognosis is a major component of the clinical encounter. For someone with a 
diagnosis of head and neck cancer (HNC), the outcome of their disease is a major concern.  
The challenge for the clinician is to predict the course of the cancer (e.g. the likelihood of 
metastasis or death in a given timeframe) in a particular individual, in order to inform 
treatment decisions. 
 
Prognostic models (also known as clinical prediction rules) can help clinicians to both predict 
an individual’s likely clinical outcome and discuss their prognosis with them.  Existing HNC 
prognostic models which, in routine practice, are based almost exclusively on clinical 
biomarkers, such as TNM stage and tumour site, predict mortality with varying success. For 
this reason, coupled with the growing ability to capture and mine vast amounts of clinical and 
biological data on individuals, the study of prognostic factors is increasingly important. 
 
The role of certain lifestyle factors such as smoking and alcohol intake in HNC prognosis 
have been investigated. However, measures of such exposures are prone to error because 
they often rely on self-report, leading to potentially inaccurate estimates of the effect of these 
exposures on HNC outcomes. In addition, many studies looking at potential prognostic 
factors have been small, and therefore underpowered, or they have lacked data on important 
confounders.  
 
The overall aim of this thesis is to investigate, using a combination of self-reported 
phenotypes, DNA methylation-based predictors of exposures, and information on circulating 
metabolites, whether specific lifestyle traits and life-course exposures predict all-cause 
mortality and should be considered for inclusion in HNC prognostic models. The findings of 
this analysis could enhance clinical decision making in this population and help stratify 
people with disease in future epidemiological studies and clinical trials.   
 
1.2. Organisation  
This thesis starts by describing the biological and clinical aspects of HNC and provides an 
overview of its epidemiology. It then summarises the existing prognostic literature in this 
29 
 
area and some of the major challenges encountered when trying to measure lifestyle 
exposures that could potentially serve as prognostic biomarkers. In the next section, I 
describe the clinical cohort study from which the data for this PhD was obtained. I provide a 
brief overview of the data collection methods and the baseline characteristics of the overall 
cohort, before describing the specific analytic datasets used in my analysis. The main 
research questions addressed in the subsequent results chapters are presented in Figure 1.
 
 Figure 1: Research questions addressed in this thesis. 
 
 
The first results chapter examines the potential associations of self-reported smoking and 
alcohol intake with all-cause mortality, using data collected on a subset of Head and Neck 
5000 (H&N5000) participants with cancers of the oral cavity, oropharynx and larynx. Given 
the known limitations of self-reported lifestyle data, the second results chapter investigates 
the strength of the associations between these exposures and other complex traits including 
body mass index (BMI) and educational attainment, with all-cause mortality, using DNA-
methylation (DNAm) based predictors for these traits. Here, the analysis is restricted to 
cohort members with oropharyngeal cancer (OPC) only. The next two results chapters also 
focus on OPC, specifically. The third results chapter examines the predictive utility of DNAm-
based predictors of biological aging on all-cause mortality. The fourth results chapter 
explores the possible association between participants’ circulating metabolic profiles and all-
cause mortality. A summary of my main findings and potential future work is provided in the 
final discussion chapter. 
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Chapter 2: Introduction to head and neck cancer 
2.1. What is head and neck cancer?  
HNC is an umbrella term used to describe malignancies at several different sites in the head 
and neck region.  These malignancies include cancers of the mouth, throat (larynx), thyroid, 
nasal cavity, and sinuses.  Skin cancers and brain tumours are not usually included under 
this definition 1 2.  Around 90% of HNCs are squamous cell carcinomas (SCC) 3, meaning 
that the arise in the thin, flat cells that line the surfaces of these structures. Other types of 
HNCs include adenocarcinomas (cancers that originate in the mucous glands), melanomas 
(cancers that develop from melanocytes in the epidermis), lymphomas (cancers that start in 
the lymph nodes or lymph gland tissue), and sarcomas (cancers that develop in the 
connective tissue e.g., in the bone, fat, muscle or cartilage) 4. The term “head and neck 
cancer” as discussed here will be restricted to SCC as they make up the majority of cases 
and because they share common risk factors.  
2.2. Head and neck cancer sub-sites 
The head and neck region is one of the most complicated anatomical structures in the 
human body.  This is because it provides the mechanisms for many basic functions, 
including speech, swallowing, hearing and breathing.  HNCs are defined by the area in 
which they arise.  The major sites include: the oral cavity (mouth), the nasopharynx, the 
oropharynx, the larynx (voice box), the hypopharynx, and the nose and paranasal sinuses 
(Figure 2).  Each major anatomical site is further divided into several subsites, as outlined 
below. 
2.2.1. Oral cavity 
includes the mucosal surfaces of the lip, the lining inside the cheeks and floor of the mouth 
(buccal mucosa), the front two-thirds of the tongue, the bony structure at the top of the 
mouth (hard palate), and the small area of gum behind the wisdom teeth (retromolar triangle) 
5 (Figure 3).  
2.2.2. Nasopharynx  
the upper section of the pharynx (throat), which connects the back of the nose to the back of 




the part of the throat that includes the soft palate, base of the tongue, uvula, palatine tonsils 
and tonsillar pillars 6 (Figure 4). 
2.2.4. Larynx 
the area of the throat that is located below the oropharynx and in front of the hypopharynx 7.  
It is subdivided into three subsites: the supraglottis, glottis, and subglottis (Figure 5). The 
supraglottic larynx includes the epiglottis (a small flap of tissue that closes off the larynx 
when eating to prevent food from entering the airways), the ventricular bands (false vocal 
cords), the arytenoids cartilages, and the aryepiglottic folds.  The glottis consists of the true 
vocal cords and their anterior and posterior commissures. The subglottic region begins just 
below the true vocal cords and extends to the lower edge of the cricoid cartilage, a ring of 
cartilage that surrounds the trachea (windpipe) 6. 
2.2.5. Hypopharynx 
the region between the oropharynx and the oesophagus (the tube that connects the throat to 
the stomach; Figure 2). The major subsites of the hypopharynx include the pyriform sinuses, 
the post-cricoid region, and the lateral and posterior pharyngeal walls 6.  The vast majority of 
hypopharynx cancers arise in the pyriform sinus 8.  
2.2.6. Nose and paranasal sinuses 
includes the lining of the nasal cavity (medial maxillary walls), the nasal septum, and four 
pairs of air-filled hollows in the bones around the nose. These include the maxillary sinuses, 
which are located under the eyes, the superior frontal sinuses, which are located below the 
eyes, the bilateral ethmoid sinuses, which sit between the eyes, and the sphenoidal sinuses, 
located behind the eyes 9 (Figure 2). 
 
Cancers can also arise in the thyroid gland. However, SSC of the thyroid are extremely rare, 
representing <1% of all primary carcinomas of the thyroid 10. Similarly, SCC only make up 
0.9% to 4.7% of all major salivary gland tumours 11, therefore these cancers will not be 




Figure 2: Anatomy of the Head and Neck. 
 
For the National Cancer Institute © 2016 Terese Winslow LLC.
 
Figure 3: Anatomic regions of the oral cavity. 
 
For the National Cancer Institute © 2016 Terese Winslow LLC. 
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Figure 4: Anatomy of the oropharynx. 
 
For the National Cancer Institute © 2016 Terese Winslow LLC.
  
Figure 5: Areas where laryngeal cancer may form or spread. 
 
For the National Cancer Institute © 2016 Terese Winslow LLC.
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2.3. ICD codes 
Given the complex topography and histology of HNC, standardised classification systems 
are necessary to register diagnoses and to facilitate the systematic analysis and comparison 
of morbidity and mortality data. The International Classification of Diseases and Related 
Health Problems, more commonly referred to by the acronym ICD, is the standard diagnostic 
classification tool used by physicians, policy makers and epidemiologists 12.  
 
The ICD is currently in its tenth revision (ICD-10), although the eleventh revision (ICD-11) 
was released in June 2018 and will be come into effect on 1 January 2022 13.  
The ICD system is based on a unique set of alphanumeric codes. Codes in the current 
revision can be three, four, five, six or seven characters in length.  A detailed description of 
the classification system along with full coding guidelines can be found in the second volume 
of the International statistical classification of diseases and related health problems 10th 
Revision (sections 2.3 and 2.4) 14.  At its simplest level, the first three-character codes, 
known as ‘rubrics’, specify the category of the diagnosis (Figure 6). The first character is 
always a letter.  In this case, the letter “C” indicates that the diagnosis relates to a neoplasm 
or cancer. As an example, when “C” is used in conjunction with the numerals “0” and “3”, this 
indicates that the diagnosis falls into the category of malignant neoplasm of the gum.  
Characters four to six describe in greater detail the cause, anatomic location (e.g. laterality) 
and severity of the disease.  Using the above example, cancer of the gum (ICD-11 C03) can 
be subdivided into the upper gum (ICD-11 C03.0) and the lower gum (ICD-11 C03.1) using 0 
or 1 in the fourth position.  Not all codes include all the positions and the seventh character 
is typically only used for injury and external cause-related codes. Table 1 lists the ICD-10 
medical diagnostic codes used for malignant neoplasms of the head and neck. 
 
The way in which individual ICD codes (sub-sites) are grouped varies in the epidemiological 
literature and across Cancer registries 15. In particular, there is considerable debate around 
which sites should be classified as oral cavity cancer and which sites should be classified as 
oropharyngeal. The decision is partly based on anatomical location but also on where HPV 
infection, an established risk factor for oropharyngeal cancer, is found 16 17. Based on a 
review of the epidemiological literature, Conway et al propose that oropharyngeal cancer 
(OPC) should be defined as the sites: base of tongue (C01), lingual tonsil (C2.4), tonsil 
(C09), oropharynx (C10), and pharynx unspecified including Waldeyer’s ring /over-lapping 
sites of oral cavity and pharynx (C14); while oral cavity cancer includes: the inner lip (C00.3 
– C00.9), other and unspecified parts of the tongue (C02) (excluding lingual tonsil [C2.4]), 
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gum (C03), floor of the mouth (C04), palate (C05), and other and unspecified parts of the 
mouth (C06) 15. A breakdown of the ICD-codes used to identify HNC sites in this thesis is 
provided in Chapter 5.  
 
Figure 6: ICD code structure. 
 
*Every letter except “U”. ** The number 1 is used to indicate right side, number 2 to indicate 
left side, number 3 to indicate bilateral, number 9 indicates side is unspecified in the medical 
record.***Required for certain codes, including 'S' codes (injuries and external causes), to 
provide information about the characteristic of the encounter: A= internal encounter, 
B=subsequent encounter, C=Sequelae (complications that arise as a direct result of a 
condition). 
 
Table 1: ICD-10 diagnosis codes for cancers of the head and neck 18. 
Lip 
C00.0 External upper lip 
C00.1 External lower lip 
C00.2 External lip, NOS 
C00.3 Mucosa of upper lip 
C00.4 Mucosa of lower lip 
C00.5 Mucosa of lip, NOS 
C00.6 Commissure of lip 
C00.8 Overlapping lesion of lip 
C00.9 Lip, NOS (excludes Skin of lip C44.0) 
Base of tongue 
C01.9 Base of tongue, NOS 
Other unspecified parts of the tongue 
C02.0 Dorsal surface of tongue, NOS 
C02.1 Border of tongue 
C02.2 Ventral surface of tongue, NOS 
C02.3 Anterior 2/3 of tongue, NOS 
C02.4 Lingual tonsil 
C02.8 Overlapping lesion of tongue 
C02.9 Tongue, NOS 
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Table 1 continued. 
Gum 
C03.0 Upper gum 
C03.1 Lower gum 
C03.9 Gum, NOS 
Floor of the mouth 
C04.0 Anterior floor of mouth 
C04.1 Lateral floor of mouth 
C04.8 Overlapping lesion of floor of mouth 
C04.9 Floor of mouth, NOS 
Palate 
C05.0 Hard palate 
C05.1 Soft palate, NOS (excludes Nasopharyngeal surface of soft palate C11.3) 
C05.2 Uvula 
C05.8 Overlapping lesion of palate 
C05.9 Palate, NOS 
Other and unspecified parts of the mouth 
C06.0 Cheek mucosa 
C06.1 Vestibule of mouth 
C06.2 Retromolar area 
C06.8 Overlapping lesion of other and unspecified parts of mouth 
C06.9 Mouth, NOS 
Paratoid gland* 
C07.9 Parotid gland 
Other and unspecified major salivary glands* 
C08.0 Submandibular gland 
C08.1 Sublingual gland 
C08.8 Overlapping lesion of major salivary glands 
C08.9 Major salivary gland, NOS (excludes minor salivary gland, NOS C06.9) 
Tonsil 
C09.0 Tonsillar fossa 
C09.1 Tonsillar pillar 
C09.8 Overlapping lesion of tonsil 
C09.9 Tonsil, NOS (excludes lingual tonsil C02.4 and pharyngeal tonsil C11.1) 
Oropharynx 
C10.0 Vallecula 
C10.1 Anterior surface of epiglottis 
C10.2 Lateral wall of oropharynx 
C10.3 Posterior wall of oropharynx 
C10.4 Branchial cleft (site of neoplasm) 
C10.8 Overlapping lesion of oropharynx 
C10.9 Oropharynx, NOS 
Nasopharynx 
C11.0 Superior wall of nasopharynx 
C11.1 Posterior wall of nasopharynx 
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Table 1 continued. 
C11.2 Lateral wall of nasopharynx 
C11.3 Anterior wall of nasopharynx 
C11.8 Overlapping lesion of nasopharynx 
C11.9 Nasopharynx, NOS 
Pyriform sinus 
C12.9 Pyriform sinus 
Hypopharynx 
C13.0 Postcricoid region 
C13.1 Hypopharyngeal aspect of aryepiglottic fold, NOS (excludes laryngeal 
aspect of aryepiglottic fold C32.1) 
C13.2 Posterior wall of hypopharynx 
C13.8 Overlapping lesion of hypopharynx 
C13.9 Hypopharynx, NOS 
Other and ill-defined sites in the lip, oral cavity and pharynx 
C14.0 Pharynx, NOS 
C14.2 Waldeyer's ring 
C14.8 Overlapping lesion of lip, oral cavity and pharynx 
Nasal cavity and middle ear 
C30.0 Nasal cavity (excludes Nose, NOS C76.0) 
C30.1 Middle ear 
  
Accessory sinuses 
C31.0 Maxillary sinus 
C31.1 Ethmoid sinus 
C31.2 Frontal sinus 
C31.3 Sphenoid sinus 
C31.8 Overlapping lesion of accessory sinuses 





C32.3 Laryngeal cartilage 
C32.8 Overlapping lesion of larynx 
C32.9 Larynx, NOS 
Thyroid gland* 
C73.9 Thyroid gland 
 
*Rarely SCC. Abbreviations: NOS, not otherwise specified.
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2.4. How are head and neck cancers diagnosed? 
2.4.1. Signs and symptoms 
The symptoms of HNC vary according to the site of the tumour, but commonly include: a 
lump or ulcer in the mouth or throat that will not heal; difficulties when chewing, swallowing 
(dysphagia) or speaking (dysphonia); pain when swallowing (odynophagia); bleeding in the 
mouth; bad breath (halitosis); headache; tooth mobility without evidence of periodontal 
disease; persistent hoarseness or a change in voice; ear pain (otalgia) or stuffiness of ears; 
and swelling in the neck caused by an enlarged lymph node 19 20.  Enlargement of a cervical 
lymph node (often painless) as the first presenting symptom is not unusual, especially in 
people with tumours in so-called “silent” sites e.g. base of tongue, supraglottis, and 
nasopharynx 3. 
2.4.2. History and physical exam 
The starting point of any diagnosis is the history and physical exam 21.  Here, the clinician 
will enquire about the presence and duration of any symptoms and record any other relevant 
medical, behavioural, and psycho-social history, paying particular attention to key risk factors 
such as prior cancer history, smoking history, alcohol consumption, occupational exposures, 
prolonged sun exposure and gastro-oesophageal reflux 22. Following the history, the 
physician performs a comprehensive physical examination of the head and neck region, 
regardless of suspected primary site, owing to the frequent occurrence of multiple primary 
tumors in people with HNC. The examination follows a systematic approach, including: 
inspecting the face for asymmetry or swelling, examining the skin for ulcers, pigmentation or 
suspicious lesions, looking for abnormal discharge, bleeding, effusions from the ears or 
nose, and palpating the tongue and lymph nodes 22. It is also helpful to listen to the 
individuals’ voice and speech because this can provide an indication of the tumour location 
e.g. a raspy, hoarse voice may point towards a laryngeal neoplasm 23. The doctor may also 
examine the nose and throat using a nasendoscope, a thin flexible tube that has a light and 
camera on the end 24. Before inserting the nasendoscope, a local anesthetic is sprayed into 
the nostril to numb the area.  
2.4.3. Diagnostic tests 
To confirm a diagnosis of cancer and to determine whether it has spread, clinicians use a 
combination of biopsy and imaging tests. A biopsy is the removal of a small sample of tissue 
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to check for the presence of cancerous cells under the microscope. The common methods 
used in cases of suspected HNC are incision or punch biopsies and fine needle aspiration 
cytology (FNAC) 25. The type of biopsy used will depend on the size and location of the 
tumour. FNAC is usually performed alongside an ultrasound.  The ultrasound scanner uses 
high frequency sound waves to create a detailed image of the neck, which is then used to 
guide the needle to the correct position.  A small sample of cells is then drawn up through 
the needle, like a blood test. A biopsy may also be carried out alongside a laryngoscopy. 
Similar to a nasendoscopy, laryngoscopy involves inserting a tube with a light and camera 
on the end into the mouth and throat, but it is usually done under a general anaesthetic 24. 
If a diagnosis has not been made after extensive clinical evaluation and FNAC, an open 
excisional biopsy may be performed (i.e. the entire growth or lesion is removed).   
 
The goals of imaging in HNC are: to determine the extent of the primary tumour and whether 
it has spread to regional lymph nodes; to detect whether the cancer has spread 
(metastasised) to other parts of the body; and to detect synchronous primary tumours. All 
these factors contribute substantially to prognosis and management of the disease.  Staging 
of the tumour or node is upgraded from the original clinical stage in at least 30% of cases 
following imaging 3. The imaging modality of choice is governed by the anatomic region 
under consideration 26.  For instance, tumours of the larynx, oropharynx, and hypopharynx 
are frequently imaged with computerised tomography (CT) because this technique is less 
affected by breathing and swallowing artefacts than other scanning procedures such as 
magnetic resonance imaging (MRI) 27; It does however carry a radiation cost.  The main 
advantage of MRI is that it is excellent for assessing the soft tissue extent of the tumour 28 
i.e., it is able to distinguish between a mass and the surrounding soft-tissue structures.  
Other potential imaging techniques include nuclear magnetic resonance (NMR) scans, 
positron emission tomography (PET) scans, and chest X-rays, which are used to identify 
metastases or a second primary 26.  
 
2.5. Staging of head and neck cancer 
Clinical staging is paramount to the successful management of HNC and provides a 
common language through which physicians can communicate.  It is the standard process of 
describing where the cancer is and how much of it there is.  This information comes from 
various tests, including physical examination, imaging, and biopsies of affected areas. 
Knowing the cancer’s stage helps clinicians develop a prognosis and determine the most 
appropriate course of treatment for their patient. 
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2.5.1. TNM staging 
The tumour, node, metastasis (TNM) staging system is the most commonly used staging 
system across the world.  It was developed by the American Joint Committee on Cancer 
(AJCC) and the Union for International Cancer Control (UICC) 29. The system is based on 
local tumour growth (T), the degree of regional lymph node involvement (N), and the 
absence or presence of distant metastases (M). The most common site of metastases is the 
lungs, followed by the liver and bones 30.  
 
Two types of TNM staging are applied in practice: i) clinical TNM (cTNM) staging, which is 
based on clinical examination in addition to ancillary techniques such as radiological 
investigations (i.e. MRI or CT); and ii) pathological TNM (pTNM) staging, which is derived 
from the histopathological examination of the tumour specimen (i.e. surgical pathology 
reports) 31. The pTNM is considered superior to cTNM in that it provides better prediction of 
prognosis 32. Thus, it is generally used when deciding if adjuvant therapy is needed. 
Previous work suggests a concordance rate between clinical and pathological N 
classification of between 43% and 83% depending on the tumour site 33. 
 
As a general rule, the T stage will take a value between 0-4 depending on the size and 
extent of the tumour; the N stage will be a number between 0–3 depending on the number of 
local lymph nodes involved, their location and their size, and the M stage will be either a 0 if 
the cancer is restricted to its primary site, or a 1 if it has spread to other parts of the body 34. 
Specific subdivisions may exist for each stage. For instance, T4a disease is considered 
“moderately advanced” but resectable, whilst T4b disease is deemed “very advanced” and 
unresectable, due to the aggressive nature of the cancer 35. The staging of the different 
types of HNC are all slightly different, although most HNC sites (except the thyroid and 
nasopharynx) use the same classification system for regional lymph nodes 36. Tables 2a and 
2b provide the T-and N- classification according to anatomical site according to the 8th 
edition of the AJCC Cancer staging manual.
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Table 2a: Tumour (T) staging according to anatomical site 37. 
Oral cavity 
TX Primary tumour cannot be assessed. 
T0 No evidence of primary tumour. 
Tis Carcinoma in situ. 
T1 Tumour <2 cm in greatest dimension. 
T2 Tumour > 2 but < 4 cm in greatest dimension. 
T3 Tumour > 4 cm. 
T4a Moderately advanced local disease. Tumour invades through cortical 
bone, inferior alveolar nerve, floor of mouth, or skin of face—that is, chin 
or nose. Tumour invades adjacent structures (e.g., through cortical bone, 
into deep [extrinsic] muscle of tongue [genioglossus, hypoglossus, 
palataglossus, and styloglossus], maxillary sinus, skin of face). 
T4b Very advanced local disease. Tumour invades masticator space, 
pterygoid plates, or skull base and/or encases internal carotid artery. 
Oropharynx 
TX Primary tumour cannot be assessed. 
T0 No evidence of primary tumour. 
Tis Carcinoma in situ. 
T1 Tumour <2 cm in greatest dimension. 
T2 Tumour > 2 cm but < 4 cm in greatest dimension. 
T3 Tumour > 4 cm or extension to lingual surface of epiglottis. 
T4a Moderately advanced local disease. Tumour Invades the larynx, 
deep/extrinsic muscle of tongue, medial pterygoid, hard palate, or 
mandible. 
T4b Very advanced local disease. Tumour invades prevertebral space, 
encases carotid artery, or invades mediastinal structures. 
Larynx  
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
Tis Carcinoma in situ 
Supraglottis  
T1 Tumour limited to one sub site, with normal vocal cord mobility 
T2 Tumour invades mucosa of more than one of the supraglottis or glottis or 
region outside the supraglottis (e.g., mucosa of base of tongue, 
vallecula, medial wall of pyriform sinus) without fixation of the larynx 
T3 Tumour limited to the larynx with vocal fold fixation and/or invades any of 
the following: postcricoid area, pre-epiglottic tissues, paraglottic 
space, and/or inner cortex of thyroid cartilage 
T4a Moderately advanced local disease. Tumour invades through the thyroid 
cartilage and/or invades tissues beyond the larynx (e.g., trachea, soft 
tissues of neck including deep extrinsic muscle of the tongue, strap 
muscles, thyroid, or oesophagus). 




Table 2a continued. 
Glottis  
T1 Tumour limited to vocal cord(s), with normal mobility. 
T1a Tumour limited to one vocal cord. 
T1b Tumour involves both vocal cords. 
T2 Tumour extends to supraglottis, and/or subglottis, and/or with impaired 
vocal cord mobility. 
T3 Tumour limited to the larynx with vocal fold fixation and/or invasion of 
paraglottic space, and/or inner cortex of the thyroid cartilage. 
T4a Moderately advanced local disease. Tumour invades the outer cortex of 
the thyroid cartilage and/or invades tissues beyond the larynx (e.g., 
trachea,  
T4b Very advanced local disease. Tumour invades prevertebral space, 
encases carotid artery, or invades mediastinal structures. 
Subglottis  
T1 Tumour limited to subglottis. 
T2 Tumour extends to the vocal cord(s) with normal/impaired mobility. 
T3 Tumour limited to the larynx with vocal cord fixation. 
T4a Moderately advanced local disease. Tumour invades cricoid or thyroid 
cartilage and/or invades tissues beyond the larynx (e.g., trachea, soft 
tissues of the neck including deep extrinsic muscles of the tongue, strap 
muscles, thyroid, or oesophagus). 
T4b Very advanced local disease. Tumour invades prevertebral space, 
encases carotid artery, or invades mediastinal structures. 
Salivary gland 
TX Primary tumour cannot be assessed. 
T0 No evidence of primary tumour. 
T1 Tumour <2 cm in greatest dimension without extraparenchymal 
Extension. 
T2 Tumour >2 cm but <4 cm in greatest dimension without 
extraparenchymal extension** 
T3 Tumour >4 cm and/or tumour having extraparenchymal extension**. 
T4a Moderately advanced local disease. Tumour invades the skin, mandible, 
ear canal, and/or facial nerve. 
T4b Very advanced local disease. Tumour invades the skull base and/or 
pterygoid plates and/or encases the carotid artery. 
Hypopharynx  
TX Primary tumour cannot be assessed. 
T0 No evidence of primary tumour. 
Tis Carcinoma in situ. 
T1 Tumour limited to one subsite of the hypopharynx and is <2 cm in 
greatest dimension. 
T2 Tumour invades more than one subsite of the hypopharynx or an 
adjacent site, or measures >2 cm but < 4 cm in greatest dimension 
without fixation of the hemilarynx or extension to the oesophagus. 
T3 Tumour >4 cm in greatest dimension or with fixation of the hemilarynx or 
extension to the oesophagus. 
T4a Moderately advanced local disease. Tumour invades thyroid/cricoid 
cartilage, hyoid bone, thyroid gland, oesophagus, or central 




Table 2a continued. 
T4b Very advanced local disease. Tumour invades prevertebral fascia, 
encases carotid artery, or involves mediastinal structures. 
Nasal cavity and paranasal sinuses 
TX Primary tumour cannot be assessed. 
T0 No evidence of primary tumour. 
Tis Carcinoma in situ. 
maxillary sinus     
T1 Tumour limited to the maxillary sinus mucosa with no erosion or 
destruction of bone. 
T2 Tumour causing bone erosion or destruction, including extension 
into the hard palate and/or middle nasal meatus, except extension 
to the posterior wall of the maxillary sinus and pterygoid plates. 
T3 Tumour invades any of the following: bone of the posterior wall of 
the maxillary sinus, subcutaneous tissues, floor or medial wall 
of the orbit, pterygoid fossa, or ethmoid sinuses. 
T4a Moderately advanced local disease. Tumour invades anterior orbital 
contents, skin of cheek, pterygoid plates, infratemporal fossa, cribriform 
plate, sphenoid or frontal sinuses. 
T4b Moderately advanced local disease. Tumour invades any of the 
following: orbital apex, dura, brain, middle cranial fossa, cranial nerves 
other than maxillary division of trigeminal 
nerve [V2], nasopharynx, or clivus. 
nasal cavity & 
Etmoid sinus  
T1 Tumour restricted to any one subsite, with or without bony invasion. 
T2 Tumour invades two subsites in a single region or extending to involve 
an adjacent region within the nasoethmoidal complex, with or 
without bony invasion. 
T3 Tumour extends to invade the medial wall or floor of the orbit, 
maxillary sinus, palate, or cribriform plate. 
T4a Moderately advanced local disease. Tumour invades any of the 
following: anterior orbital contents, skin of nose or cheek, minimal 
extension to anterior cranial fossa, pterygoid plates, sphenoid or frontal 
sinuses. 
T4b Very advanced local disease. Tumour invades any of the following: 
orbital apex, dura, brain, middle cranial fossa, cranial nerves other 
than V2, nasopharynx, or clivus. 
Nasopharynx 
TX Primary tumour cannot be assessed. 
T0 No evidence of primary tumour. 
Tis Carcinoma in situ. 
T1 Tumour confined to the nasopharynx or tumour extends to the 
oropharynx and/or nasal cavity without parapharyngeal extension. 
T2 Tumour with parapharygeal extension. 
T3 Tumour involves bony structures of skull base and/or paranasal sinuses. 
T4a Tumour with intracranial extension and/or involvement of cranial nerves, 





Table 2a continued. 
Thyroid gland 
TX Primary tumour cannot be assessed. 
T0 No evidence of primary tumour. 
T1 Tumour <2 cm or less in greatest dimension, limited to the thyroid. 
T1a Tumour <1 cm or less, limited to the thyroid. 
T1b Tumour >1 cm but <2 cm in greatest dimension, limited to the thyroid. 
T2 Tumour > 2 cm but <4 cm in greatest dimension, limited to the thyroid. 
T3 Tumour >4 cm in greatest dimension, limited to the thyroid or 
any tumour with minimal extrathyroid extension (e.g., extension to 
sternothyroid muscle or perithyroid soft tissues). 
T4a Moderately advanced local disease. Tumour of any size extending 
beyond the thyroid capsule to invade subcutaneous soft tissues, larynx, 
trachea, oesophagus, or recurrent laryngeal nerve. 
T4b Very advanced local disease. Tumour invades prevertebral fascia or 
encases the carotid artery or mediastinal vessels. 
Table 2b: Classification of lymph nodes by anatomical site 37 
Excluding the nasopharynx and thyroid 
NX Regional lymph nodes cannot be assessed. 
N0 There is no regional nodes metastasis. 
N1* Metastasis is in a single ipsilateral lymph node, < 3 cm in greatest 
dimension. 
N2* Metastasis is in a single ipsilateral lymph node, > 3 cm but < 6 cm in 
greatest dimension; or metastasis is in multiple ipsilateral lymph nodes, 
none > 6 cm in greatest dimension; or metastasis is in bilateral or 
contralateral lymph nodes, none > 6 cm in greatest dimension. 
N2a* Metastasis is in a single ipsilateral lymph node, > 3 cm but < 6 cm in 
greatest dimension. 
N2b* Metastasis is in multiple ipsilateral lymph nodes, none > 6 cm in 
greatest dimension. 
N2c* Metastasis is in bilateral or contralateral lymph nodes, none > 6 cm in 
greatest dimension. 
N3* Metastasis is in a lymph node > 6 cm in greatest dimension. 
Nasopharynx 
NX Regional lymph nodes cannot be assessed. 
N0 No regional lymph node metastasis. 
N1 Unilateral metastasis in cervical lymph node(s), 6 cm or less in greatest 
dimension, above the supraclavicular fossa, and/or unilateral or 
bilateral 
retropharyngeal lymph nodes, 6 cm or less in greatest dimension. 
N2 Bilateral metastasis in cervical lymph node(s), 6 cm or less in greatest 
dimension, above the supraclavicular fossa. 
N3 Metastasis in lymph node >6 cm and/or to supraclavicular fossa. 
N3a Greater than 6 cm in dimension. 
N3b Extension to the supraclavicular fossa. 
45 
 
Table 2b. continued. 
Thyroid 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis. 
N1 Regional lymph node metastasis. 
N1a Metastasis to Level VI (pretracheal, paratracheal, and prelaryngeal/ 
Delphian lymph nodes). 
N1b Metastasis to unilateral, bilateral, or contralateral cervical Levels I, II, 
III, IV, or V) or superior mediastinal lymph nodes (Level VII). 
 
 
2.5.2. Prognostic staging 
Based on the TNM numbers, the cancer is assigned an overall stage of 0 to IV.  In most 
cases, early-stage disease is denoted as stage I or stage II and advanced stage disease is 
denoted as stage III or stage IV.  Staging is slightly different for each particular type of HNC, 
but can be generalised as follows 38:  
• Stage 0 (also called carcinomas in situ): cancers are only found in the squamous 
cells where they began; 
• Stage I: cancers have grown into the tissue (up to 2cm across), but they have not yet 
invaded nearby lymph nodes;  
• Stage II: cancers have extended into nearby structures (2-4 cm across), but have still 
not spread to the lymph nodes or other parts of the body;  
• Stage III: cancers may have extended further (more than 4 cm across), or they may 
have spread to a single ipsilateral lymph node (a node located on the same side of 
the head or neck as the primary tumour); 
• Stage IVa: cancers may be any size with more than one ipsilateral lymph node 
involved, or they may have extended into the major structures of the head and neck 
(e.g. the tumour has invaded the skull base or encases the carotid artery), in which 
case they may or may not have spread to one ipsilateral lymph node that is smaller 
than 3cm across; 
• Stage IVb: cancers have not spread to other sites in the body, but one of the 
following is true: they have grown into major structures of the head and have spread 
to one or multiple ipsilateral lymph nodes that are more than 6 cm across; or, they 
are any size with bilateral or contralateral lymph node metastases. 
• Stage IVc: cancers may be any size but have metastasised to distant sites of the 
body.   
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2.5.3. Pros and cons of the TNM system 
The TNM classification system plays a critical role in cancer care and research.  It assists in 
making and communicating diagnoses, formulating prognoses and defining or stratifying 
study groups. Its main advantages are that it is widely applicable, easy to adhere to and 
crucially, it is universally accepted 39.   Important limitations do exist, however.  A major 
limitation of the present TNM classification system for HNC is that it is based almost 
exclusively on tumour morphology, with the exception of OPC which will be discussed below.  
Because individual-based prognostic factors (e.g. age, gender and comorbidity) and 
biological and molecular markers are not taken into account, this limits its ability to provide 
individualised prognostication 39.  
 
As alluded to above, OPC has its own distinct TNM staging system. It was first introduced in 
the eighth edition of the AJCC Staging Manual.  The new staging schema aims to provide 
improved discrimination and predictive ability and is based on emerging knowledge of the 
different clinical behaviours of human papilloma virus (HPV)-associated and non-HPV-
associated oropharyngeal tumours. Using the new prognostic stage groups for HPV-
associated OPC (Table 3), people who would have been considered stage IV under the old 
staging system may now be classified as stage I, II or III.  The stratification of OPC into HPV-
associated and non-HPV associated types is dependent on immunohistochemical staining of 
the tumour suppressor protein p16 (cyclin‐dependent kinase 2A), which is highly correlated 
with HPV infection in HNC 40.  Further details of p16 will be provided in the next chapter.  
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Table 3: AJCC (8th edition) prognostic stage groups for HPV-associated (p16+) OPC. 
 N category M category  Stage group 
Clinical 
T0, T1 or T2 N0 or N1 M0 I 
T0, T1 or T2 N2 M0 II 
T3 N0, N1, or N2 M0 II 
T0, T1, T2, T3 or T4 N3 M0 III 
T4 N0, N1, N2 or N3 M0 III 
Any T Any N M1 IV 
Pathological 
T0, T1 or T2 N0 or  N1 M0 I 
T0, T1 or T2 N2 M0 II 
T3 or T4 No or N1 M0 II 
T3 or T4 N2 M0 III 
Any T Any N M1 VI 
 
 
2.6. Head and neck cancer treatment 
The treatment of HNC is dictated by the location of the tumour, the stage of the disease, and 
the individual’s age and general health. Eliminating the cancer is always the primary goal, 
however, preserving the function of nearby organs, nerves and tissues is also important as 
this will affect the person’s quality of life (QoL) 41. For this reason, treatment decisions are 
made by a multidisciplinary team of surgeons, medical oncologists, radiation oncologists and 
rehabilitation specialists 42. The main treatment options available are surgery, radiation 
therapy, chemotherapy, targeted therapy, or a combination of treatments. 
2.6.1. Treating early stage cancers 
If the cancer is small and has not spread to lymph nodes or metastasised elsewhere, it can 
usually be treated with single-modality surgery or radiotherapy 43.  The choice between 
surgery or radiation is influenced by the location of the primary tumour and the likely 
functional sequelae.   For instance, surgery is typically preferred for floor of the mouth 
cancers due to the risk of complications from radiotherapy, but base of tongue tumours are 
less amenable to surgical resection, which could cause permanent deficits in speech and 
swallowing.  In circumstances such as this, where surgery would be associated with 
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unacceptable morbidity, radiotherapy would be preferred.  Sometimes, radiotherapy may be 
used in combination with surgery to improve prognosis and reduce the risk of locoregional 
recurrence.  It may be given before surgery (neoadjuvant radiotherapy), to try to shrink the 
tumour so that it is easier to resect, or it may be given after surgery if the cancer is very large 
or it is not feasible to remove it completely 44.  Adjuvant radiotherapy should ideally begin 4–
6 weeks following primary surgery 38. 
 
The most common type of radiation therapy is called external-beam radiation therapy 
(EBRT), which delivers radiation from a machine outside the body 45. An EBRT regime, or 
schedule, is usually fractioned, which means that the total dose of radiation to be given is 
divided into small doses (fractions) that are administered over a prolonged period.  The 
radiation dose depends on tumour size; however, for early stage disease, conventional 
radiation schedules deliver a single fraction of 2 Gy/day, 5 days a week for 7 weeks 46.  
 
Intensity-modulated radiation therapy (IMRT) describes an advanced type of EBRT that 
shapes the radiation beam to fit precisely around the tumour 47. This means that the cancer 
cells receive a high dose of radiation, whilst the surrounding healthy cells receive a lower 
dose, reducing the risk of long-term side-effects.  In one UK-based randomised trial 
comparing conventional radiotherapy (control) with IMRT, IMRT was shown to reduce 
radiation-induced xerostomia i.e. dry-mouth (the most common long-term side effect of 
standard radiotherapy), from 75% to 39% twelve months post-treatment 48. A further type of 
radiation therapy used to treat HNC is Interstitial/intracavitary brachytherapy, which delivers 
radiation directly to the tumour using removable implants (radioactive needles, wires or 
seeds) 42. Again, this approach can spare nearby critical structures such as the brain, spinal 
cord and eyes, from excessive radiation doses. Brachytherapy is often used in combination 
with externally delivered radiotherapy, or to treat recurrent cancers.   
2.6.2. Treating locally advanced cancer 
People with locally advanced tumours of the head and neck (stages III-IV, excluding T4b 
tumours) are usually treated by surgery combined with post-operative chemoradiation.  
As a single modality, chemotherapy has not been found to be effective in curing HNC, but 
when administered concurrently with radiotherapy, chemotherapy has been found to improve 
locoregional control and survival, with an absolute survival benefit of around 6.5% at five 
years (compared to radiotherapy alone) 49. Chemotherapy also plays an important role in the 
palliative treatment of HNC, to relieve symptoms and improve QoL.  The most commonly 
used chemotherapeutic agents are cisplatin (cis-diamminedichloroplatinum), and carboplatin 
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(a derivative of cisplatin), which have similar modes of action.  They crosslink with 
deoxynucleic acid (DNA), inhibiting DNA repair mechanisms, which ultimately results in 
apoptosis, or cell death.  
 
When treating recurrent or metastatic cancers, platinum-based chemotherapy is often 
augmented with a drug called Cetuximab  (also known by its brand name Erbitux) 50.  
Cetuximab is a recombinant monoclonal antibody (mAB) that binds with high affinity to the 
human epidermal growth factor receptor (EGFR), which is overexpressed in more than 90% 
of HNCs 51.  Binding inhibits the proliferation of cancer cells, which depend on EGFR 
activation for growth 52. Cetuximab is often referred to as a “targeted drug”, in that it is 
directed specifically towards molecules that promote the proliferation of cancer cells, in 
contrast to standard chemotherapy or radiotherapy, which act systemically. The treatment 
efficiency of Cetuximab is relatively low however, around 36% in combination with 
chemotherapy. 
 
2.7. Summary  
HNC can occur at a large number of subsites including the lip, mouth and pharynx.  The 
presenting symptoms vary depending on the site of the primary tumour but include 
hoarseness, difficulties swallowing and pain in the middle ear.   The diagnosis is usually 
confirmed by biopsy of the primary site and FNA of any enlarged lymph nodes. If 
inconclusive, an open excisional biopsy may be performed.  Imaging is crucial for assessing 
the site and extent of the cancer and contributes substantially to treatment decisions and 
prognosis. The most commonly used modalities are CT and MRI scans. MRI is particularly 
useful for assessing the relationship of cancer boundaries to normal anatomical structures 
and, unlike CT, it does not use damaging ionizing radiation; however, artefacts from 
swallowing, breathing and coughing can limit the quality of MRI. HNC staging is done 
according to the AJCC and UICC classification system, an anatomically-based system 
based on the extent of the tumour (T), the extent of spread to the lymph nodes (N), and the 
presence or absence of metastasis (M). Small, early-stage tumours are typically treated with 
radiotherapy or surgery, whilst larger, more advanced cancers are treated with surgery and 
post-operative chemotherapy, though the particular location of the tumour and the likely 
long-term sequelae usually determine the decision on management. Inoperable cancers may 
be treated with combinations of chemo- and radiotherapy, but in some situations only the 
symptoms of disease can be treated. The distribution, patterns and determinants of HNC are 
discussed in the next chapter. 
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Chapter 3: Head and neck cancer epidemiology, 
biomarkers and prognosis 
3.1. Introduction  
Chapter two provided a general introduction to HNC, a diverse group of tumours that arise in 
epithelial lining of the upper digestive tract. The ways in which these cancers are diagnosed 
and treated was described and the main risk factors for development were briefly mentioned.  
This chapter reviews the epidemiology of the disease, and reports on previously studied 
epigenetic and metabolomic biomarkers and other prognostic factors. It begins with an 
overview of HNC prevalence, incidence and mortality, focusing mainly on the most common 
HNC sub-sites. A more in-depth discussion of the major risk factors is then provided.  The 
final section of this chapter focusses on factors that have been purported to influence HNC 
outcomes and which may provide prognostic value, including epigenetic and metabolomic 
biomarkers, and lifestyle factors.   
3.2. Prevalence of head and neck cancer 
HNC is the sixth most common malignancy in the world today, with more than 550,000 
cases reported annually 53. The actual prevalence of the disease, i.e. the number of people 
living with HNC, is difficult to determine because cancer registries are not compulsory in 
many developing countries where the burden of disease is high e.g. India  54-59.   For this 
reason, It has been suggested that what appears in the literature is only the ‘tip of the 
iceberg’ 58.  In the UK alone, where HNC accounts for 3% of all cancers (compared to an 
estimated 30% of cancers in India 60), there were 62,500 people living with a diagnosis of 
HNC in 2015.  More than half of these people were aged 65 years or older 61. The majority of 
people living with HNC in the UK have lip and oral cavity cancers, with an estimated 5-year 
prevalence rate of 31.1 per 100,000 (Table 4). Oropharyngeal and laryngeal cancer are the 
next most common HNCs with 5-year prevalence rates of 20.8 and 12.3 per 100,000 
persons respectively 62.  A similar pattern of prevalence is seen across Europe and the USA 
e.g. the corresponding rates for oral cavity, oropharyngeal and laryngeal cancer in the USA 
are 27.0, 17.4 and 16.7. 
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Table 4: Estimated number of prevalent cases of HNC in the UK (2018) as a proportion, 
ages 20-85+ years. 
 Overall   Males   Females 




















cavity 8.5 21.2 31.1  11.5 28.6 42.0  5.6 14.2 20.9 
Oropharynx 5.2 13.8 20.8  8.1 21.1 31.8  2.4 6.8 10.2 
Larynx 3.3 8.3 12.3  5.5 13.9 20.6  1.2 3.1 4.7 
Salivary 
gland 1.0 2.4 3.3  1.1 2.7 3.8  0.9 2.1 3.0 
Hypopharynx 0.9 1.8 2.3  1.5 2.9 3.6  0.4 0.8 1.0 
Nasopharynx 0.4 1.0 1.6  0.6 1.6 2.4  0.2 0.5 0.8 
 
Proportions per 100,000. Figures based on GLOBOCAN 2018 projections 62.
3.3. HNC Incidence rates 
Cancer incidence refers to the number of new cases of cancer reported in the population per 
unit time. It is usually expressed as the number of cases per 100,000 person years at risk 63. 
This is termed the crude incidence rate.  When examining cancer trends, crude incidence 
(and prevalence) rates can be misleading if the populations or geographic regions under 
consideration have different age profiles.  For instance, if two equally sized countries - A and 
B, report identical numbers of cancer but country A has a much younger age structure than 
B, then the incidence rate in A would in effect be higher because the likelihood of developing 
cancer increases with age 64. Consequently, incidence rates are often calculated as age-
standardised rates (ASR) 65 66 to allow direct comparisons. 
3.3.1. UK incidence rates  
In the UK, there are around 13,500 new cases of HNC diagnosed each year 62, making it the 
eighth most commonly diagnosed cancer 67. Consistent with the prevalence, most of these 
cases (80-90%) occur in the oral cavity, oropharynx and larynx 64. The number of incident 
cases is much higher in males than in females, with over two-thirds (70%) of all cases 
occurring in men 64.  The exact ratios of males to females differs by anatomical subsite 
(Table 5).  Laryngeal cancer has a particularly high incidence among males, with a male: 
female ratio of around 3:1.
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Table 5: UK estimated age-standardised incidence rates of head and neck cancer by site and 
gender, all ages (2018). 
  Numbers ASIR  
ICD Cancer All Males Females All Males Females 
C00-06 Lip, oral cavity 6 087 3 880 2 207 5.0 6.8 3.3 
C32 Larynx 2 482 2 010 472 1.9 3.2 0.7 
C11 Nasopharynx 269 199 70 0.3 0.4 0.1 
C09-10 Oropharynx 3 049 2 313 736 2.9 4.6 1.3 
C12-13 Hypopharynx 782 612 170 0.6 1.0 0.2 
C07-08 Salivary gland 803 482 321 0.7 0.8 0.6 
 Total 13,472 9,496 3,976    
 
Figures based on GLOBOCAN 2018 projections 62. Abbreviations: ICD, international classification of 
diseases; ASIR, age-standardised rates per 100,000, calculated using the direct method and the 
world standard population 68.
 
There are notable regional differences in HNC incidence, as illustrated in Figure 7.  Northern 
England has higher incidence rates in both males and females compared to the rest of England 69-71, 
whilst Scotland has higher incidences than the rest of the UK.  In 2015, the European ASIR for HNC 
in Scotland was 24.6 (37.0 for males and 13.8 for females), compared to 19.2 for England (28.1 for 
males and 11.2 for females) 67.   
 
Incidence patterns of HNC likely reflect differences in the use of tobacco and alcohol, two of the 
major established risk factors for HNC.  In England, an estimated 15.8% of the UK adult population 
smoke tobacco 72 and 21% drink excessive amounts of alcohol (more than 14 units a week) 73, but 
the prevalence of these high-risk behaviours is not distributed equally 74-77.  A north–south divide, 
which is explained to some extent by socioeconomic inequalities 78 79, has been reported for 
smoking, with higher rates observed in northern regions of the country 77 80.  Similarly, in Scotland, 
the vast majority of people developing HNC come from the most disadvantaged areas where the 
prevalence of tobacco use is high 80-82. For alcohol drinking, a more complex pattern exists, with 
lower rates of excessive consumption in central and eastern regions of England and an east versus 




Figure 7: Geographical distribution of oral cavity, oropharyngeal and laryngeal cancer 
incidences, UK (2007-2009). 
 
 
Incidence data are displayed using directly age-standardised rates. Rates are presented per 
100,000 population, using European population as standard. Credit: National Cancer 
Information Service (NCIS) 83. 
 
As stated previously, HNC is strongly related to age.  In UK males, there is a sharp upward 
trend in incidence rates (all sites combined) between the ages of 35-39 years, after which 
point rates increase more steadily, eventually peaking at around 70-74 years (Figure 8).  In 
females, there is a much more gradual rise in incidence rates from the age of 35-39 years, 
with most HNC cases occurring in the 90+ age group 64 (Figure 8).  Overall, for both sexes 
combined, more than a fifth (22%) of all cases in the UK are diagnosed in people aged 75 
years or older 64.  
 
The number of cancer registrations reported across different age groups differs between 
subsites. According to the Office for National Statistics (ONS), most laryngeal cancer 
registrations in England occur between the ages of 70-74 years in males and 65-74 years in 
females; for lip, oral cavity and pharyngeal cancer, the majority of new cases for both males 
and females occur between the ages of 65-69 years; and for oropharyngeal cancer, most 
registrations occur between the ages of 60-64 years in males and 70-74 years in females 71. 
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Figure 8: Average number of incident cases of HNC per year and age-standardised 
incidence rates per 100,000 persons in the UK (2013-2015). 
 
 
Data is for ICD-10 C00-C14, C30-C32. Credit: CRUK 64
 
3.3.2. Global variations in incidence rates 
Table 6 presents the estimated global age-standardised incidence rates (ASIR) of HNC by 
site and gender based on the world population. As will be demonstrated below, however, 
there is substantial variation in the anatomic distribution of HNC, both between countries and 
within them and this is largely driven by differences in the distribution of risk factors.  
 
A full description of HNC incidence rates by site, country and region is outside the bounds of 
this thesis but the next section provides an overview of some of the major global patterns.  
An emphasis is placed on the most common anatomical sites (i.e. oral cavity, oropharynx 
and larynx) but other HNCs will be discussed in brief. Where the term “oral cancer” is used, 
ICD codes will be provided in brackets since there is inconsistency in the literature regarding 
the definition of this term. Unless otherwise stated, ASIRs are derived from GLOBOCAN 
2018 projections 62 and represent the ASIR per 100,000 world population (all ages).
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Table 6: Global estimated age-standardized incidence rates of head and neck cancer by site and 
gender, all ages (2018). 
 Number ASIR  
Cancer site  All Males Females All Males Females 
Lip, oral cavity 354 864 246 420 108 444 4.0 5.8 2.3 
Larynx 177 422 154 977 22 445 2.0 3.6 0.5 
Nasopharynx 129 079 93 416 35 663 1.5 2.2 0.8 
Oropharynx 92 887 74 472 18 415 1.1 1.8 0.4 
Hypopharynx 80 608 67 496 13 112 0.9 1.6 0.3 
Salivary gland 52 799 29 256 23 543 0.6 0.7 0.5 
Total 887,659 666,037 221,622    
 
Figures based on GLOBOCAN 2018 projections 62. Abbreviations: ICD, international classification of 
diseases; ASIR, age-standardised incidence rates per 100,000, calculated using the direct method 
and the world standard population 68.
 
3.3.2.1. Lip and oral cavity cancer 
As illustrated in Figure 9 (a.), a particularly high incidence of lip and oral cavity cancer can be seen 
in South and Southeast Asia (e.g. India, Pakistan and Bangladesh). Among Indian males 
specifically, ASIRs of lip and oral cavity cancer surpass those for any other cancer (AISR of 13.9), 
whilst in Indian females they ranked as the third most commonly diagnosed malignancies after 
breast and cervical cancer, with an ASIR rate of 4.3 62.   
 
The aetiology of lip and oral cavity cancer in Southern Asia is dominated by tobacco use, especially 
smokeless tobacco use 84.  Of the 42.4% of men and 14.2% of women in India who use tobacco, 
29.6% and 12.8% use smokeless tobacco, respectively 85. Smokeless tobacco products such as 
betel quid/areca nut, gutkha and mishri, are often held in the mouth for extended periods of time 
causing prolonged exposure to carcinogenic tobacco-specific nitrosamines 86 87. Their use is most 
common among people living in rural and low-income communities-both male and female 88. 
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Figure 9: Global incidence of HNC, by sub-site. 






All of the above maps present the estimated ASIRs in both sexes, all ages. Credit: GLOBOCAN 
2018 Graph production: IARC (http://gco.iarc.fr/today) World Health Organization. 
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Alcohol drinking is also a risk factor for oral cavity cancer in this region, although it plays less 
of a significant role than tobacco use. In a meta-analysis looking at the magnitude of the 
effect of tobacco smoking, betel quid chewing and alcohol drinking on oral cancer (ICD-10, 
codes C00–C06, C09, C10) in Southeast Asia (n=59,000), the pooled odds ratio (OR) for 
alcohol drinkers was 2.2 (95% CI: 1.6 to 3.0), compared to 3.6 for smokers (95% CI: 1.9 to 
7.0) and 7.9 (95% CI: 6.7 to 9.3) for smokeless tobacco users.  Among smoking-drinking-
chewing subjects, the odds ratio increased to 40.1 (95% CI: 35.06 to 45.83) 89, suggesting 
an interaction effect.  
 
The prevalence of alcohol drinking in Southern Asia is relatively low overall 90 (Figure 10), 
largely due to religious and cultural practices.  In many rural areas however, alcohol 
consumption rates are high 91 and therefore the proportions of oral cavity cancers attributed 
to alcohol use are expected to be greater. Low fruit and vegetable intakes and poor oral 
hygiene have also been suggested as important risk factors for oral cavity cancer among 
these communities 92 93. 
 
Outside South and Southeast Asia, Europe has some of the highest rates of lip and oral 
cavity cancer.  Of all the European countries, Hungary has the highest incidence rate overall 
(7.5), with high rates also noted in Latvia (6.9) and France (6.3). As illustrated in Figures 10 
and 11, the prevalence of alcohol drinking and tobacco smoking in Europe are also high 94 95. 
In Hungary for instance, 32% of men and almost 25% of women smoke; the rate among 
Latvian men is even higher at 48.9%. These figures are above the average for high human 
Development Index (HDI) countries 96 and probably explain, to some extent, the high 
incidence rates of oral cavity cancer in these countries.   
 
In Hungary and in a few other countries of eastern Europe (e.g. Bulgaria, Poland and 
Romania), the high incidence of lip and oral cavity cancer have been linked both to the 
pattern of alcohol consumption and the type and quality of alcohol consumed 97. Specifically, 
heavy episodic drinking or “binge drinking” (defined as drinking 60 grams or more of pure 
alcohol on at least one single occasion at least once per month 94), and the consumption of 
home-produced wines and spirits is very common. Homemade alcoholic beverages often 
contain high levels of acetaldehyde 97 which, as will be discussed later, is an established 
human carcinogen.   
 
Australia also has a high incidence of lip an oral cavity cancer. In addition to tobacco and 
alcohol exposure, solar radiation (especially to the lips), is a significant risk factor for disease 
in this region 55. 
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Figure 10: Total alcohol per capita consumption (15+ years; in litres of pure alcohol), 
2016. 
 
Credit: WHO 98 
 
Figure 11: Global prevalence of tobacco smoking among persons aged 15 years and 
older (2015). 
 
Age-standardised prevalence of tobacco smoking (%) per 100,000. 




3.3.2.2. Oropharyngeal cancer 
Regions with the highest rates of OPC include Europe, Northern America, parts of South 
America (e.g. Paraguay, Brazil and Venezuela) and Australia (Figure 9b.). Within Europe, 
Hungary, Denmark and France have the highest ASIRs overall at 4.7, 4.5 and 4.4, 
respectively.  This compares to the UK incidence rate of 2.9.  Rates in the USA and Australia 
are broadly comparable to those in the UK (USA, 2.4; Australia 2.5).  In all of these 
countries, the incidence of OPC is much higher in males than in females.  In the USA for 
example, the ASIR for males is 4.1 compared to 0.8 in females whilst in Hungary and Brazil, 
the corresponding rates are 7.3 and 2.4 and 3.3 and 0.6.  
 
Consistent evidence suggests that two main types of OPC exist; the first, which is common 
in developing countries, is driven by tobacco and alcohol use; the second, which is common 
in developed countries (e.g. Northern America and Europe), is driven by HPV infection 100 101. 
In Europe, the estimated fraction of OPCs attributable to HPV ranges from 24% (95% CI: 17 
to 30) in Southern Europe to 50% (95% CI: 39 to 57) in Eastern Europe 101, whilst in 
Northern America and Australia, the HPV-attributable fractions (AFs) are 51% (95% CI: 41 to 
57) and 41% (95% CI: 32 to 47%), respectively.  The estimated proportion of OPCs 
attributed to HPV in Latin America is comparatively low at 13% (95% CI: 5 to 23), however, 
the prevalence of HPV has not been determined in many regions, including Brazil 102. 
3.3.2.3. Laryngeal cancer 
South America and Eastern Europe (e.g. Montenegro, Republic of Moldova and Hungary) 
are characterised by high incidence rates of laryngeal cancer (Figure 9 c.). Cuba has the 
highest incidence rates overall (8.9), and among males (16.2), whilst among females, the 
highest incidence rates correspond to Montenegro (3.4), Hungary (2.0) and Cuba (1.9). 
Tobacco use is the greatest single risk factor for the development of laryngeal cancer 103 104, 
although alcohol consumption is also independently associated 104-106 and their combined 
use interacts in a multiplicative way 107, as will be discussed later in this chapter. The 
prevalence of tobacco smoking in Cuba is high at around 43% for men and 27% for women 
108, which again likely accounts for the high incidence rates in this country. In fact, in 1995 
and 2007, 82% and 84% of laryngeal cancers in Cuban males and 78% and 54% in Cuban 
females, respectively, were attributed to tobacco smoking 109. As noted above, the 
prevalence of tobacco use in Eastern Europe is also high 110 (Figure 11). In Montenegro for 
example, where laryngeal cancer incidence is high in both males and females, 37.6% of men 
and 29.4% of women smoke.  
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3.3.2.4. Other HNC sites 
Consistent with the high prevalence of tobacco and alcohol use, the country with the highest 
incidence of hypopharyngeal cancer, both overall and in sex-specific analyses, is 
Bangladesh (ASIRs: overall, 5.1; males, 8.6; females, 1.5). Hungary also has a high 
incidence among men (6.5).  
 
A disproportionally high incidence of nasopharyngeal cancer (NPC) can be seen in 
Southeast Asia, especially China. For all of Southeast Asia combined, the incidence rate is 
6.4 cases per 100,000 males and 2.0 per 100,000 females 111. These rates may sound low 
but globally NPC is relatively rare with an estimated ASIR of 1.5 (2.2 for males and 0.8 for 
females) (Table 5).  Intake of preserved foods such as salted fish and foods containing 
volatile nitrosamines at an early age has been linked to NPC risk in this population 112-114. 
Other recognised risk factors include smoking, Epstein Barr virus, the use of traditional 
herbal medicines and occupational exposures to formaldehyde, wood dust, smoke, and 
chemicals 115. High rates of NPC are also seen in Northern Africa. In Morocco for instance, 
NPC is the most common HNC, accounting for 7–12 % of all cancers in men  116. Dietary 
factors such as the consumption of rancid butter, rancid sheep fat and preserved meats like 
quaddid (dried mutton stored in oil) have been found to be associated with an increased risk 
of NPC in this region 117. 
 
Salivary gland cancer is a rare cancer globally (Table 6), however the highest incidence 
rates are found in Sweden (3.0) and Finland (2.0). The reasons for this are unclear as the 
aetiology of the disease is not well defined-largely because it is so uncommon. Unlike the 
majority of HNCs however, tobacco and alcohol use have not been strongly associated with 
salivary gland cancer 118 119. The only well-established risk factor is Ionizing radiation, though 
some studies have suggested links between salivary gland cancer and occupational 
exposures, tobacco, ultraviolet light, and viruses 119-121. The possibility of a viral aetiology 
seems plausible as salivary gland carcinoma is often observed in immunosuppressed 
individuals 119.  
3.4. Trends in head and neck cancer incidence rates 
Over the last few decades, there has been a dramatic change in HNC incidence trends by 
sub-site, country and gender and this has been attributed to a change in the prevalence of 
risk factors (i.e. tobacco use, alcohol consumption and HPV infection)  122 123.   
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3.4.1. UK trends in incidence rates 
Overall, HNC incidence rates have increased by a third (33%) in the UK since the early 
1990s 64 (Figure 12). The increase has been larger in females than in males. Between 1993-
1995 and 2015-2017 the ASI rates increased by 43% in females and 23% in males.  
 
In contrast to the overall trend in HNC incidence rates, laryngeal cancer incidence rates 
have declined by 20% since the early 1990s, consistent with a reduction in the use of 
tobacco products though (Figure 13), rates have levelled off more recently 124 125. The overall 
increase in HNC incidence rates is largely attributed to a rise in oral cavity cancer rates. 
Between 2002 and 2011, there was a 25% increase in rates of oral cavity cancer, with rates 
having risen faster for women than for men 70.  One possible explanation for this is that, 
whilst smoking rates have decreased overall in the UK over the past 50 years or so, there 
was a lag in the ‘adoption, diffusion and abatement’ of cigarette use among women 126 127 
(Figure 13), meaning that these birth cohorts of women are only now reaching the high-risk 
age group for HNC. Specifically, consumption rates peaked among men in the mid-1960s 
but continued to increase among women up until the mid- to late-1970s 126 127. 
 
Another possible explanation for the recent increase in oral cavity cancer in the UK (and in 
several other European countries) is that alcohol consumption rates are currently at an 
historical high.  Between the mid-1950s and late 1990s, the number of litres of alcohol 
consumed per person in the UK more than doubled 128, rising from around 4 litres per head 
in 1957 to 8.1 litres per head in 1997 129.   Alcohol drinking is now on a downward trend, 
having peaked at 11.6 litres per head in 2005  (per capita consumption in the WHO 
European Region peaked at 12.2 litres in 2005 130), but rates remain high, especially among 
women 128.  For this reason, it has been suggested that the number of oral cavity cancers will 
continue to rise over the next decade or so 131.
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3.4.2. Global trends in incidence rates 
According to a review of 83 international cancer registries conducted by Simard et al (2014) 
123, rates of oral cavity cancer increased among both men and women in 7 out of 37 
countries between the periods of 1987-1993 and 1998-2002.  These countries were located 
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in Europe and Asia and included the Czech Republic, Slovak Republic, Denmark, Estonia, 
Finland, the UK and Japan. Among men, the largest increase in rates was found in Finland 
(Rate ratio [RR]= 1.61, 95% CI: 1.39 to 1.86), while Spain had the largest increase in rates 
among women (RR= 2.23, 95% CI: 1.73 to 2.88).   These findings are in-line with the 
literature which suggests a trend for increased rates of oral cavity cancer in some eastern 
and northern European countries 55 97 133 134, where similar patterns of cigarette smoking to 
the UK have been observed 135. In other southern, central and eastern European countries, 
cigarette smoking is either still increasing among women or it has stabilised 136.  
 
Several studies have also reported an increase in the incidence of OPC, predominantly in 
economically developed countries.  In one study conducted by Chaturvedi et al (2013), 
which used data from 70 registries in 23 countries across four continents, there were 
substantial increases in OPC incidence among men in several developed countries including 
the UK, USA, Canada, Australia, Denmark, Slovakia, and Japan; among women increases 
were observed exclusively in European countries (Denmark, Estonia, France, the 
Netherlands, Poland, Slovakia, Switzerland, and the UK) 137.  There were no significant 
increases in economically developing countries in South/Central America and Asia (e.g. 
Colombia, Costa Rica, Ecuador, India, the Philippines, Thailand). These findings are broadly 
consistent with those of Simard et al., who observed a trend for increased incidence of OPC 
in several eastern and northern European countries (Belarus, Czech Republic, Denmark, 
Finland, Norway, Sweden, and the UK), and a trend for decreased OPC incidence in China 
(Hong-Kong registry) and in parts of India (registry of Mumbai). 
 
As mentioned previously, the main risk factors for OPC are tobacco, alcohol use and HPV 
infection.  The recent increase in OPC incidence in developed countries has largely been 
attributed to an increase in the prevalence of HPV-associated cancers 123 137.  It is thought 
that generational changes in sexual behaviour, including the “sexual revolution” of 1960-
1980, led to an increase in the transmission of oncogenic HPV 138, the details of which will 
be discussed shortly. 
 
With respect to global trends in laryngeal cancer incidence, there is less evidence available. 
In the USA, the number of new laryngeal cancer cases has been falling by approximately 
2.4% each year over the last 10 years. As is the case in the UK, this is consistent with a 
reduction in the prevalence of smoking 139. According to The Surveillance, Epidemiology, 
and End Results (SEER) Program, the number of new laryngeal cancer cases fell from 5.2 
per 100,000 American men and women in 1975 to 2.7 in 2015. In contrast, the above study 
by Simard et al found some evidence of an increase in laryngeal cancer instance in some 
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European countries (Belarus, Estonia and Latvia) over the last few decades.  In this study 
however, the authors considered laryngeal cancer cases alongside other poorly-specified 
tumours of the lip/oral cavity, pharynx and hypopharynx (laryngeal cancers accounted for 
over two-thirds of all cases), and therefore additional studies focusing exclusively on 
laryngeal cancer instances are needed in order to confirm international trends. 
3.5. Mortality rates 
3.5.1. UK mortality rates 
According to CRUK figures, the number of people who died from HNC in the UK in 2016 was 
4,046 140. Mortality rates in Scotland are higher than the UK average - 9.4/100,000 
compared to 6.3/100,000 for England, Scotland and Wales combined. This reflects the 
higher incidence rate in this country. For the UK as a whole, between 1971-1973 and 2014-
2016, there was an 11% decrease in European age-standardised mortality rates (Figure 14). 
However, mortality rates increased by 14% between the period of 2004-2006 and 2014-
2016.   
 
Mortality trends have varied by age, gender and sub-site.  In UK males, rates have remained 
stable in the 25-49- and 60-69-year age groups, increased by 18% in the 50-59-year group 
an (Figure 15) 140. In females, rates have decreased in most broad (adult) age groups, with 
the exception of the 60-69-year age group, in which rates have remained stable (Figure 16). 
Laryngeal cancer mortality rates fell by 33% between the period of 1990 to 2002 125.  This 
may just reflect the fall in incidence rates in the UK, but it could also reflect changes in stage 
at presentation and treatment.   By comparison, OPC mortality rates increased, though the 
increase in mortality rates is less significant than the increase in the incidence rates. It has 
been suggested that this is a result of the use of more effective treatments and combined 
therapy which have improved survival 125. With regards to oral cavity cancer mortality, rates 
remained static during the same period.
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Figure 14: Head and neck Cancer mortality trends over time in the UK (1971-2016). 
 
European age-standardised mortality rates per 100,000 population. Includes ICD C00-C14, 
C30-C32 Credit: CRUK 140
 
Figure 15: Head and neck cancer European age-standardised mortality rates, by age, in UK 
males (1971-2016). 
 




Figure 16: Head and neck cancer European age-standardised mortality rates, by age, 
in UK females (1971-2016). 
 
Includes ICD C00-C14, C30-C32. Credit: CRUK 140.|
 
 3.5.2. Global mortality rates 
Globally, it is estimated that HNC is responsible for around 450,000 deaths each year 62.  Of 
these deaths, approximately 177,000 are attributed to lip and oral cavity cancers (age-
adjusted mortality rates of 2.0/100,000), 95,000 to laryngeal cancers (1.0), 73,000 to 
nasopharyngeal cancers (0.8), 51,000 to oropharyngeal cancers (0.6), 35,000 to 
hypopharyngeal cancers (0.4) and 22,000 to cancers of the salivary glands (0.2) 62. It is 
important to note however that, in addition to the difficulties already highlighted at the 
beginning of this chapter regarding the availability of reliable incidence and mortality data, 
establishing cause of death in long-term survivors of HNC is problematic and therefore 
figures represent a best estimate of the number of deaths.  Other competing causes of death 
in people with HNC include second primary malignancy, cardiovascular and pulmonary 
disease 141. 
3.6. Major risk factors for HNC 
The following section discusses the causal role of the major known risk factors for HNC.  
The WHO describe a risk factor as “any attribute, characteristic or exposure of an individual 
that increases the likelihood of developing a disease or injury” 142. As mentioned already in 
this chapter, tobacco and alcohol intake are two of the most well-established risk factors for 
67 
 
HNC, most notably for cancers of the oral cavity, pharynx, and larynx, although cancers of 
the nasal cavity and paranasal sinuses have also been causally related to tobacco use 143.   
Based on data from the INHANCE consortium of case-control studies (18 studies including 
11,221 oral cavity, oropharyngeal and laryngeal cancer cases and 16,168 controls), Hashibe 
et al (2009) estimate that tobacco and alcohol use account for 33% and 4% of HNCs 
individually 144. The effects associated with both tobacco and alcohol use were found to be 
greater than additive. That is, the combined effect of smoking and alcohol-drinking are more 
harmful than the individual effects of each exposure. Specifically, the total population 
attributable risk (PAR) for tobacco and alcohol combined was 72%.  There were differences 
by subsite.  The joint effects of tobacco and alcohol were responsible for 89% of laryngeal 
cancers, 72% of pharyngeal cancers and 64% of oral cavity cancers. Differences were also 
observed between genders. Among males, the total PAR for tobacco and alcohol was 74% 
compared to 57% among women.  
 
Although tobacco and alcohol use are responsible for the majority of HNCs, a substantial 
proportion of cases cannot be attributed to these exposures. Tumours may occur in non-
smoking, non-drinking individuals 145-147 and only a fraction of those who do smoke and drink 
develop tumours. This suggests that additional risk factors may be independently involved or 
act as co-factors for the development of HNC. HPV has already been mentioned as an 
important aetiological factor for OPC; its role in development of HNCs outside the 
oropharynx is less well-established 148.  Other recognised risk factors that will be discussed 
further include Epstein-Barr virus (EBV), low fruit and vegetable intake, low physical activity 
levels, poor oral and dental hygiene, a family history of cancer and genetic factors. 
Additional risk factors, including prolonged sun exposure 149 and certain occupational 
exposures 150-152 do exist,  but will not be considered further in this thesis.  
3.6.1. Tobacco use 
There are a wide variety of tobacco products, including rolls of tobacco that are smoked (e.g. 
cigarettes, cigars, bidi), oral preparations which are chewed, held in the mouth or placed in 
the nose (e.g. snuff, snus, betel quid), and pipes, including water pipes 153.  Within the UK, 
cigarette smoking, hereafter referred to as “smoking,” remains the most widely used form of 
tobacco use. In a pooled analysis of 15 case-control studies that included 10,244 HNC 
cases and 15,227 controls, Hashibe and colleagues found that, among never drinkers, 
cigarette smoking was associated with a two-fold increased risk of HNC (OR for ever versus 
never smoking= 2.13, 95% CI: 1.52 to 2.98) 154. There was further evidence of dose-
response relationships for frequency, duration, and number of pack-years of smoking. Even 
68 
 
for the lowest category of smoking (1-10 cigarettes per day) the risk was almost two-fold (OR 
= 1.82; 95% CI:1.28 to 2.59). When the risks were examined for specific subsites, laryngeal 
cancer was most strongly associated with cigarette smoking (OR= 6.84; 95% CI: 4.25 to 
11.01) followed by OPC (OR= 2.02; 95% CI: 1.34 to 3.05) and oral cavity cancer (OR= 1.35; 
95% CI: 0.90 to 2.01). In a separate analysis of data from the INHANCE consortium (1761 
laryngeal, 2453 pharyngeal and 1990 oral cavity cancer cases and over 8,000 controls), 
Lubin et al (2009) assessed the risk by total exposure (measured in pack-years of smoking) 
and its modification by exposure rate (number of cigarettes per day). Their results suggest 
that smoking more cigarettes per day for a shorter period of time is less harmful than 
smoking fewer cigarettes per day for a longer period of time (above 15 cigarettes/day). 
Quitting smoking has been reported to reduce the risk of HNC 155-161. Using data from 17 
studies on smoking cessation (12 040 cases and 16 884 controls), Marron et al (2010) found 
that, compared to current smokers, those who abstained from smoking for 1-4 years 
experienced a reduction in risk of HNC (OR= 0.70; 95% CI: 0.61 to 0.81). For people who 
quit smoking for 20 years or more, the reduced risk of HNC was similar to that of never-
smokers (OR= 0.23, 95% CI: 0.18 to 0.31) 156. 
 
The smoke exhaled by a smoker, termed the mainstream smoke, contains around 4,800 
identified compounds, 69 of which are known to be carcinogenic (cancer-causing) 162. Some 
of these carcinogens occur naturally in the tobacco plant, whilst others are formed during 
combustion of the cigarette.  A detailed discussion of the mechanisms by which these 
compounds induce carcinoma is beyond the scope of this review. However, the formation of 
DNA adducts are recognised as being central to the process of carcinogenesis 163 164.  When 
tobacco carcinogens (or their metabolites) bind covalently to DNA to form DNA adducts, this 
disrupts the double helical structure of DNA and interferes with its replication.  Cells have 
evolved a number of cellular repair systems, including base and nucleotide excision repair, 
mismatch repair, and double-strand break repair, which can remove DNA adducts to 
conserve the normal DNA structure 165. If repair enzymes are unable to function efficiently 
however, and the DNA adducts persist, this can result in miscoding (e.g. insertion of the 
incorrect base) and permanent mutations.  Should these mutations occur at susceptible sites 
in the genome, such as in proto-oncogene (e.g. K-ras) or tumour suppressor genes (e.g. 
p53), this can lead to loss of normal growth control and ultimately, the development of 
tumours 163 166. The situation is made worse by the presence of other chemicals in cigarettes, 
such as chromium, arsenic and nickel.  Chromium allows compounds like benzo(a)pyrene to 
bind to DNA more strongly, whilst arsenic and nickel interfere with DNA repair pathways 167. 
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3.6.2. Alcohol use 
Among never users of tobacco, Hashibe et al (2007) found that alcohol drinking was 
associated with a two-fold increased risk of HNC, but only in people who consumed three or 
more alcoholic beverages per day (OR= 2.04; 95% CI: 1.29 to 3.21 vs never drinkers) 154.  
When the analysis was stratified by cancer subsite, there were monotonic relationships 
between pharyngeal (including oropharynx and hypopharynx) and laryngeal cancer risk and 
frequency of alcohol consumption. For pharyngeal cancer, increased risks were observed for 
those drinking one to two drinks per day (OR= 1.66; 95% CI: 1.18 to 2.34), while for 
laryngeal cancer, an increased risk was observed for those drinking five or more drinks per 
day (OR= 2.98; 95% CI: 1.72 to 5.17). 
 
In contrast to their results for smoking, Lubin et al observed that, for subjects consuming 10 
drinks per day or less (above 10 drinks per day, data were limited), the strength of the HNC 
risk association with total exposure (years of alcohol drinking) increased with increasing 
exposure rate (number of alcoholic drinks per day), suggesting that greater drinks per day 
for a shorter period of time was more harmful than fewer drinks per day for a longer period of 
time 168. Excess odds ratio (EOR) per drink year estimates varied by site. The risk was 
greatest for oral and pharyngeal cancer.   
 
Marron et al (2010) found that quitting alcohol drinking was also associated with a reduction 
in the risk of HNC (OR= 0.60; 95% CI: 0.40 to 0.89 compared with current drinking), but the 
benefits were only observed after >20 years of abstaining (compared to 1 to 4 years for 
smoking cessation) 156. The risk reversal after quitting drinking for ≥20 years is observed 
across all subsites of HNC (oral cavity, oropharynx and larynx).  
 
Using data from the INHANCE consortium, Purdue et al (2009) sought to understand the 
risks associated with consuming different types of alcoholic beverages 169. Specifically, they 
calculated associations of HNC with different measures of beverage consumption in people 
who drank beer only (858 cases, 986 controls), spirits only (499 cases, 527 controls), and 
wine only (1,021 cases, 2,460 controls), using never-drinkers (1,124 cases, 3,487 controls) 
as the reference category. The authors observed similar associations with HNC among beer-
only and spirit-only drinkers; among beer-only drinkers, ORs were 1.6, 1.9, 2.2, and 5.4 for 
subjects who drank ≤5, 6–15, 16–30, and >30 ethanol-standardized drinks per week (p 
trend < 0.0001); among spirit-only drinkers, the corresponding ORs were 1.6, 1.5, 2.3, and 3.6 
(p < 0.000). For wine-only drinkers, ORs for moderate levels of consumption (≤5 and 6–15 
drinks per week) were close to null and increases in risk were only observed at higher 
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consumption levels (ORs: 1.9 and 6.3 for 16–30 and >30 standard drinks per week 
[p < 0.000], respectively). The authors provide several possible explanations for the 
observed weaker association with moderate wine consumption. Firstly, it may be the result 
of residual confounding e.g. wine consumption has been associated with higher intake of a 
healthy diet but they were unable to adjust for this in their analysis 170-172; secondly, they 
propose a possible “alcohol washing effect” (i.e. the ingestion of foods could modify the 
absorption and effect of alcohol on oral mucosa 173) since wine is more frequently consumed 
with food than other alcoholic beverages; and finally, it is possible that the carcinogenic 
effects of alcohol are offset by other anticarcinogenic compounds found in wine e.g. 
resveratrol 174. 
 
The main constituents of alcohol-containing beverages are ethanol (C2H5OH), water and 
glucose.  Whilst alcohol itself is not a carcinogen, its use can increase cancer risk in two 
main ways.  Firstly, alcohol acts as a solvent to increase the permeability of cellular 
membranes, thereby allowing other carcinogenic compounds (namely those found in 
tobacco smoke), to penetrate the mucosal surfaces of the upper digestive tract 175.  
Secondly, Acetaldehyde, the first metabolite of ethanol, has wide-ranging genotoxic and 
carcinogenic effects.  Amongst other things, acetaldehyde has been shown to: interfere with 
DNA repair mechanisms, for example by inhibiting the enzyme O6-methylguanine 
transferase, which is responsible for repairing DNA damage caused by alkylating agents; 
induce sister chromatid exchanges and gross chromosomal aberrations; introduce point 
mutations, for instance in human lymphocyte cells; and form DNA adducts 176-178. In addition 
to this, chronic alcohol consumption is associated with immune suppression, which may help 
facilitate tumour spread 175 177.  
3.6.3. Human papilloma virus infection  
HPV is one of the most common sexually transmitted diseases. Infections are usually 
asymptomatic, and the virus is cleared from the body within a couple of years.  However, for 
some people, genital HPV infection can result in clinical disease, including anogenital warts, 
cervical cancer and other anogenital cancers (e.g. cancers of the penis, vagina and anus) 
179.  In 2007, in the ninetieth volume of the IARC Monographs on the Evaluation of 
Carcinogenic Risks to Humans, the International Agency for Research on Cancer (IARC) 
concluded that there was sufficient epidemiological evidence to show that HPV is a 
causative factor for malignant transformation in a subset of HNCs 179. They found that HPV 
DNA was consistently detected in a large proportion of OPCs, with an estimated average 
prevalence of 35%. By comparison, HPV DNA was detected in some oral cavity cancers, but 
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the range of detection was wide (average of approximately 25%) and there was limited 
evidence to support the carcinogenicity of HPV in the larynx. The working group point out 
that it is not always possible to determine the precise anatomical location of the primary 
tumour and misclassifications could result in distorted prevalence estimates for individual 
sub-sites. For example, the base of the tongue is inconsistently grouped as either oral cavity 
or oropharynx. Besides differences in anatomical grouping, sample numbers, differences in 
sampling techniques (i.e. frozen, formalin-fixed or paraffin-embedded sections, scraping or 
oral rinses), and different detection methods could all influence estimated prevalence rates 
(133). The various methods of HPV detection will be discussed later in this chapter. 
 
More than 150 different sub-types of HPV are known to exist, but the vast majority of these 
are “low- risk”, meaning that they are of low carcinogenic potential 180 181.  There are 15 
“high-risk” HPV sub-types and of these, HPV 16 is the most common type associated with 
HNC.  Around 90% of HPV-associated HNCs are attributed to HPV 16 182-184, with HPV18, 
31, 33 and 35 making up the remaining cases 182. The majority of these HPV-associated 
HNCs develop in the lymphoid tissue of the oropharynx, which includes the lingual and 
palatine tonsils 185. 
 
All HPV subtypes share a common genetic structure 179 (Figure 17).  They have a small, 
circular, double stranded DNA genome of approximately 8000 base pairs in length, bound 
within a protein capsid 179.  The genomes comprise eight open reading frames (ORFs), each 
of which is transcribed from a single DNA strand. The ORFs correspond to three functional 
regions; an “early” region that encodes regulatory proteins E1-E7, a “late” region that 
encodes capsid proteins L1-L2, and a largely non-coding region that is referred to as the 
long control region (LCR) 179. The LRC contains cis elements that are necessary for viral 
DNA replication and transcription.  The oncogenic nature of HPV is attributed to the 
presence of high-risk E6 and E7 proteins, which cooperate to suppress normal cell cycle 
controls.   Further details of the role of HPV in the pathogenesis of HNC are provided later in 




Figure 17: HPV-16 genome 
 
Image source: Riemer et al (2010) 186. 
 
 
As is the case with cervical and urogenital cancers, HPV infection of the oropharynx (and 
oral cavity), has been shown to be associated with high-risk sexual behaviours, particularly 
oral sex 185. In a hospital-based, case-control study of 100 people with newly diagnosed 
OPCs and 200 controls, D’Souza et al (2007) found that the risk of developing OPC was 
three times greater for people with high lifetime numbers of vaginal- and oral sex partners 
(HR= 3.1; 95% CI: 1.5 to 6.6 for people who had had 26+ partners versus people who had 
has 0-5 partners and HR= 3.4; 95% CI: 1.3 to 8.8 for people who had had 6+ oral sex 
partners versus none) 185.  For people with HPV-16 positive tumours, the risk increased over 
four-fold and eight-fold, respectively (HR= 4.2; 95% CI: 1.8 to 9.4 for people who had had 
26+ vaginal-sex partners and HR= 8.6; 95% CI: 2.2 to 34.0 for people who had had  6+ oral-
sex partners:). In the same study, the authors sought to examine whether combined 
exposure to HPV and tobacco and/or alcohol further increased OPC risk. They found no 
evidence of a synergistic effect; however, some other studies suggest that smoking has the 
potential to promote infection and viral persistence, possibly increasing the carcinogenetic 
effect of HPV 187. In one US study, which included 284 OPC cases and 477 controls, the 
joint effect of smoking and HPV-16 seropositivity (measured using Enzyme Linked 
Immunosorbent Assay [ELISA] for detection of antibodies to L1) was associated with an 8.5-
fold increased risk of OPC (95% CI: 5.1 to 14.4), which was much stronger than the 
predicted sum of individual associations with current smoking (OR= 3.2; 95% CI: 2.0 to 5.2) 
and HPV-16 seropositivity (HR= 1.7; 95% CI: 1.1 to 2.6) 188. 
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3.6.4. Epstein-Barr virus 
EBV, the same virus that causes glandular fever, has been etiologically linked to NPC, 
especially the non-keratinizing form of NPC 189 190.  Infection with EBV alone is not sufficient 
to cause cancer. Indeed, sero-epidemiological studies indicate that globally more 90% of the 
adult population are infected 191 192 and yet only a small fraction of these infections will ever 
progress to cancer.   The reasons why some latent infections progress to cancer are not yet 
clear, but genetic susceptibility, environmental factors and interactions with other pathogens 
may all play a role. 
3.6.5. Diet and nutrition  
Epidemiological studies suggest a link between diet and HNC 193-198. In particular, a high 
intake of fruits and vegetables has been associated with a reduction in risk. In a study of 
almost 350,000 subjects included in the Prospective European Investigation into Cancer and 
Nutrition (EPIC), for example, an 80g/day increase in fruit and vegetable intake was 
associated with a 10% decrease in the incidence rate of upper aerodigestive tract (UADT) 
cancers (including pharynx, larynx, and oesophagus; RR= 0.91; 95% CI:0.83 to 1.00) 197. 
Similarly, Edefonti et al (2012) found evidence of an inverse association between an 
“antioxidant vitamins and fibre” dietary pattern, which is rich in fruit and vegetables, and risk 
of oral and pharyngeal cancer (OR: 0.57; 95% CI: 0.43 to 0.76 for the highest versus the 
lowest quintile) in a study that included 2,452 cases and 5,013 controls 193.  
 
There is evidence to suggest that fruit and vegetables may protect against the carcinogenic 
effects of tobacco and alcohol 195 196. In a pooled analysis of case-control studies conducted 
in 9 countries worldwide (1,670 cases and 1,732 controls), Kreimer et al (2006) found that 
high (versus low) fruit and vegetable intake significantly reduced oral and pharyngeal cancer 
risk, but only among ever-tobacco users (OR = 0.4; 95% CI: 0.3 to 0.6 for ever-tobacco 
users and 1.1; 96% CI:  0.6 to 2.0 for never-tobacco users) and ever-drinkers (OR = 0.4; 
95% CI: 0.3 to 0.6 for ever-drinkers and 1.0; 95% CI: 0.6 to 1.6 for never-drinkers). The 
protective effects of fruits and vegetables may be attributed in part to carotenoids, which are 
recognized antioxidants with anti-mutagenic and immuno-regulatory activities 195.  
3.6.6. Body mass index  
Most previous studies report that people with a low body mass index (BMI) i.e <18.5 
experience a higher risk of HNC compared to those of normal body mass i.e. 18.5 to <25.0 
196 199-205. However, as Gaudet et al (2010) 205 point out, it is difficult to assess the 
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independent effects of BMI on HNC risk as BMI is so strongly associated with smoking and 
alcohol drinking 206-208, such that even after adjusting for tobacco and alcohol consumption, 
the influence of residual confounding cannot easily be dismissed.  Lubin et al (2010) 
examined the relationships between BMI, smoking, and alcohol consumption in the 
INHANCE consortium and found that the relationships differed by anatomical sub-site. Low 
BMI was found to significantly enhance smoking and alcohol-related associations for oral 
cavity and pharyngeal cancer but not for laryngeal cancer 209. For oral cavity/pharyngeal 
cancer, BMI modified the strength of the relation between cancer risk and drink-years, 
specifically whilst the impact of BMI on the relation between disease risk and drink-days 
were similar across all categories of BMI.  
3.6.7. Physical activity 
There is increasing evidence to suggest that physical activity (PA) may lower cancer risk but 
so far, the data for HNC is limited and conflicting. In one study conducted by Nicolotti et al 
(2011), which included 2,289 HNC cases and 5,580 controls, subjects who participated in 
moderate recreational PA (definitions varied by study) experienced a 22% reduced risk of 
HNC in multivariable-adjusted models (OR= 0.78; 95% CI: 0.66 to 0.91), compared to those 
in the none/low PA group 210. In another prospective study (NIH-AARP Diet and Health 
Study) that followed 487,732 subjects (1,249 HNC cases) for eight years, the relation 
between PA and HNC risk substantially attenuated and became statistically non-significant 
after adjustment for smoking (additional adjustment for other potential confounding variables 
had little influence on the risk estimate) 211. These findings led the authors to conclude that 
PA is unlikely to play an important role in the development of HNC.  
3.6.8. Oral hygiene 
People with poor oral health, i.e. individuals with several missing teeth, bleeding gums or 
chronic infection, have been found to have a higher risk of developing HNC, though the 
effects are often modest 212-216. The processes underlying the apparent associations 
between oral and dental hygiene and HNC risk have yet to be fully elucidated, but plausible 
mechanisms involve: systemic inflammation and the release of cytokines and other 
inflammatory mediators 214; bacterial overgrowth, which may contribute to the formation of 
endogenous nitrosamines 214 217 218 and increased formation of the highly carcinogenic 
intermediate acetaldehyde from ethanol 214 216 219; and the facilitation of oral HPV infection, 
for example, by providing an entry point for the virus 220.  
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3.6.9. Socioeconomic position 
A 2015 study, which used pooled data from 31 studies (n=23,964 HNC cases) in 27 
countries, examined the effects of income and education on HNC occurrence 221. The 
findings were that fewer years of education and lower income were associated with an 
increased risk of disease development. Overall, low education, as defined by an 
International Standard Classification of Education (ISCED) score of 0–1 (no education, or 
completed the first stage of basic education, or at most primary education) was associated 
with a 2.5-fold increased risk of HNC (OR = 2.50; 95% CI = 2.02 - 3.09, p<0.001) relative to 
high educational attainment (ISCED 5-6) in models that adjusted for age, sex and centre (for 
multiple-centred studies). Those in the intermediate level of educational attainment had an 
intermediate increased risk (OR = 1.80; 95% CI = 1.57–2.07, p<0.001). Low relative to high 
household income (based on strata) was associated with a similar increased risk of head 
and neck cancer (OR = 2.44; 95% CI = 1.62–3.67).  
 
The authors estimated the unexplained or “direct” effect of low socioeconomic status (SES) 
on HNC risk. They found that the proportion of the increased risk estimate associated with 
low educational attainment not explained by smoking alone was 58%; by smoking and 
alcohol combined was 31%; by smoking, alcohol and diet was 29% and by smoking, alcohol, 
diet and other tobacco use was 23%. For income, 39% of this risk was not explained when 
adjusting for smoking and alcohol (income models were not adjusted for diet and other 
tobacco use in the main analysis). When the analysis was restricted to those who never 
smoked and never drank alcohol, lower educational attainment remained associated with a 
>50% increased risk (OR = 1.61; 95% CI = 1.13–2.31). Taken together, these results 
suggest that risk associated with low SES cannot entirely be explained by differences in the 
distributions of behavioural risk factors.  
 
3.6.10. Family history of head and neck cancer 
The results of three record linkage studies 222-224 suggest that the standardised incidence 
ratio (SIR), which is the ratio of the observed number of cases to the expected number of 
cases 225, for developing HNC among people with a family history ranges between 1.4 and 
8.0.  Again, using data from the INHANCE consortium (12 case-control studies including 
8,967 HNC cases and 13,627 controls), Negri et al (2009) established that having a first-
degree relative with HNC was associated with an almost two-fold increased risk (OR= 1.7; 
95% CI: 1.2 to 2.3). The risk was highest when the affected relative was a sibling (OR 
sibling: 2.2; 95% CI: 1.6 to 3.1; OR parent: 1.5; 95% CI: 1.1 to 1.8). In subjects with a family 
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history who were also alcohol and tobacco users, the risk increased seven-fold (OR= 7.2; 
95% CI: 5.5 to 9.5).  
3.6.11. Genetic risk factors 
Although most HNCs are caused by carcinogens or viral infection, a small percentage of 
cases are familial in nature. Inherited conditions which are known to increase HNC risk 
include Fanconi anaemia, ataxia telangiectasia, Bloom's syndrome and Li–Fraumeni 
syndrome 226.  
 
It is widely hypothesised that variations in genes involved in pathways such as carcinogen 
metabolism DNA repair and cell cycle control may increase the risk of tobacco and alcohol 
associated carcinogenesis 227, although the results of candidate gene studies have been 
mixed. For further discussion, the reader is directed towards reviews by Hiyama et al (2008) 
and Cadoni et al (2012) 228 229. Among the most extensively studied genes are those in the 
alcohol dehydrogenase (ADH) gene family.  Polymorphisms (i.e. genetic variants) in ADHB1 
in particular have been strongly associated with HNC susceptibility.  In an analysis of five 
ADH variants, which included 3,876 upper aerodigestive tract (UADT) cancer cases (790 
cancers of the oral cavity or pharynx, 1,659 cancers of the hypopharynx or larynx and 427 
cancers of the oesophagus) and 5,278 controls, the A-allele of rs1229984 (also known in the 
literature as ADH1B*2), which confers fast metabolism of ethanol to acetaldehyde, was 
shown to be protective against aerodigestive cancer 230. Specifically, the reduction in risk 
was between two and three-fold for oral and pharyngeal cancer (OR= 0.45; 95% CI: 0.35 to 
0.57) and 30% for laryngeal cancer (OR= 0.71; 95% CI: 0.57 to 0.88). The effect became 
more apparent with increasing alcohol consumption (P for trend = 0.0002) 230. A summary of 
some of the other most commonly cited polymorphisms is provided in Table 7.   
 
Subsequent genome-wide association studies (GWAS) have validated the single nucleotide 
polymorphism (SNPs) in ADH1B (reference SNP cluster ID: rs1229984) 231-233 and have 
identified a number of additional susceptibility loci to date, including other variants in the 
ADH gene cluster and in Aldehyde dehydrogenase 2 (ALDH2).  An overview of GWAS 
findings is provided in Table 8. In one study, McKay et al. identified five common variants 
associated with UADT cancer susceptibility in the INHANCE consortium (replication n= 
6,514 UADT cancer cases and 7,892 controls of European descent), including three located 
within the alcohol dehydrogenase genes (ADH1B, ADH1C, ADH7) that have been described 
previously 230 and two novel variants, a 4q21 variant (rs1494961), which resides near DNA 
repair related genes HEL308 and FAM175A, and a 12q24 variant (rs4767364) located in a 
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region that contains multiple genes including the (ALDH2) gene 231. The rs1229984 (4q23, 
ADH1B) association was subsequently validated by Leusseur et al. in a GWAS meta-
analysis of overall oral and pharyngeal cancer (oral, oropharynx, hypopharynx and 
overlapping cancers; n = 6,034), and in site-specific oral cancer (n = 2,990) and OPC (n = 
2,641) analyses 232.  In addition, this study identified a large association signal at 6p21.32, 




Table 7: Some of the most intensely studies genetic polymorphisms linked to HNC risk. 
Gene Activity Association with HNC  Ref 
Carcinogen metabolising genes  
Glutathione S-
transferase (GSTM1) 
GSTs are phase II xenobiotic metabolizing 
enzymes. They are involved in catalysing the 
conjugation reactions of reactive intermediates 
of electrophilic compounds with cytosolic 
glutathione (GSH) 234.  
Null GSTM1 genotype (which lacks the 
corresponding enzyme function) is associated 




Null GSTT1 genotype (which lack the 
corresponding enzyme function) is associated 




Ile/Val and/or Val/Val genotypes (GSTP1 codon 
105) are associated with increased risks vs. the 
Ile/Ile genotype. 
235 
Cytochrome P450 2E1 
(CYP2E1) 
CYP2E1 is one of the main constituents of the 
microsomal ethanol oxidation system, which 
breaks down ethanol to acetaldehyde and 
generates reactive oxygen intermediaries.  
CYP1A1 encodes enzymes that are active in 
the metabolism of several tobacco-derived pro-
carcinogens, including polyaromatic 
hydrocarbons, N-nitrosamines and aromatic 
amines.  
c2/c2 genotype associated with increased risk vs. 
c1/c1 genotype. 
236 
Cytochrome P450 1A1 
(CYP1A1) 
Ile/Val and/or Val/Val genotypes (which increase 
enzymic activity) are associated with increased 
risks vs. the Ile/Ile genotype. 
 











A key enzyme involved in the metabolism of 
numerous aromatic and heterocyclic amine 
carcinogens 228. Polymorphic changes 
regulating the acetylation capacity of NAT2 
have been implicated in the risk of developing 
several tobacco-associated cancers 238-240. 
Slow acetylation genotype associated with 







The human microsomal epoxide hydrolase 
(mEH) enzyme, which is encoded by EPHX1, 
is involved in the metabolism of many 
potentially carcinogenic or genotoxic 
Tyr/His genotype (which corresponds with low 
enzyme activity) is associated with lower risk vs. 






epoxidesincluding those derived from the 
oxidation of polyaromatic hydrocarbons 228 248.   





In the first stage of alcohol metabolism, ADH 
metabolises ethanol to acetaldehyde, a known 
carcinogen 253; In the second stage, ALDH 
rapidly breaks down acetaldehyde to another 
less toxic by-product called acetate. 
Polymorphisms of both ADH and ALDH genes 
are known to determine blood acetaldehyde 
concentrations after drinking 254 255. 
Carriers of the “slow metabolising” allele 







Carriers of the “fast metabolising” allele ADH1B*2 
(rs1229984) are at reduced risk compared to 




DNA repair genes 
Xeroderma pigmentosum 
complementary group D 
(XPD) 
 
One of the major genes involved in nucleotide 
excision repair 228, which is the main pathway 
responsible for removing lesions or sites of 
damage in the DNA, 256.  
Individuals homozygote for the variant genotype 
22541AA (XPD codon 156) have decreased risk 
compared to 22541CC homozygotes. 
 
257-260 
Individuals homozygous for the variant genotype 
A35931CC (XPD codon 751) have increased risk 
compared to A35931AA homozygotes. 
257-262 
Cell cycle repair genes 
P53  
 
Acts as the major cellular “gatekeeper” for 
growth and division. 
Conflicting evidence to suggest that a functional 
polymorphism which codes either arginine (Arg) 
or proline (Pro) at codon 72 of exon 4 is 
associated with HNC risk. Most studies suggest 
that the Pro/Pro genotype is associated with 
increased risk vs. the Arg/Arg genotype. 
 
228 
Cyclin D1 (CCND1) 
 
Cyclin D1 (CCND1) is an important regulator of 
the G1 phase of the cell cycle. It is amplified in 
30% to 50% of HNCs 263 264. 
A G870A polymorphism, which creates an 
alternative splice variant of the CCND1 gene, is 





Table 8: HNC risk loci identified in GWAS. 









OC, OPC 4q23 rs1229984 ADH1B T 2.29x10–15 232 
OC, OPC 6p21.32 rs3828805 HLA-DQB1 T 3.35x10–13 232 
OC, OPC 10q26.13 rs201982221 LHPP A 1.58x10–9 232 
OC, OPC 11p15.4 rs1453414 OR52N2/TRIM5 C 4.78x10–8 232 
OC 2p23.3 rs6547741 GPN1 G 3.97x10–8 232 
OC 4q23 rs1229984 ADH1B T 1.09x10–9 232 
OC 5p15.33 rs10462706 CLPTM1L T 5.54x10–10 232 
OC 9p21.3 rs8181047 CDKN2B-AS1 A 3.80x10–9 232 
OC 9q34.12 rs928674 LAMC3 G 2.09x10–8 232 
OPC 4q23 rs1229984 ADH1B T 8.53x10–9 232 
OPC 6p21.32 rs3828805 HLA-DQB1 T 2.21x10–12 232 
UADT 4q21 rs1494961 HEL308 C 1×10−8 231 
UADT 12q24 rs4767364 ALDH2 A 2×10−8 231 
UADT 4q23 rs1229984 ADH1B T 1×10−20 231 
UADT 4q23 rs1573496 ADH7 C 9×10−17 231 
UADT 4q23 rs698 ADH1C C 3×10−7 231 
Lar 6p21.33 rs2857595 AIF1 A 2.43 × 10−15 233 
Lar 11q12.2 rs174549 FADS1 A 1.00 × 10−20 233 
Lar 12q24.21 rs10492336 TBX5 A 4.48 x 10−14 233 
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3.7. Multi-omics profiling in HNC 
HNC (and cancer in general) is a complex disease involving alterations at multiple molecular 
levels including the genome, epigenome, transcriptome, proteome and metabolome.  As 
such, there has been a growing trend towards integrating multiple “omics” technologies into 
HNC cancer research 271 272 in order to try to obtain a better understanding of the systemic 
processes that drive cancer initiation and maintain tumorigenesis.  This thesis will be 
considering epigenetic and metabolomic biomarkers specifically but a brief description of the 
genetic changes that characterise HNC will also be presented below, in order to provide a 
more complete picture of the molecular profile of the disease. Details of the different 
epigenetic and metabolomic platforms themselves will be provided in the next chapter.  
3.7.1. Genetic landscape 
Exome-sequencing studies (i.e. studies that sequence the protein-coding regions of the 
genome 273), have revealed that HNC has a relatively high mutational load, ranking eighth 
highest in an analysis of 27 cancer types 274. The mutational rate (i.e. total number of 
mutations per coding area of a tumour genome) is broadly comparable to that of other 
smoking-related malignancies such as lung and oesophageal cancer 275. One study reported 
significantly lower mutation rates in HPV-associated HNCs, hereafter referred to as HPV-
positive cancers; in fact, the frequency of mutation was around half that of non-HPV 
associated tumours, hereafter referred to as HPV-negative cancers (mean mutation rate of  
2.28 mutations per megabase [Mb] compared with 4.83 mutations/Mb; p = 0.004 for  275 for 
HPV-negative tumours). The authors suggest that higher genome instability in HPV-negative 
cancers could lead to a higher risk of developing treatment resistance and this may go part 
way to explaining why people with HPV-positive tumours have improved survival compared 
to people with HPV-negative cancers 276.  
 
In the largest analysis of its kind to date (n=279), the Cancer Genome Atlas (TCGA) 
identified eleven genes that were consistently mutated in HNC 277. The mutational frequency 
of several of these genes, including TP53, PIK3CA, NOTCH1, TP63 and CDKN2A, were 
comparable in a later analysis by Perdomo et al (2016), which included 180 paired samples 
diagnosed with HNC in two high incidence regions of Europe and South America 277.  Among 
inactivating mutations, four genes identified in the TCGA study were found to segregate 
exclusively or predominantly in non HPV-associated tumours; these included TP53 and 
CDKN2A, which are associated with cell cycle control, and FAT1 and AJUBA, which are 
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linked to Wnt/β-catenin signalling. TP53 mutations have been associated with poor clinical 
outcomes, including inferior therapeutic response 276. Table 9 provides an overview of the 
mutational frequencies and types of alterations found in HNC, stratified by HPV status.   For 
a more in depth discussion of HNC genomics see Beck et al (2016) 278 
3.7.2. Epigenetic signatures  
Accumulating evidence suggests that epigenetic mechanisms, i.e. mechanisms that produce 
changes in gene expression without altering the underlying genetic code, play an important 
role in carcinogenesis, tumour progression, and resistance to therapy 279 280. DNA 
methylation (DNAm), which involves the addition of a methyl group to the fifth carbon of the 
cytosine DNA base, producing 5-methylcytosine (5mC), is probably the most extensively 
studied form of epigenetic regulation and will be discussed further in Chapter 4.  DNAm 
typically acts to suppress gene expression by interfering with transcription factor binding 281.  
Other mechanisms of epigenetic regulation include histone modifications, chromatin 
remodeling and noncoding ribonucleic acids (ncRNAs) 279.  
 
Studies comparing DNA extracted from head and neck tumour tissue with DNA from healthy 
or tumour-adjacent tissue have revealed noticeable differences in the pattern of DNAm 281-
284. Cancer cells are associated with both frequent gene promoter hypermethylation, which 
refers to an increase in genomic 5mC within the regulatory regions of genes 285 281 286 and 
increased global (non-specific) hypomethylation, which describes an overall decrease in the 
level of 5mC across the genome. In contrast to hypermethylation, which typically results in 
transcriptional silencing of key genes, global hypomethylation is capable of reactivating 
methylation-silenced proto-oncogenes 281.  
 
Some of the most frequently hypermethylated genes in HNC are summarised below and in 
Table 10.  These genes cover a wide range of biological pathways, including cell cycle 
control (CDKN2A, CDKN2B, p53), apoptosis (DAPK), Wnt signalling (APC, WIF1, RUNX3), 
cell adhesion (CDH1), and DNA-repair (ATM, MGMT and hMLH1) 282.  For a more 
comprehensive list of aberrantly methylated genes see Gasche et al (2012) 281. 
 
Hypermethylation of the CDH1 gene, which encodes the adhesion protein E-cadherin, has 
been associated with HNC in multiple studies, although the reported frequency of 
methylation at this gene varies considerably- from as little as 7% to as high as 85%. 281 286. 
For this reason, CDH1 hypermethylation may not provide a reliable biomarker for HNC; 
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nonetheless, there is evidence to suggest that it may be associated with invasive tumour  
behaviour 287 288; and could therefore have prognostic significance.  
 
CDKN2A and CDKN2B hypermethylation have also been associated with metastasis and 
overall poor survival in people with HNC 281. The CDKN2A gene encodes several proteins, 
two of which - p16INK4A and the p14ARF, are essential for regulating cell growth and 
division289. CDKN2A promoter hypermethylation turns off the production of these key tumour 
suppressor proteins, allowing cells to grow unchecked. The estimated prevalence of p16INK4A 
and p14ARF promoter hypermethylation in HNC varies from 12-88% and 14-44%, 
respectively, depending on the samples and methodologies used by different research 
groups 281.  CDKN2B, is another tumour suppressor gene that lies adjacent to CDKN2A. It 
provides instructions for making the cyclin dependent kinase inhibitor protein p15 INK4B, which 
controls cell cycle G1 progression 281 290. The existing evidence suggests that 9-28% of HNC 
tissues exhibit CDKN2B hypermethylation.  Healthy or tumour-adjacent normal tissues, by 
comparison, typically lack CDKN2B methylation 281. 
 
The DNA repair genes MGMT (O-6-methylguanine-DNA methyltransferase) and MLH1 
(mutL homolog 1) are also frequent targets of epigenetic modification in HNC, according to 
multiple independent studies (up to 75% of HNC tissues demonstrate MGMT and MLH1 
gene silencing via hypermethylation) 281 291. MGMT plays an important role in preventing 
carcinogenesis as it removes mutagenic adducts from O(6)-alkyl-guanine in DNA 281, whilst 
MLH1 fixes errors that are made when DNA is copied, which helps to reduce the 
accumulation of mutations and maintain genomic stability.292 Silencing of MGMT and MLH1 
via methylation are both believed to be an early events in HNC tumorigenesis 281 291.  
 
Several studies have looked for differences in the methylation profiles of HPV-positive and 
HPV-negative head and neck tumours. Collectively, there is consistent evidence to suggest 
that tumours that are associated with HPV infection exhibit a greater level of promoter 
methylation (2-5 times higher) compared with non-HPV associated tumors 293 294, however, 
HPV-positive and HPV-negative DNAm profiles remain poorly characterised overall. One 
reason for this is that most studies have only evaluated a select number of genes or have 
focused on global markers of DNAm; few have conducted epigenome-wide analyses293 294. 
In addition, surprisingly few methylation studies have focused solely on the oropharynx but 
have instead grouped multiple sites in the head and neck region together. This is surprising 
given that HPV infection is a much greater risk factor for OPC compared to other HNCs.  
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Some of the key gene families found to be differentially modulated include cell-cycle genes 
(CDKN2A, CCNA1), JAK-STAT pathway genes (JAK3, STAT5A) and cadherin family 




Table 9: Frequency of selected genes recurrently mutated in HNC. 
Gene Frequency (%) Ref(s) 
HPV (+) 
E6/E7 100% 275 296-298 
PIK3CA 22-56% 275 296-298 
TP63 16-28% 296 297 
TRAF3 22% 296 
E2F1 19% 296 
NOTCH 1/3 17% 296 
FGFR3 11-14% 296 297 
HLA-A/B 11% 296 
EGFR 6% 296 
HPV (-) 
TP53 73-84% 275 296 297 
CDKN2A 25-57% 275 296 297 
PIK3CA 13-34% 296 297 
PIK3CB 13% 297 
FADD 32% 296 
FAT1 14-32% 275 296 
CCND1 13-31% 275 296 297 
NOTCH1/2/3 16-29% 275 296 297 
TP63 19% 296 
EGFR 12-15% 296 297 
HNSCC 
CDKN2A 74% 296 
TP53 66-79% 296 298 
FAT1 46% 296 
TP63 26% 296 
CCND1 23% 296 
MAML1 23% 296 
EGFR 17% 296 
TNK2 17% 296 
AKT1 14% 296 
SRC 14% 296 
NOTCH1 14% 298 
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Table 10: Genes frequently hypermethylated in HNC. 
Gene Function Ref(s). 
APC WNT signalling 279 281 282 299 
ATM DNA damage repair 279 282 300 
CCNA1 (Cyclin A1) Cell cycle regulation 281 294 300-302 
CDH1 (E-cadherin) Cell adhesion 279 281 282 299-305 
CDKN2B (p15INK4B) Cell cycle regulation 279 281 282 300 306 307 
CDKN2A (p16INK4A/ 
p14ARF) 
Cell cycle regulation 279 281 282 299-301 304-310 
DAPK Apoptosis 
279 281 282 300 302 303 305 306 
308 310 
DCC Tumour suppressor 281 282 300 302 306 309 
EDNRB Receptor activity 281 282 309 
EPCAM Cell adhesion molecule 281 311 
FHIT Cell cycle progression 281 312 
hMLH1 DNA repair 282 291 299 303 304 313 
HOXA9 Cell differentiation 279 299 
MGMT DNA damage response 
279 281 282 299 300 302-305 308 
310 
MINT1/2 
Movement, exocytosis & 
adhesion 
281 299 302 306 
MINT27 Transcriptional regulator 281 306 
MINT31 Transcriptional regulator 281 299 306 
NPY Cell proliferation 279 299 
Notch1 Receptor activity 281 294 314 







Table 10 continued. 
pRB Tumour suppressor 282 299 
RARβ Nuclear receptor 281 282 300-302 305 
RASSF1 Cell cycle, apoptosis. 279 281 282 300 303 305 
RECK Protein binding/peptidase inhibitor 281 315 
RUNX3 WNT signalling 281 282 299 303 310 316 
SFRP family Protein binding 281 282 310 317 
TIMP3 Extracellular matrix degradation 279 282 300 302 
VHL Transcription factor binding 281 299 307 
WIF1 WNT signalling 281 282 299 303 
 
 
It is becoming increasingly apparent that environmental and lifestyle risk factors (e.g. 
smoking and alcohol drinking) are capable of instigating a range of epigenetic alterations, 
which could mediate at least some of the associations of these exposures with HNC risk.  
Smoking, which is a major risk factor for HNC, is considered one of the most significant 
environmental modifiers of peripheral-blood DNA 318.  It is associated with both promoter 
hypermethylation of tumour suppressor genes and genome-wide hypomethylation, 
especially in long-term tobacco users 281 319. One of the ways in which cigarette smoke can 
influence DNAm profiles in people with HNC is by impairing DNA methyltransferase (DNMT) 
expression, which is responsible for catalyzing the addition of a methyl group to DNA, both 
at transcript and protein level (reviewed in 320).  
 
The ability to better characterise lifestyle exposures in people with HNC using persistent 
epigenetic markers will be discussed in Chapter 4. 
 
3.7.3. Metabolomic profiles  
Altered metabolism is a hallmark of cancer, being necessary to support continuous growth 
and proliferation 321 322. More specifically, metabolic reprogramming enables cancer cells 
both to obtain and utilise potentially unconventional nutrient sources, in order to build new 
biomass, and influence surrounding normal cells.  This can in turn have direct or indirect 
effects on gene expression, for instance by mediating the addition and removal of epigenetic 
marks from chromatin 321 323. Pavlova et al (2016) 321, published a review of cancer-
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associated metabolic changes, wherein they further categorised these alterations into six 
distinct ‘hallmarks’ of cancer metabolism; these include:  
• deregulated uptake of glucose and amino acids; 
• use of opportunistic modes of nutrient acquisition; 
• use of glycolysis/TCA cycle intermediates for biosynthesis and NADPH production; 
• increased demand for nitrogen; 
• alterations in metabolite-driven gene regulation; and 
• metabolic interactions with the microenvironment. 
The reasons why cancer cells engage in seemingly inefficient energetic processes (i.e. 
aerobic glycolysis) is discussed further in Sandulache et al (2012) 324. 
 
Metabolomics, which is a relatively new but rapidly emerging technology within the omics 
field, is becoming an increasingly utilized tool for investigating the perturbations in metabolic 
pathways in HNC.  Metabolomics is defined as the systematic identification and 
quantification of all, or specific, metabolites within a biological sample (cell, tissue, blood, 
saliva or urine), at a specific time.  The term ‘metabolite’ is typically restricted to small 
molecular-weight products of metabolism, typically less than 15000 Dalton (Da). There are a 
variety of metabolomic platforms and technologies available, but the most used techniques 
include mass spectrometry (MS) and nuclear magnetic resonance (NMR) spectroscopy. A 
detailed description of these different analytical techniques, including a comparison of their 
advantages and limitations of each, is provided in Chapter 4. 
 
It is becoming increasingly apparent that people with HNC possess distinct metabolomic 
profiles compared with healthy controls and people with pre-cancerous legions, though 
studies are typically based on small samples.  A summary of metabolomic-based studies on 
HNC is provided in Table 11.  Of note, numerous studies comparing samples from people 
with HNC and healthy controls, point towards altered levels of several amino acids, such as 
alanine, glutathione, histidine, isoleucine, valine and lysine 325-328, as well enhanced glucose 
consumption and Lactate production 325 326 329-332, supporting the role of altered energy 
metabolism in HNC. In addition, elevated levels of choline-containing metabolites were also 
detected in HNC samples in numerous studies in (tissue and peripheral blood) 333-335. 
Abnormal choline metabolism has been observed in several other cancer types and is 




Abbreviations for Table 11: CE-TOF-MS, capillary electrophoresis time-of-flight mass 
spectrometry; CE-MS; capillary electrophoresis-mass spectrometry; GC, gas 
chromatography; HPLC, high performance liquid chromatography; HR-MAS, high-resolution 
magic-angle spinning; HNSCC, head and neck squamous cell carcinoma; LC-Q-TOF, liquid 
chromatography quadrupole-time of flight; MRS, magnetic resonance spectroscopy; MS, 
mass spectrometry; NHOK, normal human oral keratinocytes; NMR, nuclear magnetic 
resonance spectroscopy; OC, oral cavity; OLK, oral leukoplakia; OLP, oral lichen planus; 
OSCC, oral squamous cell carcinoma; PCA, principle component analysis; PLS-DA, partial 
least squares discriminant analysis; TCA, tricarboxylic acid cycle; UPLC-Q-TOF-MS, 
ultraperformance liquid chromatography coupled with quadrupole/time‐of‐flight mass 
spectrometry. Metabolites: Ace, acetate; Ala, alanine; Asn, Asparagine; Cho, choline; Cit, 
citrate; Cre, creatine; Crea: creatinine, Cys: Cysteine; GABA, γ‐aminobutyric acid; Gln, 
glutamine; Glu, Glutamic acid; Gluc, glucose; Glut, glutathione; Glyc, glycine; His, histidine; 
Lac, lactate; Ileu, isoleucine; leu, leucine; Pro, proline; PUFA, polyunsaturated fatty acid; Ser, 
Serine; Suc, succinate; Tau, taurine; Val, valine
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Table 11: Summary of metabolomic-based studies on HNC. 
Ref. Sample N Technology Metabolomic findings 
336 Saliva 50 HNSCC, 77 
controls 
HPLC Increased Glut levels in HNSCC cases.  
337 Saliva 20 OC, 20 OLP 
7 OLK, 11 healthy 
controls 
HPLC/MS Metabolic profiling data distinguished between OSCC, OLP and OLK, based on PCA-
approaches. 




28 metabolic traits were differentially expressed in cases compared to controls. 
339 Saliva 37 OC, 32 OLK, 
34 healthy controls 
UPLC‐
QTOFMS 
41 metabolites were differentially expressed in OSCC relative to controls and 61 metabolites 
measured were differentially expressed in OSCC relative to OLK. The most significant 
discriminant metabolites were GABA, Phe and Val, n‐eicosanoic acid and lactic acid 
335 Plasma 33 OC, 5 OLK, 
28 healthy controls 
NMR Metabolic profiling data distinguished between OC, OLP and controls based on PLS-DA. 
334 Serum 15 OSCC, 10 
healthy controls 
NMR OSCC showed a distinct signature of altered energy metabolism, which included altered 
lipolysis (an accumulation of ketone bodies), a distorted Krebs cycle (e.g. reduced Cit, Suc, 
and formate), and amino acid catabolism [increased 2-hydroxbutyrate, ornithine, Asn].  
332 Serum & 
tissue 
25 HNSCC  GC/MS Serum levels of several metabolites related to the glycolytic pathway, such as Gluc, were 
higher in patients with HNSCC. Levels of several amino acids were lower. There were 
differences in 9 metabolites in sera of individuals who had disease relapse compared to those 
who did not.  
333 Tissue 135 HNSCC 
tissue, 40 normal  
MRS Tau, Cho, Glu, lactic acid, and lipid were found to have diagnostic potential.  
 





GC/MS The urinary metabolite profiles of OSCC, OLK and healthy control samples could be clearly 
discriminated. The most differentially expressed metabolites were hippurate, 6-hydroxynicotic 
acid, Ala, Tyr, Val, Ser and Cys. 6-hydroxynicotic acid and valine in combination provided the 
best discrimination between OSCC and healthy controls. The combination of cysteine,6-




Table 11 continued. 
Ref. Sample N Technology Metabolomic findings 
327 Tissue 19 HNSCC, 13 




MRS Cho/Cre ratio was higher in tumor tissue than in normal tissue. Ala and Ileu were detected in 
15 of 19 tumor samples and found in only one of 13 samples of normal tissue. Glut, His, and 
Val were found in eight, 10, and 12 tumor samples, respectively, whereas each amino acid 
was detected in only one of 13 normal tissue samples. 
 
325 Tissue 159 OSCC (tumor 
tissues, 
neighbouring 






Malignant tissues had higher levels of Glut, Cho, phosphocholine, Lac, Ace, Tau, Glyc, Lue, 
lysine, Ileu and Ala, and lower levels of Cre and PUFA. 
 
 
326 Tissue 22 HNSCC HR-MAS 
 
 
HNSCC tissues showed elevated levels of lactate, amino acids including Leu, Ileu, Val, Ala, 
Gln, glutamate, aspartate, Glyc, Phe and Tyr, Cho containing compounds, Cre, Tau, Glut, 





Cell lines 5 HNSCC cell 
lines, 3 cultures of 
normal human oral 
keratinocytes 
NMR There were alterations in the levels of several metabolites involved in multiple metabolic 
events, including Warburg effect, oxidative phosphorylation, energy metabolism, TCA cycle, 
glutaminolysis, hexosamine pathway, osmo-regulatory and antioxidant mechanisms. 
341 Saliva 22 OSCC, 21 
healthy controls 
CE-MS 25 metabolites were identified as potential markers to discriminate between people with 




24 OC (18 SCC 
tissue), 44 controls 




85 and 45 metabolites showed significant differences between tumour and matched control 
samples, and between salivary samples from OC and controls, respectively. 17 metabolites 
showed consistent differences in both saliva and tissue-based comparisons. 
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Table 11 continued. 
Ref. Sample  N Technology Metabolomic findings 
343 Saliva 101 OCC, 58 





Glyc and Pro were different between OCC and controls. Four metabolites, including 
Glyc, Pro, citrulline, and ornithine were associated with early stage OCC. 
331 Cell lines 3 HNC cell lines 
as well as normal 
fibroblasts. 
NMR Alterations in the amounts of threonine, ribose, n-acetyl, malonate, methylmalonate, 
malonate, threitol, n-acetyl glutamate, ethanolamine, phosphoetanolamine, unsaturated 
lipids (CH2) and Lac.  





Enhancement of glucose consumption and Lac production was observed in OSCC 
tissues. Fumarate and malate in were significantly higher in OSCC tissues compared to 
control. 
 
328 Cells 5 HNSCC 
patients, NHOK 
from 3 donors 
NMR HNSCC cells exhibited altered levels of various metabolites related to Warburg effect, 
oxidative phosphorylation, energy metabolism, TCA cycle anaplerotic flux, 
glutaminolysis, hexosamine pathway, osmo-regulatory and antioxidant mechanism. 
344 Serum 140 HNC patients LC High serum levels of methionine and alanine had a positive prognostic impact in 
univariate models. High serum levels of cystine predicted lower OS. Methionine 
remained a positive prognostic factor in multivariable models. 
345  28 tissue samples 
obtained from 7 
HNC cases and 7 
controls + oral 
washes 
LC/MS Eight metabolites were elevated in tumor tissues by 1.9- to 12-fold compared to normal 
tissues. N-acetylputrescine was the most elevated. 2-hydroxyglutarate (2-HG, a TCA 
cycle analog) and glycerol-3-monophosphate (3-GMP) were only detected in tumor 
tissues. Levels of acylcarnitines were elevated in oral washes of HNC cases. 
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3.8. Survival rates after HNC diagnosis 
Depending on the type of HNC, between 61% and 86% of people are expected to survive for 
at least a year following diagnosis (Table 12). Net survival rates fall to between 28% and 
67% at five years and 19% - 59% at ten years.  Salivary gland cancers have the best 
prognosis, with a 5-year net survival rate of around 76% (2009-2013) 346.  At the other end of 
the spectrum, hypopharyngeal cancers have the worst prognosis, with a 5-year net survival 
rate of just 28%. This discrepancy is largely a reflection of late presentation. In general, 
hypopharyngeal cancers remain asymptomatic until they are advanced and consequently, 
80% of all cases present at stage III or IV 8.  
 
HNC survival rates in England are similar in males and females; however, the rate for 
females with laryngeal cancer was not available at the time of writing this thesis due to the 
low number of cases 346. 
 
For oropharyngeal cancers, the 5-year net survival rate is around 66% (Table 12).  However, 
studies have consistently demonstrated that people with HPV-positive oropharyngeal 
cancers have improved overall and disease-free survival compared to their HPV-negative 
counterparts (presenting with a the same cancer stage) 347 348, which is attributed in part to 
an improved therapeutic response 347.  Although the majority of people with HPV-positive 
OPC do well following treatment, a high price may be paid in terms of both acute and chronic 
toxicities. Because of this, there are now several on-going clinical trials looking at de-




Table 12: Head and neck survival by sub-site for males and females. 
 Overall   Males   Females 



















Hypopharyngeal 60.5 27.8 19.1  60.4 27.2 17.9  60.7 30.2 23.3 
Laryngeal * * *  85.3 65.4 54.7  * * * 
Oral cavity 78.4 56.1 45.2  77.8 53.5 42.2  79.2 59.8 49.6 
Oropharyngeal  83.7 65.6 57.7  83.8 65.5 57  83.6 66.0 59.4 
Salivary gland 85.8 67.0 59.3  82.5 58.3 50.7  89.8 77.8 70.3 
Sinus 74.8 51.4 42.6  73.0 50.3 42.5  77.5 53.2 42.5 
Based on CRUK figures 346.
3.9. Head and neck cancer prognostic factors 
Prognostic factors (also called prognostic markers) are those which, in people who have 
already developed a condition or disease, predict the outcome or natural history of that 
illness 352.  Therefore, in contrast to risk factors, prognostic factors are not necessarily 
causally related to disease. Prognostic factors can be divided into 3 main categories: those 
relating to the individual, the tumour, or the environment.  Individual or host-related 
prognostic factors include inherent demographic characteristics (e.g. age, gender, race), 
social and economic attributes (e.g. income, education, marital status) and clinical 
characteristics (e.g. comorbidity).  Tumour-related factors are those that concern tumour 
pathology, anatomic disease extent, and tumour biology.  Environment-related factors 
largely reflect lifestyle exposures, such as tobacco and alcohol use. 
3.9.1. Individual-related HNC prognostic factors 
3.9.1.1. Age 
Age is frequently reported as an independent prognostic factor for overall and disease-free 
survival in HNC 46 353-356. This can be explained in part by an increase in non-cancer-related 
mortality with increasing age 356. Older people (usually defined as people 65+ years in HNC 
studies) experience greater acute and late toxicity as the intensity of HNC treatment 
increases 357, often because of comorbidity or impaired functional status.  In particular, the 
addition of chemotherapy to radiation can increase toxicity and reduce tolerance to 
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therapy.  As a result older people may not be considered suitable candidates for 
multimodality treatment, which could impact on prognosis 357.   
3.9.1.2. Gender  
Gender is less well defined as an independent prognostic factor for HNC 358-360, though some 
studies suggest a lower risk of death among women 361-364. In one study, which included 
238,608 HNC cases from 86 cancer registries, relative survival was 75% and 67% at 1-year 
and 50% and 36% at 5 years in women and men, respectively 364 , when all HNC sites 
except larynx were combined. The reasons for this are unclear and probably complex. 
However, the authors suggest that it may be explained in part by the detection of cancer at 
an earlier stage in women than in men, which may result from the fact that women are 
typically more engaged in health and consult physicians sooner 365. The similar survival 
figures observed among men and women with laryngeal cancer in this study was attributed 
to the fatal sub-sites, particularly the supra-glottis, being more frequent in women than men 
(37% vs. 23%). 
3.9.1.3. Race/ethnicity 
There is some evidence to suggest that ethnicity is a prognostic factor for HNC survival, 
although most of the evidence comes from observational studies conducted in the US. In 
particular several studies report worse survival for African‐Americans compared to White 
and Hispanic Americans 366-371, largely attributed to socioeconomic (SE) differences. 
Nevertheless, several studies demonstrate that even after adjusting for factors such as age 
and stage at presentation, treatment modality and health insurance status, ethnicity remains 
an independent prognostic factor for OS 366 369 371.  Some authors suggest that disparities 
may be driven in part by racial differences in HPV-associated OPCs, with HPV prevalence 
being lower in African Americans 372 373.  The extent to which genetic factors could be 
contributing to racial differences is relatively unexplored.  One study reported a loss of the 
CDKN2A and a gain of SCYA3 in African Americans 374.  CDKN2A has been linked to 
malignant progression in HNC 375 376, whilst SCYA3 (otherwise known as macrophage 
inflammatory protein-1α [MIP-1-alpha]), has been implicated in tumour lymph node 
metastasis 377. 
3.9.1.4. Socioeconomic position 
Socioeconomic status (SES) affects overall survival 378-384. Estimates of the magnitude of the 
difference between the most and least deprived groups vary, however 385.  This is probably 
because studies have used different indices of socioeconomic status (SES) and/or have 
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adjusted for different confounding variables 385.  SES can be measured at an individual level 
(e.g. educational attainment, occupation, unemployment or marital status), or by using area-
based measures of deprivation.  Using the income domain of the Indices of Multiple 
Deprivation (IMD), a recent report produced by the National Cancer Intelligence Network 
(NCIN) in partnership with Cancer Research UK (CRUK) showed that between 2007-2011, 
European age-standardised HNC mortality rates in the UK were 218-298% higher for males 
living in the most deprived areas compared to the least deprived, and 59-257% higher for 
females (for cancers of the larynx, oral cavity and oropharynx) 140 386.   One explanation for 
this is that people living in low SE areas are frequently diagnosed at later disease stage, 
possibly as a result of poorer access to health care facilities or less awareness of the signs 
and symptoms of oral cancer 387 .  Another explanation is that the incidence of (non-cancer) 
smoking-and alcohol-related comorbidity is greater in deprived neighbourhoods. 
3.9.1.5. Comorbidity 
Comorbidity- the presence of one or more additional medical conditions - has been shown to 
be a strong prognostic factor for HNC survival 388-394. In a meta-analysis of 10 studies 
including 22,932 people with HNC, comorbidity was found to increase overall-mortality risk 
by around 40% (versus no comorbidity), but it did not have an impact on cancer specific 
survival.  Comorbidities are common in this population due to the association of HNC with 
tobacco and heavy alcohol use, combined with advanced age at time of diagnosis 388 394. The 
literature suggests that around 60% of people with HNC have concurrent illness, of which 
20% carry a severe comorbid burden 395 e.g. recent myocardial infarction, recent stroke or 
acute hepatic disease 396.  These figures are relatively high when compared to other cancer 
sites 397.  The presence of comorbid conditions is associated with higher rates of surgical 
and postoperative complications  398-400.  Consequently, people with comorbidities often 
undergo conservative and less radical procedures 395 401 which can affect HNC outcomes. 
Several instruments have been developed to quantify comorbidity 400; the Adult Comorbidity 
Evaluation 27 (ACE 27) and Charlson Comorbidity Index (CCI) are the most frequently used 
indices in HNC. The ACE-27, which will be referred to again throughout this thesis, was 
modified from the Kaplan–Feinstein Index for use in cancer patients. The instrument grades 
27 individual conditions as mild, moderate, or severe based on the severity of organ 
decompensation and prognostic impact and then assigns an overall comorbidity score that is 
equal to the highest ranked single ailment 402(further details are provided in Chapter 5). The 
CCI by contrast, takes into account the presence of 19 diseases; each condition is assigned 
a weight of 1 to 6 403, based on the estimated 1-year mortality HR from a Cox proportional 
hazards model 404; the weights are then summed to produce an overall comorbidity score 
97 
 
ranging from 0–37 405 406. Each comorbidity instrument is associated with its own advantages 
and disadvantages 406 407. The ACE-27 is well validated for use in people with HNC but it 
may be less well suited to retrospective or historical studies as some of the conditions 
require invasive confirmation or specialist evaluation.  The CCI is simple to apply, widely 
applied and suitable for historical studies but, as pointed out by Rotbøl Bøje et al, the 
prognostic impact of the diseases measured may have change since the instrument was first 
developed in the late 1980s 407.   
3.9.2. Tumour-related HNC prognostic factors 
3.9.2.1. Tumour stage  
In addition to tumour site, tumour staging is a well-documented prognostic factor for HNC 408-
412. People with tumours that are larger and have spread to lymph nodes and other tissues in 
the body have poorer survival 413.  For most (but not all) HNCs, lymph node involvement 
automatically places the cancer at stage III (see Chapter 2). Overall, only 25%-40% of 
people with lymph node metastasis are expected to survive 5-years, compared to 
approximately 90% of people with tumours that are limited to the primary site (i.e. people 
with cancers that have not metastasized to the lymph nodes) 414. 
 
In a report produced by the Oxford Cancer Intelligence Network (OCIN) looking at survival 
by stage, the one-year relative survival rates for early versus late stage laryngeal cancer 
were 97% and 76% respectively 412.  At three years, the difference in survival rates 
increased to almost 40% (relative survival rates of 89% for early stage disease versus 51% 
for late stage disease). For oral cancers, the one-year relative survival rates were 85% for 
early stage disease versus 72% for late stage disease and at 3-years post diagnosis, the 
corresponding rates were 82% and 66%. Compared to OPCs that were diagnosed with late-
stage disease, OPCs diagnosed at an early stage also had higher one- and three-year 
relative survival rates. However, It is worth noting that, as described in Chapter 2, the 
staging of HPV-associated OPC has been modified to downstage the disease, for the reason 
that, although people tend to present with extensive disease, their prognosis is often good 
415. 
 
The location of the lymph node metastases has particular prognostic significance. For most 
HNCs, worse survival is observed when metastases involve lymph nodes beyond the first 
draining lymph node 416. Survival is particularly poor for lymph nodes in the lower regions of 
the neck, i.e. levels IV and V (supraclavicular area) 417.   
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3.9.2.2. HPV status 
People with HPV-positive oropharyngeal tumours tend to experience better overall-survival. 
In a retrospective analysis of participants included in the RTOG 0129 study, Ang et al 
demonstrated that, after adjustment for age, race, tumour and nodal stage, tobacco 
exposure, and treatment assignment,  the risk of death for people with HPV-positive OPCs 
was 58% lower than that for people with HPV-negative tumours 418.  Here HPV status was 
determined using HPV-16 DNA ISH.  When p16 expression was used as a proxy for HPV 
status, results were similar. These two methods of assessing HPV status are discussed 
further in the next chapter.  
3.9.2.3. Genetic predictors 
A number of investigators report that mutations in the gene encoding the tumour suppressor 
protein p53 are associated with reduced survival 419-422, and this is likely due to reduced 
susceptibility of cancers cells to apoptosis. However, the evidence is inconsistent 423. HNC 
with mutations in NOTCH1, which is the second most frequently mutated gene after TP53, 
have also been shown to have a worse prognosis compared to NOTCH1 wild-type tumours 
424, and inhibition of NOTCH pathway genes has been shown to decreases cell proliferation 
and invasion in some studies 425. Loss of PTEN expression or loss of PTEN function as a 
result of mutation, which are also both common occurrences in in HNC, have also been 
identified as potential markers of high recurrence risk 426.  
3.9.2.4. Epigenetic predictors 
Whilst aberrant DNAm profiles have been associated with HNC, few studies have 
comprehensively investigated the potential prognostic value of these biomarkers.  In one 
study, Kostareli and colleagues 427 investigated whether the promoter methylation states of 
five candidate genes, including ALDH1A2, OSR2, GATA4, GRIA4, and IRX4, correlated with 
overall survival and progression-free survival in OPC.  They found that a pattern of low 
methylation levels in ALDH1A2 (which encodes the aldehyde dehydrogenase family 1 
member A2) and OSR2, and high methylation levels in GATA4, GRIA4, and IRX4 (in tumour 
tissue) were associated with improved survival in 3 independent HNC cohorts (total n=220).  
Strikingly, the authors demonstrated that the methylation score had superior prognostic 
performance compared to HPV status, as measured by HPV DNA, RNA and p16 status. 




In a more recent analysis of tumour DNA samples, Zhou et al (2018) 283 evaluated the 
prognostic value of four aberrantly methylated genes (FAM135B, ZNF610, HOXA9, and 
DCC) and confirmed that FAM135B methylation was a favorable independent prognostic 
biomarker for overall survival in HNC (HR= 0.12; 95% CI: 0.02 to 0.69).  There was no 
evidence of an association between the remaining candidate genes and overall survival (n= 
520 HNC and 44 normal control samples).  
 
Several studies have suggested that p16INK4A (CDK2NA) promoter methylation, which was 
mentioned earlier in this chapter, may serve as a useful biomarker to predict nodal 
metastasis and tumour recurrence in HNC 281 284. In one study, which included 38 people 
with SCC of the tongue, the presence of p16 promoter hypermethylation in surgical margins 
was associated with a 6.3-fold increased risk of local recurrence, compared to people with 
negative margins 428. p16 hypermethylation also had an unfavourable impact on DFS (HR= 
2.24, 95% CI: 1.35 to 3.73) in a systematic review and meta-analysis, which included five 
HNC studies (n=385) 429, but the same authors found no evidence of an association between 
p16 methylation and OS.  
3.9.2.5. Metabolic predictors 
As with DNAm, there is a paucity of studies examining the influence of differentially 
produced metabolites on prognosis in the HNC literature, even though there is growing body 
of evidence to suggest that HNCs possess a distinct metabolic signature compared to 
controls.  Yonezawa et al (2013) 332 analysed the sera of 17 people with HNC (largely 
hypopharyngeal and oral cavity cancers), using gas chromatography/mass spectrometry, 
and found that the serum levels of several glycolysis-related metabolites, namely glucose, 
ribose and fructose, were higher in individuals who experienced disease relapse (n=5) 
compared to those who did not. Conversely, those who had disease relapse had lower 
circulating levels of lysine and trans-4-hydroxy-L-proline. For oral cavity cancer specifically, 
the authors found that the amino acids methionine and ketoisoleucine were also lower in 
people who experienced cancer relapse (n=4).  It is not possible to draw any conclusions 
from these analyses given the small sample size.  
3.9.2.6. Infection biomarkers 
Numerous other molecular biomarkers have been investigated as potential prognostic 
factors for HNC. Evidence gleaned from recent studies looking at the effects of tumour 
infiltrating lymphocytes on HNC outcomes suggest that neutrophil-to-lymphocyte ratio (NLR) 
430-434 lymphocyte-to-monocyte ratio (LMR) 435 436, and platelet-to-lymphocyte ratio (PLR) 437 
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may provide prognostic value. A systematic review of data from over 40,500 individuals in 
100 studies concluded that an elevated NLR is associated with a 1.8-fold higher mortality 
risk (95% CI: 1.67 to 1.97) and this effect is detected across all HNC subgroups, sites, and 
stages.  An elevated PLR also predicts poorer over-all survival, as reported in a recent meta-
analysis of 9 studies (2327 individuals) 437.  Here, PLR greater than the cut-off value was 
associated with a 1.6-fold increase in risk of death (95% CI: 1.1 to 2.4). By contrast, pooled 
data from 4,260 individuals in seven cohorts (including all HNCs) demonstrated that an 
elevated LMR is associated with a 50% lower mortality risk (HR for OS= 0.5 [95% CI: 0.44 to 
0.57]) 435.  The importance of immune function in tumour development and progression have 
long been acknowledged in the cancer literature 438 but at present, the exact mechanism 
underlying the relationships of NLR, LMR and PLR with prognosis are poorly understood.  
3.9.2.7. Other molecular biomarkers 
Tumour hypoxia has been associated with adverse prognosis 439.  In a meta-analysis of 28 
studies, over-expression of hypoxia inducible factors (HIF 1/2α) was associated with a two-
fold higher mortality risk (HR = 2.12; 95% CI: 1.52 to 2.94; I2 74%) 440.  In another meta-
analysis, looking at the association between tumour expression of vascular endothelial 
growth factor (VEGF) and survival in HNC (oral cavity 70.8% of people, pharynx 15.2%, and 
larynx 14%),  individuals who were positive for this growth factor had almost double the risk 
of death at two years (relative risk [RR] = 1.88 [1.43 to 2.45]).   
3.9.3. Environment-related HNC prognostic factors 
3.9.3.1. Smoking 
As well as being a major risk factor for HNC, smoking has consistently been associated with 
poorer clinical outcomes 441-452 (Table 13).  The extent of its effects is poorly defined 
however, in part because studies have used different methodologies and measures of 
tobacco exposure.  For instance, Duffy et al (2009) report a 2.4-fold higher all-cause 
mortality risk in current versus never-smokers 441, whilst Mayne et al observed an almost 
five-fold higher mortality risk in people with >60 pack-years of smoking compared to never-
smokers 442.  Both studies were small -504 and 264 people respectively, limiting their 
statistical power to detect an effect.  In addition to this, participants were enrolled from a 
single medical centre or clinical trial in the US, which effects the generalisability of their 
results. Historical analyses are typically larger, but they have often lack information on 
potentially important confounders such as socioeconomic status and comorbidities.  Studies 
have also included different subpopulations of people, i.e. they have included different 
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cancer sites or tumour stages and therefore it is unclear whether the effects of tobacco 
exposure vary by cancer type.  Moreover, few investigators have examined the potential 
interaction between tobacco smoking and HPV status. 
3.9.3.2. Alcohol drinking  
The prognostic role of alcohol consumption in HNC has yet to be fully elucidated. Table 14 
provides a summary of the results of studies looking at the relationship between alcohol 
drinking behaviours and HNC outcomes.  The evidence is conflicting.  In the same studies 
mentioned above, Mayne et al (2009) reported a five-fold increased mortality risk for people 
who drank >35 drinks per week compared to those who abstained 442.  Duffy et al (2009), by 
contrast,  found no difference in mortality risk between people with and without an alcohol 
problem at the time of diagnosis (based on an Alcohol Use Disorders Identification Test 
(AUDIT) score cut-off of >8 453) 441. There is some evidence to suggest that heavy alcohol 
intake may increase the risk of second primary tumour (SPT) development.   In a multicentre 
population-based case control study that included 876 people with laryngeal and 
hypopharyngeal cancers, Dikshit et al 448 found that people who consumed >121 grams of 
alcohol per day were nearly twice as likely to develop a SPT compared to people who drank 
0-40 grams per day (HR=1.9; 95% CI: 1.1 to 3.2).  In support of this, Do et al reported a risk 
ratio (RR) for SPT development of 1.4 for current versus never-drinkers, although with wide 
confidence intervals (95% CI: 0.9 to 2.2)  451. 
 
3.9.3.3. Diet 
In addition to pre-treatment smoking and drinking behaviours, dietary intake may have an 
influence on survival, although the evidence is limited and generally under-powered.  In a 
small, historical study of just over 200 individuals with laryngeal cancer, Crosignani et al  
found that the consumption of vegetables, citrus fruit and olive oil was associated with a 
better prognosis 449.  Low fruit intake but not low vegetable intake was negatively associated 
with survival in another study by Duffy et al (HR=1.6; 95% CI: 1.1 to 2.1), however the effect 
attenuated on adjustment for age, marital status, education, cancer stage, and comorbidity 
(HR=1.3; 95% CI: 0.9 to 1.8) 441. Similarly, in a recent analysis in H&N5000, fruit and 
vegetable intake were both associated with improved survival in models that adjusted for 
age and gender but following adjustment for health risk behaviours (smoking, alcohol 
drinking, fried food consumption and either fruit or vegetable intake depending on the 
exposure of interest), the association disappeared for fruit intake and attenuated for 
vegetable intake 454. 
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Table 13: The association of pre-treatment smoking with head and neck cancer outcomes. 
Ref. Study design N Site(s) Exposure(s) Outcome(s) Association 
449 Historical case 
control study (Italy) 
213 Larynx Cigarettes/day OS HR=1.3 (95% CI: 0.8, 2.0) for upper (mean 50 
cigarettes/day) vs. lowest (mean 17.5 cigarettes/day) 
tertile. 
455 Prospective cohort 
study 
355 Larynx Cigarettes/day OS HR=1.8 (95% CI: 1.1, 2.9) for 28+ cigarettes/day vs. 0-
15 cigarettes/day. 


















case control study 
(SE Europe) 
876 Larynx & 
HP 
Cigarettes/day 
& pack years 
SPT HR=1.3 (95% CI: 0.8, 2.1) for 26 + cigarettes/day vs 0-
15 cigarettes/day; HR=1.6 (95% CI: 0.8, 2.1) for 60+ 
pack-years of smoking vs 0-20 pack-years. 
456 Prospective cohort 
study (Netherlands) 
81 Tonsils Smokers vs. 
non-smokers 
OS HR=5.5 (95% CI: 1.3, 23.6) for smokers vs. non-
smokers. 





Smoking status  OS HR=2.4 (95% CI: 1.3, 4.4) for current vs. never-




Table 13 continued. 
Ref. Study design N  Site(s) Exposure(s) Outcome(s) Association 










HR=1.3 (95% CI: 1.2, 1.5) for former vs. never 
smokers; HR= 1.8 (95% CI: 1.5, 2.0) for current vs. 
never-smokers. 
HR=1.5 (95% CI: 1.2, 1.8) for current vs. former 
smoker. 
442 People enrolled in 
an RCT of β-















HR=2.1 (95% CI: 0.28, 16.5) for former vs. never-
smokers; HR=4.91 (95% CI: 0.7, 36.0) for current vs. 
never-smokers. 
HR=5.4 (95% CI: 0.7, 40.1) for 60+ pack-years of 
smoking vs none. 
457 Prospective study 
(US) 




HR=5.2 (95% CI: 1.1, 24.4) for HPV-positive current 
vs. never-smokers; HR=2.9 (95% CI: 0.6,13.6) for 
HPV-positive former vs. never-smokers; HR=1.8 (95% 
CI: 0.7,4.8) for HPV-positive current vs former-
smokers. 
446 Retrospective study 
of people enrolled in 
the RTOG 9003 
RTOG 0129 trials 
(US) 








HR RGOT 9003= 3.9 (95% CI:2.0, 7.5) for current vs 
never-smokers. HR RGOT 0129: 2.0 (95% CI:1.0, 4.3) 
for current vs never-smokers. 
HR RTOG 9003= 2.1 (95% CI: 1.4, 3.3) for >10 vs. < 
10 pack-years of smoking. HR RTOG 0129: 1.8 (95% 
CI: 1.1, 3.0) for >10 vs. < 10 pack-years of smoking. 
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Table 13 continued. 
 
Ref. Study design N  Site(s) Exposure(s) Outcome(s) Association 
458 Historical cohort 
study (US) 
132 OP Smoking status  Distant 
metastases 
HR=12.7 (95% CI: 3.5–46.0) for active vs. non-active 
smokers. 




Smoking status OS HR male=1.6 (95% CI: 1.0, 2.6) and HR female=1.0 
(95% CI: 0.5, 1.7) for current vs. never-smokers; HR 
male=1.7 (95% CI:1.2, 2.) and HR female=1.0 (95% 
CI: 0.5,1.8) for current vs. former-smokers; HR males= 
2.1 (95% CI: 1.4, 3.1) and HR females=0.5 (95% CI: 
0.,3,0.9) for current smoker vs. recent quitter. 
444 Prospective cohort 
study (US) 
89 All sites Smoking status Post-
operative 
complications 
Compared with never smokers, former and current 








Smoking status DSS HR=1.4 (95% CI:1.2, 1.5) for current vs never-
smokers; HR=1.1 (95% CI: 1.0,1.3) for former vs 
never-smokers. 
459 Prospective cohort 
study (US) 















HR=2.1 (95% CI: 1.3, 3.3) for current vs never-
smokers; HR=2.1 (95% CI: 1.3, 3.4) for former vs. 
never-smoker. 
HR=1.87 (95% CI:1.1, 3.3) for current vs never-
smokers*; HR=2.2 (95% CI: 1.2, 3.9) for former vs. 
never-smokers. 
Worse survival associated with every ten- year 
increase in pack-years in univariable models. 
Abbreviations: C,: confidence interval; DSS, disease-specific survival; HR, hazard ration; LC, local control; N, sample number; OC, oral cavity; O,: 
oropharynx; OS, overall survival; HP, hypopharynx; Ref, reference; RFS, recurrence free survival; RR, relative risk; SPT, second primary tumour; 
RTOG, Radiation Therapy Oncology Group; SE, South-east; US, united states.
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Table 14: Association of pre-treatment alcohol consumption with head and neck cancer outcomes. 
Ref. Study design N site(s) Exposure(s) Outcome(s) Results 
449 Historical 
population-based 
case control study 
(Italy) 
 
213 Larynx g/day OS HR=1.12 (95% CI: 0.7, 1.8) for upper tertile of alcohol 
consumption (mean=139.8 g/day) vs. lower tertile 
(mean=22.9 g/day). 
455 Prospective cohort 
study 
355 Larynx g/day OS HR=1.1 (95% CI: 0.7, 1.9) for people who 
consumed >121g/day of alcohol vs. people who 
consumed 0-40 g/day. 
 
 451 Participants 













SPT RR=1.4 (95% CI: 0.9, 2.2) for current drinkers vs. 
never-drinkers; RR=1.2 (95% CI: 0.8,1.9) for former 
drinker vs. never-drinkers. 
 447 Multicentre 
population-based 




g/day OS HR=1.3 (95% CI: 1.0, 1.6) for people who 
consumed >121g/day vs. people who consumed 0-40 
g/day; HR=1.2 (95% CI: 0.9, 1.5) for people who 
consumed 81-120 g/day vs. 0-40 g/day; HR=0.9 (95% 
CI: 0.8,1.2) for people who drank 41-80 g/day vs. 0-40 
g/day. 
 







OS HR=1.32 (95% CI: 0.9,1.9) for people with a pre-
treatment alcohol problem vs. people without. 
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Table 14 continued. 
 
Ref. Study design N site(s) Exposure(s) Outcome(s) Results 
448 Multicentre 
population-based 




g/day SPT HR=1.9 (95% CI: 1.1, 3.2) for people who 
consumed >121g/day vs. people who consumed 0-40 
g/day; HR=1.6 (95% CI: 0.9, 2.7) for people who 
consumed 81-120 g/day vs. 0-40 g/day; HR=1.4 (95% 
CI: 0.9, 2.4) for people who drank 41-80 g/day vs. 0-40 
g/day. 
 












HR=1.3 (95% CI: 1.2,1.4) for active drinker vs. never-
drinkers; HR=1.1 (95% CI: 1.0, 1.2) for former drinker 
vs. never-drinkers. 
HR=1.3 (95% CI: 1.2, 1.5) for active drinker vs. never-




enrolled in an RCT 
of β-carotene for 





Drinks/week OS HR=4.87 (95% CI: 1.5, 16.3) for >35 drinks/week vs. 
none; HR=2.4 (95% CI: 0.6,9.3) for 22-35 drinks/week vs. 
none; HR=1.4 (95% CI: 0.4,5.4) for 8-21 drinks/week vs. 
none; HR=1.5 (95% CI: 0.4,6.1) for 1-7 drinks/week vs. 
none. 
 
Abbreviations: CI, confidence interval; DSS; g/day, grams of alcohol per day; HR, hazard ration; LC, local control; N, sample number; OC, oral cavity; 





3.9.4. HNC prognostic models  
Prognostication is a fundamental part of medicine.  From the clinician’s point of view, attaining an 
accurate prognosis for their patient is important as it has a decisive impact on treatment decisions 
(e.g. curative treatments versus palliative care). From the point of view of the individual with cancer, 
evidence suggests that people often find it easier to cope with a cancer diagnosis if they know what 
their expected prognosis is; it can give them time to make important decisions such as whether they 
want treatment, how best to manage treatment side effects, and how to take care of financial, 
family, and legal matters, amongst other things 460-462.  Making an accurate HNC prognosis can be 
very challenging even for the most experienced physician, as disease outcomes are based on the 
presence and interaction of multiple factors 463, as evidenced above.  The relative contribution of 
these individual prognostic factors varies.  Prognostic models, also referred to as clinical prediction 
models or clinical prediction rules, are statistical equations that predict an individual’s risk of a future 
outcome (typically death or recurrence of disease) within a specific period of time, based on the 
combination of values of multiple predictors (e.g. age, gender, biomarkers) 464.  There are several 
papers describing the methods of model development 465 466, therefore they will not be described in 
detail here, but in brief, prognostic models are usually developed using multivariable regression 
techniques such as logistic models and survival analysis models. 
 
There are three main phases in prognostic model research, as outlined in the Prognosis Research 
Strategy (PROGRESS) framework 464:  
1) Model development, including internal validation;  
2) External validation;  
3) Evaluation of model impact in clinical practice (e.g. influence on decision making, individual 
outcomes, and costs). 
Most publications describe the model development phase, with few models being implemented in 
clinical practice 467.  Models are more likely to perform well, and therefore have clinical utility, if they 
are developed using large, high quality datasets, are based on a pre-defined study protocol and are 
validated in independent datasets selected from different settings 468. The final point is important 
because the predictive performance of a model estimated on a training dataset, or development 
data, is frequently optimistic, owing to issues of multiple testing in a limited sample size 464.  This 
impacts on the generalisation of prognostic models.  Another important point is that model 
performance may diminish over time, perhaps due to improvements in making diagnoses earlier or 
advances in treatments.  It is recommended that researchers should first consider whether it is 
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possible to improve or augment existing models, either by recalibrating them (i.e. adjusting the 
intercept of the model and/or the relative weights of the predictors) or by adding additional 
predictors such as novel biomarkers or results from new imaging techniques, before developing new 
models 464 468. However, the independent effects of new prognostic markers need to be quite large in 
order to achieve a clinically meaningful improvement compared to standard models, which generally 
include the most important predictors 464 (e.g. age, tumour stage and HPV status in the case of 
HNC). 
 
Table 15 summarises the results of a scoping review of HNC prognostic models in Ovid Medline. 
The purpose of which was to determine the size and nature of the evidence base in this area. 






6. 1 or 2 or 3 or 4 or 5 
7. calculat*.m_titl. 






14. 7 or 8 or 9 or 10 or 11 or 12 or 13 















28. 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 
29. 15 and 28 
30. Limit 29 cancer 
 
A manual search in the bibliographies of selected articles was also conducted. Only studies that 
meet the following criteria are included:   
1) The outcome of interest is survival (overall, disease-specific or recurrence-free);  
2) Only prognostic factors that are available at the time of diagnosis were considered for 
inclusion in the model;  
3) Models are multivariable (i.e. multiple biological/clinical/ lifestyle factors were considered for 
inclusion in the model).   
Of the fourteen models identified, six were applicable to multiple tumour sites, three were specific to 
OPC, one to HPV-negative OSCCs (tongue and oral cavity), one to oral cavity cancer, one to 
laryngeal cancer and one to tongue cancer.  The most frequently occurring predictors were age and 
tumour stage, which were included in eleven and twelve models, respectively.  The next most 
common predictors were comorbidity (five models), tumour grade (three models) and cigarette 
smoking (five models), which was defined by number of pack years of smoking or smoking status 
(e.g. current/former/never). 
 
Some of the authors derived and integrated prognostic scores into their prediction models, which 
were based on either gene expression profiles or clinicopathological features of the tumour.  Mes et 
al  (2017) for example, built a multivariable genomic model that included a 40-gene overall survival 
signature, in addition to established clinical and pathological prognostic variables 469.  By itself, the 
overall-survival signature only modestly predicted survival with an AUC of 0.63 (95% CI: (0.57-0.68); 
when combined with clinical and pathological variables (age at diagnosis, smoking, pTNM and a 
composite variable that was scored positive if extra capsular spread or tumour-positive margins or 
multiple metastatic lymph nodes were present), the prognostic accuracy of the model increased, 
yielding an AUC of 0.74 (95% CI: 0.69-0.79).  This compares to an AUC of 0.51 (95% CI: (0.47-
0.57) for standard pTNM staging only and an AUC of 0.66 (95% CI: 0.59-0.73) for a model that 
included pTNM, age and pack-years of smoking.   
 
Almangush et al (2015), included a tumour budding-depth of invasion score in their model. Tumour 
budding was defined in this analysis as “as the presence of single cancer cells or small clusters of 
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cells (<5 cells) at the invasive front” Individuals were scored “0” if neither budding nor depth of 
invasion were higher than a pre-defined cut-off value , “1” if only one of the parameters was higher 
than the cut-off, or “2” if both parameters were higher than the cut-off  470.   On multivariate analysis, 
a high-risk score (BD score 2) was strongly associated with cancer-specific mortality (HR= 5.11; 
95% CI: 2.05 to 12.75) in early stage oral tongue squamous cell carcinoma (OTSCC). The authors 
suggest that the novel tumour-budding model provides a promising prognostic tool that may enable 
clinicians to identify people with aggressive cases of early stage disease who could benefit from 
multimodality treatment. In order for tumour budding scores to be introduced into routine pathology 
reporting, however, standardized studies including different HNCs are needed, both to identify the 
optimal cut-off point for characterising tumour budding in each cancer type, and to establish the best 
scoring method to use (e.g. which areas of the invasive front to analyse). 
 
Two of the prediction models described in Table 15 have been converted to online tools 471 472, 
which are intended to assist (not replace) clinicians with their prediction of an individual's future 
mortality risk. A screen shot of the first web-based calculator, which was built by Emerick et al. is 
depicted in Figure 18.  The underlying model was developed using data from over 50,000 people 
included in the SEER database and validated externally in a dataset containing around 13,000 
individuals entered into the Massachusetts General Hospital tumour registry between 1980 and 
2009. The user inputs the individual’s age, gender, race, tumour site, tumour dimension, tumour 
extension, N-stage, number of positive lymph nodes, extracapsular spread and histological type (i.e. 
squamous cell), by using either a drop-down menu or by entering the value manually.  The 
calculator then predicts survival (risk of death from HNC, risk of death from non-cancer causes and 
overall risk of death) for each of the first ten years after diagnosis, alongside estimates of the 10-
year Kaplan-Meier cancer-specific death rate and the impact of disease on life expectancy.  The 
authors were unable to incorporate HPV data into their model due to lack of HPV-related data and 
cite this as a limitation.  A positive feature of the online tool is that the survival information can be 
viewed in a number of different formats, including survival curves, death curves, pie charts or 
“smiley face” charts, making it a useful tool for clinicians to communicate prognostic information to 
their patients.   
 
The second on-line tool, which was developed by Velazquez et al (2014) 472, was fitted on data from 
a sample of 168 people with OPC and validated in an external dataset of 189 people. The factors 
evaluated for their prognostic potential included age, gender, HPV status, tumour site, TNM 
classification, comorbidity (measured using the ACE-27), pre-treatment haemoglobin levels and 
smoking (pack-years) and alcohol history.  For overall-survival specifically, the factors that remained 
in the model (and which were integrated into the on-line tool), were male gender, low pre-treatment 
haemoglobin levels (<median), higher T-stage, N2b-N3 stage, negative HPV status and high 
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comorbidity (moderate to severe).  Prediction of overall-survival using the model yielded 
concordance statistics (C-index) of 0.82 (95% CI: 0.76 to 0.88) and 0.73 (95% CI: 0.66 to 0.79) in 
the training and validation datasets, respectively, indicating good (but not optimal) calibration. As a 
comparison, the C-index for TNM staging alone was 0.66 (95% CI: 0.61 to 0.75) and HPV alone 
0.68 (95% CI: 0.61 to 0.72).  Based on the values entered for the individual, the output of the on-line 
calculator includes estimates of two- and five- year risk probabilities for overall and progression-free 
survival. This information is presented visually as a histogram, and an accompanying summary of 
the information is provided in text beneath. The bars of the graph appear as green, orange or red, 
depending on whether the individual is classed as being at ‘low’, ‘medium’ or ‘high’ risk of death. 
 




The on-line tool is straightforward to use and could provide a useful aid in clinical decision-making. 
However, it is important to note that, whilst the model was validated in an independent cohort, the 









Outcome(s) Final predictors Tool Externally 
validated 
 




DSS Age, gender, tumour grade, TNM stage, 









OS Site of the primary tumour, age at diagnosis, 
gender, T-, N-, and M-stage, and prior 
malignancies. 
Equation Y 
474 OSCC  192 Participants 





Three IncRNA panel (TN1-AS1, LINC00460 
and RPS-894A10.6) and tumour grade. 
Equation  N 
475 OSSC 446 Hospital-recruited 
cases (China) 
OS TNM stage, tumour grade, ill-fitting 
dentures, oral hygiene and cigarette 
smoking. 
Equation Y 






OS Age, sex, tumour location, T-, N-, M- stage, 




471 All HNCs 50,145 Participants 
included in the 
SEER dataset  
(US) 
OS, DSS Tumour size (T), no. of positive lymph 
nodes, anatomic site, tumour extension, N-









(Germany and US) 
OS 40 gene overall survival signature, age, 
pack-years of smoking, pathological 
composite variable (including extracapsular 
spread, tumour positive margins and 










Outcome(s) Final predictors Tool Externally 
validated 
 
478 OPC 493 Participants enrolled in the 
NRG Oncology RTOG 






Age, pack-years of smoking, Zubrod 
performance status, education, 
anaemia, tumour p16 status, T-stage, N-
stage. 
 
Age, Zubrod performance status, p16 
status, weight loss, education, marital 
status, pack years of smoking, T-stage 
and N-stage. 
Nomogram Y 








Age, race, tobacco status (never/ever 
smoker), comorbidity (defined using the 
WUHNCI) tumour diameter and clinical 
N-stage.  
 
Tumour size, nodal status, subsite and 
bone metastasis. 
Nomogram N 
480 OC, OP, 
HP, larynx 
1010 Hospital-recruited cases 
(US) 
OS Age, alcohol use, symptom severity 
stage, comorbidity (based on KFI) and 
TNM stage. 
Equation N 
481 Larynx 788 Hospital-recruited cases  
(Netherlands) 
OS Age, cTNM stage, ACE-27 comorbidity 
score, BMI and anaemia. 
Equation N 







Age, gender, comorbidity, pack years, T-
stage, N-stage and HPV status.  
 
Age, gender, comorbidity, T-stage, N-
















197  Hospital recruited 
cases 
(Sweden) 
3-year D/R Age, stage, diagnosis (TSCC or 
BOTSCC), HLA Class I expression, 
and CD8+TIL counts. 
Equation Y 











HPV status, comorbidity, T- and N- 
classification, pack years of smoking, 
gender and pre-treatment 
haemoglobin levels. 
 
Gender, comorbidity, T-stage, N-






Abbreviations: BSCC, basaloid squamous cell carcinoma; BOTSCC, base of tongue squamous cell carcinoma; cTNM, clinical tumour-node-
metastasis; CSD, cause-specific death; DFS, disease-free survival; D/R: death or relapse; DSS, disease specific survival; HNC, head and neck 
cancer; HP, hypopharyngeal; HNSCC, head and neck squamous cell carcinoma; lncRNA, Long non-coding RNAs; KFI, Kaplan-Feinstein index; 
m, months; OC, oral cavity; OP, oropharyngeal; OS, overall survival; OSCC, oral squamous cell carcinoma; PFS, progression free survival; 
RTOG: Radiation Therapy Oncology Group; SCCOC; squamous cell carcinoma of the oral cavity; SUVmax, maximum standardised uptake 
value; TILs: tumour infiltrating lymphocytes; TSCC, tongue squamous cell carcinoma; WUHNCI, Washington University Head and Neck 




3.10. Summary  
HNC is a global health burden.  Most incident cases occur among older individuals and 
among males, though the disease also represents a significant cause of morbidity and 
mortality among women.  Development of HNC is a multifactorial process with a wide variety 
of individual and social risk factors, including diet, genetics and environmental exposures.  
The most common risk factors overall are tobacco and alcohol use, which together account 
for around two-thirds of all cases.  Accordingly, HNC is especially common in regions of the 
world where tobacco and alcohol consumption rates are high. Polymorphisms in tobacco 
and alcohol metabolizing genes such as CYP gene family, glutathione S-transferases and 
ALDH may explain differences in people’s risk for developing tobacco and alcohol-related 
HNCs, since not everyone who smokes, and drinks goes on to develop the disease.  
 
HPV infection is another well-established risk factor for a sub-set of OPCs. HPV-positive 
OPCs are particularly prevalent in economically developed countries, where incidence rates 
have been increasing over the last few decades.  Although HPV-positive tumours are often 
detected at an advanced stage, they tend have a better prognosis. 
 
The recognition that HNC is not a single disease entity but rather a group of distinct cancer 
types, each of which may have different and interacting etiologies and clinical outcomes, has 
led to the development of several multifactorial prognostic models. The goal of prognostic 
research, which relates to the current movement towards stratified medicine, is to provide 
individualized outcome prediction. A review of the literature suggests that integrating clinical, 
molecular and histopathological variables into prognostic models could facilitate more 
accurate prediction. The contribution of genetic, proteomic and metabolomic measures to 
HNC outcome prediction is a particularly active area of research at present, but so far, no 
such markers have been adopted in clinical practice. Age, cancer site and stage remain the 




Chapter 4: Capturing exposures to biological, 
environmental and lifestyle risk factors 
4.1. Introduction 
An “exposure”, in an epidemiological context, is any factor that may be associated with an 
outcome of interest 485. This includes the primary explanatory variable as well as any 
additional variables that may be related to the outcome, for example confounders or effect 
modifiers, which should be taken into consideration in the statistical model. An important 
concern in any study design, therefore, is how to identify and characterise exposure to a 
given factor.  
 
The previous chapter identified the main biological and lifestyle exposures related to HNC 
risk and prognosis, including tobacco and alcohol use, HPV infection, BMI and 
socioeconomic status. This chapter addresses the issue of how these exposures can be 
measured. It starts by looking at some of the instruments that are available for assessing 
health-related behaviours and other characteristics linked to healthy life expectancy such as 
biological age; it then goes on to explore different methods for detecting HPV infection, 
which is particularly significant for studies that include OPC. The chapter ends by 
highlighting the growing potential of metabolomics for identifying intermediate biomarkers 
linking exposure and disease outcomes. 
4.2. Self-reported phenotypes 
Information on health-related behaviours and socioeconomic position are commonly 
obtained via self-administered questionnaires. This may be the only method available to 
researcher. It is relatively inexpensive, easy to perform and it provides a means of assessing 
exposures in a way that is non-invasive and generally acceptable to respondents. As such, 
self-report can facilitate research that may otherwise be impossible to carry out. However, in 
order to obtain accurate information, respondents must have good insight into their own 
behaviours, must answer the questions honestly and understand what the questions are 
asking. Even small changes in the way a question is worded, the order the questions appear 
or the format of the questions (e.g. open-ended or fixed response) could result in different 
responses.  The effects of mode of questionnaire administration and design on data quality 
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falls outside the scope of this thesis, however an excellent summary is provided in Bowling, 
(2005) 486. 
 
There are many reasons why individuals may provide biased estimates of their own 
behaviours. Often, they may answer in a way that makes them ‘look good’, even if the 
questionnaire is anonymous, a phenomenon known as social desirability bias 487.  Here, a 
person’s answer is determined by what they perceive as being socially acceptable, rather 
than what is true. This can result in under-reporting of unhealthy or undesirable behaviours, 
like smoking and alcohol drinking, and over-reporting of healthy or desirable behaviours, 
such as exercise. That said, self-reported smoking has been validated in numerous 
populations and in general, high agreement has been found between self-report and 
measurements of cotinine, a nicotine metabolite that is often used as an index of smoking 
status 488 489.  Self-reported alcohol intake is less precise, with studies suggesting that heavy 
drinkers are more likely to under-estimate their alcohol intake compared to light or moderate 
drinkers 489 490.  
 
Assessments of tobacco exposure are largely based on retrospective reports of the average 
number of cigarettes smoked per day, which is often converted into ‘pack-years’ of smoking. 
This measure has been shown to be variable in terms of reliability and validity, largely due to 
individual differences in the way in which people smoke. Variations in smoking habits (e.g. 
frequency of puffs, puff volume and puff duration), which is termed smoking topography 491, 
as well as differences in the brand of cigarette smoked can lead to different levels of 
exposure, even in individuals who smoke the same number of cigarettes.  In addition to this, 
the average number of cigarettes smoked per day may change over a person’s lifetime. Self-
report questionnaires may not fully capture cumulative life-time exposure, particularly if the 
respondent is unable to recall past behaviours. 
 
Self-reported alcohol consumption is measured in a number of ways and there is an 
extensive literature comparing the advantages and disadvantages of each approach 492 493. 
The quantity/frequency (QF) method, which focus on ‘typical’ intake, and the graduated 
frequency (GF) approaches 494, which enquires about the frequency of drinking days for 
graded amounts of alcohol (e.g. the number of occasions when one or two drinks, three to 
four drinks, etc. were consumed), are among the most commonly utilised methods. Evidence 
suggests that GF produces higher estimates of alcohol intake than QF because of its ability 
to measure day-to-day drinking variability but QF is quick and simple to complete 495, which 
is important if response fatigue is an issue. Both approaches rely on recall of actual drinking 




4.3. Biochemical measures of tobacco and alcohol exposure 
As alluded to above, chemical biomarkers of tobacco and alcohol intake such as serum or 
urinary cotinine can provide an objective measure of exposure, including passive exposure 
in the case of smoking, as they do not rely on valid self-report and are not therefore 
vulnerable to issues of inaccurate recall or social desirability bias. However, the “window of 
assessment”, that is the amount of time that the marker continues to be positive following 
exposure to tobacco or alcohol,  is often limited 496.  The half-life of cotinine for example, i.e. 
the time required for the concentration in the body to decrease by half, ranges from between 
2-3 days (possibly more if it is detected in hair); As such, cotinine can only provide a 
measure of recent tobacco exposure.  Similarly, the physical presence of ethanol in the body 
is short-lived. Several indirect biomarkers of (predominantly heavy) alcohol consumption 
have been identified (Table 16), including Gamma–glutamyltransferase (GGT), Ethyl 
glucuronide (EtG) and the ratio of Hydroxytryptophol (5–HTOL) to 5–hydroxyindole–3–acetic 
acid (5–HIAA), but even these can only characterise drinking patterns over the last few 
weeks, and hence, are better suited for use in alcohol treatment studies i.e.  to evaluate 
treatment efficiency. For studies which aim to assess the health risks accumulated over time, 
biomarkers of long-term tobacco and alcohol exposure are needed. 
4.4. Epigenetic predictors of health and lifestyle 
As stated in Chapter 3, epigenetic mechanisms are modifications that affect the activity of 
the DNA without altering the DNA sequence itself, as indicated by the prefix “epi-” which 
literally means “on top of” or “over” 497 498.  DNA methylation, which is described in detail 
below, is by far the most frequently studied form of epigenetic modification. Studies of the 
temporal stability of DNAm indicate that it typically very stable over time. Indeed, past 
smoking has been associated with DNAm levels decades after cessation 499. In this way, the 
epigenome can act as an “historical archive” of past exposure to cancer risk factors 500, 
which could be important in in the context of epidemiological studies. 
 
4.4.1. What is DNA methylation? 
DNAm involves the addition of a methyl group (CH3) to the fifth carbon atom of a cytosine 
base, producing 5-methylcytosine (5mC) (Figure 19).  The chemical addition of the methyl 
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group at the cytosine base is made by a covalent bond, which, as highlighted above, is 
relatively stable over time. Methylation typically occurs at cytosine–phosphate–guanine 
(CpG) sites, which are regions of the DNA where a cytosine nucleotide (C) precedes a 
guanine (G) nucleotide in a 3-5’ linear sequence 501, resulting in two methylated Cs situated 
diagonally from each other on opposite strands of the DNA.  CpG sites are predominantly 
concentrated in the promoter regions of genes, which is where the transcription of DNA to 
RNA is initiated.   When CpGs in the promoter region of a gene are methylated, the gene is 
typically inactive, i.e. transcription is “dimmed down” or turned off.  As such, DNAm plays a 
vital role in several important biological processes such as embryonic development, genomic 
imprinting and X-chromosome inactivation502. Whilst DNAm marks are considered relatively 
stable over time, they are often modifiable, a feature that is important for the regulation of 
developmental processes 500. 
 
Multiple techniques for DNA methylation analysis, including bisulfite sequencing, 
pyrosequencing and methylation-specific polymerase chain reaction (PCR) and have 
developed over the past couple of decades. The different analytic techniques have been 
reviewed in depth elsewhere 503 504.  This thesis focuses on array-based approaches, which 
are a popular choice because they facilitate simultaneous analysis of a large number of 
samples and are relatively cost-effective
 
Figure 19: Regulation of transcription by DNAm  
 
Top panel: unmethylated CpG dinucleotides (open circles) allow binding of transcription 
factors (TF) to gene regulatory regions and gene expression is activate. Bottom panel: 




Table 16: A summary of some of the characteristics of available alcohol biomarkers, Adapted from 496 and 505. 





Continuous, rather than episodic, heavy 
drinking (∼ 70 drinks/wk for several 
weeks). Returns to normal levels with 6 
weeks of abstinence. 
Inexpensive, widely available. 
Used clinically. 
Not very sensitive (61%) 506. Elevated 
GGT levels may also arise as a result 
of hepatobiliary disorders, obesity, 
diabetes, hypertension, and 
hypertriglyceridemia. Large numbers 




Heavy drinking (undefined). Returns to 
normal levels within 7 days, but 
considerable variability in declines with 
abstinence. 
Can be analysed by a relatively 
simple immunochemical procedure, 
for which antibodies against ASAT 
are commercially available.  




Heavy drinking (undefined). Unknown 
half-life. 
Used clinically. Less sensitive than AST. Several 
sources of false positives. 
Macrocytic volume Heavy drinking (undefined). Half–life of 
∼ 40 days. 
The testing methodology is easy 
and inexpensive. 





60+ g/d for at least 2 weeks. Normalise 
with a mean half–life of 2–4 weeks of 
abstinence. 
Low rates of false positives. Kits to 
isolate and quantitate CDT in 
serum are commercially available. 
Difficult to measure accurately. 
Relatively high rate of false negative 
results. Women tend to have higher 






Table 16 continued. 




At least 10 days of drinking > 60g/d. 
Serum levels return to normal after 7–
10 days of abstinence whilst urine 
levels normalise after 4 weeks.  
Specificity of 96 % for serum and 
urine markers combined. 
Elevated serum levels can occur with 
liver diseases, hypertension, diabetes 
mellitus, silicosis, myocardial 
infarction & thyrotoxicosis. 
Sialic acid (SA) Positive relationship between alcohol 
intake and SA levels in serum. 
Can be measured in saliva. The dose of alcohol needed to 
increase SA is undefined. Levels also 
rise in conditions other than heavy 
drinking, including people suffering 
from tumours, inflammatory 
conditions, diabetes, & 
cardiovascular disease. 
5-HTOL/5-HIAA Recent consumption of even quite low 
levels of alcohol. Returns to normal 
levels after 3–4 days (half-life 2–3 hr). 
The response of 5–HTOL to 
alcohol is dose dependent. 
The role of confounders such as age, 
sex, or concomitant diseases are 
unclear. 





Best detects heavy versus light drinking 
over five days. 
Present in various body fluids and 
hair. Age, sex, ethnicity, and 
severity of liver disease have no 
influence. Very specific for alcohol. 
Investigations of EtG are preliminary 
in nature. No commercial kits have 
been marketed. Bacterial degradation 
possible (urine).  
Fatty acid ethyl 
esters (FAEE) 
Recent, heavy alcohol use 506. Up to 100% sensitivity, 90% 
specificity reported  506.  




4.4.2. DNAm-based predictors of smoking, alcohol consumption, educational attainment 
and BMI 
There are multiple examples of the utility of DNAm in trait prediction in the literature. 
Methylation levels at a single loci (cg05575921) within the aryl hydrocarbon repressor gene 
(AHRR) for example, has been shown to provide a sensitive and specific biomarker for 
cigarette consumption, yielding an AUC of 0.99 507. The effects of smoking on DNAm at this 
site are unaffected by alcohol drinking, meaning that smoking and alcohol consumption - 
behaviours that frequently co-occur, can be estimated simultaneously 508.  
 
Cigarette smoking has in fact been found to have a broad impact on the genome. In a large 
meta-analysis of genome-wide DNAm that included blood samples taken from nearly 16,000 
participants included in the Heart and Aging Research in Genetic Epidemiology (CHARGE) 
Consortium (including 2,433 current, 6,518 former, and 6,956 never smokers) 509, Joehanes 
et al. (2016)  identified 2,623 CpG sites, annotated to 1,405 genes, that were differentially 
methylated between current and never smokers, based on a Bonferroni-adjusted p<1×10−7. 
When a less stringent False Discovery Rate (FDR) of <0.05 was applied, over 18,700 CpGs 
were detected 509. Of these sites, 185 were significant (p<1×10−7) in former versus never-
smokers, providing evidence of both a persistent pattern of altered methylation in former 
smokers, and attenuation or reversal after smoking cessation. In addition, Joehanes and 
others have found that these methylation biomarkers are highly informative of several 
smoking-related traits, including pulmonary function, cancers, inflammatory diseases and 
heart disease 509 510. 
 
Around the same time that Joehanes and colleagues published their findings, Lui et al. 
(2016) developed four separate DNAm-based alcohol models as biomarkers of alcohol 
intake using least absolute shrinkage (LASSO) regression techniques, also in the CHARGE 
consortium. The models comprised a set of 5, 28, 78 and 144 CpGs, respectively. Of these 
four models, the one corresponding to 144 CpGs provided the best discrimination, with 
AUCs upwards of 0.90 (in four replication cohorts) for current heavy drinkers versus non-
drinkers, where the definition of ‘heavy drinker’ was men who drank ⩾42 g per day and 
women who drank ⩾28 g per day 511.  This analysis was well-powered and the proportion of 
variance in alcohol consumption explained by the DNAm biomarker was promising. 
However, Hattab et al. (2018) point out that the reported performance of the model may be 
inflated, since the authors did not use the coefficients from the discovery set, which was 
used to identify the 144 CpGs, to determine out-of-sample prediction 512. Instead, the 
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authors ran their LASSO regression in their training dataset, which selected the variables 
that were important enough to remain in their model, then re-estimated the value of their 
coefficients by fitting separate logistic regression models in their replication cohorts. 
 
In 2018, Dr Riccardo Marioni’s group in the Centre for Genomic and Experimental Medicine 
described the developed of four DNAm-based predictors of complex traits using data derived 
from whole blood samples in two large cohort datasets, namely Generation Scotland 
(training dataset) and the Lothian Birth Cohort 1936 (test dataset). The traits of interest 
included alcohol consumption, smoking status, BMI and educational attainment. Again, using 
penalised regression techniques (i.e. LASSO), the authors identified predictors based on 
287 (smoking), 371 (alcohol), 1,099 (BMI) and 281 (educational attainment) CpG sites.  The 
DNAm-based predictors explained different proportions of the phenotypic variance, ranging 
from 2.6% for education to 60.6% for smoking. When the authors obtained AUC estimates 
for binary categorisations of these phenotypes, they found near-perfect discrimination 
between current and never smokers (AUC=0.98), whilst the discriminatory power for the 
identification of obese individuals (versus non-obese) and heavy drinkers (versus light-to-
moderate drinkers) was moderate (AUCs of 0.67 and 0.74, respectively); poor discrimination 
was obtained for those with more years of full-time education (AUC=0.59). Interestingly, as 
with previous EWAS analysis of education 513, many of the CpGs identified overlapped with 
smoking-related DNAm signals, including cg11902777, which is located in the AHRR gene. 
In fact, this site had the fourth largest coefficient in the education DNAm LASSO model.  
 
Overall, it appears that DNAm predictors are able to predict lifestyle factors with varying 
success. Smoking seems to be particularly amenable to detection using DNAm biomarkers, 
which may provide more accurate measurements than self-report, thereby improving 
disease prediction and risk stratification in both clinical and epidemiological settings. 
Moreover, unlike biochemical biomarkers such as cotinine, DNAm could serve as stable 
biomarker for lifetime exposure. 
4.4.3. Epigenetic biomarkers of aging  
As we age, the cells, tissues, and organs of our bodies undergo biological changes, which 
are accompanied by a progressive loss of function and an increased risk of morbidity and 
mortality. Chronological age is an imperfect surrogate measure of the aging process, 
however,  because ageing does not affect people, or tissues, uniformly 514.  Instead, 
research suggests that these changes may be influenced by endogenous or exogenous 
stress factors 515. The search for reliable indicators of biological age has been an active area 
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of research since the early 1980s 516. In the last decade or so, a number of mathematical 
models predicting age from DNAm profiles, also referred to as “epigenetic clocks”,  have 
been developed and this has largely been catalysed by the completion of the Human 
Genome Project, as well as a shift in scientific culture which has fostered the use of open 
access data sources 514.  A comparative review by Jylhävä et al. (2017), which considered 
six potential types of biological age predictors: epigenetic clocks, telomere length, 
transcriptomic predictors, proteomic predictors, metabolomics-based predictors, and 
composite biomarker predictors, concluded that predictors based on DNAm age (i.e. 
epigenetic age) currently perform best 516, although more longitudinal validation is required. 
 
Epigenetic clocks are essentially a weighted measure of DNAm levels at specific CpGs. 
Selection of the most informative CpGs, along with their associated weights, is typically 
achieved using penalised regression models such as LASSO or elastic net, which, as 
touched on above, automatically screen for the best predictors 514. Here, estimates are 
derived by regressing chronological age (dependent variable) on DNAm levels (covariates) 
514. Many of the CpGs that are incorporated into the algorithm provide limited predictive 
value on their own, however, the linear combination of CpG methylation beta values is highly 
correlated with chronological age. In addition, some clocks have been shown to predict 
aging-related diseases, such as coronary heart disease, diabetes, and some forms of cancer 
517 518.   Different clocks exhibit varying degrees of accuracy depending on the set of CpGs 
used and the specific tissue. 
4.4.3.1. Single-tissue DNA methylation-based age estimators 
The first DNAm age estimator, described by Bocklandt et al. back in 2011, was built using 
DNA extracted from saliva (n=34 males) 519. The model, which was based on methylation at 
just two CpG sites on the Illumina Infinium HumanMethylation27beadchip array (Illumina 27k 
array), explained 73% of the variance in age in an independent dataset (31 males and 29 
females aged 18 to 70 years) and was able to predict an individual’s age with an average 
accuracy of 5.2 years. A couple of years later, Hannum et al. (2013) built a multivariable 
linear regression model for aging in whole blood samples (n= 656). “Hannum’s clock” 
integrated 71 CpG sites from the Illumina 450k array 520.  The model was accurate, with a 
correlation between age and predicted age of 96% in the training cohort and 91% in the 
validation cohort (n=171). The corresponding errors were 3.9 years and 4.9 years, 
respectively. Most of the methylation markers included in Hannum’s model are found in or 
near genes with known functions in aging-related conditions, such as Alzheimer’s disease 
and cancer. A limitation of Hannum’s clock is that it may be confounded by age-related 
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changes in blood composition 521 522; however, in blood, the model outperforms other ‘multi-
tissue’ age-predictors 516.   
4.4.3.2. Multi-tissue DNA-methylation based age estimators 
Multi-tissues age estimators are so called because, unlike the models described above, they 
are applicable to all cell types and tissues across the entire lifecourse 514. The obvious 
challenge when developing such a model is that there are well-established differences in 
DNAm patterns among different cell types and tissues, which may differ in early and later 
life. There are nonetheless age-related DNAm marks at specific sites across the genome, for 
instance within the bivalent chromatin domains and targets of Polycomb repressor 2 (PRC2), 
that appear to be conserved across different cell types 514. The first, and arguably the most 
well-known multi-tissue age-estimator, was constructed by Horvath in 2013. “Horvath’s clock’ 
was trained on 7,844 samples, including 51 different (non-cancer) tissues and cell types, 
derived from 82 publicly available datasets (measured on the Illumina 27K or Illumina 450K 
array platform) 523. To build the model, a transformed version of chronological age was 
regressed on the CpGs using elastic net regression, which selected a set of 353 CpGs. 
Using this transformed outcome measure, Horvath uncovered an interesting phenomenon: 
the rate of change of DNAm age, likened to the ticking rate of the epigenetic clock, slows 
down after adulthood. The high accuracy of this clock (age correlation 0.97 and 0.96, error = 
2.9 years and 3.6 years in training and validation datasets, respectively) has been confirmed 
in hundreds of independent datasets 514. 
4.4.3.3. Phenotypic age estimator 
The so-called ‘first generation’ epigenetic clocks described above, i.e. the blood-based 
algorithm by Hannum and the multi-tissue algorithm by Horvath, were developed specifically 
to predict chronological age. Consequently, they only include CpG sites that exhibit strong 
time-dependent changes in DNAm.  They do not capture CpG sites that account for 
differences in risk among individuals of the same chronological age 514 524. Therefore, whilst 
these DNAm-based age predictors are associated with many age-related diseases and 
outcomes, including life expectancy, the effect sizes are typically modest. Conversely, work 
by Levine and others has shown that “phenotypic aging measures”, derived from clinical 
biomarkers, provide strong predictors of mortality risk and functional decline 524.  
 
The phenotypic age estimator developed by Levine et al (2018) was also built using a 
penalised regression model, but instead of chronological age as the dependent variable, the 
authors constructed a surrogate measure of biological age based on a weighted average of 
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ten clinical characteristics: chronological age, albumin, creatinine, glucose, C-reactive 
protein levels, lymphocyte percentage, mean cell volume, red blood cell distribution width, 
alkaline phosphatase and white blood cell count 524. This novel measure of ‘phenotypic age’, 
which was developed using clinical data from nearly 10,000 adults in the third National 
Health and Nutrition Examination Survey (NHANES III), signifies the age that corresponds 
with that person’s mortality risk, based on the general population. So, a person with a 
phenotypic age of 55 years, for example, has the average mortality risk of someone who is 
55 years old chronologically, irrespective of their own chronological age.  These values were 
regressed on DNAm levels in blood from 456 participants in the Invecchiare Chianti 
(InCHIANTI) study, which automatically selected 513 CpGs (out of a possible 20,169 CpGs 
available on the 27k, 450k and EPIC arrays). The weighted average of the 513 CpGs yields 
a DNAm based estimator of phenotypic age, which the authors call ‘DNAm PhenoAge’.  
 
DNAm PhenoAge outperforms Horvath and Hannum DNAmAge measures in predicting 10- 
and 20-year mortality and is strongly related to a number of age-related morbidity outcomes, 
including number of coexisting morbidities, likelihood of being disease-free and 
cardiovascular disease 524. Moreover, DNAm PhenoAge has been associated with an 
increased risk of lung cancer incidence and mortality, after adjusting for chronological age, 
race/ethnicity, pack-years, and smoking status 524. Similar to Hannum’s clock however, 
DNAm PhenoAge was developed using whole blood and may therefore produce biased age 
estimates in non-blood tissue 514, though the authors provide empirical evidence to suggests 
that their age predictor performs remarkably well across a wide a range of different tissues 
and cell types 524. 
4.4.3.4. GrimAge 
In 2019, Horvath’s group published a paper describing the development of a novel biomarker 
of biological aging that is a linear combination of chronological age, gender, and DNAm-
based surrogate biomarkers for smoking pack-years and seven plasma protein levels 525. 
The composite biomarker, named DNAm GrimAge owing to the fact that high values signify 
“grim news”, outperforms existing DNAm-based biomarkers in terms of its ability to predict 
time-to-death.   
 
DNAm GrimAge was developed using a two-stage approach.  In the first stage, surrogate 
markers for pack-years of smoking, which is a significant risk factor for morbidity and 
mortality, and plasma protein levels were defined and validated using data from the 
Framingham Heart Study (n=2,356, split randomly into a training dataset, n=1,731, and a 
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test data set, n=625). In total, 12 of the 88 plasma protein levels (adrenomedullin, beta-2 
microglobulin, cystatin C, growth differentiation factor 15, leptin, plasminogen activation 
inhibitor 1 and tissue inhibitor metalloproteinase 1) exhibited a correlation coefficient r >0.35 
between their measured levels and their respective DNAm-based surrogate markers, when 
the analysis was restricted to CpGs that are present on the Illumina 450k array and the 
Illumina EPIC array.   In the second stage, time-to-death (all-cause) was regressed on 
chronological age, sex and the above mentioned DNAm-based surrogates.  The resulting 
values, i.e. the linear combination of covariates produced from the elastic net cox regression, 
were transformed to give units of years.  
 
Consistent with previous publications, the authors defined an age-adjusted measure of 
GrimAge (i.e. GrimAge acceleration [AgeAccelGrim]), which, by definition is not correlated 
with chronological age.  AgeAccelGrim is associated with a range of age-related 
conditions/outcomes, including but not restricted to, incident coronary heart disease, 
hypertension, lower physical functioning, type 2 diabetes and comorbidity index and time-to-
cancer (any) 
4.4.3.5. Epigenetic age acceleration 
The discrepancy between DNAm age, as measured by the epigenetic clock, and 
chronological age may provide a reliable indicator of healthy aging 514. When an individual’s 
predicted methylation age exceeds their chronological age, implying that they are biologically 
older than their years, they are described as exhibiting “positive epigenetic age acceleration” 
514.  The reverse situation, whereby an individual’s tissue is aging slower than would be 
expected based on chronological age, would be described as “negative epigenetic age 
acceleration”. Higher epigenetic age acceleration (EAA) has been associated with higher risk 
of all-cause mortality and poorer measures of physical and cognitive performance 517 521 522 
526 527.  
 
There are a several different measures of EAA described in the literature. Broadly speaking, 
EAA measures can be categorised into two groups: those that are independent of age-
related changes in blood-cell composition, described in previous publications as ‘intrinsic’ 
epigenetic age acceleration (IEAA), and those that incorporate age-related changes in cell 
composition, referred to in previous studies as ‘extrinsic’ epigenetic age acceleration (EEAA) 




Briefly, IEAA is defined as the residual resulting from regressing epigenetic age on 
chronological age and measures of blood immune cell counts (naive CD8+ T cells, 
exhausted CD8+ T cells, plasmablasts, CD4+ T cells, natural killer cells, monocytes, and 
granulocytes). EEAA, by comparison, “up-weights” the contribution of three cell types whose 
levels are known to change with age (naive cytotoxic T-cells, exhausted cytotoxic T-cells), 
before regressing on chronological age 522 528 529. As such, EEAA is able to capture aspects 
of immunosenescence, i.e. the age-related functional decline of the immune system. 
 
Regardless of the type of measure used, age acceleration is useful because it identifies 
outliers or deviations from the norm, which may provide better prediction of age-related 
health outcomes than chronological age. The mechanisms that drive EAA are not well 
understood, however, Quach and others have shown that certain lifestyle factors can 
influence epigenetic aging rates 529. Specifically, lower EEAA was found to be associated 
with lower BMI, higher education, higher fish intake, moderate alcohol consumption and 
higher blood carotenoid levels (an indicator of fruit and vegetable consumption) in data from 
older women within the Women's Health Initiative (WHI); lower IEAA was associated with 
poultry intake and lower BMI. Both EEAA and IEAA were found to relate to indicators of 
metabolic syndrome. The authors found no association with current smoking status. 
 
A summary of the different EAA measured used in this thesis is provided in Chapter 9. 
 
4.5. HPV detection methods in HNC 
As highlighted in Chapter 3, the distinction between HPV- and non-HPV associated disease 
(i.e. cancers that are, and are not, linked with HPV infection) is important in relation to 
clinical prediction and disease management. Accurate detection of viral status is also 
essential for the purposes of research. As yet, no consensus has been reached on the 
optimal way to determine HPV status in HNC. The ideal test would be non-invasive, 
economical, easy to perform and interpret, and easy to incorporate into routine clinical 
practice. The objective of this section is to outline the main detection methods available and 
consider some of the advantages and disadvantages of each. An emphasis will be placed on 
HPV serological testing as this is the method used to determine HPV status in this thesis.  
Additional methodologies that are discussed include immunohistochemical (IHC) staining for 
p16, HPV polymerase chain reaction (PCR) testing and HPV in situ hybridization (ISH) 
analysis. An overview of this information, as well as information on some additional 




Before the different approaches are discussed, it is necessary to provide a brief description 
of the molecular pathogenesis of HPV infection. As mentioned previously, the viral proteins 
E6 and E7 are fundamental to the development of cancer.  The E6 oncoprotein forms a 
complex with the cellular ubiquitin-protein ligase E6AP, which targets the TS protein p53 for 
ubiquitination and degradation 530. This impairs normal cellular responses to DNA damage 
(i.e. G1 cell cycle arrest or induction of programmed cell death) and allows infected cells to 
proliferate. The E7 protein on the other hand, promotes transformation by binding to the 
retinoblastoma (Rb) protein, again targeting it for ubiquitination. Degradation of pRb releases 
E2F transcription factors from their negative control, which then stimulates the synthesis of 
enzymes needed to drive the cell forwards into S-phase 531 532. The continuous degradation 
of pRb by HPV E7 also results in significant overexpression of the TS protein p16, via a 
feedback interaction 533.  
4.5.1. p16 immunohistochemistry 
Since HPV-driven carcinomas (i.e. carcinomas that express viral oncogenes) demonstrate 
overexpression of the p16 TS protein in response to loss of cell cycle control, p16 staining of 
tumour tissue by IHC presents a reasonable surrogate marker for HPV infection (14, 15). 
Within the UK, the National Institute for Health and Care Excellence (NICE) recommends 
p16 IHC for all cases of OPC 534.  Its main advantages are that it can be performed at low 
cost, has high sensitivity [94%], can easily be incorporated into clinical laboratories and can 
be performed on formalin-fixed paraffin embedded (FFPE) tissue blocks 534. Some studies 
have also described the use of p16 IHC on fine needle aspirates (FNA), saliva, brush 
cytology and serum/plasma, thereby avoiding the need for surgical biopsy 535 536. One 
potential limitation of the method is that interpretation of IHC staining can be subjective, 
however, only strong staining is considered indicative of HPV positivity (current UK 
guidelines recommend >70% staining).   Examples of HPV-positive and HPV-negative 
tumours by IHC are depicted in Figure 20. The main limitations of p16 IHC are that it has 
lower specificity than alternative detection methods such as DNA ISH and DNA/RNA 
polymerase PCR, i.e. ICH analysis does not differentiate HPV serotypes, and p16 can be 
elevated by mechanisms other than HPV, leading to false positive results 537 538. Indeed, 
some studies report that up to 20% of p16-positive OPCs are actually HPV-negative (20). On 
the other hand, the p16 (CDKN2A) TS gene is also one of the most frequently deleted genes 
in HNC and this could result in a false negative assessment of the presence of HPV 538.  
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4.5.2. HPV in situ hybridization 
DNA ISH, a method which is based on the use of radioactive or fluorescently-labelled nucleic 
acid probes that hybridize to target HPV DNA sequences, permits simultaneous identification 
and localisation of HPV DNA within a tissue sample 539.  It has the advantage of being highly 
specific in that probes can be designed to detect DNA sequences that are unique to 
individual HPV sub-types, in addition to sequences that are common to multiple subtypes.  
One of the major limitations of ISH is that it lacks sensitivity when HPV DNA copy numbers 
are low. The limit of its sensitivity is generally recognised as 10 viral copies per cell, however 
with the development of improved reagents and techniques, it is now possible to detect as 
few as one to two copies of HPV DNA per cell.  In addition to potential sensitivity issues, ISH 
cannot provide direct evidence of transcriptional activity, even though it can differentiate 
between episomal and integrated DNA, since the presence of DNA does not necessarily 
indicate viral gene expression. Detection of mRNA E6/E7 transcripts is generally regarded 
as the “gold standard” for HPV detection, however the approach is technically challenging to 
perform and requires complex tissue processing (e.g. microdissection of fresh frozen tissue). 
For this reason, its use has traditionally been restricted to research laboratories 539 540. 
Recent advances, including the development of RNAscope 540-542, permit visualisation of viral 
transcripts in routine clinical testing i.e. in FFPE samples 543, but so far the platform is not 
widely available in diagnostic laboratories. 
4.5.3. HVP polymerase chain reaction testing  
PCR is a type of targeted amplification technology which duplicates fragments of DNA, in 
this case HPV DNA, from a known sequence, thereby providing concentrated samples 544. 
The inherent strength of this technique is that it requires small amounts of DNA and the 
technology is also widely available, making it a popular method of HPV detection in 
epidemiologic investigations. PCA has two main disadvantages. First, like DNA ISH, it 
cannot distinguish ‘clinically significant’ HPV infections from ‘non-clinically significant’ 
infections (i.e. HPV infections that results in transcriptional activity), although quantitative 
real-time PCR (Q-PCR) does permit assessment of HPV-16 viral load, which may suggest 
active replication. Second, samples are easily contaminated by previously amplified 
specimens or from surrounding non-neoplastic/stromal tissue that is HPV infected, leading to 
false-positives 539 543. Regarding viral gene expression, the presence of E6 and E7 mRNA 
positivity can determined using reverse transcriptase PCR (RT-PCR), a technique which 
creates cDNA sequences from mRNA and subsequently amplifies them using traditional 




Figure 20: Microscope images of HPV-positive and HPV-negative oropharyngeal 
tumours by ISH and p16 IH. 
 
 
A: HPV-positive tumour by ISH (positive staining identified as blue nuclear dots) B: HPV-
negative tumour by ISH. C: p16-positive tumour by IHC, showing strong and diffuse nuclear 
and cytoplasmic staining in 70% or more of the tumour cells. D: p16-negative tumour by IHC 
staining. Credit: Chernock et al (2009) 545. 
 
4.5.4. HPV serological testing  
 
Serum antibodies to HPV proteins, especially the E6 and E7 early proteins, have been 
detected in people with several HPV-associated cancers 546.   For OPC specifically, studies 
conducted in Europe and the US report that 35%-42% of people with OPC are HPV-16 E6 
seropositive up to 10 years before diagnosis, compared to fewer than 1% of healthy controls 
(yielding ORs as high as 274; 95% CI: 110 to 681) 547 548, and 85% are seropositive at the 
time of diagnosis 549. As such, HPV-16 E6 seropositivity presents a promising biomarker for 
OPC detection and screening. Moreover, several studies suggest that pre- and post-
treatment HPV-16 E6 antibody levels may be associated with risk of OPC recurrence 546 547 
550-552.  
 
Conventional serologic methods include enzyme-linked immunosorbent assays (ELISA) 
which are well-validated, having been used for over 30 years to examine antibody responses 
to bacterial/viral infections 553.  A schematic illustration of the ELISA is presented in Figure 
21. The main limitation of this technology is that each sample can only be analysed for 
antibodies against one genotype of HPV in each well, resulting in low through-put of sera 
and high serum consumption 553 554.  Waterboer and his colleagues at the German Cancer 
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Research Center (DKFZ) have developed a high-throughput ‘multiplex’ HPV serology 
platform that allows simultaneous analysis of antibodies against multiple (>100) viral 
antigens in a single reaction 553 554. The assay, which uses Luminex fluorescent bead-based 
technology (Figure 21), can screen up to 1,000 sera per day.   
 
This thesis utilises data derived from this novel multiplex serology platform. The protocol has 
been described in depth elsewhere 547 and further details will be provided in the next 
chapter; briefly, bead sets carrying different antigens (affinity-purified, bacterially expressed 
fusion proteins with N-terminal Glutathione S-transferase [GST]) are mixed with a small 
amount of serum in a single well-format and incubated; biotinylated secondary antibodies 
and fluorescent detection conjugates are then added to detect antibodies bound to beads 
and reporter fluorescence is determined using a flow cytometry-like analyser. Mean 
fluorescence intensity (MFI) values are dichotomized as antibody positive or negative using 
pre-defined cut-off values 555.  
 
The multiplex serology assay is well-suited for epidemiological purposes because it is high-
throughput, robust, requires small specimen volumes (50 μL), is relatively low-cost 
compared to alternative assays and can simultaneously measures responses to multiple 
HPV subtypes 554 555.  One limitation, which is applicable to serologic tests in general, is that 
it is not site-specific and therefore it could be argued that infections outside the head and 
neck could influence the specificity of the assay.  
 
In summary, there is no single test that has perfect specificity and sensitivity to detect HPV-
associated tumours.  The current ‘research gold standard’ test for HPV biologic activity, as 
suggested by the literature, is detection of E6/E7 viral transcripts using RT-PCR. However, 
this method is arduous to perform and the need for FF tissue is often cited as a reason why 
it is unsuitable for use in epidemiologic studies and clinical trials. For this reason, p16 IHC 
and HPV DNA ISH in combination are generally recommended. The recent development of 
a multiplex HPV serology assay provides an exciting addition to the field since HPV-16 
E6/E7 antibodies may provide a tool for the early detection and/or prognosis of HPV-





Figure 21: A comparison of antibody-capture enzyme-linked immunosorbent assay (left) 
and bead-based multiplex serology (right). 
 
A: The basic set-up of a capture ELISA assay. To detect viral proteins, a capture antibody, 
directed against the protein of interest, is first immobilised on a plate. The sample is added, 
and if viral antigens are present, they will bind to the immobilised antibody. The bound viral 
antigen is then detected using a biotinylated secondary antibody linked to a streptavidin-
enzyme conjugated with alkaline phosphatase or horseradish peroxidase. A coloured product, 
proportion to the amount of the viral protein present in the sample is formed 556 557.  
 
B: A schematic representation of a bead-based multiplex serology assay. Binding of antigens 
is mediated by the interaction between the GST domain of the fusion proteins and glutathione 




Table 17: HPV detection methods in HNC. 
Technique Description Advantages Disadvantages 
Routine histology The presence of HPV is inferred 
from the tumour morphology. 534 
539. 
• Universally available. 
• Low cost. 
• No additional equipment required. 
 
• Small number of HPV-positive tumours do 
not exhibit typical features. 
Southern blotting 
(SB) 
Genomic DNA is extracted from 
a specimen and ‘digested’ by 
restriction enzymes. Fragments 
are separated by gel 
electrophoresis and transferred 
to a membrane before being 
hybridized with cloned HPV 
genomic probes 559. 
 
• Well established. 
• Can detect as little as 0.1 copies of viral 
DNA per cell 559. 
• Has the ability to differentiate between 
episomal and integrated DNA 559. 
• Cannot be applied to FFPE samples. 
• Technically complex. 
• Requires a significant amount of DNA. 
• No practical/clinical utilization 559. 
p16 IHC Uses labelled antibodies to bind 
specifically to p16 antigens in 
situ. 
• High sensitivity (94-100% %) 560 561. 
• High inter-observer agreement. 
• Relatively undemanding and 
inexpensive. 
• Readily available and interpretable 
(when signal intensity is high) 
• Has independent prognostic significance 
(in populations with high prevalence of 
HPV driven OPC). 
 
• Surrogate marker for transcriptionally active 
HPV. 
• Lower specificity (79-82%) than ISH/PCR 
560 561. 
• Subject to interpretation when staining is 
weak (<5% of cases) 562. 
• Some studies show elevated expression of 
p16 in HPV DNA or E6/E7 transcript-
negative OPCs 539 
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Table 17 continued.  
Technique Description Advantages Disadvantages 
DNA ISH Uses labelled complementary 
DNA or synthetic 
oligonucleotides [i.e. probes] to 
localize to a specific HPV DNA 
sequence in a portion or 
section of tissue. 
 
 
• High specificity [88-100%] 560 561. 
• Readily available probes for the detection 
of all known HPV strains. 
• FFPE tissue can be analysed for high-risk 
HPV sub-types using an automated 
platform and viewed with conventional 
light microscopy. 
• Can be used on FNA specimens. 
• 99% concordance between HPV detection 
in E6/E7 mRNA and HPV DNA ISH 540. 
•  
• Does not confirm transcriptionally active 
HPV. 
• Low sensitivity when DNA copy numbers in 
tumour tissue are low. 
• Low overall sensitivity (83-88%) compared 
to p16 IHC 560 561. 
• More expensive to perform compared to 
p16 IHC. 
• 11% reporter inter-observer variability 562. 
 
RNA ISH A labelled probe is used to 
hybridize to a known target 
RNA within a sample. The 
labelled probe is then detected 
using an antibody specific to 
the label on the probe.  
• Confirms the presence of transcriptionally 
active HPV (superior to DNA ISH). 
• Amplifies low viral signal. 
• Lower risk of contamination (single test). 
• Easily interpretable results. 
• More sensitive and specific than DNA ISH 
(97 and 93% vs 88 and 88%). 
 
• Technically difficult to perform. 
• Test is not routinely available. 
• Not available on an automated platform. 
• Limited clinical evidence of efficacy. 
• Not yet approved for clinical use. 
HPV DNA PCR A sequence of DNA is 
amplified using pre-specified 
HPV primers. The PCR 
products may be separated by 
electrophoresis or hybridised 
onto a chip. 
• High sensitivity (97%) 560. 
• Cost effective. 
• Numerous commercial assays available. 
• Can be used on FNA/saliva/brush 
cytology/serum/plasma specimens. 
 
• Easily contaminated. 
• Detected DNA may not be from tumour 
tissue 559. 
• May not correlate with actual HPV DNA 
cellular integration. 





Table 17 continued. 
Technique Description Advantages Disadvantages 
HPV mRNA PCR Used to qualitatively detect 
gene expression through the 
creation of complementary 
DNA [cDNA] transcripts from 
E6/7 mRNA in combination 
with the amplification and 
detection steps of PCR. 
• Provides evidence of transcriptionally 
active HPV. 
• High sensitivity. 
• Expensive and time consuming. 
• Requires specialist research laboratory 
techniques. 
• As a consequence of RNA instability, 
testing has (until recently) relied on the 
analysis of fresh frozen tissue 561. 





Measures antibodies against 
early/late HPV capsid proteins. 
• Does not require biopsy. 
• Individuals can produce a serologic 
response <10 years before. 
• Currently no validated commercially 
available kits. 
• Serological biomarkers are not site-specific 
but can arise due to HPV infections at sites 
other than the head and neck (potentially 
affecting the specificity of the assay). 
• The significance of HPV seropositivity 




4.6. Metabolomic assessment of exposure 
Chapter 3 summarised the published literature on the use of metabolomics as a tool to study 
HNC. The purpose of this section is to provide an overview of the different approaches used 
in metabolomics studies (i.e. target or untargeted) and describe the two most common 
analytical technologies for the generation of metabolomics data. 
 
To recap, metabolomics is the study of the metabolite composition (including amino acids, 
organic acids, sugars, fatty acids, lipids, steroids, inflammatory markers, etc.) of a cell, 
tissue, or organism 563. The total complement of low molecular weight compounds 
(metabolites) present within a biological sample is called the ‘metabolome’ and represents a 
“snapshot” of the response to of the biological system to both environmental exposures and 
upstream genetic, transcriptomic, and proteomic variation.  As such, metabolomics offers a 
unique opportunity in which to examine the link between environmental and lifestyle 
exposures and health/disease outcomes. For example, previous metabolomic studies have 
identified both blood plasma and urinary metabolite correlates of traditional risk factors for 
cardiovascular disease, including blood pressure and hypertension 564. 
 
Metabolomics experiments can be categorised as “targeted” or “untargeted”, based on the 
study objective - discovery (untargeted) versus hypothesis testing (targeted) 563. Targeted 
metabolite profiling techniques aim to quantify a predefined subset of metabolites, typically 
metabolites with related chemical structures and/or biological activities 563, whilst untargeted 
metabolomics studies aim to analyse of all the measurable metabolites within a biological 
sample, including unknown analytes. Untargeted metabolomic profiling studies often 
compare the metabolome of healthy and diseased groups (or control and test groups), in 
order to identify differences between them which may be relevant to specific biological 
conditions.  By definition, untargeted metabolomics do not require any previous knowledge 
of the sample or a referential database. However, due to the comprehensive nature of 
untargeted metabolomics data, advanced chemometric techniques are needed to reduce it 
into a more computationally manageable set of signals 565 566. The data analysis workflow for 
targeted and untargeted metabolomic studies have been described previously 565. 
 
Two different but complementary technologies, which were introduced in Chapter 3, are 
recongnised as being particularly well-suited to analysing metabolites- NMR and MS  567. 
NMR is based on the principle that when certain materials, such as tissue, are placed in a 
strong magnetic field, the atom nuclei take on a resonant characteristic, i.e. they can absorb 
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and then re-emit electromagnetic radiation at a specific frequency, and they become 
magnetized. The frequency of the radiation needed for absorption of energy depends on the 
chemical environment of the nucleus 568. MS, by contrast, measures the mass-to-charge 
ratio of charged ions 569. The choice of platform determines, to some extent, what can be 
measured, and each approach has its own advantages and disadvantages 567. There are a 
number of excellent reviews published on the strength and limitations of NMR and MS as 
tools applicable to metabolomic analyses 570 571.  Some of the main points are summarised in 
Table 18. In brief, NMR is a highly reproducible, non-destructive analytical technique that 
can detect many metabolites simultaneously in a short time period, but its sensitivity is low, 
and the apparatus is expensive to purchase and maintain. MS, by comparison, is inherently 
more sensitive with lower limits of detection, but sample preparation is more demanding, and 
samples cannot be recovered (i.e. they are destroyed), though only small amounts of sample 
are required 570 571.  
 
There are several methodological and statistical challenges when handling metabolomics 
data sets, which are pertinent to this thesis and which may affect the interpretation of results. 
They relate to the high-dimensional nature of the data, the biological variance and 
correlation structures of metabolite measures, not to mention analytical biases 572.  There are 
multiple methods available to help reduce complexity, identify variables of interest, and 
generate predictive models in multivariable datasets 572, some of which will be explored in 
later in this thesis.
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Table 18: A comparison of the advantages and disadvantages of the two most common 
techniques used in metabolomics data acquisition. 
Technology Advantages Disadvantages 
MS • High sensitivity- can detect 
metabolites in the femtomolar to 
attomolar range 567. 
• Coupling MS with liquid 
chromatography (LC) or gas 
chromatography (GC) permits the 
measurement of hundreds of 
individual metabolite species within 
a single sample 567. 
• Superior for targeted analysis 571. 
• Moderate reproducibility. 
• More complex sample 
preparation required.  
• Precision - most studies 
rely on comparing peak 
area or intensity to locate 
differences in the relative 
abundance of specific 
metabolites between 
samples. 
• Quantification – signal 
intensity is affected by the 
type of sample 
preparation used and its 
molecular environment 
567.  
NMR • High reproducibility. 
• Non-destructive – can recover the 
sample completely (and use it for 
MS). 
• Minimal sample preparation and no 
need for derivatisation.  
• Ease of automation. 
• Quantification - the peak area of a 
compound in the NMR spectrum is 
directly related to the concentration 
of specific nuclei 567. 
• Versatility – can analyse 
metabolites in liquid state [serum, 
urine, plasma],  in intact tissue (e.g. 
tumours), or in vivo 567. 
• Low sensitivity- orders of 
magnitude less sensitive 
than MS 567 i.e. 
micromolar or millimolar 
concentrations. 
• Instrument is more 
expensive than MS. 
140 
 
4.7. Summary of the challenges and opportunities 
One of the main limitations in epidemiological studies evaluating the association of 
exposures with outcomes is exposure misclassification. This may be especially true if the 
exposure or risk factor of interest is a health-related trait or behaviour, since these factors 
may differ across numerous dimensions (e.g. frequency or intensity of exposure) and occur 
over a prolonged period of time, as can be the case with smoking or alcohol use, for 
example.  If these traits or behaviours are not measured accurately, this may result in a 
failure to detect an association between exposure and disease outcomes, or an attenuation 
of the relative risk.  Of particular relevance to HNC, is how to accurately detect tumours that 
are HPV-driven.  The validity of the exposure measurement in this case is improved by an 
understanding of the biology and etiologically of the agent.  To this effect, serologic testing 
for HPV antibodies presents a promising research tool because the immune response to 
HPV16-driven tumorigenesis is detectable several years (i.e. over 10 years) before OPC 
diagnosis. 
 
Self-report is a common data collection method in epidemiological studies.  It is popular for 
several reasons; it provides a non-invasive and relatively cheap way of collecting information 
and, in many circumstances, has been shown to provide an accurate assessment of 
environmental and lifestyle exposures. Self-report is however subject to misclassification 
because it relies on accurate recall.  Biological predictors, such as salivary cotinine as a 
biomarker for smoking, can provide a more accurate measure than self-report and they 
incorporate individual variability in metabolism. However, they may not be suited to studies 
examining the effects of lifetime exposure since they are often only present in the body for a 
short period of time.  
 
It has become increasingly apparent that smoking and other environmental/lifestyle 
exposures, including aging, lead to genome-wide epigenetic alterations. A number of DNAm-
based predictors of complex traits have been developed based on the findings of large 
EWAS studies. These novel DNAm-based biomarkers could be used in epidemiological 
studies to circumvent issues of recall-bias that limit self-report and help assess the totality of 
lifetime exposures. The proportion of the phenotypic variance in explained by these 
predictors is variable however, meaning that not all exposures may be amenable to 
detection using DNAm biomarkers. DNAm–based age, as predicted by the “Epigenetic 
Clock”, has been shown to predict chronological age with astonishing accuracy, though its 
greatest potential probably lies in its ability to provide biomarkers of accelerated aging, age-
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related conditions, and longevity. It is important to remember however, that the amount of 
age-associated DNAm changes are specific to cell type and tissue and this should be 
factored into any study design.  Overall however, epigenetic biomarkers may help address 
many long-standing questions in the field of HNC, including what the effect of established 
risk factors on survival is.  
 
Finally, metabolomics, which measures the complement of small molecule-weight 
metabolites present in a biofluid or tissue, offers great promise for uncovering the causal 
relationships between environmental or lifestyle factors and disease outcomes. The complex 
and dynamic nature of the metabolome and the relative infancy of the field, however, present 
a number of statistical and analytical challenges. 
 
This thesis will draw upon a combination of self-reported phenotypes, DNAm-based 
predictors of exposure, and NMR-derived metabolomics data to compare and quantify the 
effect of specific lifestyle traits and behaviours on HNC survival. HPV status will be 
determined using HPV serology assays. Further details of this and of the DNAm profiling 





Chapter 5: The Head and Neck 5000 study 
The study population for this thesis was comprised of individuals enrolled in the H&N5000 
study. H&N5000 is a large, UK-based, prospective observational study of people with HNC.  
This chapter provides a brief description of the participants included in the study and an 
overview of the data collection processes relevant to this thesis, including information on 
questionnaire design, DNAm and metabolic profiling.  For a more comprehensive description 
of the study, including study design and recruitment, please see Ness et al. 573 574. Copies of 
the H&N5000 study documents, such as the consent form, data capture form and participant 
questionnaires, are available through the study website 315.  
5.1. Study design and follow-up 
All potentially eligible individuals were identified by the multi-disciplinary team (MDT) treating 
them. The inclusion and exclusion criteria for entry into the study are outlined below. 
5.1.1. Inclusion criteria: 
• Anyone with a new primary HNC (ICD-10: C00-C14, C32 and C73); 
• People with an unknown primary cancer were eligible for inclusion if the MDT felt that 
the primary was likely to be HNC; 
• Individuals aged 16 years old or over; 
• Those who were already participating in other studies were still eligible for inclusion.  
5.1.2. Exclusion criteria:  
• Individuals who did not have HNC; 
• Anyone with lymphoma, skin cancer, a secondary HNC or a recurrence of a previous 
HNC;  
• Anyone who was considered to meet the criteria for mental incapacity or vulnerability; 
• Anyone who had already commenced their cancer treatment, unless the treatment 
was their diagnostic procedure (e.g. tonsillectomy or thyroidectomy) or people were 
being treated palliatively, in which case individuals were recruited as soon after their 




5.1.3. Consent  
At the point of enrolment, i.e. before individuals started their cancer treatment, research 
nurses (or dedicated health professionals) at each site obtained written informed consent. 
The consent form asked participants to confirm that they were happy to complete 
questionnaires and that they gave their permission for the research team to: collect, store 
and use biological samples (blood and saliva); obtain samples of stored tissue; carry out 
genetic analyses; and collect information from hospital notes and via linkage to health-
related records including disease registries 574.  
5.1.4. Recruitment rates 
Between April 2011 and December 2014, 5511 people with HNC, from 11,158 people who 
were identified as potentially eligible (49%), were recruited from 76 centres across England, 
Scotland and Wales 573 (Figure 22).  There was variation in recruitment and response rates 
by H&N5000 study centres, with recruitment rates ranging from around 20% to around 90% 
of eligible HNC cases 573. It is estimated that when all study centres were open, the study 
captured a third of all incident cases in the UK 575.  
 
Of the 5511 participants recruited, 5,373 were confirmed eligible 576.  The reasons for 
ineligibility were: 
• The tumour was not HNC (n=68) 
• There was missing tumour site data (n=37) 
• Clinical staging was 0 (n=18) 
• The participant withdrew (n=63) 
5.1.5. Baseline data collection  
The various data collection points are illustrated in Figure 23.  Once informed consent had 
been obtained, participants were given three questionnaires to take away and return by 
stamped address envelop or complete in clinic.  The first included questions on socio-
economic position (including occupation, education and housing) and lifestyle (including 
tobacco use and alcohol intake); the second included questions on sexual history (e.g. 
timing of first sexual intercourse, number of sexual partners), and the third asked about 
psychological status and QoL (general as well as cancer-specific).    
 
During the same clinic appointment, participants were asked to provide a blood and saliva 
sample, which were collected using a standardised protocol. Further details are provided 
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below. If an individual did not wish to provide a sample, they remained in the study for 
questionnaire completion and data capture. All baseline questionnaires and blood and saliva 
samples were done before the participant started their HNC treatment, with the exception of 
those whose treatment was their diagnostic procedure and those who were being treated 
palliatively. Where possible, paraffin embedded tissue blocks were obtained from local 
pathologists, along with an anonymised copy of the participants’ histopathological report.  
Tissue samples were not used in the current analysis, but further details are available on the 
study website. 
 
Data capture forms (DCFs) were completed by research nurses at each participating site, 
using information extracted from participants’ medical records (for those participants who 
had consented). The data extracted included information on diagnosis (e.g. date of 
diagnosis, ICD code, histology), treatment (e.g. cancer care plan intent and sequence) and 
existing comorbidity (which did not include the index cancer).  
 
The intended cancer care plan for the patient’s HNC at baseline could be either curative, 
palliative, supportive,  The terms “palliative” and “supportive” are often used interchangeably 
and both are given in the knowledge that the cancer cannot be cured; the distinction is that 
supportive care refers explicitly to all non-cancer focused treatment i.e. it is just intended to 
prevent and/or relieve the symptoms of cancer (e.g. hospice care), whilst palliative anti-
cancer care is given in combination with anticancer treatment (e.g. chemotherapy or 
radiotherapy) with the aim of extending an individual’s life for as long as is possible and 
comfortable. If a participant decided that they did not want to receive any treatment, this 
would be entered in the DCF as “No specific anti-cancer plan”.  
 
Comorbidity was defined using the Adult Comorbidity Evaluation-27 (ACE-27) index 577, 
which was described in Chapter 3.  ACE-27 is a 27-item assessment tool that has been 
validated for use in multiple patient groups 396 578 579.  Using the tool, nurses graded 
participant’s comorbidities into one of four categories according to the severity or organ 
decompensation: none (coded 0), mild (coded 1), moderate (coded 2), or severe (coded 3). 
An overall comorbidity score was assigned according to the severity of the highest ranked 
medical condition, excepted in cases with two or more grade 2 ailments in different organ 
systems, in which instance a final score of three would be assigned. The comorbidity grade 
that corresponded to final comorbidity score was entered into the DCF (i.e. no-comorbidity, 
mild decompensation, moderate decompensation, or severe decompensation, or ‘unknown’). 
Research nurses were not asked to record the underlying conditions that resulted in this 
score, and as a result, responses could not be cross-checked or grouped in any way.  
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5.1.6. Response rates 
Response rates to the baseline health and lifestyle questionnaire ranged from <30% to 
>90% and the percentage of participants providing a blood sample varied from <50% to 
>90% 573. Altogether, 5,474 (99%) DCFs and 4,099 (74%) health and lifestyle questionnaires 
were completed 573.  As of May 2019, there were 3,391 people with valid stage, baseline 
health and lifestyle data and a blood sample available 576. There are 2,993 participants with 
tissue blocks (most are primary HNC, but some are neck node; personal communication).  
5.1.7. Follow-up 
At four months and twelve months after enrolment, participants were sent a follow-up 
questionnaire pack. The follow-up questionnaire included questions around concerns (e.g. 
fear of cancer recurrence), loss of function (e.g. as speech or swallowing), treatment 
received, personal costs (e.g. time off work, travel expenses or home help) and QoL.  
Further medical data were extracted from the hospital notes by research nurses.  
Between November 2016 and April 2019, participants who had been in the study for a 
minimum of three years were asked to complete an extended lifestyle questionnaire that 
contained additional questions around smoking and alcohol drinking histories (including 
behavioural change), marijuana use, tonsillectomy and dental health, amongst other things.  
Of the 76 H&N500 original centres, 63 agreed to take part in the extended follow-up. To date 
(May 2019) 2,185 of 3,540 (62%) of questionnaires and 4,328 (91%) of DCF have been 
completed and returned to the study team. Information obtained from these questionnaires is 
not used in the current analysis but will form the basis of future research. 
 
Throughout the study, the H&N5000 study team obtain on-going updates from the NHS 
Central Register (NHSCR) and NHS digital (formerly called the Health and Social care 
information Centre [HSCIC]) informing them of any new cancer diagnoses or deaths among 
participating individuals. Specifically, the study team receive information on date of death, 
place of death and cause of death, as recorded when deaths are certified and registered. 
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Figure 22: The 76 H&N5000 Study centres 580. 
 
Image source: 580 
 
Figure 23: H&N5000 data collection points. 
 




5.2. Methods for collecting and processing materials 
5.2.1. Blood sample collection, processing, and storage 
At baseline outpatient clinics, research nurses or trained phlebotomists collected 16 ml of 
venous blood from participants, in accordance with the local standard operating procedures 
for drawing blood. Sample were collected in two EDTA tubes (10 and 6 ml each) and 
labelled with the participant’s study ID number and a numeric ID barcode label. All samples 
were posted first class to the Bristol Bioresource Laboratories 
(https://www.bristol.ac.uk/population-health-sciences/research/groups/bblabs/] at ambient 
temperature, using the transfer kits provide by the H&N5000 study team. Over 60% of 
samples arrived within 48 hours and over 85% within 72 hours.  On receipt, samples were 
checked for any sign of damage. Laboratory staff ensured that both EDTA tubes were 
labelled and that the accompanying transfer sheet displayed the same sample ID. Blood 
samples were separated using a Thermo Scientific Heraeus Megafuge 16 centrifuge and 
spun at 3500rpm for 10 mins at 4-5⁰C. Up to 10 x 500 μl and 15x 200μl were aliquoted from 
the 10ml and 6ml EDTA tubes and placed in 0.5ml apex tubes.  Where insufficient sample 
was available to obtain all aliquots, a mixture of 500μl and 200μl aliquots were taken. 
Plasma samples were kept for biochemical, proteomic and metabolomic measures. The 
buffy coat layer (the fraction that contains most of the white blood cells and platelets) was 
extracted from each EDTA tube and put into separate 2ml sterile tubes for DNA extraction. 
All samples were stored at -80 °C. The freezers in the repository are alarmed and covered by 
a 24hr a day call out system. In total, 4,587 baseline blood samples were obtained (oral 
cavity, n=1,147; oropharynx, n=1,611; larynx, n=924). 
5.2.2. Genotyping and imputation 
Samples were genotyped using the Illumina “OncoArray”, which was specifically designed by 
the OncoArray Consortium (part of the Genetic Associations and Mechanisms in Oncology 
(GAME-ON) consortium) to evaluate genetic variants associated with common cancers 581. 
The custom array, which covers approximately 600k SNPs, comprises a genome-wide 
backbone, which provides coverage of most common genetic variants, together with specific 
markers of interest for each of the five GAME-ON cancers (breast, colon, lung, ovary, and 
prostate), and SNPs associated with multiple common cancer phenotypes and risk factors 




Genotype calls were made by the INHANCE Dartmouth team using GenomeStudio software 
(Illumina, Inc.). Initial quality control (QC) steps and analyses were performed at IARC, Lyon. 
After removing duplicates, related samples, samples with sex discrepancy and population 
outliers, imputation of unknown genetic variation was performed using the Michigan 
Imputation Server 582. Genotypes were pre-phased (i.e. their haplotypes were inferred) using 
SHAPEIT v2 583 and imputed with Minimach v3 584 using the Haplotype Reference Panel 
(HRP) 585, which is a large collection of human haplotypes (n = 64,976) obtained from 
multiple initiatives including the 1000 genomes project. After imputation, SNPs with an 
imputation quality (R2) lower than 0.7 were removed from the datasets.  
5.2.3. DNA methylation profile generation 
Genome-wide methylation status was assessed in a subgroup of participants with 
oropharyngeal tumours. Individuals were selected on the basis that they had OncoChip 
genotype data (see above), baseline questionnaire data and data capture information 
available (i.e. baseline questionnaire and DCFs had been completed and returned to the 
H&N5000 study team).   Determination of tumour site was based on clinical ICD codes. 
Following extraction, genomic DNA (isolated from buffy coats) was first bisulphite-treated 
using the EZ DNA MethylationTM kit (Zymo, Irvine, CA, USA), which converts unmethylated 
cytosine into uracil, leaving 5-methylcytosine (5-mC) unchanged.  Genome-wide methylation 
status was then measured at >850,000 cytosine positions across the genome using the 
Infinium MethylationEPIC BeadChip 586. Full details of the array have been published 
elsewhere 587. Briefly, the bead chip, which can run multiple samples simultaneously, 
contains a series of microwells and inside these wells are oligonucleotide probe sequences 
attached to silicon beads. The bisulfite converted DNA was first hybridised to the array, then 
single-base extension of the probe was used to incorporate fluorescently labelled 
dideoxynucleotides triphosphates (ddNTPs) at the 3’ CpG. The bead chip was scanned 
using an Illumina iScan, which uses a laser to excite the fluorophore of the single-base 
extension product on the beads. The iScan output includes high-resolution images of the 
light emitted from the fluorophores. Initial quality review of the intensity signals was 
assessed using GenomeStudio. The raw data (IDAT files) from GenomeStudio were then 
imported into R and pre-processed (i.e. quality control and normalisation steps were 
performed) using the meffil package (available at https://github.com/perishky/meffil/). Firstly, 
for every sample, a detection p-value was generated for each CpG, which provides an 
indication of the quality of the signal. The detection p-value compares the total signal (M + U, 
where M and U refer to the average fluorescence intensity from the methylated and 
unmethylated target CpG respectively), to the background signal level, which is estimated 
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from the negative control probes.  Very small p-values suggest a reliable signal whilst large 
p-values (>0.1), usually indicate a poor-quality signal. Mean detection p-values were plotted 
for each sample and those with a high value, implying many failed probes, were excluded 
from further analysis. Raw probe intensities were normalized (to reduce technical variability 
and batch effects) using functional normalization in order to minimise the non-biological 
differences between probes, as described in Min (2018) 588.  
 
The proportion of DNA methylation present at each CpG site was reported as a β-value, 
which is ascertained by taking the ratio of the methylated probe intensity and the overall 
intensity: β=M/ (M +U +α), where α = 100 (to protect against division by zero). The β-value 
can range between 0 and 1, with 0 indicating a completely unmethylated CpG site and 1 
indicating a fully methylated site 589. At the time of writing this thesis, DNA samples have 
been analysed for 448 participants. Of these, 440 passed quality control (2 samples with 
incorrect sex prediction, 3 samples with sex detection outliers, 1 sample with an outlier in 
predicted median methylated vs unmethylated signal, 2 duplicate samples). An additional 32 
samples were subsequently excluded owing to pathological re-classification, leaving 408 
participants with epigenetic data available for analysis. 
5.2.4. Metabolite quantification 
Metabolic profiling was done on all participants with oropharyngeal tumours who had 
adequate blood available for analysis. Aliquots of stored plasma samples were analysed 
using an automated high-throughput NMR spectroscopy-based platform (Nightingale Health 
Ltd, Helsinki, Finland), which is hosted by the Department of Chemistry, University of Bristol. 
Details of the NMR platform have been published previously 590 591. Briefly, 70 µL of plasma 
and 70 µL of sodium phosphate buffer (75 mM Na2HPO4, 0.08% sodium 3-(trimethylsilyl) 
propionate-2,2,3,3-d4, 0.04% sodium azide in 80%/20% H20/D2O, pH 7.4) were first mixed 
together using an automated Gilson 215 Liquid Handler.  The resulting solution was 
transferred to 96-format racks of NMR tubes using a Varispan Janus liquid handling robot 
(PerkinElmer).  The sample racks were inserted into one of the five well-plate positions in the 
SampleJet™ (Bruker BioSpin GmbH, Germany) sample changer, which sits on top of the 
superconducting magnet, where the actual NMR measurements take place. To prevent 
degradation of samples whilst they await measurement, the sample charger includes a 
cooling unit that keeps the prepared samples at refrigerator temperature (6 °C).  The NMR 
spectra were acquired using a Bruker Avance III HD 600MHz spectrometer, equipped with a 
cryogenically cooled triple resonance probe head (CryoProbe Prodigy TCI). The profiling 
approach in based on three ‘molecular windows’, two of which (LIPO (lipoproteins) and 
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LMWM (low-molecular-weight molecules) were applied to the native plasma and one to the 
plasma lipid extracts (LIPID).  NMR spectra are automatically transferred to a centralised 
server, which performs a number of additional spectral processing steps, including an overall 
signal check for missing or extra peaks, background control, baseline removal, and spectral 
area-specific signal alignments. In addition to this, spectral information is also compared 
against the spectra of the two quality control samples. Regression modelling is then 
performed to produce the quantified molecular data, as described previously (11,12,16). 
The combination of the three molecular windows captured by the platform provides 
simultaneous quantification of over 200 metabolic measures for each sample, including 14 
lipoprotein subclasses, multiple fatty acids, glucose, various glycolysis related measures, 
ketone bodies, and amino acids in absolute concentration units 590-592. The 14 lipoprotein 
subclasses include 593:  
• six sub-classes of very low-density lipoproteins (LDLs): 
- “extremely large”, with an average particle diameter of >75 nm, 
-  “very large” (64.0 nm), 
- “large” (53.6 nm), 
-  “medium” (44.5 nm), 
- “small” (36.8 nm),  
- and “very small” (31.3 nm);  
• three subclasses of low-density lipoproteins (LDLs): 
- “large” (25.5 nm),  
- “medium” (23.0 nm), 
- and “small” (18.7 nm);  
• intermediate density lipoproteins (IDLs), with an average particle diameter of 28.6 
nm;  
• and four subclasses of high-density lipoproteins (HDLs):  
- “very large” (14.3 nm),  
- “large” (12.1 nm),  
- medium” (10.9 nm),  
- and “small” (8.7 nm).  
 
For each of the 14 lipoprotein subclasses, the following measures are provided:  
• the circulating concentration of total lipids in the particles (sum of free and esterified 
cholesterol, triglycerides and phospholipids),  
• the particle concentration,  
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• the absolute circulating concentration of five main lipids (free, esterified and total 
cholesterol, triglycerides and phospholipids),  
• and the relative proportions of these five lipids in each particle subclass 594.  
This NMR metabolomics platform has been widely applied in genetic and observational 
epidemiological studies 593-603. Indeed, as of March 2018, there were over 100 scientific 
articles published in biomedical journals that had applied this technology 604. One of the main 
advantages of this approach is that in comparison with standard clinical chemistry assays, 
the NMR metabolomics platform can facilitate simultaneous quantification of many more 
biomarkers in a single experiment, whilst still preserving the accuracy achieved using routine 
clinical assays594. This makes it a very cost-effective method for the identification and 
validation of biomarkers in large-scale epidemiologic studies. In addition to this, NMR is 
highly reproducible and because samples never come into contact with the radiofrequency 
detector in the NMR spectrometer, the technique suffers no discernible batch effects, which 
can be an issue in studies that use alternative MS approaches (15). A more comprehensive 
comparison of the two approaches (NMR and MS) was provided in Chapter 3. 
5.2.5. Determination of HPV status 
As noted in the previous chapter, there are several different HPV detection methods 
available.  The gold standard test is the detection of viral DNA and viral RNA in tumour 
tissue because this provides evidence that the viral DNA is incorporated and actively 
transcribed (i.e. tumour is HPV driven). However, the choice for an HPV test should be 
driven by practical considerations and by the intention for its use. For example, HPV 
serology has been shown to provide a robust surrogate marker for HPV driven cancer in the 
absence of suitable tumour tissue 548 605. 
 
Various HPV detection methods were used in H&N5000.  This thesis focuses on HPV 
serological data specifically, but further molecular markers including HPV DNA and RNA and 
cellular protein p16ink4a were measured on <1000 formalin fixed tissue blocks; blocks were 
selected on the basis of their HPV serology and location.  For the serological testing, 
baseline blood samples were sent on dry ice to the German Cancer Research Centre 
(DKFZ) in Heidelberg and analysed using multiplex assays 606, a bead-based high-
throughput hybridization technique that facilitates the simultaneous detection and genotyping 
of multiple HPV types. The method has been described in detail elsewhere 547. Briefly, 
plasma samples were analysed for antibodies to the major capsid protein (L1), the early 
oncoproteins (E6, E7), and other early proteins (E1, E2, E4) of the following carcinogenic 
HPV subtypes: HPV16 and HPV18 (L1, E1, E2, E4, E6, and E7); HPV31, HPV33, HPV45, 
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and HPV52 (L1, E6, and E7).  Further details are provided in the methods section of this 
thesis.  
5.3. Variable description  
The following section of this chapter provides a description of the ‘core’ phenotypic variables 
used in this thesis. Core variables refer to those variables that are included in all H&N5000 
collaborator datasets; they capture data collected from baseline questionnaires and DCFs. 
Additional variables have been derived for the purpose of specific analysis. Graphical 
summaries of each of the variables are provided to highlight the distribution (continuous 
variables) and proportion (categorical variables) of values within each category. These 
figures are based on the entire H&N5000 cohort (data release v2.5). A summary of the 
baseline descriptives of participants included in each of the analytic datasets is provided in 
the next chapter.  
5.3.1. Demographic variables  
5.3.1.1. Gender 
Gender is a binary variable that takes a value of 1 for males and 2 for females. It is based on 
respondents’ own self-reported gender, as reported in question A4c of the baseline About 
You questionnaire. Participants were predominantly (72%; n=3,928/5,402) male (Figure 24).
 





5.3.1.2. Age at consent 
Participant’s age is captured in a continuous variable. It was derived from question A2 of the 
baseline About You questionnaire, which asks respondents to provide their date of birth 
using the format: day/month/year. The median age of participants was 61 years (interquartile 
range (IQR) = 53 to 68), and the range was 18–95 years (Figure 25)  
 
Figure 25: Histogram showing age distribution in H&N5000.  
 
5.3.1.3. Ethnicity 
Participants’ ethnicity was obtained from their medical notes and entered into the DCF 
(section A9).  Research nurses were asked to enter an ethnicity code based on one of the 
following groups: 
1) White –British 
2) White -Irish 
3) Any other White background 
4) Mixed -White and Black Caribbean 
5) Mixed -White and Black African 
6) Mixed -White and Asian 
7) Any other Mixed background 
8) Asian -Indian or British Indian 
9) Asian -Pakistani or British Pakistani 
10)  Any other Asian background 
11)  Black -Caribbean or British Caribbean 
12)  Black -African or British African 
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13)  Any other Black background 
14)  Chinese 
15)  Any other Ethnic group 
16)  Not stated/given 
17)  Patient refused 
Approximately 97% (n=5,068/5,235) of participants were white (Figure 26).  
 
Figure 26: Bar chart of ethnicity in HN5000. 
 
 
5.3.2. Clinical variables 
5.3.2.1. Primary Diagnosis 
A grouped ICD variable was created based on the ICD-10 classification codes described in 
Chapter 2: 
Oral cavity C00, C00.1, C00.3, C00.4, C00.9, C02.0, C02.1, C02.2, C02.3, 
C02.8, C02.9, C03.0, C03.1, C04.0, C04.1, C04.8, C04.9, C05.0, 
C05.2, C05.9, C06.0, C06.1, C06.2, C06.8 
Oropharynx  C01, C02.4, C05.1, C05.8, C09.-, C09.0, C09.1, C09.8, C09.9, 
C10.-, C10.2, C10.3, C10.8, C10.9 
Nasopharynx C11.0, C11.1, C11.2, C11.3, C11.8, C11.9 
Hypopharynx C10.0, C12, C13, C13.0, C13.1, C13.2, C13.8, C13.9 




Salivary gland C06.9, C07, C08.-, C08.0, C08.1, C08.9 
Nasal cavity C30.0 
Sinuses C31.-, C31.0, C31.1, C31.2, C31.3, C31.8, C31.9 
Unknown 
primary 
C76, C76.0, C80.-, C80.0, C80.9 
 
N.B. these definitions are slightly different to those described by Conway et al (see Chapter 
2), which were published later. Using the newer classification, pharynx, NOS (C14.0) and 
Waldeyer’s ring (C14.2) are grouped under oropharynx wilst soft palate NOS (C05.1) and 
overlapping lesion of the palate (C05.8) are classified as oral cavity 15.  
 
In the first H&N5000 data release, ICD codes were determined using the information 
provided in the baseline DCF, which was based on clinical examination/histology (i.e. pre-
treatment). In the second data release, which was used in the current analyses, an updated 
ICD variable was made available. The updated variable used pathologically confirmed ICD 
codes in the first instance; where pathological reports were unavailable (n=763), clinical ICD 
codes were used.  For 290 people, the pathology ICD code did not concur with the clinical 
ICD code.  In such situations, individual cases were reviewed by Dr Miranda Pring 
(Consultant Senior Lecturer in Oral Maxillofacial Pathology) and Professor Steve Thomas 
(Professor in Oral and Maxillofacial Surgery) and assigned a “best fit” ICD code.  
 
As illustrated in Figure 27, the most common tumour sites, using the revised ICD codes, 





Figure 27: Proportion of HNCs by sub-site in H&N5000. 
 
 
5.3.2.2. TNM staging 
Based on the initial clinical ICD codes, a simplified staging variable was created which 
collapsed the eight possible stage groups outlined in Chapter 1 into four groups: I, II, III and 
IV, i.e. all stage 2 tumour groups were combined into one category and all stage 4 tumour 
groups were combined into one category. Separate codes were entered for incomplete T 
and/or N and/or M codes or unacceptable TNM combinations.   When the ICD coding 
variable was updated using pathologically confirmed ICD codes (i.e. in the second data 
release), the grouped TNM variable was also updated to provide the ‘best’ (i.e. post-
treatment) staging information available. Most cases were diagnosed at a high tumour stage 





Figure 28: Bar chart showing the proportion of HNCs in each TNM stage group in 
H&N5000. 
 
5.3.2.3. HPV status 
MFI values were dichotomized as antibody positive or negative using predefined cut-offs. 
HPV16 E6 positivity was defined using a cut-off of > 1000 MFI. A binary variable was 
created to capture HPV status (positive or negative) based on this threshold. In total for all 
oral cavity, oropharyngeal and laryngeal cancers combined, 72% (n=3,274/4,541) of cases 
were HPV-negative (Figure 29).  When restricted to oropharyngeal tumours specifically, 





Figure 29: Bar chart showing the proportion of HN5000 participants who were HPV-
positive or HPV negative, as determined by HPV-16 seropositivity. 
  
 
5.3.2.4. Body mass index  
BMI is a measure of weight relative to height and is defined as the body mass divided by the 
square of the body height (weight (kg) / (height (m))2).  The values needed to derive this 
measure were obtained from questions A3 and A4 of the About You questionnaire. 
Participants’ could provide their height in centimetres (cm) or feet and inches and their 
current weight in kilograms (kg) or stone and pounds (lbs).  Using the formula defined above, 
his information was used to create a continuous variable for BMI at time of diagnosis.  Early 
versions of the baseline questionnaires did not enquire about participants’ height and weight 
and as a result, BMI data is missing for just over 40% of participants.  The median BMI for 
H&N5000 participants was 26 (IQR=23 to 29). The range was 13 to 64 (Figure 30)  
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Based on the ACE-27 scores, which were described earlier in this chapter, a categorical 
comorbidity variable was derived corresponding to extent of decompensation- “none”, “mild”, 
“moderate or severe”. Around 43% (n=2,295/5,284) of participants had no comorbid illness, 
other than their HNC (Figure 10); 34% (n=1,781) had mild comorbidity and 23% (n=1,208) 
had moderate or severe comorbidity (Figure 31). 
 




5.3.2.6. Cancer care plan intent 
Cancer care plan intent, as described in the baseline data collection section, refers to the 
intended course of treatment assigned at the time of diagnosis.  The information needed to 
code this variable was obtained from the baseline DCF (section B1). The majority (96%; 
n=5,197/5,391) of participants were expected to be treated curatively (Figure 32).   
 




5.3.3. Socioeconomic variables 
5.3.3.1. Annual household income 
Participants’ annual income was derived from question A21 of the About You Questionnaire. 
Respondents were asked to describe their total household income from all sources, before 
tax and other deductions; they could select one of eight possible responses: 
1) Less than £3,999; 
2) £4,000 to £7,999; 
3) £8,000 to £11,999; 
4) £12,000 to £17,000; 
5) £18,000 to £22,999; 
6) £23,000 to £28,999; 
7) 29,000 to £34,999; 
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8) £35,000 or more. 
Responses were further categorised into three groups: <£18,000, £18,000 - £34,999 and 
>£35,000. Approaching half (46%; n=1,773/3,447) of respondents reported earning £18,000 
or less (Figure 33). 
 
Figure 33: Bar chart of participant income in H&N5000. 
 
 
5.3.3.2. Highest education level obtained 
In question A7a of the baseline About You questionnaire, participants’ were asked: “What is 
the highest educational level you obtained?” The possible answers were: 
1) Primary school; 
2) Secondary school; 
3) School or college sixth form; 
4) College of Further Education; 
5) Polytechnic or University; 
6) Some other type of college 
Alternatively, participants were given the option to specify their own attainment level 
themselves in a free-text box. Responses were collapsed into three categories, 
corresponding to "School education" (responses 1 and 2), "College" (responses 3, 4, 6), or 
"Degree" (response 5). Around half (47%; n=1,791/3,805) of respondents were educated to 




Figure 34: Bar chart showing the education structure of respondents in H&N5000. 
 
 
5.3.3.3. Marital status 
Baseline marital status was determined from responses to question A5 of the About You 
questionnaire. Participants were asked to indicate which of the six following statements best 






6) Living with a partner. 
This information was coded as a categorical variable, as follows: “Single” (response 1), 
“Currently in a relationship” (responses 4 and 6) “No longer with spouse” (responses 2, 3, 5). 
The majority of participants (68%; n=2,718/3,987) were in a relationship at the time of 
enrolment into the study (Figure 35).
163 
 
Figure 35: Bar chart showing H&N5000 participants’ marital status. 
 
 
5.3.4. Lifestyle behaviour variables 
5.3.4.1. Alcohol consumption 
Two core alcohol variables were derived based on information provided by participants in the 
baseline “About You” questionnaire. In question A14, respondents were asked: “Just before 
you became ill, how many alcoholic drinks did you have each week?”.  They were instructed 
to enter the number in the box. From these responses, a categorical variable was derived 
that provides the number of days per week (0-7) that alcohol was consumed before the 
individual became ill. In question A15, participants were asked: “About how many bottles of 
wine, spirits and pints of beer did you drink on average each week?”  The question was 
divided into three parts corresponding to the three different alcoholic beverages-bottles of 
wine, bottles of spirits and bottles of beer, and respondents were asked to tick the box that 
best described their weekly intake.  For example, in the bottles of wine column, participants 
could select one of seven boxes, ranging from ‘None’ to ’11 or more’. Average alcohol intake 
was calculated based on the number of units of alcohol consumed, where one unit is 
measured as 10ml or 8g of pure alcohol 607. 
 
In this thesis, four drinking categories were created based on UK guidelines (ref): none, 
moderate, hazardous and harmful. Moderate drinkers included men and women who drink < 
14 units/week; hazardous drinkers included men who consumed 14 – 50 units/week and 
women who consumed 14 – 35 units/week; harmful drinkers included men who consumed > 
50 units/week and women who consumed > 35 units/week. Participants were classed as 
non-drinkers if both drink-days per week was zero and units per week was zero.  Overall, 
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28% (n=1,107/3,901), of respondents fell into the non-drinking category, 22% (n=873) were 
moderate drinkers, 36% (n= 1,385) were hazardous drinkers and 14% (n=536) were harmful 
drinkers (Figure 36).  
 
Figure 36: bar chart showing the alcohol consumption levels of participants in 
H&N5000.  
 
5.3.4.2. Baseline smoking status 
Baseline smoking status was based on participants’ self-report.   In Question A8 of the 
“About You” questionnaire, participants were asked whether they would describe themselves 
as a “current”, “former” or “never” user of tobacco.  The definition of a “never-user”, as 
outlined in the questionnaire, was someone who had never used tobacco on a regular basis, 
i.e. one tobacco product per day for a period of one year. By that definition, current smokers 
were defined as smokers of at least 1 cigarette per day over the course of a year at the time 
of blood sample collection. In total, 25% of participants (n=941/3,824) reported being never-








5.4. Representativeness of the cohort 
 
The ideal setting in which to carry out unbiased evaluations of associations between 
exposures and outcomes is a representative sample - one that is representative of the 
population in which you want to generalise your results to.  The sample should be 
representative both in terms of confounders (to exposures and outcomes) and any other 
unmeasured variables that are not specified in the original study hypotheses.  
 
H&N5000 is a UK-wide clinical cohort study. In population-based cohort studies, a sample  
of a defined population is selected for longitudinal assessment of exposure-outcome 
relations 608. The extent to which a cohort sample is representative of the total population will 
depend on the completeness of the population frame available to the investigator (i.e. the 
proportion of the total population that is captured) and participation rates. If participation 
rates are low, this can challenge the interpretation of study results, both in terms of analytic 
and descriptive epidemiology. 
 
As described early, H&N5000 is estimated to have captured a third of all incident cases in 
the UK, with approximately 50% of people identified as being eligible having been recruited. 
Whilst this represents the largest cohort of its kind in the UK currently, it is important to 
consider whether those individuals included in the study are typical of the HNC population as 
a whole. Given that the response rates of the 76 H&N5000 study centres varied from 20%-
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90%, it is conceivable that certain geographic or sociodemographic areas may be over- or 
under-represented. The reasons why certain centres recruited fewer participants may be 
related to the centres themselves e.g. low motivation to partake, limited resources, or 
logistics, or to the individuals receiving care at those centres. If participation rates are low, 
this can challenge the interpretation of study results, both in terms of analytic and descriptive 
epidemiology. 
 
From the histograms presented in this chapter, it is clear that, for the majority of variables, 
there was some missing data at baseline.  The amount of missing data was less for 
variables that were recorded by research nurses on the data capture form e.g. tumour stage 
and comorbidity.  For certain variables such as annual household income and smoking 
status, which were measured via the self-completed baseline questionnaire, the proportion 
of missing data is greater.  If the people with missing data are not comparable to those 
without missing data, this could again influence the interpretation of study results. 
Missingness should therefore be considered in the study design. 
 
One positive feature of the prospective cohort study design is that individuals do not have 
the outcome of interest at the time of enrolment. Rather, the investigator will define the 
population of individuals to be included, measure the potential exposure of interest, and then 
follow the participants over time to evaluate for the occurrence of the outcome. This is an 
advantage because it limits selection bias into the study. Non-participation at follow- ups 
could introduce selection bias but because this thesis is interested in mortality risk and all 
H&N5000 participants were flagged with NHS digital at the start of the study for regular 






Chapter 6: A description of the datasets used in the thesis 
6.1. Introduction 
The H&N5000 dataset (version 2.5) comprises data on 5,404 participants. However, not all 
these individuals were included in the following analyses.  The purpose of this chapter is to 
describe the baseline characteristics of the different analytic samples (primary analyses) 
used in this thesis. Values may differ in different releases of the H&N5000 dataset. The 
descriptive tables provide information on a range of clinical and sociodemographic variables 
but, for the purposes of analysis, some of these variables (e.g. IMD) may not have been 
included in the survival models. Full details of each of the models used will be provided in 
the relevant chapters.   
 
Figure 38: number of participants included in each of the primary analysis conducted in 
this thesis. 
 
“Cigarette” icon by Yeong Rong Kim, “Alcohol” icon by Aleksandr Vector, “DNA” icon by 
Milinda Courey, “Alarm clock” icon by kiddo, “Molecule” icon by Creative Stall from the Noun 
Project.  
 
There are four separate results chapters in this thesis, as illustrated in Figure 38.  The first 
chapter (Chapter 7) uses data on 1,403 individuals with cancers of the oral cavity, 
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oropharynx and larynx; the second and third chapters (chapters 8 and 9) use a dataset that 
includes 408 individuals with OPC, for whom epigenetic and genetic data are available; and 
the final results chapter (Chapter 10) uses a dataset of 703 individuals with OPC and 
metabolomic data available.  
 
6.2. Participants included in the observational analysis 
Table 19 describes the baseline characteristics of the 1,403 individuals included in the 
primary analysis, stratified by cancer site. In total, the sample population includes 404 
individuals with oral cavity cancers, 656 with OPC and 343 with laryngeal cancer. There are 
differences in gender, age, tumour stage, HPV status, comorbidity, BMI, educational 
attainment, annual household income, deprivation level, relationship status and smoking 
status between tumour groups.  There is no evidence of a difference in alcohol intake. The 
approximate ratio of males to females in each group is 3:2, 4:1 and 6:1 for oral cavity, 
oropharyngeal and laryngeal cancer, respectively. People with laryngeal cancer are 
generally older, with a mean age of 65 years (standard deviation [SD]=10.1) compared to 61 
(SD=11.9) years for people with oral cavity cancers and 58 (SD=9.0) years for people with 
OPC. Mean BMI is highest among people with OPC (26.9 [SD=5.1] compared to 26.0 
[SD=5.0] and 25.5 [SD=5.2] for people with oral cavity and laryngeal cancers). The 
proportion of current or former smokers in each group is 74%, 70% and 92% for oral cavity, 
oropharyngeal and laryngeal cancer, respectively. As expected, the proportion of HPV-
positive individuals is substantially higher in OPC group (73% compared to 3% and 2% for 
oral cavity and laryngeal cancers, respectively).  
 
The demographic and clinical attributes of people with HPV16 E6-seropositive and HPV- 
HPV16 E6 seronegative OPCs are compared in Table 20. People who were seropositive, 
hereafter referred to as HPV-positive, were more likely to have been diagnosed at an 
advanced tumour stage (75% were diagnosed at stage IV compared to 62% in the 
seronegative group), were less likely to be current smokers (6% versus 40%) and were less 
likely to drink hazardous to harmful amounts of alcohol (48% versus 62%).  Groups were 
similar with respect to age at diagnosis (mean ages 59 and 58 for HPV-negative and HPV-
positive individuals, respectively), gender and educational attainment but HPV-positive 
individuals had a higher BMI (28 versus 25) and were more likely to have an annual 
household income of over £35,000 (39% of people versus 23% in the HPV-negative group).
169 
 
Table 19: Baseline characteristics of the study sample, stratified by tumour site (n=1,403). 
 
* p-value for difference. Abbreviations: TNM, tumour, node and metastasis; BMI, body mass 
index; HPV, human papilloma virus; IMD, index of multiple deprivation 
Characteristic N Frequency N Frequency N Frequency p-value*
Gender
Male 249 61.6% 533 81.3% 292 85.1%
Female 155 38.4% 123 18.8% 51 14.9% <0.001
TNM stage 
I 161 39.9% 21 3.2% 150 43.7%
II 91 22.5% 73 11.1% 85 24.8%
III 31 7.7% 86 13.1% 53 15.5%
IV 121 30.0% 476 72.6% 55 16.0% <0.001
HPV status
Negative 392 97.0% 176 26.8% 336 98.0%
Positive 12 3.0% 480 73.2% 7 2.0% <0.001
Comorbidity
None 179 44.3% 357 54.4% 136 39.7%
Mild 137 33.9% 208 31.7% 121 35.3%
Moderate/severe 88 21.8% 91 13.9% 86 25.1% <0.001
Education
School education 183 45.3% 278 42.4% 186 54.2%
College 143 35.4% 247 37.7% 115 33.5%
Degree 78 19.3% 131 20.0% 42 12.2% 0.003
Annual household income
<£18,000 205 50.7% 225 34.3% 197 57.4%
£18000-£34,999 112 27.7% 205 31.3% 95 27.7%
>£35,000 87 21.5% 226 34.5% 51 14.9% <0.001
IMD 
Low Deprivation 136 33.7% 219 33.4% 154 44.9%
Moderate Deprivation 84 20.8% 151 23.0% 72 21.0%
High Deprivation 184 45.5% 286 43.6% 117 34.1% 0.002
Relationship status
single (never married) 56 13.9% 66 10.1% 43 12.5%
currently in relationship 255 63.1% 484 73.8% 224 65.3%
No longer with spouse 93 23.0% 106 16.2% 76 22.2% 0.003
Smoking status
Never 107 26.5% 194 29.6% 29 8.5%
Former 204 50.5% 362 55.2% 236 68.8%
Current 93 23.0% 100 15.2% 78 22.7% <0.001
Alcohol intake
non-drinker 106 26.2% 159 24.2% 90 26.2%
moderate drinker 86 21.3% 159 24.2% 75 21.9%
hazardous-harmful drinker 212 52.5% 338 51.5% 178 51.9% 0.786
N Mean (SD) N Mean (SD) N Mean (SD)
Age  (years) 404 61.1 (11.9) 656 58.3 (9.0) 343 65.3 (10.1) <0.001
Body mass index (kg/m2) 404 26.0 (5.01) 656 26.9 (5.1) 343 25.5 (5.2) 0.024
Oral cavity (n=404) Oropharynx (n=656) Larynx (n=343)
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Table 20: Baseline characteristics of the individuals with oropharyngeal tumours, stratified by 
HPV status (n=656).  
 
* p-value for difference. Abbreviations: TNM, tumour, node and metastasis; BMI, body mass 
index; HPV, human papilloma virus; IMD, index of multiple deprivation 
Characteristic N Frequency N Frequency p-value*
Gender
Male 137 77.8% 396 82.5%
Female 39 22.2% 84 17.5% 0.176
TNM stage 
I 15 8.5% 6 1.3%
II 30 17.0% 43 9.0%
III 22 12.5% 64 13.3%
IV 109 61.9% 367 76.5% <0.001
Comorbidity
None 78 44.3% 279 58.1%
Mild 61 34.7% 147 30.6%
Moderate/severe 37 21.0% 54 11.3% 0.001
Education
School education 76 43.2% 202 42.1%
College 67 38.1% 180 37.5%
Degree 33 18.8% 98 20.4% 0.893
Annual household income
<£18,000 86 48.9% 139 29.0%
£18000-£34,999 50 28.4% 155 32.3%
>£35,000 40 22.7% 186 38.8% <0.001
IMD 
Low Deprivation 55 31.3% 164 34.2%
Moderate Deprivation 46 26.1% 105 21.9%
High Deprivation 75 42.6% 211 44.0% 0.497
Relationship status
single (never married) 25 14.2% 41 8.5%
currently in relationship 109 61.9% 375 78.1%
No longer with spouse 42 23.9% 64 13.3% <0.001
Smoking status
Never 23 13.1% 171 35.6%
Former 83 47.2% 279 58.1%
Current 70 39.8% 30 6.3% <0.001
Alcohol intake
non-drinker 35 19.9% 124 25.8%
moderate drinker 32 18.2% 127 26.5%
hazardous-harmful drinker 109 61.9% 229 47.7% 0.005
N Mean (SD) N Mean (SD)
Age  (years) 176 59.1 (9.5) 480 58.0 (8.8) 0.148
Body mass index (kg/m2) 176 24.9 (4.8) 480 27.6 ( 5.0) <0.001
HPV negative (n=176) HPV positive (n=480)
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6.3. Participants included in the epigenetic analyses 
 
The majority (78%) of individuals included in the epigenetic dataset are male (Table 21). 
Around 70% are HPV positive and over 85% were diagnosed with high stage tumours (TNM 
stages III or IV). The majority (71%) of individuals have a history of smoking (52% former 
smokers; 20% current smokers) and half reported drinking hazardous to harmful amounts of 
alcohol prior to getting ill.  
 
Table 22 compares the characteristics of HPV-positive and HPV-negative individuals. There 
is evidence of a difference between groups with respect to age, tumour stage, comorbidity, 
BMI, annual household income, marital status, smoking status and alcohol intake but there is 
no apparent difference in gender, educational attainment or deprivation level. People with 
HPV-negative tumours are, on average, 3.3 years older than people with HPV-positive 
tumours. Compared to the HPV-positive group, the HPV-negative group are more likely to be 
former or current smokers (86% versus 66%) and are more likely to have drunk hazardous 
to harmful amounts of alcohol prior to their HNC diagnosis (61% versus 48%). The HPV-
negative group are also more likely to have severe comorbidity (27% versus 15%) and less 




Table 21: Baseline characteristics of all participants included in the epigenetic analyses 
(n=408). 
 
* p- value for difference. Abbreviations: TNM, tumour, node and metastasis; BMI, body mass 


























Low Deprivation 149 38.80%
Moderate Deprivation 81 21.10%
High Deprivation 154 40.10%
Relationship status
single (never married) 47 11.70%
currently in relationship 280 69.70%







moderate drinker 90 22.50%
hazardous-harmful drinker 206 51.50%
N Mean (SD)
Age  (years) 403 58.4 (9.6)
Body mass index (kg/m2) 272 26.4 (4.9)
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Table 22: baseline characteristics of participants included in the epigenetic analysis, 
stratified by HPV status (n=408). 
 
* p- value for difference. Abbreviations: TNM, tumour, node and metastasis; BMI, body mass 
index; HPV, human papilloma virus; IMD, index of multiple deprivation.
Characteristic N Frequency N Frequency p-value
Gender
Male 96 78.70% 221 77.30%
Female 26 21.30% 65 22.70% 0.753
TNM stage 
I 10 8.20% 7 2.40%
II 18 14.80% 21 7.30%
III 22 18.00% 36 12.60%
IV 72 59.00% 222 77.60% 0.001
Comorbidity
None 47 38.80% 164 57.70%
Mild 41 33.90% 78 27.50%
Moderate/severe 33 27.30% 42 14.80% 0.001
Education
School education 52 45.60% 118 42.90%
College 44 38.60% 114 41.50%
Degree 18 15.80% 43 15.60% 0.861
Annual household income
<£18,000 60 57.10% 78 31.00%
£18000-£34,999 21 20.00% 82 32.50%
>£35,000 24 22.90% 92 36.50% <0.001
IMD 
Low Deprivation 51 42.90% 98 37.00%
Moderate Deprivation 21 17.60% 60 22.60%
High Deprivation 47 39.50% 107 40.40% 0.424
Relationship status
single (never married) 21 17.80% 26 9.20%
currently in relationship 62 52.50% 218 76.80%
No longer with spouse 35 29.70% 40 14.10% <0.001
Smoking status
Never 17 14.40% 93 33.90%
Former 50 42.40% 155 56.60%
Current 51 43.20% 26 9.50% <0.001
Alcohol intake
non-drinker 30 25.20% 74 26.30%
moderate drinker 17 14.30% 73 26.00%
hazardous-harmful drinker 72 60.50% 134 47.70% 0.020
N Mean (SD) N Mean (SD)
Age  (years) 122 60.7 (10.8) 79 57.4 (10.8) 0.002
Body mass index (kg/m2) 281 25.0 (4.8) 193 27.1 (4.9) 0.001
HPV- negative  (n=122) HPV- positive  (n=286)
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6.4. Participants included in the metabolomics analysis 
 
The primary metabolomics analysis, described in Chapter 10, included 703 individuals with 
OPC. The clinical and demographic characteristics of this analytic dataset are presented in 
Table 23.  
 
There are around four times as many males than females included in this sample. The 
proportion of people with HPV-positive cancers is comparable to that of the epigenetic 
dataset at just over 70%. Similarly, the majority of these cancers (72%) were diagnosed at 
stage IV. Over half of the people with data reported being former smokers and 15% current 
smokers, whilst half drank hazardous to harmful amounts of alcohol. 
 
Comparing the characteristics of people with and without HPV-driven tumours in this dataset 
(Table 24), there is evidence of a difference in age, stage, comorbidity, annual household 
income, relationship status and smoking and alcohol intake. HPV-positive individuals in this 
sample were younger at the time of diagnosis (around 58 years old compared to 60 years 
old), were diagnosed with higher stage tumours (77% were diagnosed with stage IV tumours 
compared to 62% in the HPV-negative group), were more likely to be in the highest income 
group (37% earned > £35,000 compared to 22% of those in the HPV-negative group) and 
were more likely to be in a relationship (79% versus 60%). Only 6% of HPV-positive 
individuals in this sample population reported being current smokers at baseline compared 
to 40% in the HPV-negative group. The proportion of hazardous to harmful drinkers was 
47% and 60% for HPV-negative and HPV-positive individuals, respectively. 
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Table 23: baseline characteristics of the study sample included in the metabolomic analysis 
(n=703). 
 
* p-value for difference. Abbreviations: TNM, tumour, node and metastasis; BMI, body mass 


























Low Deprivation 216 33.4%
Moderate Deprivation 149 23.0%
High Deprivation 282 43.6%
Relationship status
single (never married) 68 9.7%
currently in relationship 519 73.8%







moderate drinker 171 24.3%
hazardous-harmful drinker 353 50.2%
N Mean (SD)
Age  (years) 703 58.2 (9.1)
Body mass index (kg/m2) 703 27.0 (5.0)
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Table 24: baseline characteristics of the study sample, stratified by HPV status (n=703). 
 
* p-value for difference. Abbreviations: TNM, tumour, node and metastasis; BMI, body mass 
index; HPV, human papilloma virus; IMD, index of multiple deprivation.
Characteristic N Frequency N Frequency p-value
Gender
Male 144 77.8% 420 81.1%
Female 41 22.2% 98 18.9% 0.342
TNM stage 
I 18 9.7% 6 1.2%
II 28 15.1% 45 8.7%
III 25 13.5% 69 13.3%
IV 114 61.6% 398 76.8% <0.001
Comorbidity
None 79 42.7% 300 57.9%
Mild 64 34.6% 159 30.7%
Moderate/severe 42 22.7% 59 11.4% <0.001
Education
School education 81 43.8% 212 40.9%
College 71 38.4% 201 38.8%
Degree 33 17.8% 105 20.3% 0.710
Annual household income
<£18,000 95 51.4% 154 29.7%
£18000-£34,999 50 27.0% 172 33.2%
>£35,000 40 21.6% 192 37.1% <0.001
IMD 
Low Deprivation 55 32.0% 161 33.9%
Moderate Deprivation 43 25.0% 106 22.3%
High Deprivation 74 43.0% 208 43.8% 0.759
Relationship status
single (never married) 26 14.1% 42 8.1%
currently in relationship 111 60.0% 408 78.8%
No longer with spouse 48 25.9% 68 13.1% <0.001
Smoking status
Never 27 14.6% 189 36.5%
Former 85 45.9% 297 57.3%
Current 73 39.5% 32 6.2% <0.001
Alcohol intake
non-drinker 38 20.5% 141 27.2%
moderate drinker 37 20.0% 134 25.9%
hazardous-harmful drinker 110 59.5% 243 46.9% 0.014
N Mean (SD) N Mean (SD)
Age  (years) 185 59.5 (9.7) 185 57.8 (8.8) 0.030
Body mass index (kg/m2) 518 25.1 (5.0) 518 27.7 (4.9) <0.001
HPV- negative  (n=185) HPV- positive  (n=518)
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6.5. Discussion  
 
Version 2.5 of the H&N5000 database contains information on over 5,4000 individuals with 
HNC. This thesis focuses on a sub-sample of these participants. The number of individuals 
analysed at each stage varies because metabolomic and epigenetic data are only available 
for a subset of people with OPC, whilst clinical and demographic information has been 
collected on all consenting participants.  
 
The purpose of this chapter was to introduce the three main datasets used in the primary 
analyses. The tables presented here demonstrate how, within datasets, there are differences 
in many of the clinical, socio-economic, and behavioural characteristics across tumour sites 
and between people with and without HPV-driven tumours. These differences may 
potentially confound any relationships that exists between the exposures and outcomes of 
interest, demonstrating the need to control for these factors in subsequent analyses. 
 
The next chapter looks at the associations of self-reported smoking status and alcohol intake 
with survival in a group of participants with oral cavity, oropharyngeal and laryngeal cancer, 




Chapter 7: Associations of self-reported smoking status 
and alcohol use at diagnosis with survival in H&N5000 
This chapter includes sections from the publications below: 
 
Beynon, R. A., Lang, S., Schimansky, S., Penfold, C. M., Waylen, A., Thomas, S. J., Pawlita, 
M., Tim, W., Martin, R. M., May, M. & , 2018. Tobacco smoking and alcohol drinking at 
diagnosis of head and neck cancer and all-cause mortality: Results from head and neck 
5000, a prospective observational cohort of people with head and neck cancer. International 
Journal of Cancer. 143, 5, p.1114-1127. 
 
7.1. Introduction 
Earlier chapters have emphasized the importance of tobacco and alcohol use in HNC 
development. Although these behaviours together account for over 75% of new HNC cases 
144, the prognostic significance of smoking status and alcohol intake at the time of HNC 
presentation remains unclear, especially for people with HPV-driven oropharyngeal tumours.  
 
Most studies report a dose - dependent increase in mortality risk with increasing exposure to 
tobacco pre-diagnosis 441-443 445 450 455 456 459. The magnitudes of the effects vary considerably 
however, as described in chapter 3. One possible explanation for the differences in the 
reported effect estimates is that studies have frequently been undertaken in single cancer 
sites, typically the larynx or oropharynx 450 455 456. Where studies have included multiple sites, 
analyses have rarely stratified on this. In addition to this, studies have frequently been 
unable to adjust for important prognostic factors, such as comorbidity, BMI or HPV status, 
often because they were conducted retrospectively. 
 
Evidence of an association between pre-treatment alcohol use and HNC mortality risk is 
conflicting. Some studies report an inverse association between alcohol intake and survival 
408 442 450 609, whilst others have found little or no evidence of an effect 447 455. Consequently, it 
is unclear whether any association of alcohol consumption with HNC cancer mortality is 
genuine, or the result of residual confounding by smoking or other factors. The results of one 
study suggest that the effects of alcohol intake on HNC survival may differ by treatment 
method and primary site 609, but this analysis only included 427 individuals from a single 




The H&N5000 cohort provides a unique opportunity to examine the effects of smoking and 
alcohol drinking on HNC mortality owing to its large sample size, multi-center design, 
and the availability of detailed information on clinical, biological and lifestyle factors, 
including HPV status.  
 
7.2. Aims and objectives 
The overall aim of this chapter is to examine the effect of smoking status and alcohol intake, 
reported at the time of diagnosis, on survival in people with HNC in H&N5000.  The specific 
objectives are: 
1. to establish whether self-reported smoking status and alcohol consumption are 
associated with all-cause mortality in people with oral cavity, oropharyngeal and 
laryngeal cancer, after adjusting for important clinical, biological and socioeconomic 
factors; 
2. to investigate whether any associations of smoking status and alcohol intake with all-
cause mortality differ by tumour site; 
3. to investigate whether any effects of smoking status and alcohol intake on all-cause 
mortality are influenced by HPV status (in OPC); 
4. to explore the potential interactions of smoking and alcohol drinking and HPV status 
and smoking and/or alcohol drinking with all-cause mortality. 
 
The results of an earlier analysis, which used version 2.3 of the H&N5000 data release, have 
been published in The International Journal of Cancer 575. The analysis described here 
adopts the same statistical methods as the published analysis, but the sample numbers are 
slightly different, and the follow-up period is approximately one-year longer in the present 
analysis.  In addition, this analysis is restricted to participants with SSC. 
7.3. Methods    
7.3.1. Study population  
Included participants were those that: 
• had cancers of the oral cavity, oropharynx and larynx (C01-C06; C09-C10; C32); 
• had SCCs; 
• had baseline questionnaire data and data capture available;  
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• were being treated with curative intent (at baseline); 
• described their ethnicity as white. 
 
Full details of the study including baseline data collection and follow-up have been provided 
in Chapter 5. To recap, participants were asked to complete three self-administered 
questionnaires at baseline (i.e. before their cancer treatment had commenced). The 
questionnaires enquired about social and economic circumstances, lifestyle behaviours, 
general health, and past sexual behaviours.  Up-to-date treatment and cancer recurrence 
information was extracted from participants’ medical records and entered into a data capture 
form.   
7.3.2. Outcome assessment  
The outcome of interest was all-cause mortality. Follow-up for survival analysis was defined 
as the time in years from study enrolment to the first of: date of death from any cause or the 
date of censorship (mortality records linked up until 11/10/2018).  Participants were 
censored if they have not been observed long enough for the event to occur, i.e. the dataset 
closed before the event could be observed, or they were lost to follow-up. Given that 
participants were flagged with NHS digital (for mortality updates), the number of participants 
loss to follow-up is expected to be low in this analysis. 
7.3.3. Defining exposures  
Information on tobacco and alcohol history was obtained at baseline via the self-
administered questionnaire. Full details are described in Chapter 5. Briefly, participants were 
asked to report their current smoking status (“never”, “former” or “current”) and the number 
of bottles of wine, spirits, and pints of beer they drank on an average week (prior to their 
HNC). Baseline drinking categories were then defined as “none”, “moderate”, or “hazardous 
to harmful”. Smoking categories were preserved to allow comparison with the published 
literature, wherein most authors have adopted these classifications 441-443 445 450 451 456 457 459. 
Alcohol consumption categories were derived based on current UK-drinking guidelines607 , to 
provide clinical ease of interpretation.  
7.3.4. Assessment of HPV status 
Plasma was analysed for antibodies against the HPV16 E6 oncoprotein, using a median MFI 
cut-off of ≥1,000 MFI (See chapter 5 for details). Participants with values below this cut-off 
were classed as HPV16 E6- seronegative, hereafter referred to as “HPV-negative”, and 
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those with values above the cut off were defined as HPV16 E6 seropositive, hereafter “HPV-
positive”. 
7.3.5. Statistical analysis 
Analyses were completed using Stata version 15.1. (StataCorp. 2015. Stata Statistical 
Software: Release 14. College Station, TX: StataCorp LP).   
7.3.5.1. Descriptive analysis 
Baseline descriptive data were stratified by tumour site and HPV status (oropharyngeal 
only). P- values were calculated with the χ2 test for categorical variables and analysis of 
variance (ANOVA) for continuous variables. 
7.3.5.2. Accounting for missing data 
Missing data is a common problem in epidemiologic studies, particularly for research using 
questionnaire data.  There are several ways of dealing with missing data.  Commonly, 
complete-case analyses are performed, whereby data is only analysed on the individuals 
who had data recorded on all variables of interest. Depending on the mechanism of missing 
data however, this approach can produce biased estimates 610. That is, if the remaining 
subjects are not representative of the original population, then the results will be misleading. 
Even if the results are not biased, the analysis is inefficient because potentially useable data 
is ignored. As such, complete case analyses may lead to a loss of precision and power 610-
612.   
 
An alternative approach is to impute missing data. Multiple imputation (MI) involves 
generating a set of plausible replacements for each missing value (using the correlations in 
the observed dataset), running the analysis in each imputed dataset, and then combining the 
point estimates in a way that reflects the uncertainty around the true value 610. The correct 
number of new ‘complete’ datasets to be generated, i.e. the number of imputations to be 
performed (m), is an area of debate, but it is often stated that m should be at least 5 610.  An 
appropriate m will however depend on the amount of missing data being imputed. Overall, 
the validity of the resulting analysis depends on the assumptions made about the ‘missing 
mechanism’.  If data are missing not at random (MNAR), that is if missingness is related to 
the value of the missing observation, then MI will not solve the problem.  For instance, BMI 
would be MNAR if a participant was less likely to report their weight if they knew they were 
overweight. By contrast, if data were missing completely at random (MCAR) or missing at 
random (MAR), i.e. data are missing purely by chance or missingness is related to other 
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factors that are recorded within the dataset and not on unobserved values, then MI may 
increase the efficiency and precision of the analysis. 
 
In the current analysis, BMI was missing for a large proportion of participants (further details 
on the proportion of missingness below) because information on height and weight were not 
collected at the start of the study.  It was therefore assumed that the missingness 
mechanism for BMI was MAR, since missingness was dependent on the date of enrolment. 
Several other variables had missing data. The missing status of each of these variables was 
considered using the Stata command mvpatterns, which produces a table showing how 
frequently missing values in each of the variables occur together. Missing values were 
imputed using the ice package for multiple chained equations in Stata 613. Twenty imputed 
datasets were generated for each of the three tumour sites and combined using Rubin's rule 
to obtain valid statistical inferences 614. The three resulting datasets were merged into one 
single analytical dataset. Imputation models included all of the variables in the substantive 
Cox model, the event status (i.e. a binary variable indicating whether the participant 
experienced the event (death) or not), and the Nelson-Aalen estimator of the cumulative 
hazard 615. 
7.3.5.3. Survival analysis 
Kaplan-Meier survival curves were first plotted to visualize differences in survival between 
tumour sites in relation to smoking and alcohol status.  The log-rank test was used to test the 
null hypothesis that there was no difference between groups with respect to the probability of 
the event (death) at any time point. The variance in survival explained by smoking and 
alcohol intake was calculated via the str2d Stata module using the method of Royston and 
Sauerbrei 616. The explained variation statistic (R2) is based on their index of discrimination 
(D) for proportional hazards for censored survival data.  
 
The primary analyses included complete cases only i.e. participants with complete data for 
confounders used in the adjusted models and information on smoking and alcohol 
consumption (as per the published manuscript).  Cox proportional hazards models, stratified 
by tumour site, stage and HPV status, were used to examine the associations of baseline 
smoking status and alcohol intake with survival. Only oropharyngeal cases were considered 
in the HPV stratified models because the role of HPV in tumours outside the oropharynx is 
uncertain, as is the ability of serology to detect HPV driven tumours in other anatomical 
sites. HRs and 95% CIs for mortality were calculated for each category of smoking and 




The equation for the Cox model can be written as:  
 
h(t) = h0(t)  x  exp(β1x1 + β2x2 + ….+ βmxm) 
 
Where h(t) is the hazard function, i.e., the probability of having the event (death) at time t 
given the individual survived to time t, h0(t) is the baseline hazard, i.e., the hazard for the 
respective individual when all covariate values are equal to zero, and β1x1 + β2x2 + ….+ βmxm 
represents the covariate effects. The predicted hazard (i.e., h(t)), is therefore the product of 
the baseline hazard (h0(t)) and the exponential function of the linear combination of the 
predictors.  
 
A major assumption of the Cox proportional hazards (PH) model is that hazards between 
levels of covariates are constant, or proportional, over time. This means that if a person’s 
risk of dying at some initial time point is twice as high as that for another person, their risk of 
death remains twice as high at all other time points. This assumption of proportional hazards 
should be tested. In the current analysis, The PH assumption was checked by plotting the 
log of the cumulative hazard against time (log-log plots) and checking for parallelism and 
using statistical tests and graphical diagnostics based on the scaled Schoenfeld residuals 617 
(implemented using the “estat phtest” command in Stata). The PH assumption is violated 
when there is a significant relationship between residuals and time.  
 
Four different Cox models were fitted:  
 
1) a minimally adjusted model that included age and gender;  
2) a model that additionally adjusted for clinical factors (TNM stage, HPV status, BMI 
and comorbidity); 
3) a model that additionally adjusted for socioeconomic factors (annual household 
income, education level and marital status);  
4) a fully adjusted model that included both smoking and alcohol intake, in addition to 
clinical and socioeconomic factors. 
 
  
The covariates were selected on the basis of the strength of prior evidence linking them with 




Potential interactions between tumour stage and smoking, tumour stage and alcohol 
consumption, HPV status and smoking, HPV status and alcohol consumption and 
smoking and alcohol intake were investigated by fitting an interaction term in the models and 
using a likelihood ratio test. As above, HPV analyses were restricted to the subset of 
participants with oropharyngeal tumours. 
 
To control for the fact that people treated in some HNC centres may be more likely to die 
than others for unobserved reasons not captured by the model covariates, a ‘shared frailty’ 
term was fitted (with gamma distribution) to model 4 (the fully adjusted model) as a 
sensitivity analysis, to assess for the presence of heterogeneity between recruitment 
centres. The significance of the frailty component was tested using a likelihood‐ratio test. 
Finally, the primary analysis was repeated in the imputed dataset. All reported p-values are 
two-sided. 
7.4. Results 
The dataset included 5,404 people with HNC (Figure 39). Of those, 3,890 had cancers of the 
oral cavity, oropharynx and larynx and were eligible for inclusion in the analysis (i.e. they had 
SCC, were being treated with curative intent and were white). The complete case analysis 
included 1,403 individuals. Missing covariate data was imputed for 2,487 participants.   
7.4.1. Missing data 
The distribution of missing data stratified by tumour site and HPV status is shown in Table 
25. Overall, the largest proportion of missing data was present for BMI (41%), followed by 
annual household income (36%) and education (29%).  Smoking and drinking data were 
missing for 28% and 27% of participants, respectively.  The proportion of missing data was 




Figure 39: Flow of Head and Neck 5000 participants through the study. 
 
* Participants with SCC, being treated with curative intent, and who describe their ethnicity as 
white. ** Age, gender, TNM stage, HPV status, BMI, comorbidity, education, annual household 
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Variable N (%) N (%) N (%) N (%) N (%) N (%) 
Age 23 (0.6) 11 (1) 1 (0.1) 11 (0.6) 1 (0.2)  8 (0.8)  
Gender 0 0 0 0 0 0 
TNM stage 10 (0.3) 3 (0.3) 0 7 (0.4) 1 (0.2)  5 (0.5)  
HPV status 608 (15.6) 174 (15.1) 151 (15.6) 283 (16.0) 0 0 
Comorbidity 74 (1.9) 23 (2.0) 22 (2.3)  29 (1.6) 7 (1.5)  15 (1.5)  
BMI 1599 (41.1) 480 (41.7) 381 (39.3) 738 (41.7) 208 (45.7)  389 (37.7)  
Household income 1383 (35.6) 430 (37.4) 362 (37.3) 591 (33.4) 181 (39.8)  290 (28.1)  
IMD 367 (9.4) 118 (10.2) 98 (10.1) 151 (8.5) 86 (8.3) 31 (6.8) 
Education 1133 (29.1) 331 (28.8) 300 (30.9) 502 (28.4) 152 (33.4)  241 (23.4)  
Marital status 996 (25.6) 283 (24.6) 254 (26.2) 459 (25.9) 140 (30.8)  215 (20.8)  
Smoking status 1101 (28.3) 318 (27.7) 278 (28.7) 505 (28.5)  145 (31.9)  251 (24.3)  
Alcohol intake 1061 (27.3)  309 (26.9)  274 (28.3) 478 (27.0) 144 (31.7)  227 (22.0)  
 
Abbreviations: BMI, body mass index; HPV, human papillomavirus; IMD, index of multiple deprivation; n, number; % , percent missing.
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7.4.2. Baseline characteristics of study population  
The demographic and clinical attributes of the 1,403 individuals (oral cavity, n=404; 
oropharynx, n=656; larynx, n=343) included in the complete case analysis were presented in 
Chapter 4 (Table 19 by tumour site; Table 20 by HPV status). When considering similarities 
and differences across tumour sites, groups were different with respect to all of the 
characteristics considered, except for alcohol intake, where approximately 50% of people in 
each group drank hazardous to harmful amounts of alcohol. People with laryngeal cancers 
tended to be older overall and were more likely to be male and were more likely to be current 
smokers. People with HPV-positive OPC were more likely to have high stage tumours 
(stages III and IV) and were generally more affluent than people with HPV-negative cancers.  
 
The baseline descriptives of individuals included in the imputed analysis (n=3,890) are 
presented in the supplementary material (Appendix 1). As was the case with the complete 
case dataset, there were differences across tumour groups in all variables except alcohol 
intake (p=0.660). The ratio of males to females in each tumour group was comparable to the 
complete case dataset, as were the mean ages of participants (oral cavity, 62 years 
[SD=12.3]; oropharynx, 59 years [SD=9.0]; larynx, 65 years [SD=10.4]) and the proportion of 
former and current smokers (oral cavity, 75%; oropharynx, 73%; larynx, 81%). 
 
Differences between the sample of people with complete data and those with missing data 
are compared in Table 26.  There were differences between the two groups with respect to 
the burden comorbidity (p-value for difference <0.001), HPV status (p=0.009), educational 
level (p=0.052), income (p=0.031) and deprivation level (p<0.001). The sample of people 
with missing data were more likely to: have higher comorbidity, be HPV-negative, be lower 
educated, and be in a lower income group. However, people with missing data were less 
likely to live in the lowest deprivation group than people with complete data. It is important to 
note that IMD index was not available for Scotland. There was no evidence to suggest that 
people with missing data differed from those with complete data with respect to age, sex, 




Table 26: A comparison of the baseline characteristics of participants who did and did not 
have missing data. 
 
Characteristic N Frequency N Frequency p-value
Tumour site 
Oral Cavity 746 30.00% 404 28.80%
Oropharynx 1114 44.80% 656 46.80%
Larynx 627 25.20% 343 24.40% 0.495
Gender
Male 1868 75.10% 1074 76.60%
Female 619 24.90% 329 23.40% 0.315
TNM stage
I 532 21.50% 332 23.70%
II 439 17.70% 249 17.70%
III 337 13.60% 170 12.10%
IV 1169 47.20% 652 46.50% 0.316
HPV serology group
HPV-negative 1292 68.80% 904 64.40%
HPV-positive 587 31.20% 499 35.60% 0.009
Comorbidity 
None 941 39.00% 672 47.90%
Mild 877 36.30% 466 33.20%
Moderate/Severe 595 24.70% 265 18.90% <0.001
Education level
School education 686 50.70% 647 46.10%
College 439 32.40% 505 36.00%
Degree 229 16.90% 251 17.90% 0.052
Annual household income 
<£18,000 549 49.70% 627 44.70%
£18000-£34,999 307 27.80% 412 29.40%
>£35,000 248 22.50% 364 25.90% 0.031
IMD 
Low Deprivation 936 44.20% 509 36.30%
Moderate Deprivation 459 21.70% 307 21.90%
High Deprivation 725 34.20% 587 41.80% <0.001
Relationship status
Single (never married) 188 12.60% 165 11.80%
Currently in relationship 998 66.90% 963 68.60%
No longer with spouse 305 20.50% 275 19.60% 0.607
Smoking status
Never 291 21.00% 330 23.50%
Former 815 58.80% 802 57.20%
Current 280 20.20% 271 19.30% 0.273
Alcohol consumption 
Non-drinker 377 26.40% 355 25.30%
Moderate drinker 292 20.50% 320 22.80%
Hazardous-harmful drinker 757 53.10% 728 51.90% 0.313
N Mean (SD) N Mean (SD)
Age (years) 2464 61.76 (10.84) 1403 60.80 (10.54) 0.241
BMI 888 26.35 ( 5.32) 1403 26.55 ( 5.12) 0.204
Missing data (n=2,487) Complete data (n=1,403)
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7.4.3. Kaplan-Meier survival plots 
There were 329 deaths (oral cavity, n=118 [29%]; oropharynx, n=119 [19%]; larynx, n=89 
[26%]) during a median follow-up time of 4.3 years (IQR=3.7 years - 5.1 years). Overall, 
there was a difference in the probability of survival across tumour sites (p<0.001; Figure 40). 
On visual inspection of the Kaplan-Meier plot, the survival probability was lowest for people 
with oral cavity cancers. Up to 2-years post diagnosis, there was little difference in survival 
probabilities for OPC and laryngeal cancer cases but after 2-years, the cumulative survival 
probability for people with laryngeal cancer was lower than for people with OPC.  
 




As illustrated in Figure 41, the risk of death increased with increasing smoking exposure in 
all cancer groups (log-rank p-value across all three smoking categories: oral cavity, p<0.001; 
oropharynx, p=0.001; larynx, p=0.001). For oral cavity cancers, the risk of death (post 2-
years) appeared to be similar for former and current smokers. Considering alcohol exposure, 
there was evidence of a difference in the probability of survival across categories of intake in 
the oral cavity and OPC groups (log-rank p-value across all three alcohol categories: oral 
cavity, p=0.013; oropharynx, p=0.066).  Kaplan-Meier plots suggest that moderate drinkers 
had the lowest mortality risk. The amount of alcohol consumed did not appear to influence 
survival in the laryngeal cancer group (log-rank p-value across all three alcohol categories: 
p=0.577). When plots were stratified by HPV status (Figure 42), there was a trend for 
increasing mortality risk with increasing tobacco exposure in the HPV-negative OPC group 
(log-rank p-value across all three smoking categories: p=0.018). In the HPV-positive group, 
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current smokers appeared to have a higher mortality risk compared with never-smokers (log-
rank p-value for never vs. current smokers: 0.076).  There was evidence of a difference in 
survival probability across alcohol categories in the HPV-positive group (log-rank p-values: 
across all three alcohol categories p=0.013; for non-drinkers vs hazardous-harmful drinkers 






Figure 41: Kaplan-Meier plot of overall survival by smoking status and alcohol 
consumption, stratified by tumour site. 
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Figure 42: Kaplan-Meier plot of overall survival by smoking status and alcohol 




7.4.4. Variation in survival explained by smoking status and alcohol intake 
A minimally adjusted model that included age and gender accounted for 6% of the variation 
in survival (R2=0.06 [95% CI:0.02, 0.10]). Inclusion of self-reported smoking status led to an 
increase in the proportion of explained variation of 7% (R2=0.13 [95% CI:0.08, 0.19]). Adding 





7.4.5. Smoking status and survival 
For all cancer sites combined (n=1,403), there was strong evidence of an association 
between smoking status at diagnosis and survival.  Compared to never smokers, the HR for 
current smokers was 3.3 (95% CI: 2.3, 4.7; p for trend <0.001) in the minimally adjusted 
model; this attenuated to 2.0 (95% CI: 1.4, 3.0; p <0.001) in the fully adjusted model (Table 
27).  For former smokers, the HR was 1.7 (95% CI: 1.2, 2.3; p <0.001) when models were 
minimally adjusted and 1.6 (95% CI: 1.2, 2.3; p = 0.001) on full adjustment. 
 
In stratified analyses, the associations of smoking status with survival were present across 
all tumour groups in the minimally adjusted models, but only the oral cavity and laryngeal 
cancer groups were robust to adjustment (Table 27).  In the oral cavity cancer group, the HR 
for current smokers was 2.2 (95% CI: 1.2, 3.8; p = 0.012) in the minimally adjusted model 
and 2.3 (95% CI: 1.2, 4.4; p = 0.010) in the fully adjusted model for people with laryngeal 
cancers, the respective HRs were 4.4 (95% CI: 1.5, 12.4; p <0.001) and 3.4 (95% CI: 1.1, 
10.3; p for trend =0.001).  
 
Results of the imputed analysis (n=3,890; number of deaths: oral cavity, n=378/1,150; 
oropharynx, n=425/1,770; larynx=268/970) were comparable to those of the complete case 
analysis (Appendix A2).  In minimally adjusted models, the hazard ratio was 3.2 (95% CI: 
2.6, 4.0) and 1.7 (95% CI: 1.3, 2.1; p <0.001) for current and former smokers, respectively. 
In fully adjusted models, the corresponding hazard ratios were 1.9 (95% CI: 1.5, 2.5) and 1.5 
(95% CI: 1.2, 1.9; p for trend <0.001). In the stratified analysis, the associations of smoking 
status with survival were robust to adjustment in all tumour groups (HR for former vs. never 
smokers = 1.7 (95% CI: 1.1, 2.6; p = 0.006); 1.9 (95% CI: 1.2, 3.1; p = 0.004) and 3.1 (95% 
CI: 1.5, 6.4; p <0.001) for oral, oropharyngeal and laryngeal cancers, respectively). 
 
7.4.6. Alcohol intake and survival 
In the minimally adjusted model, the HR for hazardous to harmful drinkers compared to non-
drinkers was 1.2 (95% CI: 1.0, 1.6; p = 0.042) (Table 27). On full adjustment, there was no 
evidence for an increase in mortality risk (HR= 1.0 [95% CI: 0.8, 1.3; p = 0.554]).  There was 
a suggestion that moderate drinkers experienced improved survival compared to non-
drinkers (minimally adjusted HR= 0.7 [95% CI: 0.5, 1.1; p = 0.042]; fully adjusted HR= 0.8 




When models were stratified by tumour site, there was little evidence of an association 
between alcohol consumption and survival (Table 27). Hazard ratios for hazardous to 
harmful drinkers were 0.92 (95% CI: 0.58, 1.45; p = 0.789), 1.28 (95% CI: 0.80, 2.05; p = 
0.263) and 0.94 (95% CI: 0.55, 1.59; p = 0.798) for oral cavity, oropharyngeal and laryngeal 
cancers, respectively. 
 
In the imputed analyses (Appendix A2), a comparable pattern of association between 
alcohol drinking and survival was observed (minimally adjusted HRs: 1.2 [95% CI: 1.0, 1.4; p 
= 0.012] and 0.9 [95% CI: 0.7, 1.1] for hazardous/harmful drinkers and moderate drinkers 
respectively; corresponding fully adjusted HRs:1.1 [95% CI: 0.9, 1.3; p = 0.321] and 0.9 
[95% CI: 0.7, 1.1]). As was the case in the primary analysis, there was little evidence that 
alcohol consumption influenced mortality risk in the stratified analysis. 
 
7.4.7. Heterogeneity between centres 
Unobserved heterogeneity by recruitment centre was examined using a shared frailty model, 
wherein the random effect is common or “shared” by people in the same centre or “cluster” 
618. The likelihood ratio test of theta (θ) =0 (testing the null hypothesis that the variance 
component in the variable “centre” is not different from zero) gave a chi-squared of 0.46 with 
an estimated p-value of 0.250, suggesting there is little variance in survival time among 
centres. 
 
7.4.8. Influence of tumour stage on the associations of smoking and alcohol intake with 
survival 
There were 581 people with low-stage tumours (stages I-II) and 822 with high-stage tumours 
(III-IV) in the analysis. Of those, 109 people in the low stage group and 220 in the high stage 
group died during the follow-up period. In minimally adjusted models (Table 28), the HR of 
death for current versus never-smokers was 4.0 (95% CI: 1.9, 8.3; p< 0.001) in the low-
stage group and 3.6 (95% CI: 2.4, 5.4; p <0.001) in the high-stage group. On full adjustment, 
the corresponding HRs were 2.8 in the low stage group (95% CI: 1.3, 6.2; p = 0.011), and 
1.9 in the high stage group (95% CI: 1.2, 3.0; p <0.003). The point estimates for moderate-
drinkers in the low-stage group were similar after adjustment (minimally adjusted HR= 0.80 
[95% CI: 0.90, 2.32]; fully adjusted HR= 0.78 [95% CI: 0.42, 1.44]). For hazardous/harmful 
drinkers, the HR attenuated slightly (minimally adjusted HR=1.44 [95% CI: 0.90, 2.32]; fully 
adjusted HR=1.30 [95% CI: 0.81, 2.09]). In the high-stage group, the HR for moderate-
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drinkers was 0.66 in the minimally adjusted model (95% CI: 0.44, 0.99) and 0.73 in the fully 
adjusted model (95% CI: 0.48, 1.11). The corresponding HRs for hazardous/harmful drinkers 
were 1.10 (95% CI: 0.80, 1.52) and 0.97 (95% CI: 0.70, 1.35). 
 
Comparable results were found in the imputed analysis (Appendix A3). In the low stage 
tumour group, current smokers had a 2.6-fold increased risk of death compared to never 
smokers (fully adjusted HR=2.6 (95% CI: 1.6, 4.2; p<0.001), whilst former smokers were 
80% more likely to die during follow-up (fully adjusted HR=1.8 [95% CI: 1.1, 2.9].  Among the 
high stage tumour group, current and former smokers had a 70% and 30% increased risk of 
death, respectively (fully adjusted HR=1.7 [95% CI: 1.3,2.3; p<0.001] and 1.3 [95% CI: 1.0, 
1.7]). As was the case in the primary analysis, alcohol intake was not associated with 
survival in either group, after adjusting for clinical factors.  
 
7.4.9. Influence of HPV status on the associations of smoking and alcohol intake with 
survival 
In total, 176 of the 656 OPC cases were HPV negative (Table 29).  There were 61 deaths in 
each group.  There was limited evidence of an association of smoking with survival when 
models were stratified (possibly due to limited statistical power). In the HPV-negative group, 
smoking status was associated with survival in the minimally adjusted model, but CIs were 
wide (HR=6.9 [95% CI: 1.6, 29.4] for current smokers and HR=5.21 [95% CI: 1.24, 21.96; 
p=0.005]) for former smokers. There was some attenuation on adjustment (fully adjusted 
HRs of 2.66 [95% CI: 0.55, 16. 12.80] and 3.70 [95% CI: 0.82, 16.78; p=0.492] for current 
and former smokers, respectively). The effect estimates and corresponding CIs were smaller 
in the HPV-positive group (minimally adjusted HRs of 2.18 [95% CI: 0.91, 5.19] and 1.00 
[95% CI: 0.57, 1.74; p=0.272] for current and former smokers; fully adjusted HRs of 2.13 
[95% CI: 0.84, 5.14] and 1.04 [95% CI: 0.59, 1.84; p=0.311] for current and former smokers).  
 
Considering alcohol consumption and survival, there was weak evidence of an association in 
the HPV-negative group (minimally adjusted HRs of 0.82 [95% CI: 0.28, 2.38] and 2.20 [95% 
CI: 1.03, 4.73; p=0.012] and fully adjusted HRs of 1.55 [95% CI: 0.50, 4.80] and 2.44 [95% 
CI: 1.07, 5.59; p=0.074] for moderate and hazardous/harmful drinkers, respectively), but 
drinking did not appear to influence mortality in the HPV-positive group, based on the fact 
that all of the CIs crossed one (minimally adjusted HRs of 0.81 [95% CI: 0.41, 1.59] and 0.72 
[95% CI: 0.39, 1.32; p=0.301] and fully adjusted HRs of 0.85 [95% CI: 0.42, 1.71] and 0.71 




Results of the imputed analysis are presented in Appendix A4. Current smokers were at a 
higher risk of death compared to non-smokers, regardless of HPV status (fully adjusted HR= 
2.5 [95% CI: 1.0, 6.5; p for trend=0.057] and 2.0 [95% CI: 1.1, 3.6; p for trend=0.020] for 
HPV-negative and HPV-positive groups, respectively). There was little evidence that alcohol 
consumption influenced mortality risk. 
 
Results of the sensitivity analysis indicate that the association of smoking with survival is 
unlikely to be modified by HPV status (p for interaction in the fully adjusted model =0.092).   
There was weak evidence to suggest that the effect of alcohol may differ by HPV status (p 
for interaction= 0.070). 
 
7.4.10. Interaction of tobacco and alcohol  
There was little evidence of an interaction between smoking and alcohol consumption on 
survival in this analysis (p for interaction = 0.607 in the fully adjusted model).
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Table 27: Mortality hazard ratios (HR) according to baseline smoking and drinking status stratified by tumour site. 
 
Model 1 (minimally adjusted): adjusted for age and sex; Model 2: additionally adjusted for clinical features (TNM, comorbidity, BMI, HPV); Model 3: additionally 
adjusted for social features (education,  income, IMD and marital status); Model 4 (fully adjusted): additionally includes smoking or drinking. * test for linear 
trend. Values with p<0.05 are shown in bold. Abbreviations: HR, hazard ratio; CI,  95% confidence interval.
HR Lower CI Upper CI p-value* HR Lower CI Upper CI p-value* HR Lower CI Upper CI p-value* HR Lower CI Upper CI p-value*
Smoking
Former 1.69 1.22 2.34 2.15 1.29 3.60 1.56 0.96 2.54 1.62 0.59 4.50
Current 3.27 2.30 4.65 <0.001 2.13 1.19 3.83 0.012 3.97 2.33 6.76 <0.001 4.36 1.54 12.37 <0.001
Alcohol amount
Moderate 0.74 0.53 1.05 0.68 0.38 1.22 0.84 0.47 1.48 0.72 0.38 1.35
Hazardous/harmful 1.24 0.95 1.62 0.042 1.20 0.77 1.87 0.309 1.38 0.87 2.18 0.086 1.00 0.60 1.66 0.873
Smoking
Former 1.69 1.21 2.35 2.71 1.60 4.61 1.41 0.87 2.30 1.46 0.52 4.09
Current 2.21 1.52 3.22 <0.001 2.09 1.13 3.87 0.023 2.08 1.15 3.77 0.016 2.99 1.03 8.64 0.001
Alcohol amount
Moderate 0.72 0.52 1.02 0.59 0.33 1.06 0.87 0.49 1.55 0.65 0.34 1.24
Hazardous/harmful 1.08 0.83 1.41 0.330 1.04 0.66 1.62 0.673 1.18 0.75 1.87 0.351 0.98 0.59 1.64 0.856
Smoking
Former 1.67 1.19 2.34 3.04 1.77 5.24 1.36 0.83 2.23 1.64 0.56 4.77
Current 2.13 1.44 3.14 <0.001 2.22 1.16 4.25 0.009 1.66 0.88 3.12 0.068 3.45 1.13 10.53 0.001
Alcohol amount
Moderate 0.75 0.53 1.06 0.62 0.34 1.13 0.94 0.52 1.69 0.67 0.35 1.28
Hazardous/harmful 1.09 0.84 1.43 0.312 1.08 0.69 1.69 0.521 1.31 0.82 2.10 0.222 1.02 0.60 1.73 0.888
Smoking
Former 1.63 1.16 2.28 3.15 1.82 5.45 1.29 0.78 2.14 1.60 0.55 4.66
Current 2.03 1.37 3.01 <0.001 2.29 1.18 4.44 0.010 1.55 0.81 2.96 0.087 3.36 1.10 10.28 0.001
Alcohol amount
Moderate 0.76 0.54 1.07 0.55 0.30 0.99 0.98 0.54 1.76 0.68 0.36 1.29
Hazardous/harmful 1.03 0.78 1.34 0.554 0.92 0.58 1.45 0.789 1.28 0.80 2.05 0.263 0.94 0.55 1.59 0.798











Model 1 (minimally adjusted): adjusted for age and gender; Model 2: additionally adjusted for clinical 
features (TNM stage, comorbidity, BMI and HPV); Model 3: additionally adjusted for social features 
(education, annual household income, IMD, marital status); Model 4 (fully adjusted): additionally 
includes smoking or drinking. *Test for trend Abbreviations: HR, hazard ratio; CI, 95% confidence 
interval. 
 
HR Lower CI Upper CI p-value* HR Lower CI Upper CI p-value*
Smoking
Former 2.37 1.17 4.78 1.65 1.14 2.40
Current 3.98 1.90 8.32 <0.001 3.59 2.39 5.40 <0.001
Alcohol amount
Moderate 0.80 0.43 1.46 0.66 0.44 0.99
Hazardous/harmful 1.44 0.90 2.32 0.080 1.10 0.80 1.52 0.268
Smoking
Former 2.20 1.09 4.44 1.44 0.99 2.10
Current 3.00 1.42 6.35 0.004 1.99 1.28 3.08 0.002
Alcohol amount
Moderate 0.77 0.42 1.42 0.68 0.45 1.02
Hazardous/harmful 1.36 0.85 2.18 0.135 0.98 0.71 1.36 0.772
Smoking
Former 2.17 1.06 4.42 1.46 0.99 2.15
Current 3.01 1.39 6.54 0.006 1.87 1.17 2.98 0.002
Alcohol amount
Moderate 0.79 0.43 1.46 0.69 0.46 1.05
Hazardous/harmful 1.41 0.88 2.28 0.110 0.99 0.71 1.37 0.726
Smoking
Former 2.06 1.01 4.22 1.46 0.99 2.15
Current 2.83 1.29 6.18 0.011 1.87 1.17 2.98 0.003
Alcohol amount
Moderate 0.78 0.42 1.44 0.73 0.48 1.11
Hazardous/harmful 1.30 0.81 2.09 0.210 0.97 0.70 1.35 1.000











Model 1 (minimally adjusted): adjusted for age and gender; Model 2: additionally adjusted for 
clinical features (TNM stage, comorbidity and BMI); Model 3: additionally adjusted for social 
features (education, annual household income, IMD and marital status); Model 4 (fully 
adjusted): additionally includes smoking or drinking. *Test for trend. Abbreviations: HR, 
hazard ratio; CI, 95% confidence interval.
HR Lower CI Upper CI p-value* HR Lower CI Upper CI p-value*
Smoking
Former 5.21 1.24 21.96 1.00 0.57 1.74
Current 6.93 1.64 29.37 0.005 2.18 0.91 5.19 0.272
Alcohol amount
Moderate 0.82 0.28 2.38 0.81 0.41 1.59
Hazardous/harmful 2.20 1.03 4.73 0.012 0.72 0.39 1.32 0.301
Smoking
Former 4.61 1.09 19.49 1.03 0.59 1.79
Current 3.99 0.92 17.19 0.186 2.22 0.92 5.32 0.254
Alcohol amount
Moderate 1.10 0.37 3.28 0.83 0.42 1.65
Hazardous/harmful 2.20 1.02 4.77 0.019 0.70 0.38 1.28 0.259
Smoking
Former 5.26 1.19 23.18 1.02 0.58 1.79
Current 3.38 0.72 15.82 0.356 2.04 0.81 5.14 0.347
Alcohol amount
Moderate 1.72 0.56 5.32 0.82 0.41 1.65
Hazardous/harmful 3.03 1.35 6.83 0.017 0.73 0.39 1.39 0.382
Smoking
Former 3.70 0.82 16.78 1.04 0.59 1.84
Current 2.66 0.55 12.80 0.492 2.13 0.84 5.43 0.311
Alcohol amount
Moderate 1.55 0.50 4.80 0.85 0.42 1.71
Hazardous/harmful 2.44 1.07 5.59 0.074 0.71 0.38 1.35 0.402







7.5. Discussion  
7.5.1. Principal findings 
This chapter assessed the potential relationships between self-reported smoking status and 
alcohol intake with all-cause mortality in people with cancers of the oral cavity, oropharynx 
and larynx. My main finding was that, even after adjusting for a wide range of prognostic 
factors (confounders), smoking status at the time of HNC diagnosis was associated with 
worse survival. In fully adjusted models, the mortality risk for current smokers was around 
twice that of never smokers, whilst former smokers were over 60% more likely to die during 
follow-up. There was no evidence of heterogeneity by treatment centre, which suggests that 
the relationship between smoking status and mortality risk was not influenced by factors 
such as the preferred treatment approach, level of care provided, or the general 
affluence/deprivation of the area. I found no strong evidence that alcohol intake was 
associated with overall mortality risk in this analysis, though participants who reported 
drinking moderate amounts of alcohol tended to experience better survival compared to non-
drinkers.  
 
These findings are in line with those of earlier studies, which suggest that smoking at the 
time of HNC diagnosis may result in poorer clinical outcomes and reduced survival 441-444. 
Estimates of the size of the effect have varied considerably however, ranging from a 2.4-fold 
higher all-cause mortality risk in current versus never-smokers 441 to an almost fivefold 
higher mortality risk in people with >60 pack-years of smoking versus never-smokers 442. 
There are several possible explanations for this. First, much of the evidence is based on 
retrospective analyses of population-level cancer registries, which are often incomplete or 
incorrect 619.  As a result, studies frequently have missing information on important clinical 
and lifestyle factors such as comorbidity, BMI, and socioeconomic position, which could 
potentially confound the association of smoking with survival. Those studies which have 
been conducted prospectively are small, typically five hundred persons or fewer 441-443, 
limiting their statistical power to detect the true measure of the effect. Second, estimates 
have been derived from different subpopulations of people, i.e. different HNC sites or tumour 
stages, which are often not considered separately. This could bias estimates of the effect of 
smoking on survival if mortality risk is greater or lesser in certain tumour groups. 
 
With respect to alcohol consumption, the existing literature is limited and conflicting. The 
results of the current analysis support those of Duffy et al. who found no difference in 
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mortality risk between active drinkers and non-drinkers after adjusting for a wider range of 
confounders 441. In contrast to this however, Mayne et al. reported a fivefold increased 
mortality risk for persons who drank >35 drinks per week compared to those who abstained 
442. Both previous studies were relatively small (504 and 204 people, respectively), and 
enrolled participants from either a single centre 441 or a single clinical trial 442, limiting their 
generalisability.  
 
A J-shaped association between alcohol intake and mortality has been observed in some 
previous studies, though it has been suggested that the link between low-moderate intake 
and improved survival is not causal. Rather, higher socio-economic status is linked with 
moderate alcohol intake and socio-economic status is a strong predictor of longevity 620 621.  
 
It is biologically plausible that, as well as being risk factors for HNC, smoking could reduce 
survival following a diagnosis. One way in which smoking could influence survival is through 
its effects on treatment response. A growing body of evidence suggests that smokers have 
an increased risk of treatment-related adverse events and poorer clinical outcomes following 
radiotherapy, compared to no-smokers 622 623. The biological mechanisms explaining this 
association are not fully understood, but increased tumour hypoxia, resulting from increased 
carboxyhaemoglobin (the binding of carbon monoxide to haemoglobin) in smokers, is a 
possible explanation 624. In addition to this, it has been suggested that tobacco reduces the 
efficacy of radiotherapy through triggering a p53 mutation that could promote resistance to 
apoptosis 625. Smoking is also known to effect inflammatory responses 626 
and immune competence 627, which could increase the likelihood of adverse clinical 
outcomes. 
7.5.2. Strengths and limitations of the study 
This study has several strengths. These include the prospective study design, the large 
sample size, and the ability to adjust for a wide range of biological, clinical and lifestyle 
covariates, including HPV. In addition to this, the risk of bias due to missing data was 
explored by employing a multiple imputation approach. Results of the imputed analysis was 
broadly consistent with those of the complete case analysis, suggesting that the presence of 
missing covariate data did not unduly influence the effect estimates, and hence the 
conclusions that can be drawn from the data.  
 
This work does have several limitations. First, as in most previous studies, assessments of 
smoking and alcohol intake were based on participants’ self-report; this could result in an 
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underestimation of the effects of smoking and drinking on HNC survival if participants under-
reported their tobacco and alcohol use (see Chapter 3). Moreover, the physical 
characteristics of an individual’s smoking behaviour, that is their “smoking topography”, will 
influence their level of exposure to tobacco, meaning that no two “current smokers” are alike. 
Similarly, non-drinkers in this study make up a complex group, with some people abstaining 
from alcohol out of choice and some people refraining from drinking alcohol because of their 
health. More objective measures of tobacco and alcohol intake would provide more reliable 
estimates of the exposure-outcome association. 
 
Second, although models were adjusted for multiple confounders, residual confounding by 
unmeasured or poorly measured factors, such as a delay in receiving treatment or other 
lifestyle factors related to smoking and drinking behaviours (e.g., physical activity and dietary 
intake), is possible.  
 
Third, whilst the sample size was sufficient to detect the main effects of baseline smoking 
status and alcohol intake on survival, it was insufficient to examine interactions between 
these two exposures and HPV in determining mortality. It also had limited the potential to 
investigate whether the effects of smoking and drinking on survival were modified by cancer 
site. This was because there were only a small number of events (deaths) in each subgroup. 
The analysis was nevertheless exploratory in design, as there were no prior hypotheses that 
smoking or alcohol intake would have a greater or lesser effect on survival in any one cancer 
group. 
 
Fourth, HPV status was determined based on HPV-specific antibody levels but, as 
discussed in Chapter 5, the presence of HPV16 RNA is considered the gold standard 
measure. That said, previous studies have confirmed that detection of antibodies against E6 
and E7 oncoproteins shows good correlation with HPV DNA in the tumour tissue. In their 
study, Kreimer et al. showed that high HPV viral load increased the odds of HPV16 E6 
seropositivity 57-fold and HPV16 E7 seropositivity 26-fold  628. In addition to this, HPV16 E6 
antibodies have also been shown to be independent favourable prognostic factors in OPCs 
551 552.  Some HPV-related OPCs are mediated by other HPV genotypes, including HPV18 
(1–8% of OPCs), and less commonly HPV33, −35, −56 and −67 629. Only HPV-16 was 
considered in the current analysis. This was because 73% of the participants with OPCs 
were HPV16 E6 positive, compared to just 1% who were HPV18 E6 positive. 
 
Finally, it was not possible to examine whether baseline smoking status and alcohol intake 
influenced cancer-specific mortality as cause-specific mortality data were not available for all 
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participants at the time of this analysis. Previous studies suggest that death from non-
cancerous causes (competing mortality) and second primary malignancies are important 
events in HNC 630 and could provide greater insight into the biological mechanisms that 
underlie the associations of smoking and drinking with survival. It is important to note 
however,  that cause of death information death certificates is often inaccurate 631. Accuracy 
of all-cause mortality is solely dependent on the number of deaths identified and is arguably 
a more reliable outcome measure. 
 
7.5.3. Conclusions 
This chapter shows that smoking status at the time of HNC diagnosis is associated with 
poorer survival and may improve prognostication in this population, but there was no 
apparent difference in mortality risk among people who consumed different amounts of 
alcohol pre-diagnosis. The confidence in the model estimates is curbed by the fact that 
exposure levels were based on participants’ self-report. DNA-methylation based biomarkers 
of tobacco and alcohol consumption can provide more robust estimates of exposure than 
self-reported intake, as discussed in Chapter 3. With that knowledge in mind, the ensuing 
chapter looks to investigate the relationships between DNA methylation predictors of 
smoking and alcohol (and other lifestyle traits) and mortality risk in H&N5000. 
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Chapter 8: Epigenetic prediction of complex traits and 
mortality in oropharyngeal cancer in H&N5000 
 
This chapter includes sections from the publication below: 
 
Langdon R.J*., Beynon R.A*., Ingarfield K., Marioni R.E., MacCartney D.M., Martin R.A., 
Ness R.A., Pawlita M., Waterboer T., Relton C., Thomas S.J., Richmond R.C. Epigenetic 
prediction of complex traits and mortality in a cohort of individuals with oropharyngeal cancer 
(2020) Clinical Epidemiology. 12  
 
* These authors contributed to the manuscript equally. 
8.1. Introduction 
The findings of the previous chapter confirm that smoking status at the time of HNC 
diagnosis is associated with survival, but there was no strong evidence to show that alcohol 
intake influenced mortality outcomes. Whilst this analysis was one of the largest of its kind to 
date, estimates of the effects of these modifiable behaviours on survival were based on 
participant’s self-report which, for reasons that have already been discussed at length in this 
thesis, are often unreliable. Moreover, smoking and alcohol exposures were pigeon-holed 
into three categories – never-, former-, or current smoker and non-drinker, moderate-drinker, 
or hazardous-to-harmful drinker. In reality, these behaviours do not sit neatly into groups but 
represent a continuum of exposure- a cumulative ‘hit’ 632. Consequently, the results of this 
analysis may not fully capture the relevant smoking and alcohol-related behaviour and its 
relationship with mortality risk. Such limitations underline the need for objective measures of 
lifestyle exposures for precise classification in epidemiological studies. 
 
In Chapter 3, I described how biological predictors of certain lifestyle traits can improve 
exposure assessment and may facilitate improved risk prediction in epidemiological and 
public health settings.  Advances in epigenome-wide profiling have permitted the 
identification of “epigenetic signatures” (i.e. DNAm patterns), for a variety of lifestyle factors 
associated with health and mortality. These include DNAm predictors for smoking, alcohol 
intake, BMI, waist-to-hip ratio, body fat percentage, HDL cholesterol and education 509 511 633. 
These predictors explain varying proportions of the phenotypic variance seen in their 
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respective traits, with methylation-based predictors of smoking demonstrating particularly 
good discrimination between current and never smokers (AUC=0.98) 633.  
 
The relationship between DNAm scores and all-cause mortality have been assessed among 
general populations, but there is currently a paucity of studies conducted in clinical settings. 
In one study, which used data from the Lothian Birth Cohort 1936 (LBC1936), higher 
mortality risk was associated with higher DNAm scores for smoking (HR = 1.29, 95% CI: 
1.05, 1.57; p = 0.013), alcohol consumption (HR = 1.24, 95% CI: 1.08, 1.43; p = 0.003), and 
waist-to-hip ratio (HR = 1.24, 95% CI: 1.08, 1.42; p = 0.002), whilst a higher DNAm score for 
education was associated with lower mortality risk (HR = 0.81, 95% CI = 0.71, 0.93; p = 
0.004) 633.  In this chapter, I report on a novel application of DNAm risk scores for health and 
lifestyle related traits to a clinical cohort of individuals with head and neck cancer - 
H&N5000.  
 
8.2. Aims and objectives 
The specific aims of this analysis were, firstly, to assess whether externally derived DNAm 
predictors for 4 complex traits, namely smoking, alcohol consumption, BMI and educational 
attainment, could provide an accurate prediction of directly-measured phenotypes in a 
subset of participants with oropharyngeal tumours (OPC) and secondly, to examine the 
association of these DNAm predictors with mortality risk in the same sub-set of individuals 
with OPC, using Cox proportional hazards regression models.  
8.3. Methods 
8.3.1. Study population  
The study population for this analysis included a sub-set of H&N5000 participants with OPC 
(selected based on ICD-10 coding- pathological where available), for whom OncoChip 
genotype data, baseline question and data capture data were available (n=448). Full details 
of the study method and overall population from which these participants were drawn are 
described in Chapter 4.  
8.3.2. Assessment of tobacco, alcohol, BMI, and education   
Information on participants’ smoking histories, use of alcohol prior to receiving their HNC 
diagnosis, highest educational attainment and BMI were obtained at baseline via the self-
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administered questionnaires, as described in chapter 4. In line with the previous analysis, 
smoking categories were preserved as “current”, “former” and “never” and drinking 
categories were grouped as “non-drinker”, “moderate-drinker” and “hazardous to harmful-
drinker”, based on current UK guidelines (i.e. moderate drinkers includes those drinking <14 
units of alcohol a week and hazardous to harmful-drinkers includes those drinking 14 units or 
more each week). BMI was calculated as weight (kg) per height (m) squared.   Education 
levels were defined as “school”, “college” (which includes sixth form and further education), 
or “Degree” (which includes polytechnic or university).  
8.3.3. Epigenetic profiling and pre-processing  
The epigenetic data for this analysis were made available thanks in large part to work by 
Matthew Suderman, Rebecca Richmond, and Ryan Langdon at the Integrative Epidemiology 
Unit (IEU), University of Bristol.  Full details are provided in the “Methods for collecting and 
processing materials” section of Chapter 5. Briefly, following extraction, DNA was bisulphite-
converted using the Zymo EZ DNA MethylationTM kit (Zymo, Irvine, CA, USA). Genome-
wide methylation status of over 850,000 CpG sites was then measured using the Infinium 
MethylationEPIC BeadChips (EPIC array) (Illumina, USA), according to the manufacturer’s 
protocol. The arrays were scanned using an Illumina iScan (version 2.3). 
Raw data files (IDAT files) were pre-processed and normalised using the R package meffil 
(https://github.com/perishky/meffil/) 634, which excluded 8 of the total samples for not meeting 
the quality control criteria (n=440/448). A further 32 samples were removed following 
pathological re-classicisation (i.e. the tumours from which the samples originated did not 
originate in the oropharynx), leaving a final sample of n=408 (Figure 43).  
8.3.4. Epigenetic risk score generation 
DNAm predictors for smoking, alcohol, education, and BMI were computed for each 
participant using different sets of coefficients made available from the largest or most 
recently published EWAS of methylation of CpG sites in relation to these traits. Scores were 
calculated as β1M1+β2M2+…+βnMn, where β refers to the β-regression coefficient of the 
selected CpG and M refers to the normalised methylation level at that locus (in H&N500). An 
overview of the different scores, including the number of CpG sites included in each model, 




8.3.5. Multiple imputation  
The number of participants with OPC and epigenetic data available is relatively small. To 
avoid case deletion due to missing data on baseline covariates, primarily BMI which was 
missing for 33% of participants (Table 31), missing data were imputed by multiple 
imputations.  As mentioned in the previous chapter, information on participants height and 
weight was not collected at the start of the study, meaning that BMI could not be calculated 
for all participants.  The missingness mechanism was presumed to be MAR because it could 
be explained by other variables in the dataset (i.e. date of enrolment).  Missing values were 
imputed using the ICE package for multiple chained equations in STATA, as per the 
previous chapter. Twenty imputed datasets were generated and then combined using 
Rubin's rules 614. The imputation model included the event indicator, the Nelson-Aalen 
estimator of the cumulative hazard, all the variables that were used in substantive Cox 
models and any other available variables that could help to explain the missing data, such as 
household income and marital status. .
Figure 43:  Flow of participants included in the analysis. 
 
* OPC cases were selected for epigenetic analysis using clinical ICD codes.  v2.5 of the 
HN5000 dataset uses Pathology ICD codes where available.** Data available for age, gender, 




Table 30: An overview of the DNAm scores employed in the current analysis. 




Linear mixed models (also called “multilevel 
models”) were conducted, then combined in 
a random-effects model meta-analysis. One 
set of CpGs was selected based on a 
Bonferroni threshold of P<1 x 10-7 (485,381 
tests) and another was selected based on a 
genome-wide FDR threshold of P<0.05. 
2623 509 
Joehanes FDR 18760 
Zhang An epigenome-wide screen for cotinine 
associated loci was first carried out in a 
discovery set (n=500) using median quantile 
regression and a Bonferroni threshold 
p<1.13 x1 0-7. 61 CpGs were taken forward 
to the replication phase (n=500). 40/61 CpGs 
replicated in the validation set (p<8.2 x 10-4).  
The final DNAm score was developed 
through stepwise selection (with significance 
levels for deletion from and adding to the 
model of 0.01) of the confirmed CpGs. 
3 635 
McCartney smoking The DNAm predictors were built on a subset 
of 5087 individuals from GS using penalized 
regression models. Tenfold cross-validation 
was applied and the mixing parameter 
(alpha) was set to 1 to apply a LASSO 
penalty. Coefficients for the model with the 
lambda value corresponding to the minimum 
mean cross-validated error were extracted 
and applied to an independent validation 





Table 30 continued. 
DNAm predictor Model development  CpG sites Ref. 
Alcohol consumption 
McCartney alcohol See McCartney smoking. 450 633 
Liu model 1 First, a meta-analysis was performed in 8 
European ancestry cohorts using an 
inverse-variance weighted random-effects 
model and CpGs were selected at a 
threshold P<5 × 10−6. CpGs selected from 
the meta-analysis were then taken forward 
and simultaneously included in a LASSO 
regression, which was performed in an 
independent cohort (the FHS cohort).  Four 
sets of CpGs were selected using s=0.08 
(model 1), s=0.12 (model 2), s=’lambda.1se’ 
(model 3) and s=’lmabda.min’ (model 4), 
which represents the penalty apllied. The 
criterion s= ‘lambda.min’ selected the 
largest number of CpGs and s=0.12 yielded 
the most parsimonious set of CpGs. 
5 511 
Liu model 2 23 
Liu model 3 78 
Liu model 4 144 
Body mass index 




See McCartney smoking. 373 633 
 
Abbreviations: CpG, cytosine-phosphate-guanine site; FDR, false-discovery rate; FHS, 
Framingham Heart Study; GS, Generation Scotland; LASSO, least absolute shrinkage elector 
operator; LBC, Lothian birth cohort; Ref., reference.
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Table 31: Proportion of missing data in the epigenetic dataset (n=408). 
 
Statistical analysis 
8.3.5.1. Associations of epigenetic scores with self-reported phenotypes 
Linear regression analyses of epigenetic risk scores against directly measured phenotypes 
(i.e. self-reported traits) were performed to determine how much of the variance in each 
phenotype was explained by the corresponding score(s). This was undertaken in two-stages: 
in the first stage, the DNAm score was regressed on age and gender; in the second stage, 
the directly measured phenotype was regressed on the residual obtained from stage 1. The 
percentage of the variance explained was captured in the R2 statistic from the second 
model. 
8.3.5.2. Proportion of variance in survival explained by DNAm scores 
The variation in the outcome (survival) accounted for through the DNAm predictors was 
assessed using an analogue of the R2 for censored survival data 616 and implemented using 
the str2d command in Stata. 
8.3.5.3. Survival analysis 
The end point of this study was all-cause mortality, defined as the time in days from study 
enrolment to date of death from any cause or the date of censorship (i.e., the last date of 
follow-up). Kaplan-Meier survival curves and log-rank test were used to investigate the 
univariate impact of covariates on mortality (Appendix B1).  Mortality risk was then assessed 





Treatment group 0 0
HPV status 0 0
Comorbidity 3 0.74
BMI 136 33.33
Annual household income 51 12.5
Education 19 4.66
Marital status 6 1.47
Smoking status 16 3.92
Alcohol consumption 8 1.96
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in relation to each of the DNAm scores using Cox proportional-hazards models. Given that 
the DNAm scores have different scales (Appendix B2-B13), I standardise them to facilitate 
direct comparison between scores. Using smoking as an example, I standardised the 
methylation scores of individuals xi by dividing by the difference in mean DNAm scores 






Standardising each of the methylation scores in this way means that the HR per unit 
increase in standardised score is comparable across all the methylation scores. The 
interpretation of the HR is:  
 
. 
An example of the code used to standardise DNAm scores is provided in the supporting 
material (Appendix B14).  For alcohol, BMI, and education, using the same equation, I 
calculated the average increase in score experienced by non-drinkers compared with 
hazardous to harmful drinkers, overweight people compared with not overweight people, and  
degree-educated people compared with school-educated people.  Individuals were classed 
as being overweight if they had a BMI >25 and not overweight if they had a BMI of <24. NHS 
cut-offs define someone who is healthy as having a BMI of 18-25 and someone who is 
underweight as having a BMI of <18 but since only 4/408 people fell into the latter (range 
15.6 to 17.9), it was decided that these groups would be combined into a single “not 
overweight” category. 
 
Four separate models were fit to examine the relationship between DNAm scores with 
mortality:  
1) a minimally adjusted model that adjusted for age, gender, cell counts and batch 
effects; 
2) a ‘clinical model’ that additionally adjusted for tumour stage, HPV status and 
comorbidity (i.e. information that would be available to physicians);  
HR = the change in risk per unit of standardised methylation score, where 1 unit 
increase in standardised methylation score corresponds to the average increase 
in the measured methylation score experienced by current smokers compared 
with never smokers. 
Standardised score = xi /(mc-mn) 
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3) a model that additionally adjusted for the corresponding directly measured phenotype 
(e.g. models that examined the association of smoking related DNAm scores with 
mortality adjusted for self-reported smoking status); 
4)  a model that additionally adjusted for the other directly measured phenotypes.  
Cell types included B-cells, CD4+ T-cells, CD8+ T-cells, eosinophils, monocytes, neutrophils 
and natural killer cells. Counts were estimated in whole blood using the method of 
Houseman et al 636. Clinical variables were selected based on prior knowledge of 
established risk factors (see Chapter 2). Results of the imputed analysis are presented here. 
A complete case adjusted analysis was also performed as a sensitivity analysis.  
 
The PH assumption was tested for each of the covariates included in the Cox model (without 
adjustment) using a combination of graphical and statistical tests based on Schoenfeld 
residuals, using the estat phtest command in stata (which tests for a non-zero slope of 
Schoenfeld residuals versus time). Covariate-specific and global tests were then performed 
after fitting the adjusted survival models to ensure that the assumption held. Graphical and 
formal tests indicated that the variables HPV status and comorbidity may not satisfy the PH 
assumption (see Appendix B15 and B17) for Kaplan–Meier observed survival curves versus 
Cox predicted curves and B16 and B18 for log-log survival curves). However, the statistical 
power to detect violations is limited due to the limited number of events (i.e. deaths) in the 
current analysis 637, particularly after 3-years (see Appendix B1) As a further sensitivity 
analysis, the data were split (i.e. censored) at 3-years and the above analyses were 
repeated.  
8.4. Results 
8.4.1. Baseline characteristics of the study population 
The study sample was described in detail earlier in Chapter 6 (Tables 21 and 22).  Overall, 
78% of people included in the analysis were male and 70% had HPV-positive tumours. 
There were differences in clinical and lifestyle characteristics between HPV-positive and 
HPV-negative individuals, including differences in tumour stage (HPV-positive individuals 
tended to be diagnosed at a later tumour stage), income (HPV-negative individuals tended to 
earn less as a household) and smoking status (HPV-negative individuals were more likely to 
be current smokers).  
 
Histograms showing the distribution of DNAm scores stratified by their respective directly-
measured phenotypes are presented in Appendices B2 to B13. AHRR was unique in 
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displaying a bimodal distribution, with higher DNAm scores in non-smokers. Mean DNAm 
scores stratified by 3-year mortality are provided below in Table 32. There was strong 
evidence of a difference between groups in all of the scores except for the education and 
BMI-related DNAm scores derived by McCartney. 
 
The baseline descriptives of the analytic dataset (i.e. individuals with OPC and epigenetic 
data available) were compared against participants without epigenetic data available (all 
other people with OPC in HN5000). Overall, the sample of people with epigenetic data were 
fairly representative of the OPC population as a whole (Table 33), with the exception that 
there was evidence of a difference in comorbidity levels between groups (p=0.034). In the 
group without DNAm data, 46% had no comorbidity, 36% had mild comorbidity and 18% had 
severe comorbidity. This compares to 52%, 29% and 19%, respectively, in the group with 
DNAm data available. 
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Table 32: Average DNAm values for people who are alive at 3-years compared to people 
who are dead at 3-years. 
 
 Dead at 3 years  
(n=77) 
Alive at 3 years 
 (n=331) 
 
DNAm Score mean (SD) mean (SD) p-value 
Smoking 
AHRR 0.06 (0.22) 0.14 (0.97) <0.001 
Joehanes Bonferroni 0.03 (0.13) -0.04 (0.25) 0.001 
Joehanes FDR -0.01 (0.08) -0.02 (0.19) <0.001 
Zhang -0.02 (0.11) -0.02 (0.50) 0.038 
McCartney  -0.47 (1.01) -0.02 (0.21) 0.002 
Alcohol consumption 
McCartney 0.06 (0.22) -0.01 (0.12) 0.013 
Liu 5 CpG 0.08 (0.25) -0.02 (0.23) 0.001 
Liu 23 CpG 0.03 (0.14) -0.01 (0.14) 0.030 
Liu 78 CpG 0.18 (0.54) -0.05 (0.49) <0.001 
Liu 144 CpG 0.29 (0.84) -0.07 (0.74) <0.001 
Educational attainment 
McCartney  0.12 (0.29) 0.00 (0.07) 0.127 
BMI 
McCartney 0.12 (0.67) 0.00 (0.11) 0.103 




Table 33: A comparison of the baseline characteristics of people with epigenetic data and 
people without epigenetic data available (OPC only). 
Characteristic N Frequency N Frequency p-value
Gender
Male 1178 79.20% 317 77.70%
Female 310 20.80% 91 22.30% 0.519
TNM stage
I 66 4.50% 17 4.20%
II 145 9.80% 39 9.60%
III 210 14.20% 58 14.20%
IV 1059 71.60% 294 72.10% 0.993
HPV serology group
Negative 384 32.80% 122 29.90%
Positive 788 67.20% 286 70.10% 0.286
Comorbidity 
None 665 45.70% 211 52.10%
Mild 524 36.00% 119 29.40%
Moderate/Severe 267 18.30% 75 18.50% 0.034
Education level
School education 422 44.10% 170 43.70%
College 340 35.50% 158 40.60%
Degree 196 20.50% 61 15.70% 0.071
Annual household income 
<£18,000 340 38.10% 138 38.70%
£18000-£34,999 277 31.10% 103 28.90%
>£35,000 275 30.80% 116 32.50% 0.722
IMD 
Low Deprivation 531 39.30% 149 38.80%
Moderate Deprivation 306 22.60% 81 21.10%
High Deprivation 515 38.10% 154 40.10% 0.723
Relationship status
Single (never married) 109 11.00% 47 11.70%
Currently in relationship 704 71.00% 280 69.70%
No longer with spouse 178 18.00% 75 18.70% 0.871
Smoking status
Never 252 26.50% 110 28.10%
Former 542 56.90% 205 52.30%
Current 158 16.60% 77 19.60% 0.246
Alcohol consumption 
Non-drinker 229 23.60% 104 26.00%
Moderate drinker 216 22.20% 90 22.50%
Hazardous-harmful drinker 527 54.20% 206 51.50% 0.578
N Mean (SD) N Mean (SD)
Age (years) 1479 59.19 ( 9.06) 403 58.43 ( 9.63) 0.145
BMI 826 26.83 ( 5.24) 272 26.45 ( 4.94) 0.283
Without epigenetic data 
(n=1,178)




8.4.2. Correlation between covariates 
The Pearson’s correlation coefficient’s (r) for each pair of covariates are presented in Table 
34.  There was strongest evidence of an association between the following covariates: HPV 
status and smoking (r=-0.36; p<0.001), age and comorbidity (r=0.34; p<0.001), gender and 
alcohol intake (r=-0.25; p<0.001), BMI and smoking (r=0.22-; p<0.001), HPV status and 
comorbidity (r=-0.19; p<0.001), and HPV status and TNM stage (r=0.18; p<0.001). There 
were further associations between HPV status and BMI (r=0.19; p<0.01) comorbidity and 
BMI (r=0.15; p<0.05) and education and smoking (r=-0.13; p<0.05) and age and HPV status 
(r =-0.16; p<0.1). 
 
8.4.3. Correlation between DNAm predictors 
As expected, the two smoking-related DNAm scores developed by Joehanes were strongly 
correlated with one another (r = 0.92; p<0.001), as were the alcohol DNAm scores 
developed by Lui (values ranging from r= 0.65; p<0.001 to r= 0.96; p<0.001) (Table 35). 
There was a strong positive correlation between the Joehanes smoking predictors and both 
the AHHR DNAm score (r=0.63 and 0.82; p<0.001 for Joehanes FDR and Joehanes 
Bonferroni, respectively) and the smoking DNAm score developed by McCartney (r=0.82; 
p<0.001). There was strong evidence of a moderate negative correlation between the DNAm 
predictor for education and the DNAm predictors for smoking (r values of between -0.17; 
p<0.001 to -0.30; p<0.001). The BMI DNAm score was negatively correlated with the AHRR 
DNAm score (r=-0.12; p<0.05) and the alcohol DNAm score (r=-0.22; p<0.001). The BMI 
predictor was not correlated with any of the smoking scores in this analysis.  
 
8.4.4. Proportion of variance in phenotype explained by the DNAm scores 
Age and gender-adjusted linear regression models showed that the DNAm predictors 
explained a small proportion of the phenotypic variance in educational attainment (0.7%), a 
moderate proportion of the variance in BMI (22%) and alcohol (7-16%) and a variable 
proportion of the variance in smoking (5-49%) (Table 36). The DNAm predictor that 
explained the greatest proportion of the variance in alcohol consumption was the DNAm 
score developed by Liu et al based-on methylation at 144 CpG sites.  The methylation status 
of AHRR explained the greatest proportion of the variance in smoking (49%), followed by the 
McCartney score (44%).  The Zhang DNAm predictor explained the least amount of the 
variance in smoking (5%).
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Table 34: Pearson’s correlation coefficient matrix for included covariates. 
  
Age Gender TNM stage HPV status Comorbidity BMI Education Smoking Alcohol 
Age 1         
Gender 
-0.02 
 (-0.12, 0.08) 






1       
HPV status 
-0.16** 















1     
BMI 
-0.07 









1    
Education 
-0.10 











1   
Smoking 
0.05 

































p<0.05*  p<0.01**  p<0.001***   
  
 
Abbreviations: BMI, body mass index; HPV, human papillomavirus; TNM, tumour-node-metastasis. Missing values were handled by pairwise 
deletion, meaning all available observations are used to calculate each pairwise correlation (as opposed to listwise deletion in which the entire 
observation is omitted from the estimation sample if any of the variables are missing for that observation).
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p<0.05* p<0.01** p<0.001***  
Abbreviations: Joe Bonferroni, Joehanes Bonferroni-adjusted smoking scores; Joe FDR, Joehanes false discovery rate-adjusted smoking scores; Smoking, 
McCartney smoking scores; Alcohol, McCartney alcohol scores; Education, McCartney education scores; BMI, McCartney body mass index scores; Liu 5, Liu 
alcohol scores based on a set of 5 CpGs; Liu 23, Liu alcohol scores based on a set of 23 CpGs (the base cytosine (C) linked by a phosphate bond to the base 
guanine (G) in the DNA nucleotide sequence); Liu 78, Liu alcohol scores based on a set of 78 CpGs; Liu 144, Liu alcohol scores based on a set of 144 CpGs. 
Missing values were handled by pairwise deletion.
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Table 36: The proportion of phenotypic variance explained in each trait by the respective 
DNAm-based predictor. 
DNAm Score Variance explained (%) 
Self-reported smoking  
McCartney  44.14 
AHRR 48.65 
Joehanes (FDR) 22.10 
Joehanes (Bonferroni) 38.41 
Zhang 5.05 
Self-reported alcohol 
McCartney  7.19 
Liu 5 CpG 14.42 
Liu 23 CpG 10.90 
Liu 78 CpG 15.70 
Liu 144 CpG 16.00 
BMI 




8.4.6. Proportion of variance in survival explained by the DNAm scores 
Table 37 compares the explained variation in survival for models that included age, gender, 
cell counts and batch effects and each of the twelve DNAm-based predictors, respectively. 
The basic model that included age and gender accounted for 24% of the variation in survival. 
The addition of DNAm predictors for smoking added between 6% (Joehanes FDR R2=0.30 
[95% CI=0.20,0.40]) and 10% (AHRR R2=0.34 [95% CI=0.23, 0.44]) to the proportion of 
variance explained. Models that included DNAm predictors for alcohol intake, BMI and 
educational attainment did not explain much more of the variation in survival than the basic 
model including only age and gender (Table 37). 
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Table 37: The proportion of variance in survival explained by DNAm-based predictors for 
smoking, alcohol intake, BMI and educational attainmetn (n=408). 
 
 
*Includes age, gender, cell counts (CD4 T-cells, CD8 -cells, eosinophils, monocytes 
neutrophils natural killer) and batch effects.  
 
8.4.7. Association of DNAm predictors with all-cause mortality 
There were 105 deaths during a median follow-up time of 5.4 years (Inter quartile range 
(IQR)=4.9 to 6.0 years). The results of the Cox regression analyses are presented in Figures 
44 a. to 44 d. In minimally adjusted models, which controlled for age, gender, cell counts and 
batch effects, all of the smoking and alcohol DNAm predictors were strongly associated with 
mortality risk (Figure 44 a.), with HRs ranging from 1.28 (95% CI: 1.12, 1.47; p=4.07 x 10-4) 
to 2.99 (95% CI: 1.96, 4.56; p=3.67 x 10-7) for smoking and 1.15 (95% CI: 1.02, 1.28; p=1.69 
x 10-2) to 1.19 (95% CI: 1.07, 1.32; p=1.78 x 10-3) for alcohol. There was evidence that 
higher BMI and higher educational attainment scores were protective (HRs= 0.88, 95% CI: 
0.77, 1.01; p=6.25 x 10-2 and 0.94, CI: 0.89, 1.00; p=4.57 x 10-2, respectively). When the 
models were additionally adjusted for clinical factors (tumour stage, HPV status and 
comorbidity), there was little evidence that the DNAm predictors for education or the DNAm 
Lower Upper
Basic model* 0.24 0.14 0.35
Smoking 
AHRR 0.34 0.23 0.44
McCartney 0.31 0.20 0.41
Joehanes FDR 0.30 0.20 0.40
Joehanes Bonferroni 0.32 0.21 0.41
Zhang 0.29 0.19 0.40
Alcohol 
McCartney 0.26 0.16 0.36
Lui 5 CpG 0.27 0.17 0.37
Lui 23 CpG 0.25 0.15 0.35
Lui 78 CpG 0.26 0.16 0.36
Lui 144 CpG 0.26 0.16 0.36
BMI
McCartney 0.26 0.16 0.37
Educational attainment 
McCartney 0.26 0.16 0.37
Model R
2 
95% Confidence interval 
Additionally adjusted for DNAm predictors: 
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score for alcohol (based on a set of 23 CpGs) (Figure 44 b.) were associated with survival. 
On further adjusting for the corresponding directly measured phenotypes, only AHHR, 
Joehanes and Zhang DNAm scores for smoking were associated with mortality risk (HR= 
1.90, 95% CI: 1.06, 3.38; p=3.05x10-2 for AHRR, 1.56 (95% CI: 1.04, 2.34; p=3.12x10-2 for 
Joehanes (FDR), and 1.90 (95% CI: 1.17, 3.09; p=9.6 x 10-3 for Joehanes (Bonferroni); 
Figure 44 c.). Adjusting for the other directly measured phenotypes (fully adjusted model) did 
not alter the effect estimates (Figure 44 d.). 
 
In the first sensitivity analysis, which included 248 people with complete data, the Joehanes 
scores and the Zhang score were also associated with mortality risk in the fully adjusted 
model. The effect estimate for the Zhang score was broadly comparable (1.19, 95% CI: 1.0, 
1.42; p=5.02 x 10-2) but HRs were higher for the Joehanes scores (HR=1.95, 95% CI: 1.11, 
3.45; p=2.08 x 10-2 for the score derived using an FDR significance threshold and HR = 2.11, 
95% CI: 1.08, 4.12; p=2.99 x 10-2 for the score derived using a strict Bonferroni threshold). 
The AHRR DNAm score was not associated with survival following adjustment for self-
reported smoking in the complete case analysis. In comparison to the primary analysis, three 
of the alcohol predictors developed by Liu et al, based on 5, 78 and 144 alcohol related 
CpGs, were associated with survival, with HRs of between 1.26 (95% CI: 1.03, 1.54; p=2.42 
x 10-2) and 1.29 (95% CI: 1.05, 1.58; p=1.60 x 10-2). A comparison of the Cox results for the 
primary analysis (n=408) and the complete case analysis (n=248) can be found in Appendix 
B19. 
 
When the data were censored at 3 years (77 deaths), the effect estimates for the association 
of smoking related DNAm scores with survival were higher than in the primary analysis, but 
the CIs were wider (Appendix B18 to B21). In the minimally adjusted model, all of the 
smoking scores except the DNAm score developed by Zhang were associated with survival 
(AHRR HR= 3.63 [95% CI: 1.88, 6.99; p=1.20 x 10-4]; Joehanes FDR HR= 2.58 [95% CI: 
1.57, 4.23; p=1.76 x 10-4]; Joehanes Bonferroni HR=3.36 [95% CI: 1.91, 5.91; p=2.57 x 10 ]; 
McCartney HR= 3.31 [95% CI: 1.80, 6.10; p=1.21 x 10-4]). There was weak evidence to 
suggest an association between DNAm-predictors of alcohol and mortality risk, with HRs 
ranging from 1.10 (95% CI: 0.91, 1.34) to 1.20 (95% CI: 1.02, 1.42). Neither BMI nor 
education predictors were related to survival. The association of smoking-related DNAm 
scores with survival that were observed in the minimally adjusted model remained but 
attenuated after controlling for clinical variables and directly measured phenotypes (AHRR 
HR= 2.73 [95% CI: 1.08, 6.89; p=3.37 x 10-2]; Joehanes FDR HR=2.09 [95% CI: 1.10, 3.95 
p=2.36 x 10-2]; Joehanes Bonferroni HR= 2.85 [95% CI: 1.33, 6.13 p=7.24 x 10-3]; McCartney 
HR= 2.50 [95% CI: 1.10, 5.69; p=2.92 x 10-2]), but there was no apparent relationship 
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between alcohol-related DNAm scores with survival. The estimated effects of the alcohol, 
BMI, and education DNAm scores on mortality risk were broadly comparable to those 




Figure 44: Forest plots showing the estimated hazard ratios and corresponding 95% 
confidence intervals for the associations of DNAm predictors with all-cause mortality 
(n=408). 
 
a. Adjusted for gender, age, cell counts and batch effects. 
 
b. Additionally, adjusted for TNM stage, HPV status and comorbidity. 
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a. Additionally, adjusted for the respective directly measured phenotype. 
 
b. Additionally, adjusted for the other directly measured phenotypes. 
 
 
The different DNAm scores predicting smoking, alcohol drinking, BMI and education are 
displayed on the Y-axis. The X-axis shows the hazard ratio for all-cause mortality risk per SD 
unit increase in DNAm score. The 95% confidence intervals (CIs) are provided in the 




8.5.1. Principle findings 
Genome-wide DNAm profiling has enabled the development of several biological predictors 
of complex traits including smoking, alcohol consumption, BMI and educational attainment. 
This chapter provides evidence that, in this cohort of individuals with OPC, epigenetic 
predictors of smoking not only explain a high proportion of the phenotypic variance - as 
much as 49% - they are also associated with survival following diagnosis. This was the case 
even after controlling for self-reported smoking, suggesting the DNAm predictors provide 
additional information on smoking history.   The DNAm score developed by Joehanes et al, 
which applied a stringent Bonferroni threshold to select CpGs for inclusion, was consistently 
associated with all-cause mortality in both primary and sensitivity analysis. Compared to 
people with a mean (Joehanes) DNAm score for non-smokers, people with a mean 
(Joehanes) DNAm score for current smokers were around twice as likely to die during follow-
up (fully adjusted HR= 1.89 [95% CI: 1.15, 3.11; p=1.2x10-2] in the primary analysis and 2.11 
[95% CI: 1.08, 4.12; p=2.99 x 10-2] in the complete case analysis). The AHRR methylation 
score was also associated with around a two-fold increased all-cause mortality risk in the 
primary analysis (fully adjusted HR= 1.92 [95% CI: 1.06, 3.47; p=3.08 x 10-2]). These results 
support the findings of my previous chapter, which found that self-reported current smokers 
had around a two-fold increased risk of death compared with self-reported non-smokers (for 
oral, oropharyngeal and laryngeal cancers combined), suggesting that DNAm based 
predictors for smoking could provide a useful tool in epidemiological studies to identify the 
smoking profiles of individuals in the absence of reliable self-report.  
 
It was notable that the risk associated with smoking, as predicted by methylation status at 
AHRR, was as high as the risk associated by the Joehanes score; in fact, the effect estimate 
was slightly higher.  This is important because it suggests that, in prognostic studies, a 
smoking proxy based on differential methylation at a single CpG site (described by Illumina 
array probe ID cg05575921) may be just as good, if not better, than a multi-probe score 
based on thousands of CpG sites across the genome. Prior work suggests that reversion of 
AHRR hypomethylation can provide a quantitative biomarker of smoking cessation 638, 
therefore future studies could use this epigenetic predictor to examine the prognostic impact 





The DNAm predictors for alcohol consumption were associated with all-cause mortality in 
minimally adjusted models, and following adjustment for clinical factors, but associations 
were not robust to adjustment for self-reported drinking. Similarly, there was evidence that a 
higher BMI was protective in models 1 and 2, with HRs of 0.88 (95% CI: 0.77, 1.01; p=6.25 x 
10-2) and 0.86 (95% CI: 0.75, 0.99; p=3.27 x 10-2) respectively, but on adjustment for self-
reported BMI (model 3), there was little evidence supporting this association. There was little 
evidence to suggest that the DNAm based predictor for educational attainment was related 
to survival. 
 
The DNAm predictors for alcohol consumption, BMI and education explained a smaller 
proportion of the variance in their phenotypic trait than the smoking DNAm scores in this 
analysis (7-16% for alcohol, 22% for BMI and 0.68% for education, respectively). These 
findings are line with those of an earlier analysis by McCartney et al, who used data derived 
from whole blood samples in a large cohort - Generation Scotland (a healthy population), to 
generate DNAm scores. The exception being that in their dataset, the proportion of 
phenotypic variance explained by their smoking predictor was almost 61% 633. The power of 
the DNAm-based predictor for smoking was well demonstrated in their study, with near-
perfect discrimination between current and never smokers based on ROC analysis 
(AUC=0.98). Together, these findings suggest that DNAm-based predictors of smoking 
could augment phenotypic prediction of mortality in future epidemiological studies. The same 
authors reported that models including polygenic scores (i.e. genetic scores) in addition to 
DNAm scores explain a greater proportion of variance in these traits 633, albeit it is still less 
than is explained for smoking. It would be interesting to see whether these combined 
predictors are associated with mortality risk in this cohort.  
 
8.5.2. Strengths and limitations of the study 
This study represents a novel application of epigenetic prediction of phenotypes within a 
cancer cohort. Two key strengths of the study include the availability of pre-established, 
robust epigenetic risk scores (DNAm scores) from large genome-wide consortia and the 
availability of MethylationEPIC data in H&N5000. The MethylationEPIC platform, which has 
been used in multiple published EWAS, including those used to derive the epigenetic risk 
scores employed in the current analysis, includes ~400,000 more CpG sites than the 
preceding 450k array (whilst maintaining the vast majority of sites already included on the 
450K array). As such, the epigenetic risk scores used in this analysis explain a greater 
proportion of phenotypic variance than those derived using the earlier 450k array. 
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The availability of both epigenetic data and comprehensive all-cause mortality follow-up data 
in the same clinical cohort represents another major strength of this study, as does the ability 
to adjust for multiple biological, clinical and lifestyle covariates, including HPV, which are 
especially relevant to this disease. 
 
As was the case with the observational analysis described in Chapter 6, a major limitation of 
this study is that it was not possible to estimate the association of exposures (here DNAm 
scores) with OPC-specific mortality, that is, I only had information on all-cause mortality. This 
affects how the results may be used clinically. For example, it is unclear whether the 
smoking association relates to cardiovascular outcomes only or if it also affects the 
progression of OPC.  Another potential limitation of this study is that the number of 
participants with epigenetic data available was relatively small, meaning that the number of 
outcome mortality events was also small. This created multiple issues; firstly, there was 
limited statistical power to test the PH assumption and secondly there was limited power to 
detect the true effect size of any potential associations of epigenetic predictors with mortality, 
as reflected by the relatively large CIs for some of the smoking predictors. When the data 
were examined, it was noted that there were relatively few events after 3-years. In an 
attempt to address the PH issue, a sensitivity analysis was conducted in which the data were 
censored at 3-years.  The results of the primary analysis and the censored analysis were 
similar in that only the smoking predictors were associated with mortality following full 
adjustment, and the HRs overlapped.  
 
It is important to note that the aim of this analysis was to investigate whether the DNAm risk 
scores are associated with all-cause mortality; as such, these results do not establish 
whether DNA methylation explains the association of smoking with increased mortality. 
Further studies with larger sample sizes are needed to provide mechanistic insight. 
8.5.3. Conclusions 
In summary, the results of the present analysis suggest that DNAm based biomarkers of 
smoking exposure have the potential to improve exposure assessment in epidemiological 




Chapter 9: Associations of epigenetic biomarkers of 
ageing with mortality risk in oropharyngeal cancer 
 
9.1. Introduction  
We saw earlier in this thesis that the mortality rates for OPC vary considerably. The overall 
5-year survival rate is around 50% 639 but estimates range from 35-83% 180 640. As such, the 
ability to accurately predict an individual’s survival probability at the time of diagnosis is 
important for clinical decision making and the enrolment of low-risk individuals into treatment 
de-escalation trials, which aim to achieve similar efficacy as routine clinical therapies but 
with reduced toxicity and improved quality of life 641.  
 
HPV status has already been highlighted as an important prognostic factor for OPC 348 ; it is 
now included in prognostic models alongside TNM stage and comorbidity 418 483. One such 
model yielded a Harrell’s concordance statistic (C-Statistic) of 0.69 in external validation, 
indicating good (but not excellent) prediction 483. The potential for model improvement is 
currently being explored and the prognostic value of various lifestyle factors such as 
smoking and alcohol intake have been investigated 441 442 446 450 575. The prognostic role of 
epigenetic markers, including DNAm, are less well studied. 
 
In Chapter 8, I started to explore whether DNAm could enhance outcome prediction in 
people with OPC.  Specifically, I analysed the associations of DNAm-based predictors for 
smoking, alcohol intake, BMI and educational attainment - phenotypes that have all been 
linked to OPC outcomes in the literature, with survival. I found strong evidence that smoking-
related DNAm scores may provide informative molecular biomarkers for mortality risk.  
 
As well as being modified by lifestyle behaviours such as smoking, DNAm levels also vary 
considerably with age 527. Models of epigenetic ageing (“epigenetic clocks”), which were first 
introduced in Chapter 4,  have been implicated as potentially useful biomarkers for age-
related disease and mortality, including risk of cancer 518 522. To recap, epigenetic clocks 
comprise a set of CpG sites whose DNAm levels are known to increase (or decrease 
depending on the CpG site) with age, and which together predict chronological age with a 
high degree of accuracy. The majority of studies evaluating the ability of these epigenetic 
clocks to predict morbidity and mortality to date have been conducted in general (healthy) 
229 
 
populations 521 527; there are very few studies investigating their prognostic value in a clinical 
setting. One study used a Cox model to estimate HRs for the association between 
epigenetic age acceleration (EAA), that is the discrepancy between DNAm age as measured 
by the epigenetic clock and chronological age, and risk of death following cancer diagnosis 
(n=1,726 deaths) 642. After adjusting for sociodemographic and lifestyle variables (smoking, 
alcohol intake, healthy eating, physical activity, socioeconomic status and education), the 
authors found limited evidence of an association with epigenetic age acceleration based on 
an epigenetic clock derived from methylation at 353 CpG sites (EAAHorvath) 523 but mortality 
risk was 10-30% higher for the highest versus lowest quartile of age acceleration based on 
an epigenetic clock derived from methylation at 71 CpG sites (EAAHannum) 520. There was 
no evidence of heterogeneity by cancer type (breast, colorectal, gastric, kidney, lung, b-cell 
lymphoma, prostate, urothelial cell carcinoma).   
 
Using several previously published methods for modelling epigenetic age, this chapter 
investigates the potential relationships between all-cause mortality and EAA in OPC. In 
particular, it assesses associations between both the “first generation” epigenetic clocks 520 
523, derived from DNA methylation levels at CpG sites found to be strongly associated with 
chronological age (i.e. EAAHorvath and EAAHannum), as well as more-recently derived 
clocks: one optimised to predict physiological dysregulation (AgeAccelPheno) 524 and one 
optimised to predict lifespan (AgeAccelGrim) 525.  
 
9.2. Aims and objectives 
The overall aim of this analysis was to assess whether EAA is associated with all-cause 
mortality in a sub-set of individuals with OPC in H&N5000. The objectives were: 
1. To establish whether five existing measures of EAA (EEAA, IEAA, IEAAHannum, 
AgeAccelPheno and AgeAccelGrim) are associated with all-cause mortality, after 
controlling for established risk factors; 
2. To explore whether the inclusion of these biomarkers of epigenetic aging improves 
mortality prediction compared to a clinical model based on age, tumour stage, HPV 





9.3.1. Study population  
The study population for this analysis were the 408 individuals with OPC, for whom epigenetic 
data, baseline questionnaire data and data capture were available (Figure 45).  Epigenetic 
data was generated as per the previous chapter using the Infinium MethylationEpic Bead Chip 
(EPIC array). Full details are provided in the Methods Chapter (Chapter 4: The Head and Neck 
5000 study). The methylation level at each CpG site was calculated as a beta value (β), which 
is the ratio of the methylated probe intensity and the overall intensity and ranges from 0 (no 
cytosine methylation) to 1 (complete cytosine methylation). 
9.3.2. Estimation of epigenetic age 
Epigenetic biomarkers of aging were first described in Chapter 3 (Capturing exposures). The 
epigenetic aging measures for this analysis were kindly provided by Dr Rebecca Richmond 
at the Integrated Epidemiology Unit (IEU), University of Bristol. To generate the epigenetic 
aging measures in H&N5000, DNA methylation data for a subset of 27,523 CpG sites from 
the Illumina EPIC array were uploaded on to the online DNA Methylation Age Calculator  
(https://dnamage.genetics.ucla.edu/) developed by Horvath’s group, along with an 
annotation file containing data on chronological age, sex and tissue type for the samples. 
This subset of sites was chosen based on the list of 30,085 CpGs listed in the 
“datMiniAnnotation3.csv” file available for “Advanced Analysis” analysis on the DNA 
Methylation Age Calculator website. 2,562 of the CpG sites were missing due to probe 
discrepancy between the Illumina EPIC platform and Illumina 450K platform, the latter of 
which was used to derive some of the epigenetic clocks.  
 
For each of the 408 individuals, the following epigenetic aging measures were generated 
(names follow the notation of previous publications): 
• intrinsic epigenetic age acceleration based on Horvath’s multi-tissue predictor  (IEAA) 
523; 
• intrinsic epigenetic age acceleration based on Hannum’s predictor (IEAAHannum) 
520;  
• extrinsic epigenetic age acceleration (EEAA), an enhanced version of Hannum’s 
method, which up-weights the contribution of blood cell composition 522;  
• PhenoAge (AgeAccelPheno) 524; 
• and GrimAge (AgeAccelGrim) 525.  
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An overview of the different epigenetic age predictors is provided in Table 38. Intrinsic 
epigenetic age acceleration (IEAA) is defined as the residual resulting from a linear 
regression of estimated DNAm age, as predicted by the epigenetic clock, on chronological 
age and estimates of plasmablasts, naïve and exhausted CD8+ T cells, CD4+ T cells, 
natural killer cells, monocytes, and granulocytes (estimated from the methylation data). 
Extrinsic epigenetic age (EEAA), by comparison, is defined as IEAA plus a weighted 
average of three cell types that are known to change with age (naïve [CD45RA+CCR7+] 
cytotoxic T cells, exhausted [CD28-CD45RA-] cytotoxic T cells, and plasmablasts) and by 
this definition is able to capture aspects of immunosenescence 522. 
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Table 38: Overview of various measures of epigenetic age acceleration. 







The residual resulting from regressing DNAm 
age on chronological age and estimates of 











EEAA  71 Residual resulting from a univariate model 
regressing a weighted age estimate (which 
increases the contribution of 3 cell types known 





AgeAccelPheno 513 Residual resulting from a linear model  
regressing AgePheno on chronological age, 
where PhenoAge is a measure based on a 
linear combination of chronological age and 9 
clinical biomarkers (albumin, creatinine, glucose, 
serum, CRP, lymphocyte percent, mean cell 
volume, red cell distribution width, alkaline 





AgeAccelGrim 1,030 Residual resulting from a linear model 
regressing GrimAge on chronological age, 
where GrimAge is a measure based on a linear 
combination of chronological age, sex, and 
DNAm-based surrogate biomarkers for smoking 
pack-years and seven plasma protein levels 
(ADM, B2M, cystatin C, GDF-15, leptin, PAI-
1,TIMP-1). 
 
Abbreviations: ADM, adrenomedullin levels; B2M, beta-2 microglobulin; CRP, C-reactive 
protein; EAA, epigenetic age acceleration; GDF-15, growth differentiation factor 15; PAI-1, 
plasminogen activation inhibitor 1; TIMP-1, tissue inhibitor metalloproteinase 1.
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9.3.3. Statistical analysis  
Stata (Release 15.1, StataCorp) was used for all analyses described below. The study was 
split into two steps (Figure 45).  The first step explored the potential associations of EAA 
measures with survival, after controlling for established HNC prognostic factors (listed 
below); The second step investigated whether these EAA measures provide any additional 
prognostic information, over and above those factors that are routinely considered (and 
which are available) in clinical practice, namely age, gender, tumour stage, HPV status and 
comorbidity . 
9.3.3.1. Step 1: Examining the association of EAA measures with survival  
Descriptive analyses were performed to explore the distribution of, and correlations between 
EAA measures, using histograms and Pearson’s correlation coefficients. Baseline descriptive 
data were stratified by whether or not they were alive at 3-years. The univariate association of 
covariates on all-cause mortality risk was assessed using Kaplan-Meier curves and the log-
rank test. 
 
Multivariable Cox proportional hazards models were used to examine the potential 
associations of the epigenetic age measures with all-cause mortality. Again, cancer-specific 
mortality data were not available at the time of data analysis. Given that the five epigenetic 
measures of age acceleration are expressed in different units, measures were standardised 
using z-scores to allow comparison of effect estimates. To calculate the z-score, I computed 
the difference between a given value and the mean for that measure and divided it by the 
standard deviation (SD).  So, a z-score of 0 would be equal to the mean, a z-score of 1 is 1 
SD above the mean and a z-score of -1 is 1 SD below the mean. HRs and 95% CIs for all-
cause mortality were calculated for each SD increase in EAA. For each measure of 
epigenetic aging, four separate Cox models were run:  
 
1) a minimally adjusted model that only controlled for gender;  
2) a model that additionally controlled for clinical factors (TNM stage, HPV status, 
comorbidity and BMI);  
3) a model that additionally controlled for socioeconomic factors (education, annual 
house-hold income, marital status);  
4) a fully adjusted model that additionally controlled for modifiable lifestyle behaviours 




Models were selected a priori based on the existing literature linking these covariates with 
survival 388 441 643-646 (See chapter 2). 
 
Several of the covariates of interest had some missing data (details provided in Chapter 7; 
Table 30), particularly BMI as this measure was not initially collected at the start of recruitment 
into the H&N5000 study. Excluding individuals with missing covariate data would have 
reduced the statistical power to detect an association between our exposures of interest and 
survival, and so MI was performed. As mentioned previously, earlier work suggests that MI 
provides unbiased results in situations where data are missing at random 647 (see Chapter 7).  
Missing values were imputed using the ICE package for multiple chained equations in Stata 
613. Twenty imputed datasets were generated and analysed separately using standard 
statistical methods and the multiple sets of results combined using Rubin’s rules 614, as per 
the previous chapter. The imputation models contained all the variables in the analysis model 
(including the outcome) and Nelson–Aalen estimator of the cumulative hazard. No outcomes 
were imputed. As a sensitivity analysis, a complete case dataset, which only included those 
participants with data available for all of the covariates of interest, was also generated and 
analysed as above 615.  
 
9.3.3.2. Step 2: Assessing the prognostic value of EAA measures 
Evidence of an association with outcome is not enough to include novel biomarkers in 
prediction models; to be useful to clinicians they must provide added prognostic value to 
existing models 648. Therefore, step 2 of the analysis explored whether the addition of EAA 
measures to models based on established mortality risk factors (i.e. those currently 
considered in clinical decision making), improve model performance.  
 
Flexible parametric survival models were fitted using the methods of Royston and Parmar 649 
650, which model the baseline hazard (on the log cumulative hazards scale) using restricted 
cubic splines 651. Splines are mathematical functions formed by piecewise polynomials 652. 
They are fit with some constraints to ensure that the overall curve of the baseline distribution 
is smooth, meaning that more complex shapes can be fit.  Flexible parametric models are 
conceptually very similar to the Cox model, and they provide similar estimates, but they have 
certain benefits if you are interested in prediction. Unlike Cox regression, flexible parametric 
models permit absolute (as opposed to relative) measures of effect (i.e. survival probability) 
to be estimated at all time points, rather than just at event times 653. To put this another way, 
using the flexible parametric model structure, outcomes can be predicted for time points 
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other than those that the prognostic model was developed on (see Riley, 2019 for 
calculations 654). Time dependent effects (non-proportional hazards) can also be modelled 
using this approach, which is particularly useful when you are working with a wide range of 
variables (demographic, clinical and biological). This is because, as the number of variables 
in your model increases, the probability that one or more of these variables fails to satisfy the 
PH assumption becomes increasing large. Indeed, there was a suggestion in the previous 
chapter that the PH assumption might not be reasonable for HPV status (see Chapter 7; 
Supplementary figure 2).  
 
The Royston and Parmar (RP) models were fitted using maximum likelihood estimation via 
the stpm2 command in Stata.  The spline complexity for the baseline hazard function which 
best fits the data was investigated visually and through model fit statistics (Akaike 
Information Criterion [AIC] and Bayesian Information Criterion [BIC]).  The AIC is defined as 
2Log(likelihood) + 2(No. of model parameters), while BIC equals 2Log(likelihood) + (No. of 
model parameters) *Log(n). Degrees of freedom (df) ranging from 1 to 5 df (for a model with 
no variables included) were considered. Using the hazard function plots and the AIC and 
BIC as a guide, 2 df were deemed sufficient. These 2 degrees of freedom equate to 1 
interior knot, the point where the polynomials join 655. Non-linear relationships with 
continuous predictors were considered using the multivariable fractional polynomial (MFP) 
algorithm described by Sauerbrei and Royston 656 and implemented in Stata using the mfp 
command, which selects the MFP model that best predicts the outcome variable.  
The following models were fit:  
1) a ‘clinical model’, which comprised age, gender, TNM stage, HPV status and 
comorbidity; 
2) clinical + IEAA;  
3) clinical + EEAA;  
4)  clinical + IEAAHannum;  
5) clinical + AgeAccelGrim; and 
6) clinical + AgeAccelPheno.  
Models were fit in a sub-sample of participants with complete data available for the clinical 
covariates considered in this analysis (age, gender, tumour stage, comorbidity, and HPV 
status). The performance measures examined were the AIC, which measures the relative 
goodness of fit of a model, considering both the statistical goodness of fit and the number of 
parameters used, and the C-statistic, an extension of the area under the receiver operating 
curve (AUC) to survival analysis 465 657. The interpretation of the statistic is equivalent, 
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namely, a C-statistic of 0.5 indicates no discrimination above chance (of dying or surviving), 
whereas a C-statistic of 1.0 indicates perfect discrimination, and thus superior prediction 658. 
ROC curves and AUC functions were calculated to characterize how well the fitted models 
distinguish between participants who were and were not alive three years after diagnosis.  
Internal validation was performed on the final model using 500 bootstrap samples to adjust 
performance for optimism and calculate a shrinkage factor to be applied to the models' 
regression coefficients for use in other (external) settings 659 660 .  
 
Figure 45: Flow of participants included in the Epigenetic Age analysis. 
 
*Samples were initially selected for genetic and epigenetic analysis based on clinical diagnosis 
of OPC (ICD-10: CO1, CO5, CO9, C10.0-2, C10.3, C10.8 and C10.9), as recorded by the 
study Centre. Pathology reports of individual cases were subsequently checked (where 
possible) to verify tumour site. **Data available for age, gender, TNM stage, HPV status, 




A total of 105 deaths were observed during follow-up (median=5.3 years, IQR: 4.9 to 6.0; n=408). 
The proportion of missing data in this data set was summarised in the previous Chapter (Table 30). 
Information on age, stage and HPV status were complete. The largest proportion of missing data 
corresponded to BMI (33.3%), followed by annual household income (12.5%) and education (4.7%). 
The complete case sample included 225 participants (n=49 deaths). 
 
9.4.1. Baseline descriptives 
The baseline clinical and sociodemographic characteristics of participants included in the epigenetic 
dataset stratified by tumour site and HPV status were provided in Chapter 6 (Tables 21 and 22). 
Table 39 presents the baseline characteristics and mean EAA measures of participants stratified by 
whether or not they were alive at 3-years. There were differences in TNM stage, HPV status, 
comorbidity, annual household income and smoking and alcohol intake across groups. Compared to 
the group who were alive at 3-years, the group who had died were more likely to have been 
diagnosed with stage III or IV cancer (94% versus 85%), were more likely to be HPV-negative (58% 
versus 23%), were more likely to have moderate/severe comorbidity (30% versus16%), were more 
likely to be earning <£18,000 (56% vs. 35%), were more likely to be current smokers (34% versus 
16%) and were more likely to drink hazardous to harmful amounts of alcohol (66% versus 48%). 
The average age of participants was 63 years in the group who had died and 57 years in the group 
that were alive.  Mean EAA, as measured by each of the epigenetic clocks, was higher in those 
individuals who had died at three years. There were differences between people who had survived 
and those who had died for the following epigenetic age measures: EEAA (p=0.004), IEAAHannum 
(p=0.006), AgeAccelPheno (p=<0.001) and AgeAccelGrim (p=0.002).  Only IEAA showed no 
association with survival status at 3 years. 
 
The distribution of baseline characteristics for participants included in the complete case analysis 
was broadly comparable with respect to age, gender, HPV status, smoking status, alcohol intake, 
education, income and marital status (Appendix C1). However, there was no evidence of 
differences in comorbidity (p=0.204) or TNM stage (p=0.740) between people who were and were 
not alive at 3-years in the complete case analysis.  
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9.4.2. Pairwise correlations between measures of epigenetic age acceleration 
The pairwise Pearson correlation coefficients of selected measures of EEAA is shown in Figure 46. 
The measures exhibited correlation coefficients ranging from r=0.05 to r=0.74. The strongest 
absolute association was between EEAA and IEAAHannum.
 
Figure 46: Heat map showing the pairwise correlation coefficients between epigenetic 
measures of age acceleration. 
 
The heatmap colour-codes the pairwise Pearson correlation coefficients between epigenetic 
measures of age acceleration based on the multi-tissue epigenetic clock developed by Horvath 
(IEAA) 523, the blood-based DNAm age developed by Hannum (IEAAHannum and EEAA) 520 522, 




Table 39: Baseline characteristics of the study sample stratified by 3-year mortality status (n=408). 
 
Abbreviations: EEAA, extrinsic epigenetic age acceleration; IEAA, intrinsic epigenetic age 
acceleration. P-value for difference based on the Chi-Square test (categorical) and one-way ANOVA 
(continuous).  *Comorbidity was defined using the Adult comorbidity Evaluation Index-27 (ACE-27). 




9.4.3. Explained variation in survival 
The R2 statistics for explained variation in survival are presented in Table 40. As with the 
previous chapter, which used the same dataset, the variance in survival explained by the 
basic model (age, gender, cell counts and batch effects) was 24%. The only EAA measure 
to enhance the proportion of explained variation was AgeAccelGrim. The addition of 
AgeAccelGrim to the model led to a 12% increase in explained variation (R2=0.36 [95% 
CI:0.25, 0.45]). 
 
Table 40: Proportion of variance in survival explained by the EAA measures (n=408). 
 
 
*Includes age, gender, cell counts (CD4 T-cells, CD8 -cells, eosinophils, monocytes 
neutrophils natural killer) and batch effects. 
9.4.4. Association of DNA Methylation-Based Biological Age with survival  
The results of the Cox regression analysis (imputed data; n=408) are presented in Figure 47.  
In the basic model (Figure 47 a.), which adjusted only for sex all of the epigenetic 
biomarkers of aging except the intrinsic epigenetic age acceleration measure IEAA were 
associated with survival.  All of the reported associations are in the expected directions, i.e. 
higher values of EAA are associated with higher mortality risk.  HRs ranged from 1.35 (95% 
CI: 1.10, 1.66; p=3.5 x10-03) for EEAA to 1.91 (95% CI: 1.58, 2.32; p=2.3 x10-11) for 
AgeAccelGrim, where HRs represent the difference in mortality risk per SD unit increase in 
EAA measure. With the exception of AgeAccelPheno, associations remained but were 
attenuated slightly following adjustment for clinical and socioeconomic factors (Figures 47 b. 
and 47 c.). In the fully adjusted model (Figure 47 d.), which also adjusted for smoking and 
alcohol intake, IEAAHannum and AgeAccelGrim were associated with mortality risk (HRs: 
1.32 (95% CI: 1.08, 1.61; p=6.9 x10-03) and 1.39 (95% CI: 1.06, 1.83; p=0.017), respectively, 
Lower Upper
Basic model* 0.24 0.14 0.35
IEAA 0.20 0.10 0.31
IEAA Hannum 0.24 0.14 0.34
EEAA 0.21 0.11 0.31
AgeAccelpheno 0.21 0.11 0.32
AgeAccelGrim 0.36 0.25 0.45
Model R2 




In the complete case analysis (n=225), the results of the basic model were broadly 
comparable to those of the imputed analysis (Appendix C2).  However, IEAAHannum was 
not robust to adjustment for socioeconomic factors and the association of AgeAccelGrim 
with survival attenuated following adjustment for smoking and alcohol intake.
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Figure 47: Association of epigenetic age acceleration measures with mortality risk. 
47 a: Adjusted for gender. 
 
47 b: Additionally adjusted for tumour stage (high (III and IV) versus low (I and II) stage), 





47 c: Additionally adjusted for income, education and marital status. 
 
47 d: Additionally adjusted for self-reported smoking status and alcohol intake. 
 
Solid blue circles indicate the hazard ratios per SD increase of each of the age acceleration 
measures displayed on the y-axis. The corresponding 95% confidence intervals are shown in 






9.4.5. Examination of the predictive utility of EAA measures 
 
Table 41 shows the performance measures for the fitted models. The AIC values for the 
clinical + EEAA, clinical + IEAAHannum and clinical + AgeAccelGrim model were lower than 
the clinical model. As a rule of thumb, two models are generally considered equivalent if the 
difference in their AICs is less than 2 units 662; therefore on this basis, all three of these 
models had a better overall fit than the standard clinical model. The preferred model, i.e. the 
model with the lowest AIC value, was the clinical + AgeAccelGrim model. Compared to the 
clinical model (0.73), the C-statistics were higher for the clinical + EEAA (0.76), clinical + 
IEAAHannum (0.74) and clinical + AgeAccelGrim (0.76) models. 
 
Given that the clinical + AgeAccelGrim model showed the strongest association in the Cox 
regression analysis, appeared to fit the data best and yielded the highest discrimination (i.e. 
had the highest AIC and C-statistic), I examined whether this model provided improved 
prediction at three years compared to a clinical model (including age, gender, TNM stage, 
HPV and comorbidity), by comparing AUC values. The results are illustrated in Figure 48. 
There was weak evidence to suggest the clinical + AgeAccelGrim model had superior 
predictive performance compared to the clinical model (clinical AUC: 0.77, clinical + 
AgeAccelGrim AUC: 0.80; p-value for difference=0.069), at which point there had been 76 
deaths. The bootstrap optimism corrected AUC values showed a small reduction in 
performance compared with the original model (optimism adjusted AUCs of 0.74 and 0.77 
for clinical and clinical + AgeAccelGrim models, respectively). 
 
 
The optimism-adjusted c-slope (or uniform shrinkage factor) for the clinical + AgeAccelGrim 
model, was 0.83, indicating there was some overfitting. The original predictor effects 
adjusted by this value 658. The results are presented in Table 42. In the adjusted model, each 
SD unit increase in AgeAccelGrim was associated with a 1.5-fold increased risk of death at 3 
years (optimism adjusted HR= 1.54, 95% CI: 1.2, 1.92; p=<0.001).  
 
 
Smoking has been shown to be independently predictive of mortality in H&N5000 575. The 
reduced effect estimate observed between AgeAccelGrim and mortality with adjustment for 
smoking status suggests that the enhanced prognostic ability gained from adding 
AgeAccelGrim to the clinical model could be due to the inclusion of a smoking predictor 525. 
In order to investigate this, I conducted an additional sensitivity analysis whereby I compared 
the prognostic ability of the following models: 1) clinical + AgeAccelGrim; 2) clinical + self-
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reported smoking; and 3) clinical + dnampackyears, the DNAm-based surrogate biomarker 
for pack years of smoking used to derive GrimAge (n=384 participants with smoking data 
available; no. deaths=72). At 3-years, there was a suggestion that the clinical + 
AgeAccelGrim model had better discrimination (AUC value of 0.80) than the clinical 
models including both self-reported smoking (AUC=0.77) and a DNAm surrogate for pack 
years (AUC=0.78) (Figure 49), although there was limited evidence of a difference in AUCs 
based on chi-squared tests (p=0.175). 
 
 
Table 41: Measures of model performance. 
Model  AIC C-statistic (95% CI) 
Clinical 486.93 0.75 (0.70, 0.80) 
Clinical + EEAA 483.36 0.76 (0.71, 0.81)  
Clinical + IEAA 488.14 0.76 (0.71, 0.81) 
Clinical + IEAAHannum 480.10 0.77 (0.72, 0.82) 
Clinical + AgeAccelGrim 473.14 0.78 (0.73, 0.83) 
Clinical + AgeAccelPheno 485.52 0.76 (0.71, 0.81) 
 
Abreviations: AgeAccelGrim, age acceleration based on DNAmGrimAge; AgeAccelPheno; 
age acceleration based on PhenoAge;  AIC, Akaike’s information criterion; C-statistic, 
Harrel’s concordance statistic; EEAA, extrinsic epigenetic age acceleration; IEAA, intrinsic 
epigenetic age acceleration; 95% CI, 95% confidence interval.
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Figure 48: Independent contribution of AgeAccelGrim to prognosis beyond clinical 
factors (n=408).  
 
Chi-squared p-values. Number of deaths at 3-years = 76. 
 
Figure 49: A comparison of the area under the ROC curves (AUC) obtained for the 
models included in the sensitivity analyses (n=384). 
 
 Number of deaths at 3-years =72. Abbreviations: AUC, area under the receiver operating 
characteristics curve; Clin, clinical model (including age, gender, TN|M stage, HPV status and 
comorbidity); dnampackyrs, the DNA methylation based biomarker of pack years of smoking 






Table 42: Estimated hazard ratios (uncorrected and corrected) for the clinical + 
AgeAccelGrim model.  
  Original model  




95% CI   95% CI 
Variable HR upper lower HR upper lower 
Age 1.05 1.07 1.02 1.04 1.06 1.02 
Gender 




Female  1.53 2.69 0.87 1.42 2.28 0.89 
Tumour stage 
  
   
 
  
II 1.90 17.24 0.21 1.71 10.63 0.27 
III 5.21 39.90 0.68 3.94 21.32 0.73 
IV 6.36 46.75 0.90 4.65 24.31 0.89 
HPV status 
  
   
 
  
Positive 0.39 0.65 0.23 0.45 0.70 0.29 
Comorbidity* 
  
   
 
  
mild 1.39 2.46 0.80 1.32 2.11 0.82 
moderate/severe 1.27 2.34 0.69 1.22 2.02 0.73 
AgeAccelGrim 1.69 2.19 1.30 1.54 1.92 1.25 
 
To obtain the adjusted estimates, the original model estimates (beta coefficients) were 
multiplied by the shrinkage factor (0.83) and exponentiated to convert to HRs. The beta 
coefficients are presented in Appendix C3. 
 
9.5. Discussion 
9.5.1. Principle findings  
Age-related changes in DNAm have attracted growing attention in recent years, largely due to 
their ability to predict associated morbidity and mortality among general populations.  The 
purpose of this chapter was to establish whether DNAm-based predictors of aging could 
provide useful biomarkers of mortality risk in people with OPC. The main findings were that  
two different epigenetic age estimators, IEAAHannum and AgeAccelGrim, were associated 
with increased risk of all-cause mortality and these associations were independent of 
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established mortality risk factors. AgeAccelGrim had the strongest effect estimate, with each 
SD increase in epigenetic age acceleration resulting in a 39% increase in risk of death in the 
fully adjusted model (HR=1.39; 95% CI: 1.06, 1.83). When compared to a standard clinical 
model that included age, sex, tumour stage, HPV status and comorbidity, the addition of 
AgeAccelGrim to the model showed some improvement in mortality risk prediction at 3-years 
(optimism-adjusted AUCs: 0.77 and 0.80 [p=0.069] for clinical and clinical +AgeAccelGrim 
models, respectively).  
 
These findings support the current literature, which suggests that DNAm derived “GrimAge”, 
a composite biomarker incorporating DNAm-based surrogates for smoking pack-years and 
seven plasma proteins in addition to age and sex, is a better predictor of mortality risk 
compared to the first-generation DNAm-based predictors  (i.e. Horvath and Hannum’s 
clocks) 525. Age acceleration as measured by GrimAge has not only been shown to perform 
better in predicting time to death and time to cancer among general populations, it has also 
been associated with established cancer risk factors 525.  
 
It is possible that AgeAccelGrim was most strongly related to mortality risk in the current 
analysis due to the inclusion of the surrogate measure for smoking in the GrimAge biomarker, 
since smoking has been shown to be independently predictive of mortality among HNC cases 
575. When the prognostic performance of the clinical + AgeAccelGrim model was compared 
with clinical models including both self-reported smoking and the DNAm surrogate biomarker 
for pack years of smoking, the clinical + AgeAccelGrim model had the best discrimination 
(AUC:0.80), followed by the clinical + dnampackyrs (AUC:0.78), though the improvement in 
predictive performance was marginal. These findings suggest that the methylation-based 
measure of smoking is a better indicator with less misclassification than self-report and that 
the prognostic utility of AgeAccelGrim does not appear to be driven solely by the inclusion of 
the DNAm-based biomarker for smoking.  
 
As mentioned, GrimAge is also trained on a set of proteins known to be associated with 
mortality 525, including plasminogen activator inhibitor 1 (PAI-1) and growth differentiation 
factor 15 (GDF15).  PAI-1 (aka SERPIN E1) is overexpressed in a variety of tumours and 
has been found to be a strong predictor of poor clinical outcome and poor response to 
therapy 663-665 whilst GDF15 is involved in the pathogenesis of oral squamous cell carcinoma 
(OSCC) 666-668. Several studies have demonstrated that, in people with OSCC, GDF15 is 
also associated with decreased survival and diminished response to chemotherapy 666 667 669 
670. The inclusion of DNAm-based surrogate measures for these proteins may go part way to 
249 
 
explaining the enhanced prognostic ability of AgeAccelGrim in the current analysis and 
should be investigated further.  
 
9.5.2. Strengths and limitations of the study 
This investigation has several strengths including the relatively long follow-up period, the fact 
that individuals were sampled at the time of diagnosis and the fact that DNAm was assayed 
simultaneously in the same laboratory. I was also able to account for a range of factors that 
could confound the effect estimates, including smoking, alcohol intake and BMI, all of which 
are known to influence DNAm and HNC risk 633 671. Moreover, missing covariate data were 
imputed via chained equations to minimise possible biases 610 672. 
 
Several limitations should be highlighted. First, the sample size for this analysis was small and 
I was unable to identify an independent prospective dataset to validate my findings. In an 
attempt to mitigate possible optimism in my effect estimates, I calculated a uniform shrinkage 
factor and multiplied this by the original β coefficients from the fitted model. I then presented 
the optimism-adjusted coefficients. Second, information on some of the variables used in this 
analysis were obtained via participants’ self-report, which earlier chapters explained can result 
in recall bias or misreporting. I employed a DNAm-derived measure of packyears of smoking 
in my sensitivity analysis but future studies could implement the use of other methylation 
scores to index these variables (e.g. BMI and alcohol intake) 633 671.  Fourth, there is a disparity 
in coverage between 450K and 850K Illumina platforms meaning that 19 of the 353 CpGs 
included in Horvath’s clock and 6 of the 71 CpGs included in Hannum’s clock are missing in 
H&N5000. This could be problematic, although a previous study examining the application of 
EPIC array data to predict DNAm age demonstrated that the lack of the clock-CpGs on the 
EPIC array did not undermine the utility of the epigenetic age predictors 673. Finally, I did not 
account for multiple testing of the 5 epigenetic age acceleration measures, although evidence 
of correlation between some of the epigenetic measures suggests that correction may not 
have been appropriate.  
 
9.5.3. Conclusions 
Here, I investigated the relationship between epigenetic measures of age acceleration and 
overall survival in blood samples of people with OPC. Overall, my findings provide evidence 
that DNA methylation-based estimators of ageing could provide prognostic utility, above 
established prognostic factors including age, sex, tumour stage, HPV status, comorbidity, 
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and smoking. That an accurate and easy-to-measure biomarker derived from peripheral 
blood could serve as a better predictor of mortality risk in people diagnosed with OPC is 
important as this could impact treatment planning and provide information that improves 
patient stratification in study design, e.g. treatment de-escalation trials. Nonetheless, these 










The last two chapters of my thesis focused on epigenetic biomarkers and their ability to 
predict survival in people with OPC. They provided evidence that DNAm-based estimators of 
smoking and biological aging are associated with mortality and could improve prediction 
compared to models based on conventional HNC prognostic factors, including age, tumour 
stage and HPV status. Attention now turns towards the metabolome and the identification of 
metabolic predictors of survival in this cohort. 
 
The metabolome, as described in Chapter 3, represents a functional readout of both 
upstream omics profiles (genomics, transcriptomics, proteomics) and exogenous 
environmental exposures. It provides an indication of what is happening in a cell, tissue or 
biofluid at that moment in time. In this respect, the metabolome may be considered more 
proximal to the phenotype than the genome or the proteome. Through studying metabolite 
changes that occur in response to a particular disease state or pathological phenotype, it 
may be possible to gain insight into the pathogenesis and progression of that disease and 
potentially aid in the development of novel diagnostic and prognostic biomarkers.  
 
The majority of the metabolic processes in the body, such as those responsible for the 
breakdown of carbohydrates, fats, and amino acids to generate energy, are common to all 
living cells. Cancer cells, however, are characteristically different from surrounding healthy 
cells; in order to maintain viability and proliferate in frequently nutrient and oxygen-poor 
environments, cancer cells reprogram their metabolic activities 321 322 674. The resulting shifts 
in intracellular and extracellular metabolite concentrations can have profound effects on the 
tumour microenvironment, cellular signalling, and gene expression. For this reason, 
metabolomics, the study of all the small molecular weight metabolites that make up the 
metabolome, is considered complementary to other, more established omic technologies. 
 
The application of metabolomics has led to the identification of biomarkers for diagnosis and 
prognosis in multiple cancers, including prostate, brain and ovarian cancer 674-676. My 
scoping review of the literature, however (Chapter 3), found that few studies have evaluated 
the metabolomic profiles of people with HNC, and even fewer studies have determined the 
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prognostic significance of circulating metabolites in this population. Those studies that have 
been conducted have included small sample sizes- typically fewer than 100 people, have 
generally considered multiple tumour sites together, and have used different types of 
samples (i.e., serum, plasma, saliva, urine, tissue) and analytical platforms (e.g. MS, NMR, 
liquid chromatography) 271. For an overview of the different metabolomics technologies, the 
reader is directed to Chapter 4. One recent study evaluated the serum amino acid profiles of 
140 people with histologically verified HNSCC using high-performance liquid 
chromatography in an attempt to identify possible prognostic biomarkers for OS and RFS 344. 
The authors found serum methionine levels were positively correlated with five-year OS and 
RFS in multivariable models (HR, 0.52; 95% CI, 0.31–0.90, p = 0.02), which adjusted for 
age, sex, tumour localization, T stage (T3,4 vs. T1,2), N stage (N2,3 vs. N0,1), M stage (M1 
vs. M0), histological tumour grade and treatment strategy. These findings have yet to be 
validated externally.  
 
This chapter starts to explore the association of metabolite concentrations with all-cause 
mortality in a specific subgroup of people with HNC, namely those with oropharyngeal 
tumours, using NMR spectroscopy.  Whilst exploratory in nature, this analysis is based on a 
larger dataset, with data available on a broad range of metabolites involved in multiple 
biological pathways, including amino acid metabolism, lipid metabolism and fluid balance. 
The findings of this study represent a first step towards identifying a metabolic signature, or 
profile, that could predict survival in people with OPC.  
 
10.2. Aims and objectives 
 
This analysis is not driven by an a priori hypothesis but is instead designed to be hypothesis-
generating. The objectives are, firstly, to examine whether the metabolome of people with 
HPV-driven oropharyngeal tumours differs from that of people with non-HPV-driven 
oropharyngeal tumours, and secondly, to investigate possible associations between baseline 
metabolic traits and all-cause mortality in people with OPC using Cox proportional hazards 
regression models.  
 




10.3.1. Study population  
 
All participants with OPC and baseline blood samples were eligible for inclusion in the study.  
Samples were initially picked for metabolomic analysis using the information provided in the 
baseline data capture forms, that is, samples were selected based on clinical ICD-10 coding 
of OPC (see Chapter 3 for details). A minimum of 100 μL of blood was needed for the low 
volume NMR method, as described in Chapter 5. Samples were not picked if they were the 
last aliquot available for that participant. In total, 1,595 of 1,611 potentially eligible samples 
were available for analysis: 11 participants did not have enough sample volume available 
and 5 participants had no sample at all. Of these, 112 participants were excluded from the 
analysis because subsequent pathological reports revealed the cancer originated outside of 
the oropharynx. This left a final sample size of 1,483. 
 
10.3.2. Measurement of metabolites 
 
Metabolic profiling was performed on baseline plasma samples using a high‐throughput 
serum NMR metabolomics platform (Nightingale Health®, Helsinki, Finland), originally 
described by Soininen et al. 590. Details of this platform and its use in epidemiological studies 
have been described in Chapter 5 (The Head and Neck 5000 study). Briefly, the platform 
provides quantification in molar concentration units of: routine lipids; 14 lipoprotein 
subclasses, including particle concentration and lipids transported by these particles; various 
fatty acids and fatty acids traits (e.g., chain length, degree of unsaturation); amino acids; 
ketone bodies; glycolysis and gluconeogenesis-related metabolites; fluid balance; and one 
inflammation-related metabolite (Appendix D1).  In total, 224 biochemically and metabolically 
distinct measures were obtained but for the purposes of analysis and for ease of 
interpretation, ratios (with the exception of fatty acid ratios), diameters, glycolysis-related 
metabolites (glucose, lactate and citrate) and alanine were excluded, leaving 145 discrete 
metabolic traits (Table 39). The rationale for retaining individual fatty-acid concentrations 
relative to total fatty acids is that previous work has shown that these measures reflect the 
biology of individual fatty acids better than their absolute concentration and they are 
commonly the only metric captured by standard laboratory assays 594. Moreover, fatty acid 
ratios have been linked to cancer risk and progression 677 678.  The remaining selected 
metabolic measures were excluded on the basis of recommendations provided in the 




“Many metabolite concentrations differ from what we commonly observe. Many of these 
differences point to sample degradation. For example, the observed shifts in amino acids, 
(e.g. alanine) look similar than in samples that are kept for some time as whole blood (likely 
in room temperature) before plasma separation. In addition, the samples might have been 
stored at -20°C for extended periods of time….  
 
We note that most samples display very low glucose and elevated lactate levels. This is also 
commonly seen in the case when glycolysis has been ongoing after the sample collection 
(i.e. samples have been with the cells for some time prior to plasma separation). In this case, 
the concentrations no longer reflect the biological state of the study subject and thus we 
advise to exclude glycolysis related markers from the analyses”  
 
This finding in H&N5000 can be explained by the fact that, following blood draws, samples 
were initially stored and posted at room temperature. Work by Ferreira et al demonstrates 
that pre-storage delay and incubation temperature of uncentrifuged samples can result in 
changes in levels of metabolite measures, particularly for glycolysis-related metabolites 680. 
This is because the blood cells (primarily red blood cells) and enzymes contained within the 
sample tube are still metabolically active, resulting in the uptake and release of metabolites. 
By contrast, the same authors found that lipids, lipoproteins and fatty acids, were minimally 
affected by different sample pre-analytical conditions. 
 
Overall, the mean success rate for metabolic trait detection in this analysis, which is the 
percentage of samples for which the respective metabolic trait measure was obtained, was 
97.95% (included metabolites only; Table 43). Lipoprotein concentration measures were 
obtained for all samples. The largest amount of missing data was for glutamine (77% 
success rate). This is probably because glutamine is not very stable when the sample is 
stored at room temperature for prolonged periods. It degrades to glutamate. In total, 343 out 
of 1,595 samples were tagged “Low glutamine/High glutamate” in the Nightingale report. 
Glutamine was not quantified in these samples. 
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Table 43: An overview of the metabolic biomarkers included in the current analysis 
(n=145). 
Abbreviation Metabolite trait (unit) Success rate* 
XXL-VLDL-P  Concentration of chylomicrons and extremely large VLDL particles 
(mol/l) 
100% 
XXL-VLDL-L  Total lipids in chylomicrons and extremely large VLDL (mmol/l) 100% 
XXL-VLDL-PL  Phospholipids in chylomicrons and extremely large VLDL (mmol/l)  100% 
XXL-VLDL-C  Total cholesterol in chylomicrons and extremely large VLDL (mmol/l) 100% 
XXL-VLDL-CE  Cholesterol esters in chylomicrons and extremely large VLDL (mmol/l) 100% 
XXL-VLDL-FC  Free cholesterol in chylomicrons and extremely large VLDL (mmol/l) 100% 
XXL-VLDL-TG  Triglycerides in chylomicrons and extremely large VLDL (mmol/l) 100% 
XL-VLDL-P  Concentration of very large VLDL particles (mol/l) 100% 
XL-VLDL-L  Total lipids in very large VLDL (mmol/l) 100% 
XL-VLDL-PL Phospholipids in very large VLDL (mmol/l) 100% 
XL-VLDL-C  Total cholesterol in very large VLDL (mmol/l) 100% 
XL-VLDL-CE  Cholesterol esters in very large VLDL (mmol/l) 100% 
XL-VLDL-FC  Free cholesterol in very large VLDL (mmol/l) 100% 
XL-VLDL-TG  Triglycerides in very large VLDL (mmol/l) 100% 
L-VLDL-P  Concentration of large VLDL particles (mol/l) 100% 
L-VLDL-L  Total lipids in large VLDL (mmol/l) 100% 
L-VLDL-PL  Phospholipids in large VLDL (mmol/l) 100% 
L-VLDL-C  Total cholesterol in large VLDL (mmol/l) 100% 
L-VLDL-CE  Cholesterol esters in large VLDL (mmol/l)  100% 
L-VLDL-FC  Free cholesterol in large VLDL (mmol/l) 100% 
L-VLDL-TG  Triglycerides in large VLDL (mmol/l) 100% 
M-VLDL-P  Concentration of medium VLDL particles (mol/l) 100% 
M-VLDL-L  Total lipids in medium VLDL (mmol/l)  100% 
M-VLDL-PL  Phospholipids in medium VLDL (mmol/l)  100% 
M-VLDL-C  Total cholesterol in medium VLDL (mmol/l)  100% 
M-VLDL-CE  Cholesterol esters in medium VLDL (mmol/l)  100% 
M-VLDL-FC  Free cholesterol in medium VLDL (mmol/l) 100% 
M-VLDL-TG  Triglycerides in medium VLDL (mmol/l) 100% 
S-VLDL-P  Concentration of small VLDL particles (mol/l)  100% 
S-VLDL-L  Total lipids in small VLDL (mmol/l)  100% 
S-VLDL-PL  Phospholipids in small VLDL (mmol/l)  100% 
S-VLDL-C Total cholesterol in small VLDL (mmol/l)  100% 
S-VLDL-CE  Cholesterol esters in small VLDL (mmol/l)  100% 
S-VLDL-FC  Free cholesterol in small VLDL (mmol/l)  100% 
S-VLDL-TG  Triglycerides in small VLDL (mmol/l) 100% 
XS-VLDL-P  Concentration of very small VLDL particles (mol/l)  100% 
XS-VLDL-L  Total lipids in very small VLDL (mmol/l)  100% 
XS-VLDL-PL  Phospholipids in very small VLDL (mmol/l)  100% 
XS-VLDL-C  Total cholesterol in very small VLDL (mmol/l)  100% 
XS-VLDL-CE  Cholesterol esters in very small VLDL (mmol/l) 100% 
XS-VLDL-FC  Free cholesterol in very small VLDL (mmol/l)  100% 
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XS-VLDL-TG  Triglycerides in very small VLDL (mmol/l)  100% 
Table 43 continued. 
Abbreviation Metabolite trait Success rate 
IDL-P  Concentration of IDL particles (mol/l)  100% 
IDL-L  Total lipids in IDL (mmol/l)  100% 
IDL-PL  Phospholipids in IDL (mmol/l)  100% 
IDL-C  Total cholesterol in IDL (mmol/l) 100% 
IDL-CE  Cholesterol esters in IDL (mmol/l)  100% 
IDL-FC  Free cholesterol in IDL (mmol/l)  100% 
IDL-TG  Triglycerides in IDL (mmol/l) 100% 
L-LDL-P  Concentration of large LDL particles (mol/l) 100% 
L-LDL-L  Total lipids in large LDL (mmol/l)  100% 
L-LDL-PL Phospholipids in large LDL (mmol/l)  100% 
L-LDL-C  Total cholesterol in large LDL (mmol/l)  100% 
L-LDL-CE  Cholesterol esters in large LDL (mmol/l) 100% 
L-LDL-FC  Free cholesterol in large LDL (mmol/l)  100% 
L-LDL-TG  Triglycerides in large LDL (mmol/l)  100% 
M-LDL-P  Concentration of medium LDL particles (mol/l) 100% 
M-LDL-L  Total lipids in medium LDL (mmol/l)  100% 
M-LDL-PL  Phospholipids in medium LDL (mmol/l) 100% 
M-LDL-C  Total cholesterol in medium LDL (mmol/l)  100% 
M-LDL-CE Cholesterol esters in medium LDL (mmol/l) 100% 
M-LDL-FC  Free cholesterol in medium LDL (mmol/l) 100% 
M-LDL-TG  Triglycerides in medium LDL (mmol/l)  100% 
S-LDL-P  Concentration of small LDL particles (mol/l)  100% 
S-LDL-L Total lipids in small LDL (mmol/l)  100% 
S-LDL-PL Phospholipids in small LDL (mmol/l)  100% 
S-LDL-C  Total cholesterol in small LDL (mmol/l)  100% 
S-LDL-CE  Cholesterol esters in small LDL (mmol/l)  100% 
S-LDL-FC  Free cholesterol in small LDL (mmol/l)  100% 
S-LDL-TG  Triglycerides in small LDL (mmol/l) 100% 
XL-HDL-P  Concentration of very large HDL particles (mol/l)  100% 
XL-HDL-L  Total lipids in very large HDL (mmol/l)  100% 
XL-HDL-PL  Phospholipids in very large HDL (mmol/l)  100% 
XL-HDL-C  Total cholesterol in very large HDL (mmol/l)  100% 
XL-HDL-CE  Cholesterol esters in very large HDL (mmol/l)  100% 
XL-HDL-FC  Free cholesterol in very large HDL (mmol/l)  100% 
XL-HDL-TG  Triglycerides in very large HDL (mmol/l)  100% 
L-HDL-P  Concentration of large HDL particles (mol/l)  100% 
L-HDL-L  Total lipids in large HDL (mmol/l) 100% 
L-HDL-PL  Phospholipids in large HDL (mmol/l)  100% 
L-HDL-C  Total cholesterol in large HDL (mmol/l) 100% 
L-HDL-CE  Cholesterol esters in large HDL (mmol/l)  100% 
L-HDL-FC Free cholesterol in large HDL (mmol/l)  100% 
L-HDL-TG  Triglycerides in large HDL (mmol/l)  100% 
M-HDL-P  Concentration of medium HDL particles (mol/l) 100% 
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M-HDL-L  Total lipids in medium HDL (mmol/l)  100% 
Table 43 continued. 
Abbreviation Metabolite trait Success rate  
M-HDL-PL  Phospholipids in medium HDL (mmol/l)  100% 
M-HDL-C  Total cholesterol in medium HDL (mmol/l)  100% 
M-HDL-CE  Cholesterol esters in medium HDL (mmol/l)  100% 
M-HDL-FC Free cholesterol in medium HDL (mmol/l) 100% 
M-HDL-TG  Triglycerides in medium HDL (mmol/l)  100% 
S-HDL-P  Concentration of small HDL particles (mol/l)  100% 
S-HDL-L  Total lipids in small HDL (mmol/l) 100% 
S-HDL-PL  Phospholipids in small HDL (mmol/l) 100% 
S-HDL-C  Total cholesterol in small HDL (mmol/l)  100% 
S-HDL-CE  Cholesterol esters in small HDL (mmol/l) 100% 
S-HDL-FC Free cholesterol in small HDL (mmol/l) 100% 
S-HDL-TG  Triglycerides in small HDL (mmol/l)  100% 
Serum-C Serum-C Serum total cholesterol (mmol/l)  100% 
VLDL-C  Total cholesterol in VLDL (mmol/l)  100% 
Remnant-C  Remnant cholesterol (non-HDL, non-LDL -cholesterol) (mmol/l) 100% 
LDL-C  Total cholesterol in LDL (mmol/l)  100% 
HDL-C  Total cholesterol in HDL (mmol/l)  100% 
HDL2-C Total cholesterol in HDL2 (mmol/l)  100% 
HDL3-C  Total cholesterol in HDL3 (mmol/l)  100% 
EstC  Esterified cholesterol (mmol/l)  98.6% 
FreeC  Free cholesterol (mmol/l) 98.6% 
Serum-TG  Serum-TG Serum total triglycerides (mmol/l) 100% 
VLDL-TG Triglycerides in VLDL (mmol/l) 100% 
LDL-TG  Triglycerides in LDL (mmol/l)  100% 
HDL-TG  Triglycerides in HDL (mmol/l)  100% 
TotPG  Total phosphoglycerides (mmol/l)  98.6% 
PC  Phosphatidylcholine and other cholines (mmol/l) 98.6% 
SM  Sphingomyelins (mmol/l)  98.6% 
TotCho  Total cholines (mmol/l)  98.6% 
ApoA1  ApoA1 Apolipoprotein A (g/l) 100% 
ApoB Apolipoprotein B (g/l)  100% 
TotFA  Total fatty acids (mmol/l)  96.6% 
UnSat  Estimated degree of unsaturation 96.6% 
DHA Docosahexaenoic acid (mmol/l) 96.6% 
LA  linoleic acid (mmol/l)  96.6% 
FAw3 Omega-3 fatty acids (mmol/l) 96.6% 
FAw6  Omega-6 fatty acids (mmol/l)  96.6% 
pufa  PUFA Polyunsaturated fatty acids (mmol/l) 96.6% 
mufa  Monounsaturated fatty acids (mmol/l)  96.6% 
SFA  Saturated fatty acids (mmol/l)  96.6% 
DHA/FA  Ratio of docosahexaenoic acid to total fatty acids (%)  96.6% 
LA/FA  Ratio of linoleic acid to total fatty acids (%)  96.6% 
FAw3/FA  Ratio of omega-3 fatty acids to total fatty acids (%) 96.6% 
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FAw6/FA Ratio of omega-6 fatty acids to total fatty acids (%) 96.6% 
Table 43 continued. 
Abbreviation Metabolite trait Success rate 
MUFA/FA  Ratio of monounsaturated fatty acids to total fatty acids (%) 96.6% 
PUFA/FA  Ratio of polyunsaturated fatty acids to total fatty acids (%) 96.6% 
SFA/FA  Ratio of saturated fatty acids to total fatty acids (%) 96.6% 
Gln  Glutamine  77.4% 
His  Histidine  99.9% 
Ile  Isoleucine 99.6% 
Leu  Leucine  99.6% 
Val  Valine  99.7% 
Phe  Phenylalanine 99.5% 
Tyr  Tyrosine  99.4% 
Ace Acetate  98.2% 
bOHBut  3-hydroxybutyrate  97.3% 
Crea  Creatinine 97.3% 
Alb Albumin 100% 
Gp  Glycoprotein acetylation  99.9% 
 
* Success rate refers to the percentage of samples for which the respective metabolic trait 
measure was obtained. 
 
10.3.3. Issues of multiple testing 
 
An important distinction between single biomarker studies and metabolomics analyses is the 
number of hypotheses being tested. Given that many metabolic measures are being 
analysed simultaneously, the probability of finding evidence of association by chance (i.e. 
type I errors, also known as false positives) is high. There are several methods available to 
help reduce the rate of type I errors 681 682. In my analysis, I conducted principal component 
analyses (PCA) on standardised metabolic traits data. PCA is a data reduction technique 
that uses an orthogonal transformation, which is a type of linear transformation, to convert a 
series of observations of potentially correlated variables into a (smaller) set of uncorrelated 
variables, termed principal components (PCs) 683. The first PC explains the maximum 
amount of the variability in the data and each subsequent PC explains as much of the 
remaining variability as possible. In this way, PCA reduces the dimensionality of a large 
dataset whilst preserving most of the information it contains. I used the number of PCs as 
the denominator in a Bonferroni correction to set a significance threshold which takes into 
account both multiple testing and the correlated nature of the metabolic traits, as discussed 
previously 601 684. This method assumes that the independence of the principle components 
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(PCs) is equivalent to the degree of freedom of the original metabolic traits data and that 
retaining a number of PCs that is enough to explain at least 95% of the variance will result in 
only a small chance of type 1 error. In this instance, 95% of the variance in the 145 
metabolic measures was explained by 11 PCs (this number is a proxy for the number of 
independent tests being performed). Therefore, the multiple testing correction, accounting 
for 11 independent tests using the Bonferroni method, resulted in p < 0.005 (α ÷ 11, where α 
= 0.05). P‐values below this can be interpreted as providing strong evidence of an 
association of the respective metabolic trait with overall survival. A scree plot displaying the 
amount of variation (captured by the eigenvalues), that each principal component captures 
from the data is provided in Figure 50, alongside the PCA output obtained from Stata. The 
output shows that the first two PCs capture almost 69% of the overall variance in the data 
(PC1, 46%; PC2, 22%). 
 
PC loadings were examined to determine which metabolite traits had the greatest influence 
on each component. Loadings represent the correlation between the original variables and 
the factors. Loadings range from -1 to 1, with loadings close to -1 or 1 indicating a strong 
influence on the component. Loadings close to zero, by contrast, show that the variable 
(trait) has a weak influence on the component. Considering that the first two PCs explain the 
majority of the variation in the data, I have focused primarily on their loadings. A table of 
loadings of all variables for each of the principal components that was studied is provided in 
Appendix D2. VLDL and LDL measures loaded highly on the first PC (PC1), alongside 
Apolipoprotein B (ApoB), remnant cholesterol (Remnant_C), monounsaturated fatty acids 
(mufa) and total fatty acids (TotFA) (Figure 51).  HDL measures, particularly measures of 
total cholesterol in HDLs and ApoA1 were found to contribute considerably to the second PC 
(PC2). Of note, PC11 almost exclusively captures acetate, which has a loading of 0.86 
(Appendix D3). The loadings of most of the other metabolites in PC11, with the exception of 







Figure 50: Scree plot and Stata output showing the decreasing rate at which variance is explained by additional principal components. 
 
 
The scree plot (top) shows the eigenvalues on the y-axis and the number of factors on the x-axis. In these results, the first 11 principal components 
have eigenvalues greater than 1 and together explain almost 95% of the variation in the data (bottom). Kaiser criterion suggests retaining those 
factors with eigenvalues equal or higher than 1 685.
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Figure 51: Loading to PC1 and PC2. 
 
Loadings have been rotated to maximise ease of interpretation using varimax rotation, which 
maximizes the sum of the variance of the squared loadings 686. This typically produces high or 
low (near zero) factor loadings, with few intermediates, such that a variable is more likely to 
be associated with just one PC. The variance accounted for each PC is shown in brackets. 
VLDL and HDL measures load highly to PC1, whilst HDL measures contribute most to PC2. 
 
10.3.3. Missing data decisions 
 
Missing covariate data were not imputed in the current analysis. This was because the 
imputation model would necessarily have included all the metabolic trait measures, since all 
of the variables included in the substantive model should be included in the imputation 
model. This was problematic for two reasons. Firstly, imputation by multiple chained 
equations (ICE) assumes normality for all of the continuous variables in the imputation 
model 687 but several of the metabolic traits exhibited a skewed distribution (see Appendix 
D4 ). This issue could not be corrected using log, square root, or reciprocal transformations.  
Indeed, several of the normally distributed variables became skewed after transformation. 
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Several nonnormal imputation models are currently in development 688, but this remains an 
active area of research. Secondly, as mentioned previously, ICE assumes that missing 
values are missing completely at random (MCAR) or missing at random (MAR). This is an 
issue because there was not enough information to determine why metabolite data were 
missing. Missingness among metabolite data is a common occurrence in epidemiological 
studies 681, though it is generally less of an issue with NMR data compared to MS data 
(personal communication), in part because NMR requires limited sample preparation (e.g. 
separation or derivatization) and also because of its high selectivity 689. Values may be 
missing for several reasons including biological factors (e.g. metabolites being absent), 
technical limitations (e.g. the limit of detection or issues separating metabolite signals from 
noise), or measurement error 690.   
 
In light of these two issues, it was decided that imputation would not be appropriate.  For 
information on the proportion of missing covariate data, see Appendix D3.  This left 703 of 
1813 (39%) participants with OPC for inclusion in the analysis (Figure 52).
 
Figure 52: OPC samples available for analysis 
 
 
Abbreviations: ICD, International classification of diseases; n, number; OPC, oropharyngeal 
cancer.   Pathologically confirmed where possible. 
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10.3.4. Statistical analyses 
 
Analyses were undertaken in the statistical software packages RStudio (version 1.2.5001) 
and StataMP (version 15.1). 
 
To allow comparison of magnitudes of association across measures with different units or 
with large differences in their concentration distributions, all metabolite concentrations were 
converted to standard deviation (z) scores.  
 
First, to examine whether there were differences in the baseline metabolomes of HPV-
positive and HPV-negative individuals (based on HPV16-E6 serological status, which is a 
good marker of HPV-driven tumours 628), metabolic traits were regressed on HPV status to 
get the difference in mean values by HPV status with 95% CIs and p-values for the 
differences.  Regression coefficients (Betas) represent the SD difference in mean metabolite 
concentration for HPV-positive versus HPV negative individuals.  Associations between OS 
and metabolite measures (in all OPCs) were then estimated as HRs and 95% CIs for each 
metabolite trait using the Cox proportional hazards model. The PH assumption was tested 
using statistical tests based on the Schoenfeld residuals. There was no evidence for non‐
proportionality for any of the metabolic measures or covariates included in the models. 
 
Four separate models were run on the 703 included participants:  
 
1) a minimally adjusted model that adjusted for age and gender;  
2) a model that additionally adjusted for clinical factors including TNM stage, HPV status, 
comorbidity and BMI;  
3) a model that additionally adjusted for socioeconomic factors, namely annual household 
income, educational attainment and marital status; and  
4) a model that additionally adjusted for smoking status and alcohol intake. 
 
Given that complete case analyses can lead to biased estimates if the associations amongst 
individuals included in the analysis differ from the population from which they are drawn, 
minimally adjusted models were run in the full dataset and in the complete case dataset and 





10.3.5. Sensitivity analysis 
The observed concentrations and distributions of metabolite measures are presented 
graphically in Appendix D4. Given that several of the metabolic traits exhibit a skewed 
distribution, I examined the effect of removing potential outliers, i.e. samples which deviate 
from the distribution of the majority of the data, from the dataset. Inclusion or exclusion of 
these outliers could be important and may lead to different statistical conclusions, particularly 
given the relatively modest sample size of this study. I performed three different sensitivity 
analyses: 1) I removed values that were greater than 5 SD from the mean; 2) I removed 
values above the 99th percentile for that variable; 3) I winsorized the top 5% and bottom 5% 
of data points.  
 
The SD approach for defining outliers, whereby values are classified as outliers if they are a 
given number of SDs away from the mean score for that variable- typically 3 SD, is a 
commonly applied rule 691. The practice of using plus or minus 3 SD is based on the 
characteristics of a normal distribution, where 99.7% of the data falls within this range 692.  
Some metabolomics studies use a cut-off of 4 or 5 SD from the mean 693 694. I decided to 
remove values that were greater than 5 SD from the mean, partly to preserve sample size 
and thus statistical power but also because human blood metabolites are known to vary 
widely across different individuals 695. For comparison, I used the slightly less conservative 
approach of defining outliers as values above the 99th percentile for that variable.  
 
The SD rule has been criticised as an approach for removing outliers for the reason that the 
mean and SD are very sensitive to extreme values i.e. outliers increase the SD 696 (though 
using a larger SD cut-off mitigates this to some extent). Moreover, the method assumes a 
normal distribution. For these reasons, this approach may be fundamentally problematic in 
the context of metabolomics data, where, as is the case in this analysis, data typically do not 
conform to normal distributions. Another approach which has been applied in metabolomic 
studies is winsorization 697 698 699, whereby extreme data values i.e. values in the tails of the 
distribution, are replaced with smaller values. In this way, winsorization is not equivalent to 
removing data, but rather data that is assumed to be incorrect or exaggerated is replaced 
with a more plausible value. The new value therefore represents a compromise. 
 
As a final sensitivity analysis, all metabolite variables were winsorized using values 
representing the 5th and 95th percentiles of the distribution in the sample (i.e. data points 
lying outside the 5th percentile were replaced with the 5th percentile for that metabolite 
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distribution and data points lying outside the 95th percentile were replaced with the 95th 




10.4.1. Baseline characteristics 
The primary survival analysis was performed in 703 individuals, of whom 129 died during a 
median follow-up time from diagnosis of 4.3 years (IQR: 3.8, 5.1). Over two-thirds of the 
population were HPV-positive and the majority were diagnosed with stage IV tumours. A full 
description of the baseline demographics of the sample population was provided in Chapter 
6 (overall, Table 23; stratified by HPV status, Table 24).  
 
When the baseline clinical and socio-demographic variables for participants included in the 
analytic sample were compared against those of the people who were excluded from the 
analysis (i.e. those with missing covariate data), there was evidence that people with missing 
data were more likely to be HPV-negative (33%% vs. 26%; p-value for difference =0.004), 
were more likely to have severe comorbidity (20% vs. 14%; p<0.001), and were more likely 
to be current smokers (22% vs. 15%l; p=0.005) compared with people who had complete 
data (Table 44). The mean age of people included in the analytic sample was around a year 
older than that of the excluded group (45 years vs. 52 years for the complete case group 
compared to the group with missing data). 
 
10.4.2. Differences in metabolic trait concentrations between HPV-positive and HPV-
negative individuals 
 
The SD difference in mean metabolic trait concentrations in HPV-positive versus HPV-
negative individuals is presented in (Appendix D5). There was evidence of a difference in 
approximately 75% of the traits measured (p<0.005). The strongest evidence of a difference 
was obtained for large HDL (L_HDL) measures, including cholesterol esters in L_HDL (β= -
0.50, 95% CI: -0.67, -0.34; p=2.1 x 10-09), total cholesterol in L_HDL (β= -0.50, 95% CI: -
0.66, -0.34; p=2.55 x 10-09), free cholesterol in L_HDL (β= -0.49, 95% CI: -0.66, -0.33; 
p=4.99 x 10-09), total lipids in L_HDL (β= -0.47, 95% CI: -0.63, -0.31; p=2.52 x 10-08) and 
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concentration of L_HDL particles (β= -0.47, 95% CI: -0.63, -0.30; p=3.12 x 10-08). Other 
metabolite traits that showed a difference between HPV groups included, but were not 
restricted to, creatinine (β=0.41, 95% CI: 0.25, 0.56; p=1.77 x 10-07), the amino acids 
valine (β=0.41, 95% CI: 0.25, 0.57; p=6.14 x 10-07), histidine (β=0.42, 95% CI: 0.26, 0.59; 
p=8.86 x 10-07), linoleic acid (β=0.40, 95% CI: 0.22, 0.57; p=8.87 x 10-06), leucine (β=0.33, 
95% CI: 0.16, 0.51; p=1.07 x 10-04)  and omega-3 fatty acids (β=0.33, 95% CI: 0.15, 0.51; 
p=2.73 x 10-04). 
 
10.4.3. Associations of pre-treatment metabolic traits with all-cause mortality  
 
The results of the Cox regression analysis are presented in Figures 53 and 54. Based on the 
threshold for multiple testing (p=0.006), there was evidence of an association between 37 of 
the metabolic traits and survival in the minimally adjusted model (model 1). Of these, 29 
were lipoprotein measures (see Appendix D6 for a complete list).  After additionally 
controlling for clinical factors (model 2), five metabolic measures were related to OS (Figure 
53). Each SD increase in acetate was associated with a 30% increased risk of death 
(HR=1.30; 95% CI: 1.12, 1.51; p=4.04 x 10-4), whilst SD increases in creatinine, omega-3, 
the ratio of omega-3 to total fatty acids, and histidine were associated with reduced risk 
(creatinine, HR=0.67, 95% CI: 0.52, 0.86; p=0.002; omega-3, HR=0.73, 95% CI: 0.59, 0.90; 
p=0.003; ratio of omega-3 to total fatty acids, HR=0.73, 95% CI: 0.60, 0.89; p=0.002; 
histidine, HR= 0.77, 95% CI:0.65, 0.92; p=0.004). The associations of acetate and creatinine 
with OS remained in model 3 (acetate: HR=1.30, 95% CI: 1.11, 1.51; p=0.001; creatinine: 
HR=0.68; 95% CI: 0.53, 0.89; p=0.004), indicating that socioeconomic variables had little 
confounding effect on the observed associations (Figure 54). However, there was no longer 
good statistical evidence to suggest that omega 3 and histidine were related to mortality risk. 
Only acetate was associated with mortality risk in the fully adjusted model (model 4), which 
also adjusted for smoking status and alcohol intake (Figure 54). The effect estimate 
attenuated slightly (HR=1.28, 95% CI: 1.10, 1.49; p=0.002). An extended table of results can 
be found in Appendix D6.  
 
Examining the linear correlation plot, comparing the minimally adjusted results for the 
complete case dataset and the full dataset (Figure 55), there appears to be good overall 
correlation between HRs, as indicated by an R2 of 0.82 and a slope of 1.01 ( 0.04).
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Table 44: A comparison of people included and excluded from the analytic sample. 
Characteristic N Frequency N Frequency p-value
Sex
Male 599 76.80% 564 80.20%
Female 181 23.20% 139 19.80% 0.109
TNM staging
I 30 3.90% 24 3.40%
II 70 9.00% 73 10.40%
III 121 15.60% 94 13.40%
IV 557 71.60% 512 72.80% 0.528
HPV serology group
HPV-negative 258 33.20% 185 26.30%
HPV-positive 518 66.80% 518 73.70% 0.004
Comorbidity groups
None 321 42.50% 379 53.90%
Mild 282 37.30% 223 31.70%
Moderate/Severe 153 20.20% 101 14.40% <0.001
Education level
School education 176 45.60% 293 41.70%
College 146 37.80% 272 38.70%
Degree 64 16.60% 138 19.60% 0.335
Annual household income
<£18,000 108 35.90% 249 35.40%
£18000-£34,999 94 31.20% 222 31.60%
>£35,000 99 32.90% 232 33.00% 0.989
Relationship status
Single (never married) 56 13.30% 68 9.70%
Currently in relationship 288 68.40% 519 73.80%
No longer with spouse 77 18.30% 116 16.50% 0.095
Smoking status
Never 95 24.90% 216 30.70%
Former 201 52.80% 382 54.30%
Current 85 22.30% 105 14.90% 0.005
Alcohol consumption
Non-drinker 104 25.70% 179 25.50%
Moderate drinker 80 19.80% 171 24.30%
Hazardous-harmful drinker 221 54.60% 353 50.20% 0.191
N Mean (SD) N Mean (SD)
Age (years) 770 59.49 ( 9.11) 703 58.21 ( 9.07) 0.007
BMI 177 26.79 ( 5.27) 703 26.98 ( 5.05) 0.647






Figure 53: Cox regression results for models 1 and 2 
 
Hazard ratios represent the increase in mortality risk per SD increase in metabolic trait. Model 
1 (minimally adjusted) adjusted for age and gender; model 2 (clinical model) additionally 
adjusted for TNM stage, HPV status, comorbidity and BMI. Lipoprotein metabolic  trait 





Figure 54: Cox regression results for models 3 and 4. 
 
Hazard ratios represent the increase in mortality risk per SD increase in metabolic trait. Model 
3 (socioeconomic model) adjusted for income, education and marital status; model 4 (fully 
adjusted model) additionally adjusted for TNM stage, HPV status, comorbidity and BMI. 






Figure 55: Linear fit between complete case and full dataset models. 
 
Each blue dot represents a metabolic trait and the positions of the dots are determined by its 
association with survival. A linear fit of the overall correspondence summarises the similarity 
in effect estimates (blue solid line) between datasets. R2 indicates goodness of linear fit and 
as such is a measure of the consistency between associations. A slope of 1 with an intercept 
of 0 (grey dashed line), with all blue dots sitting on the line (R2 = 1), would indicate that the full 
and compete case dataset estimates have the same magnitude and direction.  Metabolic traits 
whose residuals are within the top 10% are labelled. Only metabolic traits with the largest 
residuals (top 10%) are marked.   
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10.4.4. Sensitivity analyses 
 
A comparison of the effect estimates obtained for selected metabolic traits in the primary and 
sensitivity analyses is presented in Table 45. Only those metabolites for which there was 
evidence of an association with survival in the primary analysis are included. 
 
When data points (samples) that were in the top 99th percentile were removed from the data 
set and the analysis was repeated (n=515 remaining), the effect estimates for omega-3 and 
histidine in the minimally adjusted model were very similar to those of the primary analysis   
(HRs = 0.65 [95% CI: 0.51, 0.83; p=0.001] and 0.69 [0.55, 0.87; p=0.002], respectively), but 
the improvement in mortality risk associated with each SD increase in acetate decreased 
(HR= 1.1 [95% CI: 0.99, 1.26; p=0.085]) as did the higher risk associated with creatinine  
(HR = 0.62 [95% CI: 0.47, 0.82; p=0.001].  In the fully adjusted model, the effect estimates 
attenuated for acetate and omega 3, compared with the primary analysis (HR acetate = 1.13 
[95% CI:0.99, 1.28; p=0.072]; HR omega-3 = 0.69 [95% C/I:0.53, 0.89; p=0.005]) but were 
broadly comparable for histidine (HR=0.84 [95% CI: 0.67, 1.06; p=0.142]). There HR for 
creatinine was slightly higher (HR=0.78 [95% CI: 0.60, 1.02; p=0.071), though CIs 
overlapped with those of the primary analysis.     
 
Using the more conservative approach of removing observations within 5 SD from the mean 
(n=505 remaining), the results for creatinine, omega-3 and histidine in the minimally adjusted 
models were similar to those of analysis described above, so effect estimates for omega-3 
and histidine were comparable with the primary analysis (HR=0.65 [95% CI: 0.50, 0.83; 
p=0.001] for omega-3 and 0.66 [95% CI:0.52, 0,83; p=0.001] for histidine) but the mortality 
risk associated with creatinine reduced (HR=0.62 [95% CI: 0.47, 0.82; p=0.001]; Table 43). 
There was no longer strong evidence that increased acetate improved OS (HR=0.85 [95% 
CI: 0.64, 1.14; p=0.280]). A similar pattern was seen in the fully adjusted models. 
 
When metabolite variables were winsorized, which preserved the original sample size but 
replaced extreme values in the top and bottom 5% with the 95th and 5th percentiles for that 
metabolite distribution, the results for creatinine, omega-3 and histidine were again 
comparable to those if the primary analysis: minimally adjusted HRs: 0.59 [95% CI: 0.48, 
0.72; p=4.56 x 10-04] for creatinine, 0.69 [95% CI: 0.57, 0.83; p=1.29 x 10-04] for omega-3 and 
0.69 [95% CI: 0.57, 0.83; p=9.93 x 10-04] for histidine; corresponding fully adjusted HRs= 
0.75 [95% CI: 0.61, 0.93; p=0.008], 0.77 [95% CI: 0.62, 0.94; p=0.011], and 0.81 [95% CI: 
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0.67, 0.97; p=0.023]. Again, there was no real evidence to suggest that acetate influenced 
mortality risk in this analysis (minimally adjusted HR=0.99 [95% CI: 0.83, 1.18; p=0.910]; 
fully adjusted HR=0.99 [95% CI: 0.83, 1.17; p=0.884].
 
 Table 45: The impact on effect estimates of removing potential outliers from the dataset, 
using different outlier-detection methods. 
  Min adjusted Fully adjusted 
    95% CI    95% CI   
  N HR Lower Upper p-value N HR Lower Upper p-value 
Primary analysis 
Acetate 696 1.38 1.20 1.59 <0.001 696 1.28 1.10 1.49 0.002 
Creatinine 685 0.54 0.41 0.70 <0.001 685 0.72 0.55 0.92 0.010 
Omega-3 680 0.68 0.56 0.83 1.66E-04 680 0.76 0.61 0.94 0.011 
Histidine 703 0.68 0.57 0.82 5.34E-05 703 0.81 0.68 0.97 0.024 
Remove top 99th percentile 
Acetate 515 1.11 0.99 1.26 0.085 515 1.13 0.99 1.28 0.072 
Creatinine 515 0.62 0.47 0.82 0.001 515 0.78 0.60 1.02 0.071 
Omega-3 515 0.65 0.51 0.83 0.001 515 0.69 0.53 0.89 0.005 
Histidine 515 0.69 0.55 0.87 0.002 515 0.84 0.67 1.06 0.142 
remove values 5 SD from mean 
Acetate 505 0.85 0.64 1.14 0.280 505 0.91 0.70 1.18 0.474 
Creatinine 505 0.62 0.47 0.82 0.001 505 0.77 0.58 1.01 0.056 
Omega-3 505 0.65 0.50 0.83 0.001 505 0.72 0.56 0.93 0.012 
Histidine 505 0.66 0.52 0.83 0.001 505 0.80 0.63 1.01 0.061 
Winsorized 
Acetate 696 0.99 0.83 1.18 0.910 696 0.99 0.83 1.17 0.884 
Creatinine 685 0.59 0.48 0.72 4.56E-07 685 0.75 0.61 0.93 0.008 
Omega-3 680 0.69 0.57 0.83 1.29E-04 680 0.77 0.62 0.94 0.011 





10.5.1. Principle findings 
Changes in intra- and extracellular metabolism are well documented in the cancer literature, 
yet there are currently no established metabolic biomarkers for prognosis in OPC.  Utilizing 
NMR plasma metabolomic profiling of 703 people with OPC, acetate, creatinine, omega-3 
and histidine levels were found to be associated with OS in models that controlled for 
demographic (age and gender) and clinical (TNM stage, HPV status, comorbidity and BMI) 
factors. Each SD unit increase in circulating acetate was associated with a 30% higher risk 
of death (HR= 1.30, 95% CI: 1.12, 1.51; p=4.04 x 10-4), whilst corresponding increases in 
circulating creatinine, omega-3 and histidine were associated with reduced mortality risks 
(creatinine HR= 0.67, 95% CI: 0.52, 0.86; p=0.002; omega-3 HR=0.73, 95% CI: 0.59, 0.90; 
p=0.003; histidine HR= 0.77, 95% CI: 0.65, 0.92; p=0.004). A higher ratio of omega-3 fatty 
acid relative to total fatty acid was also associated with improved survival in this analysis 
(HR= 0.73, 95% CI: 0.60, 0.89; p=0.002). The effect estimates for acetate and creatinine did 
not change considerably following adjustment for socioeconomic factors (income, education 
and marital status), however, evidence for the association of creatinine with survival was no 
longer present when models were adjusted for smoking and alcohol intake.  
 
Whilst this study identified several potential biomarkers of interest, the findings should be 
interpreted with caution because the results of the sensitivity analyses suggest that some of 
the associations are driven by extreme values (outliers) or sample size. For example, higher 
acetate levels were associated with worse survival in the primary analysis but there was no 
evidence for this after extreme observations were removed. The effect estimates for 
creatinine, omega-3 and histidine were more stable across the analyses, but further, 
adequately powered studies are required to substantiate these findings. 
 
The positive association between circulating acetate levels and all-cause mortality in this 
population of people with OPC, may reflect the observation that acetate provides an 
important respiratory substrate for metabolically stressed cancer cells 700-703. In well-
oxygenated (i.e. normoxic) conditions, acetyl coenzyme A (acetyl-CoA), a key precursor of 
lipid synthesis and energy production 704, is predominantly generated from glucose and 
glutamine-derived carbon. Under hypoxic conditions, however, isotopic tracer experiments 
have revealed that acetate, obtained from either external (e.g. diet) or internal sources, 
provides an alternative carbon source for biosynthesis, fuelling cellular proliferation 700 702 705. 
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Furthermore, it has been suggested that many cancer cells actually favour acetate as their 
carbon source 701 706 707.  
 
Exogenous acetate can be produced from the oxidation of ethanol (alcohol) 702. Typically, 
blood concentrations of ethanol range from 50–200 μM but among chronic drinkers, 
concentrations may reach 500–600 μM, or higher 702. This is noteworthy given that alcohol is 
a known risk factor for HNC and many individuals with HNC have a history of chronic heavy 
alcohol consumption. It is possible that the observed association of acetate with all-cause 
mortality in this analysis may be driven by heavy drinkers, since heavy drinking is strongly 
associated with a range of harmful traits including poor dietary habits, lower quality of life 
and greater risk of depression 708, factors which may all negatively impact upon mortality. If 
acetate is on the causal pathway, i.e. if increased acetate is a consequence of alcohol 
consumption and part of the mechanism by which it increases the risk of death, adjusting for 
alcohol in the analysis (model 4) may not have been appropriate as this would suggest it is 
not a confounder.  
 
The suggestion of a possible link between creatinine and mortality risk may warrant further 
investigation. Creatinine is a by-product of muscle metabolism, a waste product left behind 
when the body uses the amino acid creatine for energy 709 710. In healthy individuals, 
creatinine is filtered from the blood by the kidneys but if an individuals’ kidneys are not 
functioning properly, creatinine may accumulate in the blood. As such, serum creatine levels 
are widely used as a marker of renal function (glomerular filtration rate, GFR) in clinical 
practice.  Causes of low blood creatinine concentration include low muscle mass (because 
the breakdown of muscle tissue produces creatinine), liver disease, fluid overload and poor 
nutritional status 710. Reduced muscle mass - a condition known as sarcopenia - and 
malnourishment are common manifestations of HNC and cancer in general, and are 
frequently associated with poor clinical outcomes including reduced response to cancer 
treatment, treatment toxicity, and worse overall-survival 711-715. In view of this, it is possible 
that any association of plasma creatinine levels with mortality may reflect the association of 
low muscle mass with mortality 710 716.  
 
The finding that circulating omega-3 may be related to survival in this analysis was also 
interesting. As mentioned above, people with HNC are frequently malnourished and 
experience a high incidence of postoperative complications. It has been suggested that 
supplementation with omega-3 fatty acids could reduce the incidence of these complications, by 
maintaining immunocompetence during treatment 717-721. It is difficult to draw any conclusions 
however, owing to the diversity of interventions used (i.e. formulations, durations of the 
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intervention, clinical outcomes studied), and the type and stage of cancers studied 721.  The 
finding that higher omega-3 levels were associated with improved survival in this analysis (in 
models that controlled for age, gender and clinical factors), provides further motivation for 
designing an adequately powered randomised controlled trial (RCT) investigating the effects of 
omega-supplementation on clinical outcomes in HNC. 
 
10.5.2. Challenges 
I encountered several challenges when trying to investigate the association of metabolites 
with survival, and this is a reflective of the relative infancy of the field compared with other 
omics technologies. Statistical methodologies for analysing genetic and epigenetic data are 
more developed and more widely discussed in the literature, for example compared with 
metabolomics, though methods and technologies are advancing rapidly. The first problem 
that I faced was how to deal with the skewed distribution of the metabolic data. There does 
not appear to be a standard procedure for this and despite trying several different 
approaches, I was unable to transform my data so that the distributions were all 
approximately normal, indeed some methods such as log transformation made some of the 
variables more skewed.   
 
My second challenge was how to deal with the high dimensionality and inter-correlation of 
the metabolite data, which meant that the number of variables in my dataset greatly 
exceeded the number of samples and my burden of multiple testing- an issue which is 
pertinent to all ‘omics’ studies (genomics, epigenomics, transcriptomics and proteomics). At 
present, there are no existing standard protocols or optimal methodologies for analysing 
metabolomics data 722.  Some previous studies have used statistical methods such as 
Bonferroni correction and false discovery rate (FDR) to reduce the occurrence of false-
positives in metabolomics studies 681, but in other fields of study such as genetics and 
epigenetics, i.e. where high-dimensional datasets are analysed, these corrections has been 
found to be too conservative 723. This can lead to features of interest being missed. Here, a 
PCA approach, which been used in prior human metabolomics studies 680, was used to set a 
significance threshold which takes account of both the inter-correlation between individual 
metabolites and the number of statistical tests being performed. By taking account of the 
intercorrelation, this avoids generating over-conservative p-value thresholds. 
 
A third issue that I had, related to the distribution of the metabolites, was that there were a 
number of possible outliers in my data. This is potentially problematic as the presence of 
extreme values can lead to spurious associations between an exposure(s) of interest and an 
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outcome(s). However, there is no clear consensus on how to deal with outliers in 
metabolomic studies, or indeed whether they should be ‘dealt with’ at all. Ideally, one would 
have knowledge of the range of values that is biologically plausible for all measures and then 
one could make an informed judgement as to whether an observed value is likely. 
Alternatively, one would have repeat samples for each individual, in which case an average 
value could be taken, for example. I examined the effect of removing outliers using different 
techniques to determine whether this impacted on the interpretation of my findings.  
 
10.5.3. Strengths and limitations of the study 
The main strengths of this analysis include its large sample size and the wide range of 
metabolic traits studied, facilitated through the use of high-throughput NMR, which, as 
described in Chapter 4, is highly reproducible 724. I am not aware of any other HNC study 
with a similar (or larger) sample size and detailed prospectively collected phenotypic and 
metabolomic measurements. The metabolite traits captured by the targeted NMR platform 
are implicated in multiple biological pathways including lipoprotein and fatty acid metabolism, 
the citric acid cycle, amino acid metabolism and fluid balance. The platform itself has been 
used in numerous epidemiological and genetic studies, with over 200 publications having 
applied these methods to date 725.  
 
Limitations should be considered when evaluating the results of this study. The first major 
limitation is that samples were initially stored and posted at room temperature, meaning that 
it was not possible to include glycolysis related measures in the analyses. Specifically, 
glucose, lactate and citrate, biomarkers which are available from EDTA plasma samples 
(glycine, pyruvate and glycerol are only available for serum samples 725), could not be 
considered. Glycolysis provides the precursors for several major macromolecules including 
proteins, lipids, carbohydrates and nucleic acids which are all necessary to support cancer 
cell proliferation. Indeed, aerobic glycolysis or the ‘Warburg effect’ (rather than oxidative 
phosphorylation) is a key metabolic hallmark of nearly all cancers 322. Future studies, aimed 
specifically at analysing the HNC metabolome, should take these pre-analytical factors into 
consideration in order to preserve the metabolites present at the time of sampling and 
achieve the most complete metabolic profile possible. Currently, there does not appear to be 
a standard operating procedure (SOP) for sample acquisition in metabolomic studies 722 726 
and not many published papers provide a clear account of the methods they used. However, 
all studies should aim to process and freeze samples as quickly as possible. Ideally, 
samples should be centrifuged immediately (4C) or briefly kept on ice if replicates are to be 
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collected (personal communication). They should be aliquoted to prevent freeze thaw cycles 
and stored at -80°C. Storing them at this temperature ensures that sample quality is 
maintained in the long term. If samples need to be shipped, they should be transported on 
dry ice. Crucially, there must be consistency in sample collection and handling in order to 
minimize variance/systematic bias, enabling meaningful results to be obtained. 
 
A second but related issue is that only one sample was available for each participant. The 
metabolome is inherently dynamic, more so than the proteome or the genome since it 
provides a reflection of the biological processes or states at the time of sample collection 727. 
This could be problematic and therefore, ideally, blood draws would have been repeated on 
the same individual at one or more time points to account for biological variability. Metabolon 
(an alternative NMR platform) state that repeated sampling from the same subject reduces 
the number of study subjects needed to achieve a sufficiently well-powered study 728. Again, 
future studies should look to include multiple blood sampling in their study design. In 
addition, it would be interesting to look at the associations of metabolites with survival in 
other biological samples like saliva or urine.  
 
A third potential limitation of the study is that, whilst models were adjusted for a range of 
clinical and sociodemographic features, several potentially important confounding factors 
that could influence the associations of metabolic traits with survival such as dietary intake, 
physical activity levels, time of blood draw, plasma sample storage time and medication use, 
could not be controlled for in the analysis because information on these factors were not 
available. The inclusion of BMI and SE variables in the hazard models may have captured 
some of the potential confounding by diet and physical activity, but it can be the case that 
someone who is very inactive and eats a poor diet may have a BMI in the normal range.  
 
A fourth issue, which potentially affects the generalisability of my findings, relates to the fact 
that that those people with complete data (who were included in the analyses) were different 
at baseline compared to those with missing covariate data. These differences were apparent 
for comorbidity, age, HPV status and smoking status. I made an effort to examine whether 
this may have influenced my results by running the survival models in both the complete 
case dataset and the entire dataset (i.e. everyone with metabolomic data available) and 
plotting a linear fit of the overall correspondence in effect estimates. The results suggest that 
there is good correlation between HRs, as evidenced by an R2 of 0.82 and a slope of 0.04. It 
is still possible however, that the sample used in my analysis is not representative of the 




A fifth limitation is that I was unable to validate my findings in an external OPC cohort.  
I am not aware of any other existing HNC cohorts with metabolomics data available at 
present, however, Nightingale Health has applied to UK Biobank to conduct metabolic 
profiling on all of its 500,000 participants using their high-throughput NMR platform 729. A 
pilot study began in 2019 and is expected to take three years to complete. The number of 
HNC cases in this dataset will inevitably be smaller than the H&N5000 cohort, however. 
 
Finally, whilst the number of biomarkers included in the NMR platform is relatively large 
compared to other existing platforms, it still only represents a fraction of the metabolites 
present in the blood. Metabolomics is a relatively new and emerging field of science and, at 
the present time, there is no single metabolomics technology or combination of technologies 
that can characterise the entire metabolome 730, largely because it incorporates such a 
diverse variety of endogenous and exogenous classes of compounds, with varying sizes, 
polarities and concentrations.  It is likely that, with future advancements in high-throughput 
technologies enabling more biomarkers to be identified, many more mortality-associated 
biomarkers will be discovered, which may lead to improved risk prediction.  
10.5.4. Conclusion 
In conclusion, the findings of this analysis suggest that some metabolites within the 
metabolome may be related to overall mortality in people with OPC. A plasma metabolomic 
profile, characterised by high acetate levels in particular, may be associated with a poorer 
prognosis. These results should be validated externally in a large prospective cohort. 
Comparisons with the metabolomic profiles of healthy individuals should also be conducted 






Chapter 11: Discussion 
 
11.1. Introduction 
HNC develops due to an interplay of biological, lifestyle, and environmental factors. 
Similarly, many factors can affect an individuals’ prognosis once they have developed the 
disease. These include features related to the cancer, (e.g. the type of cancer, where it 
originated in the body, and its stage), and features related to the individual themselves (e.g. 
their age, how healthy they were before they developed HNC and their lifestyle behaviours). 
This thesis explored the effects and possible prognostic value of a range of exposures on 
HNC survival, using a combination of self-report, epigenomic and metabolomic techniques. It 
was split into four separate but inter-related analyses. First, I examined whether smoking 
status and alcohol intake, factors which are known to associated with HNC risk, were 
observationally associated with mortality risk in a sub-sample of H&N5000 participants with 
oral, oropharyngeal, and laryngeal cancers. Second, I used robust and easy-to-measure 
DNAm-based predictors for these behaviours and two other complex traits, namely BMI and 
educational attainment, to examine the role of these exposures on survival in people with 
OPC. Third, I investigated whether DNAm-based predictors of aging, also termed “epigenetic 
clocks”, provided prognostic information in the same sample of individuals with OPC. Finally, 
I looked at the potential relationships between circulating plasma metabolites and OPC 
cancer survival. To date, the prognostic significance of epigenetic and metabolomic factors 
have been largely overlooked in the HNC literature. 
 
An in-depth discussion of was provided at the end of each results chapter. In this final 
chapter, I will summarise the key findings from my thesis, before evaluating the potential for 
better prognostic model development in HNC. 
 
11.2. Summary of findings and implications 
Table 46 summarises the main findings of this thesis.    
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Table 46:  An overview of the research questions and findings of this thesis. 
Research Question n Main findings Chapter 
What proportion of the 
variation in survival is 
explained by self-reported 
smoking and alcohol 
intake?  
1,403 • Smoking explains an additional 7% of the variation in survival on top of age and 
gender (R2=0.13 vs 0.06 for age and gender).  
• Alcohol intake explains an additional 2% of the variation in survival on top of 
age and gender (R2=0.08 vs 0.06 for age and gender). 
7 
Is self-reported smoking 
status associated with all-
cause mortality in people 
with HNC,  after adjusting 
for clinical, biological and 
lifestyle factors? 
1,403 • Compared to people who had never smoked, current smokers were twice as 
likely to die during follow-up (HR= 2.0 [95% CI:1.4, 3.0; p for trend <0.001]) 
• Former smokers, by comparison, were 60% more likely to die compared to 
never-smokers (HR=1.6 [95% CI:1.2, 2.3; p<0.001].  
• There was no evidence of heterogeneity by treatment centre, which suggests 
that the results were not influenced by factors such as the preferred treatment 
approach at that hospital, level of care provided, or the general 
affluence/deprivation of the area.  7 
Is self-reported alcohol 
associated with all-cause 
mortality in people with 
HNC,  after adjusting for 
clinical, biological and 
lifestyle factors? 
1,403 • There was no evidence that hazardous to harmful drinkers had an increased 
risk of all-cause mortality compared to non-drinkers in a model that adjusted for 
age, sex, stage, HPV status, comorbidity, marital status, annual household 






Table 46 continued. 
Does cancer stage 
influence the association of 
self-reported smoking and 
drinking with all-cause 





• Smoking status was associated with all-cause mortality in both high- and low-
stage tumour groups (stages I and II, HR=2.8 [95% CI=1.3, 6.2; p=0.011]; 
stages III and IV, HR=1.9 [95% CI=1.2, 3.0; p=0.003]). 
• I found no evidence that alcohol drinking influenced all-cause mortality risk in 
either low- or high-stage cancer groups in fully adjusted models. 7 
Does HPV status influence 
the association of self-
reported smoking and 
drinking with all-cause 






• There was weak evidence to suggest that hazardous to harmful drinkers with 
non-HPV associated cancers had worse survival compared to their non-drinking 
counterparts (HR=2.4 [95% CI:1.07, 5.59; p for trend =0.074]), but estimates 
were based on low sample numbers.  
• The analysis was underpowered to detect an effect of smoking status on all-
cause mortality. 7 
What proportion of 
phenotypic variance is 
explained by DNAm based 
predictors of smoking, 
alcohol drinking, BMI and 
educational attainment in 
people with OPC? 
408 • DNAm predictors correlate with lifestyle factors that are associated with HNC 
risk and prognosis, but the proportion of the phenotypic variance explained 
differs. 
• Up to 48.65% of the variance in smoking and 16.0% of the variance in alcohol 
drinking can be explained by their respective predictors (AHRR and the score 
developed by Lui that includes 144 CpGs). 
• DNAm was found to explain 21.53% and 0.68% of the variation in BMI and 






Table 46 continued. 
What proportion of the 
variation in survival is 
explained by the DNAm-
based predictors of smoking, 
alcohol drinking, BMI and 
educational attainment in 
people with OPC? 
408 • On top of age and gender, DNAm-based smoking predictors increased the 
proportion of explained variation in survival by 5%-10% (R2 =0.29-0.34 vs 
0.24 for age and gender). 
• DNAm-based predictors of alcohol intake increased the proportion of 
explained variation in survival by 2%-3% (R2 = 0.26-0.27 vs 0.24 for age and 
gender). 
• DNAm-based predictors of BMI and educational attainment increased the 
proportion of explained variation in survival by 2% (R2=0.26 vs 0.24 for age 
and gender). 8 
Are DNAm based predictors 
of smoking, alcohol intake, 
BMI and educational 
attainment associated with 
all-cause mortality in people 
with OPC? 
408 • Four out of the five smoking-related DNAm scores considered (methylation 
at AHRR, both Joehanes scores and the score developed by Zhang) were 
associated with survival after controlling for age, gender, cell counts, batch 
effects, TNM, HPV status, comorbidity, income, marital status and self-
reported smoking and drinking.  
• The highest effect estimate was obtained for AHRR (HR per unit increase in 
standardised DNAm score =1.92, 95% CI:1.06, 3.47). 8 
What proportion of the 
variation in survival is 
explained by the DNAm-
based predictors of EAA? 
408 • The only age acceleration measure to increase the proportion of explained 
variation in survival (compared to the variation in survival explained by age 






Table 46 continued. 
Are DNAm based predictors 
of epigenetic age 
acceleration associated with 
all-cause mortality in people 
with OPC, after controlling for 
clinical, biological and 
lifestyle factors? 
408 • AgeAccelGrim (EAA based on GrimAge) and IEAAHannum (intrinsic EAA 
based on Hannum’s clock) were associated with all-cause mortality in 
models that adjusted for gender, clinical, SE, and behavioural (smoking and 
alcohol intake). 
• HRs: 1.32 (95% CI: 1.08, 1.61; p=6.9 x10-03) and 1.39 (95% CI: 1.06, 1.83; 
p=0.017), for AgeAccelGrim and IEAAHannum, respectively. 
9 
Does the inclusion of a 
DNAm based measure of 
epigenetic age acceleration 
to a ‘standard’ clinical 
prognostic model improve 3yr 
mortality prediction? 
408 • The addition of AgeAccelGrim to a standard clinical model that included 
TNM stage, HPV status, comorbidity and BMI, improved mortality prediction 
at 3 years, though the improvement was modest. 
• Clinical AUC: 0.77, clinical + AgeAccelGrim AUC: 0.80; p-value for 
difference=0.069. 
9 
Are circulating serum 
metabolic traits associated 
with all-cause mortality in 
people with OPC? 
703 • Acetate, creatinine, omega-3 and histidine were associated with all-cause 
mortality in my primary analysis.  
• Each SD increase in acetate was associated with a 28% increased risk of 
death in the fully adjusted model. 
• Increases in circulating creatine, omega-3 and histidine were associated with 
improved survival (28%, 24% and 19% lower all-cause mortality risk per SD 
increase in metabolite), though p-values did not reach my threshold for 




11.3. Strengths and limitations of this thesis 
11.3.1. Strengths 
11.3.1.1. Prospective study design  
Unlike many other studies which have used historical cohorts or cancer registry data to 
examine the effects of smoking and alcohol intake on survival in HNC (see chapter 3), in this 
thesis I used data that was collected prospectively. Typically, prospective studies are more 
accurate with regards to the information collected about exposures, endpoints, and 
confounders and there is less missing data 731 732. This is because there is no need for any 
recollection of the information (i.e. less recall bias) and you can potentially go back to 
respondents if any information is missing, unlike in retrospective studies where reliable data 
on exposures or confounders may be unavailable or incomplete.  In H&N5000, the study 
team went back to the recruitment site if there was information missing from a participant’s 
data capture form. This reduced the amount of missing clinical data. Given that exposures 
were assessed at baseline, before my outcome of interest (death) had occurred, this also 
allowed me to calculate estimates of absolute risk (i.e. HRs). Another related advantage of 
the prospective cohort design is that individuals do not base their decision to take part in the 
study on their future outcome, since this is unknown. This reduces the potential for 
survivorship bias, which is a where people who do well are disproportionately evaluated. 
Focusing on survivors can result in a false, or disproportionate, estimate of probability or 
effect. Finally, cohort studies generally allow multiple exposures (and possibly outcomes) to 
studied simultaneously 732, making them particularly well-suited to prognostic research.  
 
11.3.1.2.  Availability of baseline clinical, biological and lifestyle data. 
The availability of baseline data in H&N5000 is diverse and wide-ranging. As a result, I was 
able to look at the relationships of several exposures, including both biological exposures 
(DNAm levels) and modifiable behaviours (smoking and alcohol exposure), on prognosis. 
Moreover, I was able to investigate the impact of confounding on these relationships due to 
the rich amount of data available on socio-demographic and clinical variables. As illustrated 
in chapter 3, the majority of studies looking at the role of smoking and alcohol consumption 
in HNC survival did not adjust for, or were unable to adjust for, HPV status, comorbidity or 
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BMI (often because they were conducted retrospectively), factors which are known or 
purported to impact on mortality risk. In this thesis, I found that controlling for these variables 
in survival models led to an attenuation of the effect sizes. This may explain why I found no 
evidence that pre-treatment levels of alcohol consumption influenced survival in my analysis 
whilst Duffy and others 441 442 447 found that active or heavy-drinkers experienced worse 
survival.  
 
11.3.1.3. Data linkage 
A major advantage of the H&N5000 study design for survival analysis is that all consenting 
participants were linked to NHS digital at the start of the study, meaning that even if the 
study sites were unable to collect data from participants medical notes, the study team would 
be notified of any subsequent deaths among cohort members. This minimises loss to follow-
up. Loss to follow-up is a concern in any clinical study as it reduces the power of a statistical 
analyses and has the potential to introduce bias if the individuals who are loss to follow-up 
differ in any way from those that remain in the study (a problem termed attrition bias).   
 
At the time of writing this thesis, 106 people were known to have withdrawn from the 
H&N5000, but only seven of these had withdrawn from data linkage. Since the exposures in 
my analyses were measured at baseline and my dataset only included people with baseline 
data, any withdrawals from follow-up questionnaires would not have influenced my data. The 
seven people who withdrew from linkage, for whom my event (death) had not occurred, 
would have been censored in my dataset, but this is unlikely to have influenced my overall 
findings, given my overall sample size.  
 
11.3.1.4. Sample size relative to other HNC studies 
H&N5000 is one of the largest prospective clinical cohorts of people with HNC in the world, 
with a wide range of information available to researchers (biological, clinical and patient-
reported). Of note, very few HNC cohorts, if any, have accompanying metabolomic data. As 
such, the metabolic perturbations occurring during the pathogenesis of HNC and their 
correlation with clinical outcomes is generally not well studied. In my scoping review 
(Chapter 3; table x), the largest metabolomics study I found included 159 OSCC samples. 
This included tumour tissues, neighbouring margins, and bed tissues. The largest study in 
blood included 140 HNC serum samples. On this basis, my analysis is the largest of its kind 
to date, with a final sample size of 703. In addition, most of the studies I identified compared 
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the metabolomes of people with and without HNC, with the view to identifying diagnostic or 
screening biomarkers, rather than investigating the prognostic role of metabolites. My 
analysis therefore addressed a gap in the existing literature.  
11.3.2. Weaknesses   
11.3.2.1. Selection into the H&N5000 study  
It was estimated that when all study centres were open, H&N5000 captured a third of all 
incident cases in the UK.  It is rare for selection bias to occur in cohort studies as bias only 
arises when a factor causing bias (e.g. inclusion) is related to both the exposure and the 
outcome.  As outcome is in the future in a prospective cohort like HN5000 and participants 
did not base their decision to take part in the study upon the future outcome, selection forces 
may not actually bias.  However, it is conceivable that this sample is not representative of 
the HNC population as a whole.  The decision to participate may correlate with social, 
educational and health circumstances and these factors may themselves correlate with risk 
factors for mortality.  Generally speaking, non-participation and tend to occur more 
commonly among less affluent, less healthy people and this can result in cohort studies 
being made up of relatively healthy, affluent sub-populations 733.   
 
Of note, the majority of participants in H&N5000 are white. People of other ethnicities may 
have been less likely to be recruited into the study due to language barriers, or alternatively, 
white people may be more likely to participate in research. Factors such as smoking status 
and BMI may have a greater or lesser influence on mortality risk in different ethnicities, due 
to genetic variation.  
 
Taken together, these issues may affect generalisability. Further studies, using larger 
numbers of subjects of all ethnicities are required in order to establish whether my findings 
can be generalised to the HNC population as a whole.  
 
11.3.2.2. Selection into the analytic sample 
Whilst selection bias is unlikely to be problematic in H&N5000 overall, it may be an issue in 
my thesis because individuals were only included in the analyses if they had baseline blood 
samples and questionnaire data available. If the decision to participate in baseline data 
collection is correlated with risk factors for the outcome under study (mortality), then possible 
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bias due to baseline selective participation cannot be ruled out. This issue may be further 
compounded in complete case analyses.  
 
11.3.2.3. Missing covariate data 
Some of the covariates considered in this thesis had missing data, either because baseline 
questionnaires were not fully completed by some of the respondents (intentionally or by 
mistake) or because necessary information was not collected at the start of the study (i.e. 
height and weight). This presented various problems. For instance, most statistical packages 
will eliminate cases when they encounter missing data for any of the variable included in the 
analysis, which in turn reduces statistical power. So, even if each individual variable only has 
a small amount of missing data, when examined in combination with the other variables 
included in the model, this can result in a drastic reduction in the number of individuals 
available for analysis. Another potential problem is that missing data can introduce bias, 
giving rise to misleading results. For instance, in my analysis, annual household income had 
some of the highest amounts of missing data. If people who were very affluent chose not to 
disclose their income, they would be under-represented in the sample and my results could 
be different, perhaps because people who are more well-off have better survival, irrespective 
of lifestyle exposures.  
 
In my thesis, I attempted to minimise the effects of missing data by performing MI, which 
involves creating several simulated complete versions of the data set, analyses each of 
these new data sets separately, and pooling the results 672.  The advantage of using this 
approach is that it makes use of all the available data and thus preserves sample size. As 
discussed in my results chapters however, MI will only produce unbiased estimates in 
situations where the data is MCAR or MAR; if the reasons for missing data are related to the 
variables under investigation, this indicates sampling bias and MI would not appropriate. 
Given that there is no formal test for establishing the mechanism of missingness and that 
sampling bias could not be ruled out in my analysis, I also conducted complete-case 
analyses and compared the results. Overall, I found that the results of my imputed and 





11.3.2.4. Power and sample size 
Statistical power is an important consideration when designing prospective studies 734. 
Power calculations are used to determine how many study participants are needed in order 
to avoid a type II (“false negative”) error 735. The “power” of the study is equal to 1- β, where 
β is the proportion of results that were incorrectly reported as being negative. Most studies 
accept a power of 80%, meaning that they are willing to miss a real difference or effect 20% 
of the time.   
 
The H&N5000 study was calculated as having 80% power to detect a difference in survival 
of around four percentage points for an intra-class correlation coefficient (ICC) of 0.005 574, 
based on a sample size of 4,000 people (allowed for exclusions of rarer cancer types, 
withdrawals from the study, incomplete data and loss to follow-up from the target total of 
5,000).  This power calculation was based on the aim of the study, however, which was to 
evaluate the impact of centralisation of care for people with HNC; therefore, its relevance to 
my analyses is limited.  
 
In my thesis, which only included a sub-sample of H&N5000 participants, I did not determine 
the power of the analyses performed but instead used all of the data that was available. This 
is limiting because it is difficult to know whether I can trust a negative result, that is whether 
the test had sufficient statistical power to detect an effect if it exists. I could have performed 
a post-hoc power calculation, using the observed effect size and one of several free on-line 
calculators (e.g. G* Power, OpenEpi, EpiTools) 736. However, the use of retrospective power 
analysis has been heavily criticised in the literature 734 737-740 and on online statistical forums, 
though editors often ask authors to include them. There are two main arguments to support 
this. Firstly, post hoc power calculations assume that the observed effect is similar to the 
true effect, but in reality, the true values are typically unknown. Secondly, as explained by 
Hoenig & Heisely 738, observed (post-hoc) power and p-values are inextricably linked 
because the observed significance level of a test, i.e. the p-value, also determines the 
observed power. As such, non-significant p-values will always correspond to low observed 
powers and observed power will add nothing to the interpretation of results. Overall, it seems 
that observed power is a tautology because the question you are asking is “What was the 
probability of finding a statistically significant result, assuming that the actual effect is the 
same as the observed effect?” but the results of the study already exist, so there is no real 
likelihood of producing such a statistically significant result 739 741. Plate et al liken this to 
asking what the probability of winning the lottery is, when you already know that you have 
not won 741. Goodman and others suggest that CIs are more useful for evaluating “non-
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significant” results than host-hoc power calculations 739, since the width of the CI gives an 
indication of the likelihood of the true (population) effect size being equal to zero.  
 
11.3.2.5. Lack of cancer-specific mortality data 
The end-point or outcome of interest in my thesis was death by any cause. I would have 
liked to have also examined the effect of my exposures on HNC-specific mortality, but this 
data was not available at the time of my analyses. Ideally, cause of death would be 
determined by a panel of experts (e.g. clinicians, oncologists, pathologists) with access to 
the individuals’ medical history, but this requires a considerable investment in time and 
resources. A project is currently underway to determine cause of death in H&N500, so future 
studies may be able to examine the role of biological and lifestyle traits on HNC-specific 
mortality. 
 
Both outcomes, i.e. all-cause mortality and disease-specific mortality, have their advantages 
and disadvantages. Cancer‐specific mortality is sometimes criticised because of possible 
biases in the determination of cause of death 742. For example, based on evaluation by 
expert panels and/or autopsy reports, 15-35% of death certificates are estimated to 
misclassify cause of death 742.  Overall mortality is, by contrast, an objective measure. 
However, where the study population has high mortality rates from co-occurring conditions, 
as is the case with HNC, differences in survival between groups due to the exposure of 
interest may be overshadowed by deaths due competing causes e.g. cardiovascular 
disease, chronic obstructive pulmonary disease and second primary cancers in the case of 
HNC 743. Given that a considerable proportion of individuals may die from causes other than 
their HNC, larger sample sizes are however needed to detect an effect of the exposure on 
cancer-specific mortality.  
 
Ultimately, a person with disease may be less concerned about what they will die of and 
more about their chance of survival, in which case all-cause mortality may be a better study 
outcome. 
 
11.3.2.6. Sample collection and handling 
The initial overall aim of the H&N5000 study was to evaluate the outcome of centralisation in 
HNC. As such, whilst one of the objectives was to create a resource for translational and 
applied research in HNC, the study was not designed specifically to conduct metabolomic 
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analyses. The opportunity to do so was born out of the success of the study and the 
research team. The upshot of this was that sample collection and handling procedures were 
not well-suited for metabolomic studies. Most significantly, the samples were not 
immediately frozen following blood draw and they were posted to the study laboratory at 
ambient temperature. As a result, I was not able to use all of the NMR metabolite data, 
including glycolysis-related measures, because of sample degradation. I would have been 
interested to investigate the role of circulating biomarkers of glycolysis, given that cancer 
cells, in general, show an increased dependence on aerobic glycolysis (termed the Warburg 
effect) 744. 
 
11.3.2.7. Limited epigenetic and metabolomic data  
Epigenetic and metabolomic data are currently unavailable for the entire H&N5000 cohort, 
limiting the sample size in my analyses and my ability to stratify by cancer site and HPV 
status. Samples were selected for epigenetic profiling based on a clinical ICD code of OPC 
and the availability of baseline questionnaire data, data capture and biological samples. This 
meant that, of the 1,896 individuals who received an initial diagnosis of OPC, epigenetic data 
was only available for 445 of them.  Five samples had to then be excluded because they 
failed QC and a further 32 were removed from my analysis because the cancers were 
recoded based on further pathological information.  
 
I obtained metabolomic data for all of the OPC cases with adequate blood available. This 
gave me an initial sample size of 1,595. However, 112 cases were removed as a result of 
pathological re-coding. Whilst I was unable to look at the effect of the plasma metabolome 
on survival in other HNC sites, this sample size is still large relative to other metabolomic 
studies in the HNC literature, as highlighted above. 
 
11.3.2.8. External validity 
The uptake of biological biomarkers in clinical practice requires vigorous validation in 
external settings. It was not possible to validate the findings of my PhD in an external 
population because I am unaware of any other existing prospective HNC cohorts with 
epigenetic, metabolomic and mortality data currently available. The extent to which my 
findings can be applied to other settings and other populations cannot therefore be 
determined at present, though I attempted to adjust some of my results for over-fitting.  




11.4. Future work 
There is a lot of scope to extend my thesis and develop a formal HNC prognostic model. 
Below I outline some of the possible future projects that would be interesting and potentially 
informative. 
11.4.1. Mendelian randomization study of metabolite profiles 
My metabolomics analysis was hypothesis generating in design. It uncovered several 
metabolites that might be able to predict mortality risk in HNC, but whether or not these 
biomarkers are causally related to HNC survival was not established. 
 
Mendelian randomization (MR) provides an opportunity to test for causal effects between the 
metabolites I identified in my analysis and risk of death. MR is a type an instrumental 
variable analysis which is being increasingly used in epidemiological research 745. It uses 
genetic variants robustly associated with your trait of interest (here, my metabolite traits) as 
‘proxies’ for that exposure. The underlying principle or assumptions of MR are that the 
allocation of genetic variants (alleles) from parent to offspring are random and unrelated to 
factors other than that trait, that is, they are not affected by confounding 746.  In this way, MR 
is often described as ‘nature’s randomized controlled experiment’ because in MR people are 
allocated to different exposure levels (“treatment groups”) based on their genetic make-up, 
which is randomised at conception 747. This randomisation event ensures that confounders 
are distributed approximately equally across exposure groups, irrespective of whether or not 
they are measured or whether they have been measured accurately.  
 
In the future, I would look to employ a two-sample MR approach to estimate the causal effect 
of metabolite concentrations on HNC survival 747. This means that the effects of the 
instrumental variable-risk factor association (i.e. the single-nucleotide polymorphisms 
(SNPs) - exposure association) and the instrumental variable-outcome association (i.e. the 
SNP- outcome association) would not have to be obtained from the same set of individuals. 
Instead, I could make use of publicly available GWAS summary data. This approach has 
several advantages over one-sample MR, as discussed in Lawlor (2016), including 
increased power and the fact that in two-sample MR, weak instrument bias is towards the 




I would first have to identify appropriate genetic instruments for acetate, creatinine, omega-3 
and histidine that can be used within an MR framework, which I could do using the on-line 
platform MR-base 748 749.  The literature shows that there are strong associations between 
SNPs and metabolite levels 597 750, and therefore these SNPs could be used in an MR 
framework, providing they are in linkage disequilibrium (i.e. they are independent). For 
instance, Kettunen et al (2016) observed that the proportion of variance explained for 
metabolite- SNP associations in their analysis ranged from 0.2% for acetoacetate to 12.5% 
for glycine, with a median of 5% 597.  
 
Approaches such as MR required very large sample sizes and at present, there are limited 
HNC datasets with genome-wide genetic available for use. Collaborative efforts, including 
those of the International Head and Neck Cancer Epidemiology Consortium (INHANCE), a 
collaboration of over 40 studies with approximately 40,000 cases and controls, are ongoing. 
That said, many of the studies contributing to INHANCE are relatively old.  Further 
genotyping in newer cohorts such as HN5000 are hopefully in the pipeline. Indeed, funding 
to complete genotyping of over 2,500 HNC cases (oral, oropharyngeal and laryngeal 
cancers) from HN5000 has been secured by Dr Tom Dudding at the University of Bristol, 
who is also working closely with collaborators at IARC to obtain funding to genotype a further 
5,351 HNC cases and 4,351 controls. 
 
Of note, MR for survival analysis can be complicated by issues of collider bias, that is bias in 
a measure of association between two variables due to conditioning on a common effect of 
exposure and outcome 751 752. This is less of a problem if you are interested in prediction, 
however, rather than causal association. 
 
11.4.2. Saliva and tissue metabolites and survival in HNC 
I identified several candidate biomarkers for prognosis in plasma. In addition to blood 
samples, the H&N5000 bioresource also holds 4,899 pre-treatment saliva samples (oral 
cavity, n=1,199; oropharynx, n=1,752; larynx, n=986) and 2,518 surgically resected tissue 
samples (oral cavity, n=710; oropharynx, n=839; larynx, n=486), offering the potential for 
further metabolomic analyses, though there may be similar limitations around storage and 
handling of saliva as there were for blood samples. The analysis of the salivary metabolomic 
profile, in particular, presents an attractive alternative for prognostic research given its close 
proximity to tumour site 753. In addition, saliva is readily available and it can be collected 
easily and non-invasively, compared to blood collection which requires a trained 
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phlebotomist 754. Saliva is a very complex biofluid. It contains a cocktail of secretions from 
the major and minor salivary glands and gingival crevicular fluid, as well as serum and blood 
derivatives from oral wounds, desquamated epithelial cells, bronchial and nasal secretions, 
bacteria and bacterial products, viruses and fungi 755 756. As such, it is considered an 
important source of biological information. Previous studies have proposed using saliva 
metabolites to differentiate between pre-cancerous and malignant HNC lesions 271, but so 
far, studies have yet to determine if they can provide prognostic value.  
 
11.4.3. HNC prognostic model development 
Variable selection is a fundamental issue when developing any prognostic model. In this 
thesis, I used evidence from the existing literature and survival analysis techniques to 
identify a list of candidate predictor variables. The next obvious step in my investigation 
would be to develop a parsimonious prediction model that includes as few predictor 
variables as possible, i.e. a model that accomplishes the best prediction with as few 
parameters as possible. An over-complicated model including unreliable variables would not 
be adopted in clinical practice.  
 
There are a number of automated model selection methods available, including backward-
elimination, forward selection, stepwise forward/backward algorithms, information criterion 
and penalized likelihood methods such as LASSO and elastic net regression 757. The latter 
methods of which are popular in high‐dimensional model selection (e.g. the selection of 
metabolite variables 758 759).  
 
11.4.4 Application and impact of a new HNC prognostic model in clinical practice 
Before embarking on developing an entirely new prognostic model, it is important to consider 
whether it is likely to be useful in clinical practice.  As pointed out in Chapter 2, prognostic 
models are relatively abundant in the HNC literature; yet whilst multiple prediction models 
are being developed to predict health outcomes in this population, the exploitation of  
lifestyle and molecular data for the improvement of prognosis and treatment selection has 
not yet become routine, with the exception of p16 expression.  There are a number of 
reasons why this may be the case.  Firstly, before any model can be adopted in clinical 
practice, it is vital that it is shown to perform well (i.e. provide accurate predictions) outside 
the specific context of the sample in which it was developed, yet only a small number of 
studies report external validation. Secondly, the addition of new markers may yield only 
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moderate benefit given that standard models generally include the most important or 
influential predictors. Finally, models are only practical if clinicians can easily obtain the data 
required to make their prediction.467 
 
With these factors in mind, I propose that, rather than attempting to develop a new HNC 
model from scratch in H&N5000, it would be better to build upon existing HNC models to see 
whether they can be improved or recalibrated. Indeed, the Prognosis Research Strategy 
(PROGRESS) series recommends that “rather than developing a steady stream of new 
prognostic models, researchers should shift to validation, updating, and impact studies of 
existing models” 464.  
 
The performance of existing models may diminish over time if, for example, HNC cases are 
getting identified earlier or if treatment changes. Additionally, new markers may become 
available. In this current era of biomarkers and “omics,” assessment of the extent to which 
novel markers add value to existing models is increasingly important. 
 
Another possible motivation for updating a model may be that existing predictors are prone 
to substantial measurement error or reporting bias (e.g. smoking status). I would look to 
consider whether existing prognostic models could be improved by adding the novel 
biomarkers identified in this thesis, namely DNAm based measures of smoking, alcohol 
intake and biological aging.  
 
As stated above, a model is only likely to be adopted by clinicians if the data needed to 
make predictions is readily available. A limitation of using the epigenetic predictors from this 
thesis is that DNAm profiling is not routinely collected at the time of a HNC diagnosis. 
Therefore, the addition of peripheral, blood-based DNAm scores to standard clinical 
prognostic models would have to add substantial prognostic information in order to advocate 
changing clinical practice. Whilst more affordable methods for DNAm analysis are becoming 
available, cost remains a significant factor for the Health Service. Moreover, blood collection 
and handling is time-consuming and adds an additional burden to both the clinician and the 
individual with HNC.  If however, an easy to measure DNAm-based predictor of lifestyle 
exposure did improve prognostic model performance sufficiently, this could have the 
potential to play an important role in pathways towards improved health, including clinical 
decision-making and the development, evaluation, and targeting of interventions in people 




11.5. Concluding remarks   
In summary, this thesis demonstrates the potential to improve upon existing HNC prognostic 
models by integrating epigenetic and metabolomic technologies. In particular, I have shown 
that DNAm-based biomarkers for smoking, and to a lesser extent epigenetic aging, may 
augment prognostication in this population. The ability of biological predictors to inform on 
(potentially modifiable) exposures could lead to an improved understanding of disease 
variance and individual risk and help patient stratification. Existing DNAm predictors for 
alcohol, BMI and educational attainment do not appear to provide added prognostic 
information, beyond established risk factors such as cancer stage and HPV status, but the 
phenotypic variance explained by these biomarkers is limited. Future EWAS studies may 
identify additional CpG sites whose methylation levels are related to these exposures, which 
would in turn benefit subsequent epidemiological studies of disease risk and prognosis.  
 
The development of metabolomic biomarkers for HNC prognosis is at present hampered by 
the lack of standardised analysis approaches and operating procedures for use in sample 
collection and handling. However, the feasibility of metabolomics for biomarker discovery in 
this area is supported by the knowledge that malignant transformation causes disruption of 
biochemical pathways, fuelling disease progression. Further, well-designed studies in 
different biological samples along with internal and external validation of study findings are 





Appendix A  
A1: Baseline descriptives of people included in the imputed analysis (n=3,890). 
Characteristic N Frequency N Frequency N Frequency p-value*
Gender
Male 707 61.50% 1403 79.30% 832 85.80%
Female 443 38.50% 367 20.70% 138 14.20% <0.001
TNM stage 
I 390 34.00% 74 4.20% 400 41.20%
II 268 23.40% 174 9.90% 246 25.40%
III 92 8.00% 254 14.40% 161 16.60%
IV 397 34.60% 1261 71.50% 163 16.80% <0.001
HPV status
Negative 943 96.60% 455 30.60% 798 97.40%
Positive 33 3.40% 1032 69.40% 21 2.60% <0.001
Comorbidity
None 431 38.20% 834 47.90% 348 36.70%
Mild 401 35.60% 595 34.20% 347 36.60%
Moderate/severe 295 26.20% 312 17.90% 253 26.70% <0.001
Education
School education 382 46.60% 562 44.30% 389 58.10%
College 281 34.30% 465 36.70% 198 29.60%
Degree 156 19.00% 241 19.00% 83 12.40% <0.001
Annual household income
<£18,000 367 51.00% 449 38.10% 360 59.20%
£18000-£34,999 202 28.10% 358 30.40% 159 26.20%
>£35,000 151 21.00% 372 31.60% 89 14.60% <0.001
IMD 
Low Deprivation 406 39.30% 638 39.40% 401 46.00%
Moderate Deprivation 216 20.90% 358 22.10% 192 22.00%
High Deprivation 410 39.70% 623 38.50% 279 32.00% <0.003
Relationship status
single (never married) 129 14.90% 147 11.20% 77 10.80%
currently in relationship 542 62.50% 935 71.30% 484 67.60%
No longer with spouse 196 22.60% 229 17.50% 155 21.60% <0.001
Smoking status
Never 208 25.00% 348 27.50% 65 9.40%
Former 430 51.70% 696 55.00% 491 71.00%
Current 194 23.30% 221 17.50% 136 19.70% <0.001
Alcohol intake
non-drinker 230 27.30% 317 24.50% 185 26.60%
moderate drinker 176 20.90% 285 22.10% 151 21.70%
hazardous-harmful drinker 435 51.70% 690 53.40% 360 51.70% 0.660
N Mean (SD) N Mean (SD) N Mean (SD)
Age (years) 1139 62.2 (12.3) 1759 58.9 (9.0) 969 65.1 (10.4) <0.001









A2: Mortality hazard ratios (HR) according to baseline smoking and drinking status stratified by tumour site (n=3,890). 
 
Model 1: adjusted for age and gender; Model 2: additionally adjusted for clinical features (TNM stage, comorbidity, BMI, HPV); Model 3: 
additionally adjusted for social features (education, annual household income, IMD and marital status); Model 4: additionally includes smoking or 
drinking. * test for linear trend. Values with p<0.05 are shown in bold. Abbreviations: Haz, hazardous; HR, hazard ratio; Lower CI, lower 
confidence interval; Upper CI, upper confidence interval. 
HR Lower CI Upper CI p-value* HR Lower CI Upper CI p-value* HR Lower CI Upper CI p-value* HR Lower CI Upper CI p-value*
Smoking
Former 1.66 1.34 2.06 1.54 1.12 2.12 1.95 1.40 2.73 2.00 1.02 3.89
Current 3.18 2.55 3.98 <0.001 2.08 1.46 2.99 <0.001 4.31 2.97 6.26 <0.001 4.36 2.13 8.89 <0.001
Alcohol amount
Moderate 0.89 0.73 1.09 0.86 0.62 1.21 1.01 0.72 1.41 0.78 0.51 1.19
Hazardous/harmful 1.21 1.02 1.44 0.012 1.09 0.83 1.44 0.452 1.38 1.02 1.85 0.021 1.06 0.74 1.53 0.608
Smoking
Former 1.56 1.25 1.96 1.63 1.17 2.27 1.66 1.17 2.35 1.76 0.88 3.49
Current 2.20 1.74 2.80 <0.001 1.84 1.25 2.73 0.002 2.37 1.53 3.66 <0.001 3.11 1.51 6.39 <0.001
Alcohol amount
Moderate 0.89 0.72 1.09 0.83 0.59 1.16 1.05 0.74 1.49 0.73 0.47 1.14
Hazardous/harmful 1.09 0.91 1.30 0.207 1.00 0.75 1.34 0.868 1.18 0.88 1.58 0.245 1.03 0.70 1.51 0.689
Model 3
Smoking
Former 1.49 1.19 1.88 1.61 1.15 2.25 1.55 1.08 2.23 1.73 0.86 3.47
Current 1.98 1.54 2.55 <0.001 1.71 1.14 2.56 0.006 1.98 1.25 3.13 0.003 3.16 1.53 6.56 <0.001
Alcohol amount
Moderate 0.92 0.75 1.14 0.85 0.60 1.20 1.16 0.81 1.67 0.75 0.48 1.18
Hazardous/harmful 1.13 0.94 1.35 0.102 1.00 0.75 1.33 0.861 1.30 0.95 1.76 0.085 1.09 0.73 1.64 0.591
Smoking
Former 1.48 1.17 1.87 1.63 1.16 2.31 1.53 1.06 2.21 1.71 0.85 3.44
Current 1.94 1.51 2.50 <0.001 1.74 1.14 2.64 0.006 1.94 1.23 3.08 0.004 3.09 1.50 6.40 <0.001
Alcohol amount
Moderate 0.91 0.74 1.13 0.81 0.58 1.15 1.17 0.82 1.67 0.75 0.48 1.18
Hazardous/harmful 1.06 0.89 1.28 0.321 0.90 0.67 1.22 0.697 1.26 0.93 1.71 0.132 1.04 0.69 1.58 0.776
Model 2
Model 4




A3: Mortality hazard ratios (HR) according to baseline smoking and drinking status stratified 
by tumour stage. 
 
 
HR Lower CI Upper CI p-value* HR Lower CI Upper CI p-value*
Smoking
Former 2.01 1.26 3.20 1.69 1.33 2.15
Current 3.68 2.34 5.80 <0.001 3.37 2.62 4.34 <0.001
Alcohol amount
Moderate 0.81 0.56 1.18 0.90 0.70 1.14
Hazardous/harmful 1.11 0.81 1.52 0.413 1.25 1.01 1.53 0.015
Smoking
Former 1.94 1.23 3.07 1.40 1.09 1.79
Current 2.96 1.85 4.72 <0.001 1.95 1.48 2.57 <0.001
Alcohol amount
Moderate 0.82 0.58 1.17 0.91 0.71 1.18
Hazardous/harmful 1.07 0.78 1.46 0.554 1.13 0.91 1.40 0.116
Smoking
Former 1.83 1.15 2.91 1.33 1.04 1.72
Current 2.64 1.63 4.28 <0.001 1.76 1.31 2.36 <0.001
Alcohol amount
Moderate 0.87 0.61 1.25 0.93 0.72 1.21
Hazardous/harmful 1.12 0.81 1.55 0.391 1.15 0.92 1.42 0.115
Smoking
Former 1.82 1.14 2.90 1.32 1.02 1.70
Current 2.60 1.60 4.21 <0.001 1.71 1.28 2.30 <0.001
Alcohol amount
Moderate 0.85 0.59 1.22 0.93 0.72 1.21
Hazardous/harmful 1.03 0.75 1.41 0.718 1.10 0.89 1.37 0.249
Model 4






A4: Mortality hazard ratios (HR) according to baseline smoking and drinking status stratified 
by HPV status. 
 
HR Lower CI Upper CI p-value* HR Lower CI Upper CI p-value*
Smoking
Former 2.81 1.09 7.24 1.46 0.99 2.15
Current 4.10 1.59 10.56 0.001 2.44 1.37 4.34 0.003
Alcohol amount
Moderate 1.03 0.59 1.79 0.95 0.61 1.48
Hazardous/harmful 1.35 0.87 2.09 0.136 1.03 0.70 1.53 0.814
Smoking
Former 2.54 1.00 6.46 1.46 0.98 2.15
Current 3.25 1.26 8.40 0.011 2.28 1.28 4.08 0.005
Alcohol amount
Moderate 1.05 0.61 1.82 1.02 0.65 1.60
Hazardous/harmful 1.26 0.82 1.94 0.242 1.04 0.70 1.56 0.836
Smoking
Former 2.31 0.91 5.88 1.42 0.95 2.12
Current 2.65 1.03 6.84 0.043 1.97 1.08 3.60 0.018
Alcohol amount
Moderate 1.17 0.65 2.09 1.12 0.71 1.78
Hazardous/harmful 1.37 0.86 2.18 0.165 1.16 0.77 1.76 0.416
Smoking
Former 2.20 0.85 5.66 1.42 0.94 2.13
Current 2.52 0.97 6.50 0.057 1.98 1.07 3.64 0.020
Alcohol amount
Moderate 1.14 0.64 2.04 1.15 0.73 1.83
Hazardous/harmful 1.30 0.82 2.05 0.220 1.15 0.76 1.74 0.504
Model 4




































B2: Histograms showing the distribution of AHRR DNAm scores, overall and by self-reported 
smoking status (n=408).  
 
 
B3: Histograms showing the distribution of Joehanes (Bonferroni) DNAm scores, overall and 
by self-reported smoking status. 
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B4: Histograms showing the distribution of Joehanes (FDR) DNAm scores, overall and by 
self-reported smoking status. 
 
 









B6: Histograms showing the distribution of McCartney DNAm scores, overall and by self-
reported smoking status. 
 
 
B7: Histograms showing the distribution of Lui DNAm scores (based on 5 CpGs), overall and 




B8: Histograms showing the distribution of Lui (23 CpG) DNAm scores, overall and by self-
reported alcohol consumption. 
 
 
B9: Histograms showing the distribution of Lui (78 CpG) DNAm scores, overall and by self-




B10: Histograms showing the distribution of Lui (144 CpG) DNAm scores, overall and by 
self-reported alcohol consumption. 
 
 
B11: Histograms showing the distribution of McCartney DNAm scores, overall and by self-




B12: Histograms showing the distribution of McCartney DNAm scores, overall and by self-
reported educational attainment level. 
 
 




B14: Stata code used to standardise DNAm scores, to allow direct comparison across 
scores with different scales. 
 
The two smoking predictors Joehanes and AHRR have been used as a exemplars. 
 
• Step 1:  Obtain mean values (of DNAm score) for each category of smoking status. 
 
table smoking, c(mean joehanes_scores)  
self-reported 
smoking status mean(joehan~s) 
Never -0.09904  
Former -0.02009  
Current 0.192333   
 
table smoking, c(mean ahrr_scores)  
 
 
• Step 2: Subtract the mean methylation value for current smokers from the mean 
methylation value for never smokers. 
 
di .1923333 - -.0990415  
.2913748 
 
An increase in the Joehanes DNAm score of 0.29 corresponds with a change from never to 
current smoker. 
 
di -1.249833 - 0.8479779   
 -2.0978109 
 
A decrease in AHRR of -2.10 corresponds with a change from never to current smoker. 
 
• Step 3: Generate a new standardised variable. 
gen joehanes_scores_stnd = joehanes_scores/.2913748 
gen ahrr_scores_stnd = ahrr_scores/- 2.0978109   
* Dividing by a negative value reverses the sign of the AHRR score. Therefore, for the 
standardised AHRR score, low is ‘good’ (i.e. never smokers have a low standardised score) 
and high is ‘bad’ (i.e. current smokers have a high standardised score). The standardised 
AHRR score and the standardised Johannes score are now directly comparable as they are 
both in the same direction and have the same units. This means that hazard ratios for the 
standardised scores in models for mortality are directly comparable. 
self-reported  
smoking status mean(ahrr_S~S) 
Never 0.8479779 
Former 0.0340207 





B15: Kaplan-Meier observed survival curves and cox predicted survival for the variable HPV 
status. 
 
In the above plot, the closer the observed values are to the values predicted by the Cox model, 
the less likely the PH assumption has been violated.  The plots suggest that up until 
approximately 3-years, there is good agreement between survival time, but after this, the PH 
assumption may be violated.  
 
B16: Log-log plot testing the PH assumption for the variable HPV status. 
 
The above plot shows the ln(-ln(survival)) curves for each category HPV status (negative 
and positive) versus ln(time). The proportional hazards (PH) assumption is violated if the 
curves are not parallel.   In this instance, the lines appear to converge slightly towards the 
upper end of the x-axis, suggesting the PH assumption may be violated. There are few 




B17: Kaplan-Meier observed survival curves and cox predicted survival for the variable 
comorbidity. 
 
There are differences between the observed and predicted values in the mild and moderate 
to severe comorbidity groups, providing evidence of non-proportionality. 
 
B18: Log-log plot testing the PH assumption for the variable Comorbidity. 
 
The above plot plots −ln−ln(survival) curves for each category of comorbidity versus 
ln(analysis time). It provides additional evidence that the comorbidity variable may violate the 




B19: A comparison of the effect estimates obtained for the associations of DNAm scores 
with survival in the primary and complete case analyses. 
 
Continued on the next page. 
 
DNAm predictor HR ll ul p -value HR ll ul p -value
AHRR 2.99 1.96 4.56 3.67E-07 2.64 1.46 4.77 1.28E-03
Joehanes (FDR) 2.13 1.54 2.93 4.29E-06 2.45 1.57 3.83 7.43E-05
Joehanes (Bonferroni) 2.63 1.82 3.80 2.26E-07 2.80 1.70 4.61 5.24E-05
Zhang 1.28 1.12 1.47 4.07E-04 1.23 1.02 1.49 2.86E-02
McCartney smoking 2.20 1.49 3.26 8.35E-05 2.19 1.28 3.75 4.31E-03
McCartney alcohol 1.15 1.01 1.30 2.85E-02 1.18 0.99 1.42 6.72E-02
Liu 5 CpG 1.19 1.07 1.32 1.78E-03 1.22 1.05 1.41 9.39E-03
Liu 23 CpG 1.15 1.02 1.28 1.69E-02 1.19 1.02 1.39 2.94E-02
Liu 78 CpG 1.16 1.04 1.29 7.05E-03 1.16 1.02 1.33 2.83E-02
Liu 144 CpG 1.15 1.03 1.29 1.13E-02 1.16 1.01 1.33 3.70E-02
McCartney BMI 0.88 0.77 1.01 6.25E-02 0.83 0.68 1.01 5.90E-02
McCartney education 0.94 0.89 1.00 4.57E-02 0.96 0.89 1.04 2.94E-01
AHRR 2.42 1.54 3.81 1.31E-04 2.51 1.32 4.75 4.82E-03
Joehanes (FDR) 1.89 1.33 2.68 3.37E-04 2.70 1.66 4.40 6.44E-05
Joehanes (Bonferroni) 2.31 1.54 3.46 5.00E-05 3.21 1.83 5.64 5.13E-05
Zhang 1.22 1.07 1.39 3.65E-03 1.25 1.04 1.51 1.75E-02
McCartney smoking 1.70 1.12 2.59 1.26E-02 1.94 1.11 3.42 2.10E-02
McCartney alcohol 1.12 0.99 1.27 8.18E-02 1.21 1.02 1.45 3.32E-02
Liu 5 CpG 1.13 1.01 1.27 3.59E-02 1.28 1.08 1.52 4.26E-03
Liu 23 CpG 1.08 0.96 1.21 2.01E-01 1.23 1.03 1.47 1.94E-02
Liu 78 CpG 1.13 1.01 1.28 3.94E-02 1.22 1.05 1.43 1.09E-02
Liu 144 CpG 1.13 1.00 1.28 4.46E-02 1.21 1.04 1.42 1.59E-02
McCartney BMI 0.86 0.75 0.99 3.27E-02 0.81 0.66 0.98 3.13E-02
McCartney education 0.97 0.92 1.03 3.74E-01 0.98 0.90 1.06 5.46E-01
Model 1
Model 2
Primary analysis (n=408) Complete case analysis (n=248)





Model 1: adjusted for age, gender, cell counts and batch effects; model 2: additionally adjusted 
for TNM stage, HPV status and comorbidity; model 3: additionally adjusted for the 
corresponding directly measured phenotype; model 4: additionally adjusted for the other 
directly measured phenotypes. Number of deaths = 105 and 56 for the primary and complete 
case analyses, respectively. Abbreviations: CI confidence interval; CpG, cytosine-phosphate-
guanine site; FDR, false discovery rate; ll, lower confidence level; ul, upper confidence level.
DNAm predictor HR ll ul p -value HR ll ul p -value
AHRR 1.90 1.06 3.38 3.05E-02 1.29 0.56 2.93 5.51E-01
Joehanes (FDR) 1.56 1.04 2.34 3.12E-02 2.01 1.15 3.51 1.48E-02
Joehanes (Bonferroni) 1.90 1.17 3.09 9.60E-03 2.15 1.11 4.15 2.28E-02
Zhang 1.17 1.02 1.33 2.03E-02 1.19 1.00 1.42 4.72E-02
McCartney smoking 1.17 0.69 1.97 5.55E-01 1.08 0.52 2.22 8.44E-01
McCartney alcohol 1.08 0.95 1.24 2.35E-01 1.19 0.98 1.44 8.02E-02
Liu 5 CpG 1.10 0.97 1.24 1.33E-01 1.25 1.04 1.51 1.89E-02
Liu 23 CpG 1.04 0.92 1.18 5.06E-01 1.19 0.98 1.43 7.48E-02
Liu 78 CpG 1.10 0.97 1.25 1.49E-01 1.22 1.02 1.45 2.99E-02
Liu 144 CpG 1.10 0.96 1.26 1.67E-01 1.21 1.01 1.45 4.01E-02
McCartney BMI 0.90 0.78 1.04 1.63E-01 0.84 0.68 1.03 9.28E-02
McCartney education 0.98 0.92 1.04 4.18E-01 0.98 0.90 1.07 7.01E-01
AHRR 1.92 1.06 3.47 3.08E-02 1.24 0.53 2.89 6.22E-01
Joehanes (FDR) 1.55 1.03 2.33 3.73E-02 1.95 1.11 3.45 2.08E-02
Joehanes (Bonferroni) 1.89 1.15 3.11 1.20E-02 2.11 1.08 4.12 2.99E-02
Zhang 1.17 1.02 1.33 2.07E-02 1.19 1.00 1.42 5.02E-02
McCartney smoking 1.21 0.71 2.05 4.78E-01 1.07 0.51 2.27 8.59E-01
McCartney alcohol 1.06 0.92 1.22 4.45E-01 1.10 0.89 1.36 3.61E-01
Liu 5 CpG 1.08 0.95 1.22 2.42E-01 1.26 1.03 1.54 2.42E-02
Liu 23 CpG 1.03 0.91 1.17 6.57E-01 1.17 0.97 1.42 9.87E-02
Liu 78 CpG 1.09 0.95 1.24 2.23E-01 1.29 1.05 1.58 1.60E-02
Liu 144 CpG 1.09 0.95 1.24 2.43E-01 1.28 1.03 1.57 2.26E-02
McCartney BMI 0.92 0.79 1.07 2.76E-01 0.87 0.69 1.08 1.97E-01
McCartney education 0.99 0.93 1.06 8.39E-01 1.00 0.91 1.08 9.11E-01
Model 3
Model 4
Primary analysis (n=408) Complete case analysis (n=248)
95% CI 95% CI
314 
 
B20: Results of the sensitivity analysis, censoring data at 3-years, adjusted for age, gender, 
cell counts and batch effects. 
 
 


















C1: Baseline characteristics of participants included in the complete case analysis.  
  Dead at 3 years (n=37) Alive at 3 years (n=188)   
Characteristic N % N % p-value 
Gender       
Male 30 81.10% 147 78.20%   
Female 7 18.90% 41 21.80% 0.695 
TNM stage group       
Low  4 10.80% 30 16.00%   
High  33 89.20% 158 84.00% 0.424 
HPV status       
Negative  22 59.50% 44 23.40%   
Positive  15 40.50% 144 76.60% <0.001 
Comorbidity status        
None 18 48.60% 116 61.70%   
Mild 14 37.80% 45 23.90%   
Moderate/severe 5 13.50% 27 14.40% 0.204 
Smoking        
Never 2 5.40% 70 37.20%   
Former  20 54.10% 97 51.60%   
Current 15 40.50% 21 11.20% <0.001 
Alcohol       
Non-drinker 7 18.90% 52 27.70%   
Moderate 5 13.50% 49 26.10%   
Hazardous/harmful  25 67.60% 87 46.30% 0.057 
Education        
School education 18 48.60% 83 44.10%   
College 14 37.80% 78 41.50%   
Degree 5 13.50% 27 14.40% 0.880- 
Annual household income       
<£18,000 23 62.20% 65 34.60%   
£18000-£34,999 5 13.50% 62 33.00%   
>£35,000 9 24.30% 61 32.40% 0.005 
Marital status       
single (never married) 7 18.90% 16 8.50%   
currently in relationship 16 43.20% 142 75.50%   
No longer with spouse 14 37.80% 30 16.00% <0.001 
        
  N mean (SD) N mean (SD) p-value 
Age at baseline  37 62.76 (12.12) 188 56.93 (8.90) 0.001 
Body mass index  37 23.83 (4.89) 188 26.70 (4.86) 0.001 
IEAA 37  1.38 (6.52) 188 -0.44 (5.64) 0.082 
EEAA 37  0.74 (3.99) 188 -0.19 (4.34) 0.226 
IEAAHannum 37  1.29 (4.69) 188 -0.33 (3.84) 0.025 
AgeAccelPheno 37  4.17 (5.42) 188 -1.14 (5.41) <0.001 
AgeAccelGrim 37  3.01 (7.30) 188 -0.55 (6.26) 0.002 
Abbreviations:  EEAA, extrinsic epigenetic age acceleration; IEAA, intrinsic epigenetic age 
acceleration. P-value for difference based on the Chi-Square test (categorical) and one-way 
ANOVA (continuous). *Based on the Adult Comorbidity Evaluation-27 (ACE-27). ** values for 
raw epigenetic age acceleration measures. 
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C2: Results of the complete case cox regression analysis (n=225). 
 
    95% confidence interval   
Epigenetic clock HR Upper Lower p-value 
Basic model 
IEAA 1.01 0.75 1.35 0.960 
EEAA  1.41 1.04 1.91 0.026 
IEAAHannum 1.36 1.04 1.80 0.027 
AgeAccelGrim  1.96 1.52 2.53 2.8 x10-07 
AgeAccelPheno  1.53 1.14 2.06 5.0 x10-03 
Clinical model 
IEAA 0.92 0.68 1.26 0.620 
EEAA 1.27 0.93 1.74 0.130 
IEAAHannum 1.34 1.01 1.77 0.042 
AgeAccelGrim  1.66 1.23 2.24 8.2 x10-04 
AgeAccelPheno  1.35 0.98 1.85 0.066 
Socioeconomic model 
IEAA 0.93 0.68 1.27 0.640 
EEAA 1.14 0.82 1.58 0.440 
IEAAHannum 1.29 0.95 1.74 0.100 
AgeAccelGrim  1.45 1.04 2.02 0.027 
AgeAccelPheno  1.23 0.89 1.72 0.210 
Fully adjusted model 
IEAA  0.90 0.66 1.24 0.520 
EEAA  1.12 0.81 1.55 0.490 
IEAAHannum 1.25 0.92 1.68 0.150 
AgeAccelGrim  1.24 0.83 1.85 0.290 
AgeAccelPheno  1.22 0.87 1.70 0.260 
Abbreviations:  EEAA, extrinsic epigenetic age acceleration; IEAA, intrinsic epigenetic age 
acceleration. Basic model adjusted for gender; clinical model additionally adjusted for tumour 
stage, HPV status, comorbidity and BMI; socioeconomic model additionally adjusted for 




C3: Estimated coefficients (uncorrected and corrected) for the clinical + AgeAccelGrim 
model. 
  Original model  




95% CI   95% CI 
Variable ᵝ upper lower ᵝ upper lower 
Age 0.05 0.02 0.07 0.04 0.02 0.06 
Gender 




Female  0.42 -0.14 0.99 0.35 -0.12 0.82 
Tumour stage 
  
   
 
  
II 0.64 -1.56 2.85 0.53 -1.29 2.36 
III 1.65 -0.38 3.69 1.37 -0.32 3.06 
IV 1.85 -0.14 3.84 1.54 -0.12 3.19 
HPV status 
  
   
 
  
Positive -0.95 -1.47 -0.44 -0.79 -1.22 -0.36 
Comorbidity* 
  
   
 
  
mild 0.33 -0.23 0.90 0.28 -0.19 0.75 
moderate/severe 0.24 -0.38 0.85 0.20 -0.31 0.70 




D1: Abbreviations, names and units of metabolic measures quantified on the Nightingale 
NMR platform. 
Abbreviation  Full Name  Unit 
Lipoprotein Subclasses 
XXL-VLDL-P  Concentration of chylomicrons and extremely large VLDL particles mol/l 
XXL-VLDL-L   Total lipids in chylomicrons and extremely large mmol/l 
XXL-VLDL-PL  Phospholipids in chylomicrons and extremely large VLDL  mmol/l 
XXL-VLDL-C  Total cholesterol in chylomicrons and extremely large VLDL  mmol/l 
XXL-VLDL-CE  Cholesterol esters in chylomicrons and extremely large VLDL  mmol/l 
XXL-VLDL-FC  Free cholesterol in chylomicrons and extremely large VLDL mmol/l 
XXL-VLDL-TG  Triglycerides in chylomicrons and extremely large VLDL  mmol/l 
   
XL-VLDL-P  Concentration of very large VLDL particles  mol/l 
XL-VLDL-L  Total lipids in very large VLDL  mmol/l 
XL-VLDL-PL  Phospholipids in very large VLDL  mmol/l 
XL-VLDL-C  Total cholesterol in very large VLDL mmol/l 
XL-VLDL-CE  Cholesterol esters in very large VLDL  mmol/l 
XL-VLDL-FC  Free cholesterol in very large VLDL  mmol/l 
XL-VLDL-TG  Triglycerides in very large VLDL  mmol/l 
   
L-VLDL-P  Concentration of large VLDL particles  mol/l 
L-VLDL-L  Total lipids in large VLDL  mmol/l 
L-VLDL-PL  Phospholipids in large VLDL  mmol/l 
L-VLDL-C  Total cholesterol in large VLDL  mmol/l 
L-VLDL-CE  Cholesterol esters in large VLDL  mmol/l 
L-VLDL-FC  Free cholesterol in large VLDL  mmol/l 
L-VLDL-TG  Triglycerides in large VLDL  mmol/l 
   
M-VLDL-P  Concentration of medium VLDL particles  mol/l 
M-VLDL-L  Total lipids in medium VLDL  mmol/l 
M-VLDL-PL  Phospholipids in medium VLDL  mmol/l 
M-VLDL-C  Total cholesterol in medium VLDL  mmol/l 
M-VLDL-CE  Cholesterol esters in medium VLDL  mmol/l 
M-VLDL-FC  Free cholesterol in medium VLDL  mmol/l 
M-VLDL-TG  Triglycerides in medium VLDL  mmol/l 
   
S-VLDL-P  Concentration of small VLDLparticles  mol/l 
S-VLDL-L  Total lipids in small VLDL mmol/l 
S-VLDL-PL  Phospholipids in small VLDL mmol/l 
S-VLDL-C  Total cholesterol in small VLDL mmol/l 
S-VLDL-CE  Cholesterol esters in small VLDL mmol/l 





Abbreviation  Full Name  Unit 
S-VLDL-TG  Triglycerides in small VLDL mmol/l 
   
XS-VLDL-P  Concentration of very small VLDL particles  mol/l 
XS-VLDL-L  Total lipids in very small VLDL mmol/l 
XS-VLDL-PL  Phospholipids in very small VLDL mmol/l 
XS-VLDL-C  Total cholesterol in very small VLDL mmol/l 
XS-VLDL-CE  Cholesterol esters in very small VLDL mmol/l 
XS-VLDL-FC   Free cholesterol in very small VLDL mmol/l 
XS-VLDL-TG  Triglycerides in very small VLDL mmol/l 
   
IDL-P  Concentration of LDL particles mol/l 
IDL-L  Total lipids in LDL mmol/l 
IDL-PL  Phospholipids in LDL mmol/l 
IDL-C Total cholesterol in LDL mmol/l 
IDL-CE  Cholesterol esters in LDL mmol/l 
IDL-FC   Free cholesterol in LDL mmol/l 
IDL-TG T Triglycerides in LDL mmol/l 
   
L-LDL-P  Concentration of large LDL particles mol/l 
L-LDL-L  Total lipids in large LDL mmol/l 
L-LDL-PL  Phospholipids in large LDL mmol/l 
L-LDL-C  Total cholesterol in large LDL mmol/l 
L-LDL-CE  Cholesterol esters in large LDL mmol/l 
L-LDL-FC   Free cholesterol in large LDL mmol/l 
L-LDL-TG  Triglycerides in large LDL mmol/l 
   
M-LDL-P  Concentration of medium LDL particles mol/l 
M-LDL-L  Total lipids in medium LDL mmol/l 
M-LDL-PL  Phospholipids in medium LDL mmol/l 
M-LDL-C  Total cholesterol in medium LDL mmol/l 
M-LDL-CE  Cholesterol esters in medium LDL mmol/l 
M-LDL-FC   Free cholesterol in medium LDL mmol/l 
M-LDL-TG  Triglycerides in medium LDL mmol/l 
   
S-LDL-P  Concentration of small LDL particles mol/l 
S-LDL-L  Total lipids in small LDL mmol/l 
S-LDL-PL  Phospholipids in small LDL mmol/l 
S-LDL-C  Total cholesterol in small LDL mmol/l 
S-LDL-CE  Cholesterol esters in small LDL mmol/l 
S-LDL-FC   Free cholesterol in small LDL mmol/l 






 D1 continued. 
Abbreviation  Full Name  Unit 
XL-HDL-P  Concentration of very large HDL particles mol/l 
XL-HDL-L  Total lipids in very large HDL particles mmol/l 
XL-HDL-PL  Phospholipids in very large HDL particles mmol/l 
XL-HDL-C  Total cholesterol in very large HDL particles mmol/l 
XL-HDL-CE  Cholesterol esters in very large HDL particles mmol/l 
XL-HDL-FC   Free cholesterol in very large HDL particles mmol/l 
XL-HDL-TG  Triglycerides in very large HDL particles mmol/l 
   
L-HDL-P  Concentration of large HDL particles mol/l 
L-HDL-L  Total lipids in large HDL particles mmol/l 
L-HDL-PL  Phospholipids in large HDL particles mmol/l 
L-HDL-C  Total cholesterol in large HDL particles mmol/l 
L-HDL-CE  Cholesterol esters in large HDL particles mmol/l 
L-HDL-FC   Free cholesterol in large HDL particles mmol/l 
L-HDL-TG  Triglycerides in large HDL particles mmol/l 
   
M-HDL-P  Concentration of medium HDL particles mol/l 
M-HDL-L  Total lipids in medium HDL particles mmol/l 
M-HDL-PL  Phospholipids in medium HDL particles mmol/l 
M-HDL-C  Total cholesterol in medium HDL particles mmol/l 
M-HDL-CE  Cholesterol esters in medium HDL particles mmol/l 
M-HDL-FC   Free cholesterol in medium HDL particles mmol/l 
M-HDL-TG  Triglycerides in medium HDL particles mmol/l 
   
S-HDL-P  Concentration of small HDL particles mol/l 
S-HDL-L  Total lipids in small HDL particles mmol/l 
S-HDL-PL  Phospholipids in small HDL particles mmol/l 
S-HDL-C  Total cholesterol in small HDL particles mmol/l 
S-HDL-CE  Cholesterol esters in small HDL particles mmol/l 
S-HDL-FC   Free cholesterol in small HDL particles mmol/l 
S-HDL-TG  Triglycerides in small HDL particles mmol/l 
   
XXL-VLDL-PL_%  Phospholipids to total lipids ratio in chylomicrons and extremely large VLDL % 
XXL-VLDL-C_%  
Total cholesterol to total lipids ratio in chylomicrons and extremely large 
VLDL % 
XXL-VLDL-CE_%  
Cholesterol esters to total lipids ratio in chylomicrons and extremely large 
VLDL % 
XXL-VLDL-FC_% 
 Free cholesterol to total lipids ratio in chylomicrons and extremely large 
VLDL % 
XXL-VLDL-TG_%  Triglycerides to total lipids ratio in chylomicrons and extremely large VLDL % 
   
XL-VLDL-PL_%  Phospholipids to total lipids ratio in very large VLDL % 
XL-VLDL-C_%  Total cholesterol to total lipids ratio in very large VLDL  % 




Abbreviation  Full Name  Unit 
XL-VLDL-FC_%  Free cholesterol to total lipids ratio in very large VLDL % 
XL-VLDL-TG_%  Triglycerides to total lipids ratio in very large VLDL  
   
L-VLDL-PL_%  Phospholipids to total lipids ratio in large VLDL  % 
L-VLDL-C_%  Total cholesterol to total lipids ratio in large VLDL  % 
L-VLDL-CE_%  Cholesterol esters to total lipids ratio in large VLDL  % 
L-VLDL-FC_%  Free cholesterol to total lipids ratio in large VLDL  % 
L-VLDL-TG_%  Triglycerides to total lipids ratio in large VLDL % 
   
M-VLDL-PL_%  Phospholipids to total lipids ratio in medium VLDL  % 
M-VLDL-C_%  Total cholesterol to total lipids ratio in medium VLDL  % 
M-VLDL-CE_%  Cholesterol esters to total lipids ratio in medium VLDL  % 
M-VLDL-FC_%  Free cholesterol to total lipids ratio in medium VLDL  % 
M-VLDL-TG_%  Triglycerides to total lipids ratio in medium VLDL % 
   
S-VLDL-PL_%  Phospholipids to total lipids ratio in small VLDL  % 
S-VLDL-C_%  Total cholesterol to total lipids ratio in small VLDL  % 
S-VLDL-CE_%  Cholesterol esters to total lipids ratio in small VLDL  % 
S-VLDL-FC_%  Free cholesterol to total lipids ratio in small VLDL  % 
S-VLDL-TG_%  Triglycerides to total lipids ratio in small VLDL  % 
   
XS-VLDL-PL_%  Phospholipids to total lipids ratio in very small VLDL  % 
XS-VLDL-C_%  Total cholesterol to total lipids ratio in very small VLDL  % 
XS-VLDL-CE_%  Cholesterol esters to total lipids ratio in very small VLDL  % 
XS-VLDL-FC_%  Free cholesterol to total lipids ratio in very small VLDL  % 
XS-VLDL-TG_%  Triglycerides to total lipids ratio in very small VLDL  % 
   
IDL-PL_%  Phospholipids to total lipids ratio in IDL  % 
IDL-C_%  Total cholesterol to total lipids ratio in IDL  % 
IDL-CE_%  Cholesterol esters to total lipids ratio in IDL  % 
IDL-FC_%  Free cholesterol to total lipids ratio in IDL  % 
IDL-TG_%  Triglycerides to total lipids ratio in IDL  % 
   
L-LDL-PL_%  Phospholipids to total lipids ratio in large LDL  % 
L-LDL-C_%  Total cholesterol to total lipids ratio in large LDL  % 
L-LDL-CE_%  Cholesterol esters to total lipids ratio in large LDL  % 
L-LDL-FC_%  Free cholesterol to total lipids ratio in large LDL  % 
L-LDL-TG_%  Triglycerides to total lipids ratio in large LDL  % 
   
M-LDL-PL_%  Phospholipids to total lipids ratio in medium LDL  % 
M-LDL-C_%  Total cholesterol to total lipids ratio in medium LDL  % 
M-LDL-CE_%  Cholesterol esters to total lipids ratio in medium LDL  % 





Abbreviation  Full Name  Unit 
M-LDL-TG_%  Triglycerides to total lipids ratio in medium LDL  % 
   
S-LDL-PL_%  Phospholipids to total lipids ratio in small LDL  % 
S-LDL-C_%  Total cholesterol to total lipids ratio in small LDL  % 
   
S-LDL-CE_%  Cholesterol esters to total lipids ratio in small LDL  % 
S-LDL-FC_%  Free cholesterol to total lipids ratio in small LDL  % 
S-LDL-TG_%  Triglycerides to total lipids ratio in small LDL  % 
   
XL-HDL-PL_%  Phospholipids to total lipids ratio in very large HDL  % 
XL-HDL-C_%  Total cholesterol to total lipids ratio in very large HDL  % 
XL-HDL-CE_% Cholesterol esters to total lipids ratio in very large HDL  % 
XL-HDL-FC_%  Free cholesterol to total lipids ratio in very large HDL  % 
XL-HDL-TG_%  Triglycerides to total lipids ratio in very large HDL  % 
   
L-HDL-PL_%  Phospholipids to total lipids ratio in large HDL  % 
L-HDL-C_%  Total cholesterol to total lipids ratio in large HDL  % 
L-HDL-CE_%  Cholesterol esters to total lipids ratio in large HDL  % 
L-HDL-FC_%  Free cholesterol to total lipids ratio in large HDL  % 
L-HDL-TG_%  Triglycerides to total lipids ratio in large HDL  % 
   
M-HDL-PL_% Phospholipids to total lipids ratio in medium HDL  % 
M-HDL-C_%  Total cholesterol to total lipids ratio in medium HDL  % 
M-HDL-CE_%  Cholesterol esters to total lipids ratio in medium HDL  % 
M-HDL-FC_%  Free cholesterol to total lipids ratio in medium HDL  % 
M-HDL-TG_%  Triglycerides to total lipids ratio in medium HDL  % 
   
S-HDL-PL_%  Phospholipids to total lipids ratio in small HDL  % 
S-HDL-C_%  Total cholesterol to total lipids ratio in small HDL  % 
S-HDL-CE_%  Cholesterol esters to total lipids ratio in small HDL  % 
S-HDL-FC_%  Free cholesterol to total lipids ratio in small HDL  % 
S-HDL-TG_%  Triglycerides to total lipids ratio in small HDL  % 
Lipoprotein Particle Size 
VLDL-D  Mean diameter for VLDL particles  nm 
LDL-D  Mean diameter for LDL particles  nm 
HDL-D   Mean diameter for HDL particles nm 
Cholesterol 
Serum-C  Serum total cholesterol  mmol/l 
VLDL-C  Total cholesterol in VLDL  mmol/l 
Remnant-C  Remnant cholesterol (non-HDL, non-LDL -cholesterol) mmol/l 
LDL-C  Total cholesterol in LDL  mmol/l 
HDL-C  Total cholesterol in HDL  mmol/l 




Abbreviation  Full Name  Unit 
HDL3-C  Total cholesterol in HDL3 mmol/l 
EstC  Esterified cholesterol  mmol/l 
FreeC  Free cholesterol mmol/l 
Glycerides and Phospholipids 
Serum-TG  Serum total triglycerides  mmol/l 
VLDL-TG  Triglycerides in VLDL mmol/l mmol/l 
LDL-TG  Triglycerides in LDL mmol/l mmol/l 
HDL-TG  Triglycerides in HDL mmol/l mmol/l 
TotPG  Total phosphoglycerides mmol/l mmol/l 
TG/PG  Ratio of triglycerides to phosphoglycerides  
PC  Phosphatidylcholine and other cholines  mmol/l 
SM  Sphingomyelins mmol/l 
TotCho  Total cholines mmol/l 
Apolipoproteins 
ApoA1  Apolipoprotein A-1 g/l 
ApoB  Apolipoprotein B  g/l 
ApoB/ApoA1  Ratio of apolipoprotein B to apolipoprotein A-I  
Fatty Acids and Saturation Measures 
TotFA  Total fatty acids  mmol/l 
DHA 22:6 docosahexaenoic acid mmol/l 
LA 18:2 linoleic acid mmol/l 
FAw3  Omega-3 fatty acids mmol/l 
FAw6  Omega-6 fatty acids mmol/l 
PUFA  Polyunsaturated fatty acids mmol/l 
MUFA  Monounsaturated fatty acids; 16:1, 18:1 mmol/l 
SFA  Saturated fatty acids  
UnSat  Estimated degree of unsaturation  
Fatty Acids (%) 
DHA/FA  Ratio of 22:6 docosahexaenoic acid to total fatty acids % 
LA/FA  Ratio of 18:2 linoleic acid to total fatty acids % 
FAw3/FA Ratio of omega-3 fatty acids to total fatty acids % 
FAw6/FA  Ratio of omega-6 fatty acids to total fatty acids % 
PUFA/FA  Ratio of polyunsaturated fatty acids to total fatty acids % 
MUFA/FA  Ratio of monounsaturated fatty acids to total fatty acids % 
SFA/FA  Ratio of saturated fatty acids to total fatty acids % 
Glycolysis Related Metabolites 
Glc Glucose  mmol/l 
Lac  Lactate  mmol/l 
Pyr*  Pyruvate mmol/l 
Cit  Citrate  mmol/l 







Abbreviation Full name  Unit 
Amino Acids 
Ala Alanine  mmol/l 
Gln  Glutamine mmol/l 
Gly* Glycine mmol/l 
His  Histidine mmol/l 
Branched-chain amino acids 
Ile  Isoleucine mmol/l 
Leu Leucine mmol/l 
Val Valine  mmol/l 
D1 continued.   
Aromatic amino acids 
Phe Phenylalanine mmol/l 
Tyr  Tyrosine mmol/l 
Ketone Bodies 
Ace Acetate mmol/l 
AcAce  Acetoacetate mmol/l 
bOHBut  3-hydroxybutyrate mmol/l 
Fluid Balance and Inflammation 
Crea  Creatinine  mmol/l 
Alb  Albumin  signal area 
Gp  Glycoprotein acetyls, mainly a1-acid glycoprotein  mmol/l 
*Not quantifiable for EDTA-plasma samples.
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D2: PC loadings for the metabolic trait measures.  
Metabolite PC1 PC2 PC3 PC4 PC5 PC6 PC7 PC8 PC9 PC10 PC11 
HDL_C -0.25 0.82 0.47 0.18 -0.01 0.06 0.00 0.04 0.02 -0.04 -0.02 
ApoA1 0.15 0.81 0.53 0.12 0.00 0.11 0.00 0.09 0.03 -0.11 -0.02 
HDL2_C -0.30 0.80 0.47 0.19 0.01 0.06 -0.01 0.04 0.02 -0.03 -0.02 
HDL3_C 0.28 0.80 0.36 0.13 -0.16 0.04 0.06 -0.03 0.03 -0.18 -0.03 
L_HDL_PL -0.35 0.79 0.38 0.32 0.05 0.01 -0.01 -0.01 0.00 -0.05 0.00 
L_HDL_P -0.35 0.76 0.35 0.41 0.09 0.02 -0.01 0.00 0.00 -0.02 0.00 
L_HDL_L -0.36 0.75 0.35 0.41 0.09 0.02 -0.01 0.00 0.01 -0.02 0.00 
XL_HDL_PL -0.24 0.75 0.10 0.57 0.16 -0.02 -0.02 0.02 0.04 -0.01 -0.02 
L_HDL_FC -0.39 0.73 0.32 0.43 0.11 0.02 -0.01 0.03 0.03 0.02 -0.01 
S_HDL_CE 0.07 0.72 0.12 -0.54 -0.34 0.03 0.06 -0.02 0.00 -0.16 -0.02 
L_HDL_C -0.39 0.72 0.32 0.45 0.13 0.03 -0.01 0.02 0.02 0.01 -0.01 
XL_HDL_P -0.06 0.72 0.07 0.65 0.20 0.01 -0.03 0.05 0.05 -0.02 -0.03 
XL_HDL_L -0.06 0.72 0.08 0.65 0.20 0.02 -0.03 0.05 0.05 -0.02 -0.03 
L_HDL_CE -0.39 0.71 0.32 0.46 0.13 0.03 -0.01 0.02 0.01 0.01 -0.01 
IDL_FC 0.65 0.70 -0.30 -0.05 -0.03 0.02 -0.01 0.02 -0.03 -0.23 0.01 
L_LDL_FC 0.65 0.69 -0.30 -0.10 -0.04 0.03 0.00 0.04 -0.01 -0.22 0.00 
XL_HDL_C 0.10 0.66 0.05 0.67 0.22 0.06 -0.03 0.09 0.07 -0.01 -0.04 
EstC 0.72 0.66 -0.08 -0.03 -0.10 0.09 0.02 0.11 0.00 -0.20 -0.02 
S_HDL_C 0.05 0.66 0.31 -0.54 -0.36 0.03 0.05 -0.03 -0.01 -0.17 -0.01 
XL_HDL_CE 0.15 0.66 0.00 0.66 0.22 0.07 -0.02 0.10 0.07 -0.01 -0.04 
XL_HDL_FC -0.03 0.65 0.16 0.68 0.20 0.03 -0.04 0.07 0.07 0.00 -0.05 
Serum_C 0.75 0.65 -0.05 -0.04 -0.04 0.06 0.00 0.06 0.00 -0.23 -0.01 
IDL_PL 0.72 0.62 -0.29 -0.05 -0.04 0.00 -0.01 0.01 -0.03 -0.25 0.01 
S_LDL_CE 0.69 0.62 -0.28 -0.22 -0.07 0.06 0.02 0.06 0.01 -0.20 -0.01 
S_LDL_C 0.71 0.61 -0.24 -0.21 -0.07 0.07 0.02 0.07 0.01 -0.19 -0.01 
M_HDL_FC -0.23 0.60 0.72 -0.17 -0.17 0.03 -0.01 -0.01 -0.02 -0.11 0.00 
L_LDL_PL 0.76 0.60 -0.22 -0.13 -0.05 0.03 -0.01 0.04 -0.01 -0.23 0.00 
LDL_C 0.73 0.60 -0.26 -0.17 -0.05 0.05 0.01 0.05 0.00 -0.21 -0.01 
L_LDL_C 0.74 0.60 -0.26 -0.14 -0.04 0.04 0.00 0.05 -0.01 -0.22 0.00 
M_LDL_CE 0.72 0.59 -0.28 -0.21 -0.06 0.05 0.01 0.06 0.00 -0.20 -0.01 
M_LDL_C 0.73 0.59 -0.27 -0.20 -0.06 0.05 0.01 0.06 0.01 -0.20 -0.01 
L_LDL_L 0.77 0.58 -0.24 -0.10 -0.05 0.02 0.00 0.03 -0.01 -0.24 0.00 
FreeC 0.77 0.58 0.04 -0.07 0.13 -0.04 -0.07 -0.08 0.01 -0.29 0.02 
M_LDL_FC 0.76 0.58 -0.18 -0.15 -0.08 0.08 0.02 0.07 0.02 -0.20 -0.02 
IDL_C 0.77 0.57 -0.26 -0.07 -0.02 0.05 -0.01 0.05 -0.02 -0.23 0.00 
TotCho 0.70 0.57 0.24 0.12 0.06 0.02 -0.03 -0.09 -0.05 -0.30 0.05 
S_LDL_FC 0.77 0.56 -0.11 -0.17 -0.09 0.11 0.03 0.09 0.03 -0.18 -0.02 
S_LDL_L 0.78 0.56 -0.16 -0.17 -0.08 0.06 0.02 0.05 0.01 -0.21 -0.02 
L_LDL_CE 0.77 0.56 -0.25 -0.15 -0.04 0.04 0.00 0.05 0.00 -0.22 0.00 
L_LDL_P 0.79 0.56 -0.23 -0.08 -0.05 0.02 0.00 0.02 -0.01 -0.24 0.00 
M_LDL_L 0.78 0.56 -0.22 -0.15 -0.07 0.04 0.01 0.04 0.00 -0.22 -0.01 
S_LDL_P 0.79 0.55 -0.15 -0.16 -0.08 0.05 0.01 0.05 0.01 -0.22 -0.01 





Metabolite PC1 PC2 PC3 PC4 PC5 PC6 PC7 PC8 PC9 PC10 PC11 
IDL_L 0.80 0.54 -0.25 -0.02 -0.03 0.01 -0.01 0.01 -0.03 -0.25 0.01 
pc 0.75 0.54 0.12 0.21 -0.13 0.05 0.01 -0.01 0.00 -0.25 0.02 
M_HDL_PL -0.14 0.53 0.80 -0.13 -0.17 -0.01 -0.02 -0.03 -0.04 -0.15 -0.01 
M_HDL_CE -0.31 0.53 0.72 -0.24 -0.12 0.09 0.01 0.04 0.00 -0.03 -0.01 
M_HDL_L -0.18 0.53 0.78 -0.18 -0.15 0.03 -0.01 0.00 -0.03 -0.11 0.00 
UnSat -0.37 0.53 -0.20 -0.22 -0.01 -0.15 0.30 0.19 0.24 0.24 -0.03 
M_HDL_P -0.16 0.52 0.80 -0.18 -0.16 0.02 -0.02 -0.01 -0.03 -0.12 0.00 
IDL_P 0.82 0.51 -0.25 0.00 -0.04 0.00 -0.01 0.00 -0.03 -0.26 0.01 
IDL_CE 0.81 0.51 -0.24 -0.07 -0.01 0.06 -0.02 0.06 -0.02 -0.22 0.00 
TotPG 0.71 0.51 0.28 0.22 -0.04 0.05 -0.03 -0.05 -0.06 -0.28 0.04 
S_LDL_PL 0.84 0.50 0.02 -0.15 -0.10 0.08 0.01 0.07 0.02 -0.22 -0.02 
L_HDL_TG 0.14 0.48 0.14 0.69 0.17 0.01 -0.05 -0.09 -0.06 -0.14 0.06 
XS_VLDL_PL 0.81 0.47 -0.28 -0.04 -0.08 -0.06 0.00 -0.04 -0.05 -0.29 0.02 
M_LDL_PL 0.86 0.47 -0.10 -0.14 -0.08 0.04 0.00 0.05 0.01 -0.23 -0.02 
FAw6_FA -0.06 0.44 0.06 -0.56 0.63 0.03 -0.12 -0.16 0.09 -0.04 -0.03 
PUFA_FA -0.03 0.43 0.09 -0.57 0.66 -0.06 -0.03 -0.09 0.05 -0.03 -0.01 
XS_VLDL_FC 0.84 0.42 -0.31 -0.06 -0.09 -0.04 0.01 -0.05 -0.06 -0.29 0.03 
FAw6 0.69 0.40 0.19 -0.31 0.41 -0.03 -0.08 -0.16 0.04 -0.25 -0.01 
pufa 0.70 0.39 0.21 -0.32 0.42 -0.08 -0.03 -0.12 0.02 -0.24 0.00 
sm 0.31 0.36 0.27 -0.34 0.48 -0.19 -0.14 -0.24 -0.03 -0.26 0.04 
la 0.63 0.33 0.19 -0.37 0.48 0.07 -0.10 -0.13 0.04 -0.19 -0.03 
XS_VLDL_C 0.84 0.32 -0.40 0.02 -0.06 -0.03 0.00 -0.04 -0.06 -0.26 0.03 
LA_FA 0.09 0.32 0.07 -0.55 0.64 0.14 -0.13 -0.12 0.06 -0.04 -0.05 
M_LDL_TG 0.80 0.29 0.01 0.37 -0.14 -0.17 -0.01 -0.21 -0.06 -0.36 0.02 
dha 0.40 0.28 0.15 0.08 0.02 -0.67 0.45 0.13 -0.02 -0.10 0.02 
XS_VLDL_CE 0.83 0.28 -0.44 0.05 -0.05 -0.02 0.00 -0.04 -0.06 -0.25 0.03 
S_HDL_L 0.04 0.27 0.75 -0.46 -0.35 -0.01 0.01 -0.07 -0.06 -0.19 0.00 
Alb 0.24 0.27 0.10 0.00 -0.36 0.13 0.27 -0.02 0.46 0.16 -0.02 
S_HDL_P 0.07 0.24 0.76 -0.45 -0.35 -0.02 0.01 -0.07 -0.07 -0.20 0.00 
XS_VLDL_L 0.91 0.24 -0.28 0.02 -0.08 -0.06 0.00 -0.07 -0.05 -0.29 0.02 
L_LDL_TG 0.83 0.21 -0.05 0.37 -0.12 -0.16 -0.02 -0.19 -0.06 -0.35 0.02 
LDL_TG 0.85 0.20 0.00 0.35 -0.12 -0.16 -0.01 -0.19 -0.06 -0.35 0.02 
FAw3 0.51 0.20 0.27 -0.25 0.39 -0.41 0.32 0.19 -0.12 -0.09 0.08 
XS_VLDL_P 0.93 0.19 -0.26 0.04 -0.08 -0.07 -0.01 -0.08 -0.05 -0.29 0.02 
DHA_FA -0.20 0.19 0.05 0.09 -0.02 -0.72 0.53 0.23 0.00 0.10 -0.01 
FAw3_FA 0.11 0.16 0.20 -0.34 0.47 -0.47 0.40 0.26 -0.14 0.04 0.09 
Remnant_C 0.98 0.14 -0.14 -0.03 -0.01 0.02 -0.01 0.03 -0.01 -0.23 0.01 
ApoB 0.98 0.14 -0.09 -0.09 -0.02 0.03 -0.01 0.05 0.01 -0.21 0.00 
TotFA 0.95 0.13 0.21 0.05 0.06 -0.05 -0.02 -0.09 -0.01 -0.28 0.02 
S_VLDL_CE 0.93 0.09 -0.27 -0.11 -0.06 -0.03 0.01 -0.03 -0.03 -0.24 0.03 
S_HDL_FC -0.07 0.07 0.91 -0.27 -0.25 0.01 0.01 -0.05 -0.05 -0.11 0.00 
S_LDL_TG 0.93 0.05 0.16 0.22 -0.10 -0.11 -0.02 -0.12 -0.03 -0.31 0.01 





Metabolite PC1 PC2 PC3 PC4 PC5 PC6 PC7 PC8 PC9 PC10 PC11 
IDL_TG 0.87 0.02 -0.09 0.33 -0.11 -0.17 -0.02 -0.20 -0.06 -0.33 0.02 
XL_HDL_TG 0.72 0.02 -0.01 0.60 0.23 0.01 -0.04 0.02 -0.01 -0.12 0.02 
Ace 0.01 0.00 0.10 0.10 -0.04 0.05 -0.03 0.05 0.00 0.01 0.86 
His 0.12 -0.02 0.06 -0.12 -0.04 0.31 0.33 0.06 0.56 0.39 0.18 
S_HDL_PL -0.11 -0.03 0.90 -0.30 -0.23 -0.02 -0.02 -0.05 -0.09 -0.12 0.01 
S_VLDL_C 0.97 -0.03 -0.16 -0.10 -0.07 -0.04 0.00 -0.04 -0.02 -0.24 0.03 
mufa 0.86 -0.04 0.13 0.30 -0.24 -0.13 -0.04 -0.16 0.08 -0.27 0.04 
Tyr 0.05 -0.05 0.07 0.18 0.18 0.45 0.43 -0.13 -0.31 0.04 0.14 
Phe 0.03 -0.06 -0.19 0.22 0.08 0.43 0.51 -0.34 -0.10 0.08 0.03 
Gln -0.12 -0.07 0.12 -0.22 0.27 -0.04 -0.01 -0.03 0.07 0.06 0.28 
VLDL_C 0.98 -0.17 -0.04 0.00 -0.01 0.00 -0.01 0.01 -0.01 -0.19 0.01 
Val 0.23 -0.17 0.04 0.00 0.07 0.34 0.74 -0.17 -0.04 0.17 -0.04 
HDL_TG 0.82 -0.18 0.25 0.42 0.03 -0.12 -0.06 -0.11 -0.05 -0.26 0.03 
M_HDL_TG 0.72 -0.22 0.46 -0.02 -0.09 -0.17 -0.07 -0.11 -0.10 -0.30 0.03 
Crea 0.13 -0.22 -0.06 -0.15 0.04 0.13 0.21 -0.22 -0.07 -0.02 -0.17 
S_VLDL_FC 0.96 -0.24 0.07 -0.06 -0.08 -0.06 -0.01 -0.05 0.00 -0.23 0.01 
Leu 0.49 -0.26 0.15 0.13 0.09 0.27 0.65 -0.15 0.03 0.12 -0.04 
M_VLDL_CE 0.95 -0.26 0.02 0.03 0.04 0.03 -0.02 0.05 0.01 -0.15 0.01 
Gp 0.58 -0.28 0.02 0.22 0.02 -0.10 0.05 -0.27 0.04 -0.17 -0.08 
S_VLDL_PL 0.93 -0.28 0.11 -0.09 -0.10 -0.08 -0.02 -0.06 0.00 -0.23 0.00 
XS_VLDL_TG 0.92 -0.29 0.02 0.11 -0.09 -0.12 -0.02 -0.13 -0.02 -0.26 0.02 
MUFA_FA 0.08 -0.30 -0.11 0.53 -0.65 -0.18 -0.04 -0.14 0.19 -0.04 0.04 
S_VLDL_L 0.94 -0.31 0.04 -0.08 -0.05 -0.05 -0.01 -0.02 0.01 -0.19 0.01 
SFA_FA -0.08 -0.33 0.01 0.21 -0.16 0.45 0.14 0.45 -0.44 0.14 -0.05 
S_VLDL_P 0.93 -0.34 0.06 -0.07 -0.04 -0.05 -0.01 -0.02 0.02 -0.18 0.00 
XXL_VLDL_CE 0.90 -0.34 0.10 0.14 0.10 0.08 -0.03 0.10 -0.02 -0.11 -0.01 
M_VLDL_C 0.92 -0.35 0.11 0.02 0.03 0.02 -0.02 0.05 0.02 -0.13 0.00 
XXL_VLDL_C 0.87 -0.39 0.18 0.13 0.09 0.07 -0.03 0.10 0.00 -0.09 -0.01 
Ile 0.61 -0.40 0.19 0.10 0.15 0.20 0.48 -0.11 0.04 0.08 -0.04 
Serum_TG 0.88 -0.42 0.19 0.06 0.00 -0.03 -0.02 0.00 0.02 -0.15 -0.01 
XXL_VLDL_PL 0.84 -0.42 0.29 0.08 0.08 0.07 -0.03 0.10 0.02 -0.08 -0.03 
XXL_VLDL_L 0.84 -0.43 0.25 0.08 0.09 0.07 -0.03 0.11 0.02 -0.07 -0.03 
XXL_VLDL_P 0.84 -0.43 0.26 0.08 0.10 0.07 -0.03 0.11 0.02 -0.07 -0.03 
M_VLDL_PL 0.88 -0.44 0.17 -0.02 0.02 0.01 -0.02 0.04 0.03 -0.11 -0.01 
XL_VLDL_FC 0.84 -0.44 0.25 0.10 0.07 0.06 -0.02 0.09 0.02 -0.08 -0.02 
XXL_VLDL_TG 0.83 -0.44 0.27 0.07 0.10 0.08 -0.03 0.11 0.02 -0.07 -0.03 
XL_VLDL_PL 0.85 -0.44 0.26 0.07 0.06 0.04 -0.03 0.08 0.03 -0.09 -0.02 
XL_VLDL_C 0.85 -0.45 0.21 0.11 0.08 0.05 -0.02 0.09 0.02 -0.08 -0.02 
M_VLDL_FC 0.87 -0.45 0.20 0.01 0.03 0.01 -0.02 0.04 0.03 -0.11 -0.01 
XXL_VLDL_FC 0.82 -0.46 0.29 0.11 0.08 0.06 -0.03 0.09 0.03 -0.07 -0.02 
L_VLDL_CE 0.87 -0.46 0.15 0.05 0.05 0.02 -0.03 0.05 0.02 -0.11 -0.01 
XL_VLDL_CE 0.85 -0.46 0.18 0.12 0.08 0.05 -0.03 0.08 0.01 -0.08 -0.01 





Metabolite PC1 PC2 PC3 PC4 PC5 PC6 PC7 PC8 PC9 PC10 PC11 
L_VLDL_PL 0.85 -0.47 0.24 0.02 0.03 0.01 -0.02 0.04 0.04 -0.11 -0.01 
L_VLDL_FC 0.83 -0.47 0.27 0.05 0.04 0.03 -0.02 0.06 0.04 -0.09 -0.02 
M_VLDL_P 0.86 -0.48 0.18 -0.03 0.03 0.01 -0.02 0.05 0.04 -0.10 -0.01 
XL_VLDL_L 0.82 -0.48 0.26 0.07 0.06 0.04 -0.03 0.08 0.04 -0.08 -0.02 
XL_VLDL_P 0.82 -0.49 0.27 0.06 0.06 0.03 -0.03 0.07 0.04 -0.08 -0.02 
L_VLDL_L 0.83 -0.49 0.24 0.02 0.04 0.01 -0.02 0.05 0.04 -0.09 -0.01 
L_VLDL_P 0.83 -0.49 0.24 0.01 0.04 0.01 -0.02 0.05 0.04 -0.09 -0.01 
S_VLDL_TG 0.84 -0.50 0.16 -0.05 -0.01 -0.03 -0.02 0.00 0.04 -0.12 -0.01 
VLDL_TG 0.84 -0.50 0.21 -0.01 0.02 0.00 -0.02 0.04 0.04 -0.10 -0.01 
XL_VLDL_TG 0.80 -0.50 0.28 0.05 0.06 0.03 -0.03 0.07 0.04 -0.07 -0.02 
L_VLDL_TG 0.81 -0.51 0.26 0.00 0.04 0.01 -0.02 0.05 0.04 -0.09 -0.02 
S_HDL_TG 0.76 -0.52 0.17 0.14 -0.11 -0.15 -0.03 -0.15 -0.04 -0.22 0.00 




D3: Proportion of missing data in the metabolomics dataset (n=1,483). 
Variable N % Missing 
Gender 0 0 
Age 10 0.67 
Ethnicity 35 2.36 
BMI 603 40.66 
hn1_ICD_gr~f 0 0 
TNM stage  2 0.13 
HPV status 4 0.27 
Comorbidity  24 1.62 
Treatment group 0 0 
Annual household income 479 32.3 
IMD group 372 25.08 
Education 394 26.57 
Marital status 359 24.21 
Smoking status 399 26.9 
Alcohol consumption 375 25.29 
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D4: Density histograms and scatter plots showing the observed data distributions of 




Only those metabolic trait measures included in Chapter 10 are presented. Each dot on the 
right hand scatter plot marks a single observation (metabolite measure). Horizontal red lines 
represent the 99th (top line), 50th (middle line) and 1st (bottom line) percentiles.  Red dots 






























































































































































































































D5: Standardised mean difference in circulating metabolic trait concentrations for HPV (+) 
vs. HPV (-) OPCs. 
Metabolite N b SE Lower CI Upper CI p-value* 
L_HDL_CE 703 -0.503 0.083 -0.666 -0.340 2.14E-09 
L_HDL_C 703 -0.501 0.083 -0.664 -0.338 2.55E-09 
L_HDL_FC 703 -0.493 0.083 -0.656 -0.329 4.99E-09 
L_HDL_L 703 -0.471 0.084 -0.635 -0.307 2.52E-08 
L_HDL_P 703 -0.468 0.084 -0.632 -0.304 3.12E-08 
XL_HDL_PL 703 -0.464 0.084 -0.628 -0.300 3.88E-08 
S_VLDL_CE 703 0.474 0.086 0.305 0.642 4.86E-08 
S_VLDL_C 703 0.458 0.085 0.291 0.625 1.03E-07 
Crea 685 0.406 0.077 0.255 0.556 1.77E-07 
L_HDL_PL 703 -0.427 0.084 -0.593 -0.262 5.06E-07 
ApoB 703 0.435 0.086 0.266 0.604 5.78E-07 
Val 702 0.413 0.082 0.252 0.573 6.14E-07 
His 703 0.423 0.085 0.256 0.591 8.86E-07 
XL_HDL_FC 703 -0.418 0.084 -0.584 -0.253 8.99E-07 
M_LDL_CE 703 0.424 0.086 0.255 0.592 1.02E-06 
S_VLDL_L 703 0.413 0.084 0.248 0.578 1.12E-06 
M_LDL_C 703 0.419 0.086 0.250 0.588 1.34E-06 
S_LDL_C 703 0.417 0.086 0.249 0.586 1.37E-06 
S_LDL_CE 703 0.417 0.086 0.249 0.586 1.41E-06 
XL_HDL_P 703 -0.410 0.085 -0.576 -0.244 1.52E-06 
XL_HDL_L 703 -0.409 0.085 -0.575 -0.243 1.59E-06 
S_VLDL_P 703 0.406 0.084 0.241 0.571 1.66E-06 
S_VLDL_PL 703 0.403 0.083 0.239 0.567 1.69E-06 
S_LDL_L 703 0.410 0.086 0.242 0.579 2.11E-06 
S_LDL_P 703 0.407 0.086 0.239 0.575 2.54E-06 
M_LDL_PL 703 0.408 0.086 0.239 0.577 2.57E-06 
S_LDL_FC 703 0.404 0.085 0.236 0.571 2.71E-06 
bOHBut 693 -0.299 0.063 -0.423 -0.175 2.71E-06 
S_VLDL_FC 703 0.392 0.084 0.227 0.557 3.61E-06 
Remnant_C 703 0.404 0.087 0.234 0.574 3.67E-06 
M_LDL_L 703 0.402 0.086 0.232 0.571 3.78E-06 
S_LDL_PL 703 0.396 0.085 0.228 0.564 4.35E-06 
LDL_C 703 0.398 0.086 0.228 0.567 4.86E-06 
Ile 700 0.382 0.083 0.218 0.545 5.26E-06 
VLDL_C 703 0.392 0.086 0.224 0.560 5.33E-06 
M_LDL_P 703 0.395 0.086 0.226 0.564 5.46E-06 
M_LDL_FC 703 0.393 0.086 0.225 0.562 5.50E-06 
L_LDL_CE 703 0.395 0.087 0.224 0.565 6.18E-06 
la 680 0.400 0.089 0.224 0.575 8.87E-06 
XS_VLDL_FC 703 0.383 0.086 0.214 0.553 1.01E-05 
M_VLDL_CE 703 0.381 0.086 0.212 0.549 1.05E-05 
L_LDL_C 703 0.375 0.087 0.205 0.545 1.75E-05 
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D5 continued.  
Metabolite N b SE Lower CI Upper CI p-value* 
L_HDL_TG 703 -0.365 0.085 -0.533 -0.198 2.10E-05 
D4 continued.        
XS_VLDL_PL 703 0.369 0.087 0.199 0.540 2.39E-05 
S_VLDL_TG 703 0.355 0.084 0.190 0.520 2.61E-05 
L_LDL_PL 703 0.368 0.087 0.197 0.538 2.66E-05 
pufa 680 0.377 0.090 0.201 0.553 2.89E-05 
M_VLDL_C 703 0.359 0.085 0.191 0.526 2.95E-05 
M_VLDL_PL 703 0.354 0.085 0.188 0.521 3.34E-05 
M_VLDL_P 703 0.354 0.085 0.187 0.521 3.41E-05 
M_VLDL_L 703 0.354 0.085 0.187 0.520 3.50E-05 
M_VLDL_TG 703 0.348 0.085 0.182 0.515 4.54E-05 
FAw6 680 0.367 0.090 0.191 0.543 4.61E-05 
L_LDL_L 703 0.355 0.087 0.184 0.526 4.91E-05 
XS_VLDL_L 703 0.353 0.086 0.183 0.522 4.96E-05 
XS_VLDL_P 703 0.349 0.086 0.180 0.518 5.78E-05 
L_LDL_P 703 0.351 0.087 0.181 0.522 5.93E-05 
IDL_CE 703 0.351 0.087 0.180 0.523 6.22E-05 
HDL2_C 703 -0.336 0.084 -0.502 -0.170 7.58E-05 
XL_HDL_C 703 -0.334 0.085 -0.501 -0.166 1.01E-04 
Leu 700 0.330 0.085 0.164 0.496 1.07E-04 
VLDL_TG 703 0.329 0.085 0.163 0.496 1.11E-04 
XS_VLDL_C 703 0.334 0.087 0.164 0.505 1.27E-04 
M_VLDL_FC 703 0.326 0.085 0.160 0.493 1.33E-04 
IDL_C 703 0.332 0.087 0.161 0.504 1.52E-04 
sfa 680 0.331 0.088 0.158 0.504 1.86E-04 
L_VLDL_CE 703 0.318 0.085 0.152 0.485 1.87E-04 
HDL_C 703 -0.316 0.084 -0.482 -0.151 1.90E-04 
MUFA_FA 680 -0.316 0.086 -0.484 -0.148 2.38E-04 
FAw3 680 0.329 0.090 0.152 0.506 2.73E-04 
L_VLDL_TG 703 0.309 0.085 0.142 0.475 3.03E-04 
L_VLDL_P 703 0.308 0.085 0.142 0.475 3.04E-04 
EstC 695 0.320 0.088 0.147 0.493 3.05E-04 
L_VLDL_L 703 0.307 0.085 0.141 0.474 3.18E-04 
L_VLDL_PL 703 0.307 0.085 0.140 0.473 3.30E-04 
IDL_L 703 0.313 0.087 0.142 0.485 3.61E-04 
L_VLDL_C 703 0.304 0.085 0.137 0.471 3.72E-04 
IDL_PL 703 0.311 0.087 0.139 0.482 4.02E-04 
IDL_P 703 0.310 0.087 0.138 0.482 4.14E-04 
XS_VLDL_CE 703 0.308 0.087 0.138 0.479 4.16E-04 
L_LDL_FC 703 0.306 0.087 0.136 0.477 4.55E-04 
Serum_TG 703 0.295 0.085 0.128 0.461 5.30E-04 
XL_HDL_CE 703 -0.295 0.086 -0.463 -0.127 6.01E-04 




D5 continued.  
Metabolite N b SE Lower CI Upper CI p-value* 
Serum_C 703 0.297 0.088 0.125 0.469 7.50E-04 
XL_VLDL_CE 703 0.288 0.085 0.121 0.456 7.71E-04 
L_VLDL_FC 703 0.288 0.085 0.120 0.455 7.78E-04 
XL_VLDL_PL 703 0.289 0.086 0.121 0.456 7.84E-04 
XL_VLDL_TG 703 0.288 0.085 0.120 0.455 7.93E-04 
XL_VLDL_P 703 0.288 0.085 0.120 0.455 7.94E-04 
XL_VLDL_L 703 0.287 0.085 0.120 0.455 8.13E-04 
TotFA 680 0.297 0.088 0.123 0.471 8.35E-04 
XL_VLDL_C 703 0.283 0.086 0.115 0.451 9.88E-04 
XXL_VLDL_P 703 0.282 0.086 0.113 0.451 0.001 
XXL_VLDL_TG 703 0.282 0.086 0.113 0.451 0.001 
XXL_VLDL_L 703 0.281 0.086 0.112 0.450 0.001 
XXL_VLDL_C 703 0.280 0.086 0.111 0.448 0.001 
S_HDL_CE 703 0.269 0.083 0.105 0.432 0.001 
XL_VLDL_FC 703 0.276 0.086 0.108 0.444 0.001 
XXL_VLDL_PL 703 0.275 0.086 0.106 0.444 0.001 
XS_VLDL_TG 703 0.266 0.084 0.101 0.430 0.002 
IDL_FC 703 0.270 0.087 0.099 0.442 0.002 
LA_FA 680 0.265 0.086 0.097 0.434 0.002 
XXL_VLDL_FC 703 0.255 0.086 0.086 0.423 0.003 
Ace 696 -0.150 0.051 -0.251 -0.050 0.003 
M_HDL_TG 703 0.234 0.083 0.072 0.396 0.005 
S_HDL_C 703 0.232 0.083 0.070 0.394 0.005 
FreeC 695 0.250 0.089 0.074 0.425 0.005 
FAw3_FA 680 0.239 0.087 0.069 0.410 0.006 
PUFA_FA 680 0.210 0.087 0.040 0.381 0.016 
S_HDL_TG 703 0.192 0.084 0.027 0.356 0.022 
S_LDL_TG 703 0.182 0.085 0.016 0.348 0.032 
FAw6_FA 680 0.182 0.087 0.011 0.353 0.037 
DHA_FA 680 -0.155 0.081 -0.315 0.004 0.056 
SFA_FA 680 0.151 0.082 -0.011 0.312 0.067 
UnSat 680 0.158 0.087 -0.013 0.328 0.070 
M_HDL_PL 703 -0.142 0.084 -0.307 0.023 0.091 
M_HDL_FC 703 -0.142 0.086 -0.311 0.026 0.098 
Alb 703 0.134 0.083 -0.029 0.297 0.107 
M_HDL_C 703 -0.128 0.086 -0.297 0.041 0.139 
M_HDL_CE 703 -0.123 0.086 -0.293 0.046 0.153 
pc 695 0.124 0.088 -0.049 0.298 0.160 
M_HDL_L 703 -0.119 0.085 -0.286 0.048 0.162 
ApoA1 703 -0.119 0.086 -0.288 0.051 0.170 
Phe 700 0.115 0.084 -0.050 0.280 0.173 
S_HDL_P 703 0.111 0.082 -0.050 0.271 0.176 






Metabolite N b SE Lower CI Upper CI p-value* 
S_HDL_L 703 0.108 0.082 -0.052 0.269 0.187 
IDL_TG 703 0.110 0.085 -0.056 0.277 0.193 
mufa 680 0.108 0.085 -0.060 0.275 0.207 
LDL_TG 703 0.074 0.085 -0.093 0.241 0.384 
sm 695 0.072 0.087 -0.098 0.243 0.405 
TotCho 695 0.069 0.090 -0.107 0.245 0.442 
S_HDL_PL 703 -0.063 0.084 -0.228 0.102 0.454 
dha 680 0.059 0.086 -0.109 0.227 0.489 
L_LDL_TG 703 0.054 0.085 -0.113 0.222 0.525 
TotPG 695 0.055 0.088 -0.119 0.228 0.537 
Gp 703 -0.049 0.086 -0.217 0.120 0.572 
S_HDL_FC 703 -0.042 0.084 -0.206 0.122 0.617 
HDL3_C 703 -0.040 0.082 -0.201 0.121 0.624 
Gln 548 -0.045 0.095 -0.231 0.142 0.639 
Tyr 702 0.037 0.080 -0.121 0.195 0.644 
HDL_TG 703 0.034 0.085 -0.133 0.200 0.692 
M_LDL_TG 703 0.032 0.085 -0.135 0.199 0.710 
XL_HDL_TG 703 -0.004 0.086 -0.172 0.164 0.961 
 
Abbreviations: b, the regression coefficient from the linear regression model; CI, 95% 
confidence interval; N, sample number. 
*P-value for difference. 
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D6: Summary of Cox PH regression results, showing only those metabolites that reached 
the threshold for multiple testing (n=703). 






Crea 685 0.54 0.41 0.695 2.69E-06 
Ace 696 1.38 1.20 1.592 7.56E-06 
His 703 0.68 0.57 0.821 5.34E-05 
L_HDL_CE 703 1.39 1.18 1.631 6.51E-05 
L_HDL_C 703 1.38 1.17 1.621 8.96E-05 
FAw3_FA 680 0.70 0.58 0.842 1.65E-04 
FAw3 680 0.68 0.56 0.831 1.66E-04 
L_HDL_TG 703 1.39 1.17 1.642 1.66E-04 
L_HDL_P 703 1.37 1.16 1.617 1.78E-04 
L_HDL_L 703 1.37 1.16 1.615 1.81E-04 
L_HDL_FC 703 1.35 1.15 1.589 2.49E-04 
S_LDL_CE 703 0.72 0.60 0.870 0.001 
S_LDL_C 703 0.72 0.60 0.871 0.001 
M_LDL_CE 703 0.73 0.61 0.874 0.001 
L_HDL_PL 703 1.34 1.13 1.585 0.001 
XL_HDL_PL 703 1.32 1.13 1.559 0.001 
M_LDL_C 703 0.73 0.61 0.877 0.001 
S_LDL_FC 703 0.73 0.61 0.881 0.001 
S_LDL_L 703 0.73 0.61 0.882 0.001 
S_LDL_P 703 0.73 0.61 0.886 0.001 
M_LDL_FC 703 0.74 0.62 0.893 0.002 
M_LDL_L 703 0.74 0.62 0.894 0.002 
LDL_C 703 0.75 0.62 0.898 0.002 
S_HDL_CE 703 0.75 0.63 0.901 0.002 
M_LDL_P 703 0.75 0.62 0.899 0.002 
S_LDL_PL 703 0.75 0.62 0.901 0.002 
M_LDL_PL 703 0.75 0.62 0.904 0.003 
S_VLDL_CE 703 0.75 0.62 0.904 0.003 
Gp 703 1.26 1.08 1.469 0.003 
L_LDL_CE 703 0.76 0.63 0.913 0.003 
XL_HDL_P 703 1.28 1.08 1.507 0.003 
XL_HDL_FC 703 1.27 1.08 1.498 0.003 
S_VLDL_C 703 0.75 0.61 0.908 0.004 
XL_HDL_L 703 1.28 1.08 1.504 0.004 
L_LDL_C 703 0.77 0.64 0.922 0.004 
Alb 703 0.77 0.64 0.923 0.005 
S_HDL_C 703 0.77 0.64 0.924 0.005 












Ace 696 1.30 1.12 1.51 0.000 
Crea 685 0.67 0.52 0.86 0.002 
FAw3_FA 680 0.73 0.60 0.89 0.002 
FAw3 680 0.73 0.59 0.90 0.003 
His 703 0.77 0.65 0.92 0.004 
Model 3 
Ace 696 1.30 1.11 1.51 0.001 
Crea 685 0.68 0.53 0.89 0.004 
Model 4 
Ace 696 1.28 1.10 1.49 0.002 
 
Abbreviations: CI, 95% confidence interval; HR, hazard ration; N, sample number.  For 
metabolite abbreviations, see Appendix D1. 
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